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ABSTRACT 
 
The pharmaceutical industry has a unique dual role within society in that the companies 
within the industry develop and distribute health care products in a for-profit manner.  
Safety and ethical concerns have resulted in an industry that is one of the most highly 
regulated globally.  Controversies have developed around perceived conflicts of interest 
emerging from this dual role due to the industry’s size, influence, and primary 
responsibility to society as a developer and provider of innovative medicines.  While 
public awareness of these controversies has grown, so have global concerns regarding 
the financial, social, and medical health of individuals. Even as the industry faces 
persistent and increasing criticism for improperly managing the social responsibilities 
attributed to its dual role, the industry has increasingly engaged in CSR activities.  
Presently, companies in the pharmaceutical industry are under pressure to be even 
more comprehensive and strategic in their approaches to CSR engagement. 
 
The purpose of this study was to examine practices and perceptions of CSR within the 
pharmaceutical industry.  Specifically, the study sought to gain an understanding of the 
perceptions of middle and senior managers of why and how their companies engage in 
CSR.   
 
The study consisted of two qualitative and complementary research methods.  The 
primary research method was semi-structured interviews with managers lasting up to 
one hour.  The secondary research method involved the collection and analysis of CSR-
related publications from pharmaceutical companies.  A multiple source approach was 
used for three specific reasons: 1) triangulate and confirm validity of primary data; 2) 
identify new areas or gaps in the literature not previously identified; and 3) create a 
more well-rounded understanding of why and how the pharmaceutical industry engages 
in CSR. 
 
For the interview portion of the study, the population consisted of middle-to-high-level 
managers of multinational pharmaceutical companies operating in North America, who 
either had significant responsibilities related to their company’s CSR decision-making 
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process or were participants in such programs.  The study population for the publication 
analysis included those pharmaceutical companies whose managers participated in the 
interview portion of the study.  Formal e-mail correspondence was used to contact and 
invite potential study participants who were informed of the purpose and scope of the 
research.  Non-random, purposive sampling was used to select those within the two key 
groups of managers deemed to be in a position to provide rich perspectives on the CSR 
decision-making process within their companies; those engaged with external 
stakeholders and those with defined roles in CSR. 
 
A constructivist grounded theory methodology was applied to the interview process, 
including the interview guide and data analysis, with the end goal of creating a 
substantive theory.  Coding and categorizing began during the collection of data, and 
proceeded in a non-linear fashion to allow for the constant comparing and analyzing of 
the data.  These iterative and circular processes developed into theoretical pathways 
that required further examining and provided additional data.  Memos and diagrams 
were used as markers for thoughts and creative tools to further analyze the components 
of the developing theory.  The result was a theory constructed from multiple 
perspectives and woven into a multi-story narrative. 
 
Managers from eleven companies (nine brand name and two generic) participated in 
the study.  In total, 22 interviews were completed, and consisted of fifteen Canadian 
managers, six American managers, and one British manager.  Additionally, there were 
three companies where interviews were conducted with managers from both Canadian 
and American affiliates of the same company.  The positions held by respondents within 
their respective companies included those directly involved in creating, implementing, 
and reporting on CSR programs and policies, and those distanced from, but still 
affected by them.  The range of perspectives based upon the positions held by 
participants provided an insightful range of interpretations regarding CSR within the 
pharmaceutical industry. 
 
The resulting substantive theory and its accompanying model present an evidence-
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based framework for the industry’s process of CSR evolution (core category) and 
articulate the relationships, interactions, and influences of its four subcategories: 1) 
social context; 2) CSR perspectives; 3) continual development and reinforcement 
process (CDRP); and 4) symbiotic continuum. 
 
The substantive theory suggests that the pharmaceutical industry is in a process of 
institutional change, with previously taken-for-granted perspectives and strategies in 
conflict with, and contested within, the social context of the industry.  CSR is no longer 
just a pragmatic/moral strategy to gain, maintain, and repair legitimacy using loosely 
coupled practices and structures.  Logical connections and framing developed and 
reinforced by institutional entrepreneurs and their resources have constructed the 
identity of CSR as an umbrella business strategy that can universally resonate with 
stakeholders and thereby create greater connectedness with operational locals and 
stakeholders.  Subsequently, CSR can be used to mitigate risks and uncertainties while 
also fostering a motivated and controlled workforce by reinforcing the internalization of 
desired meanings relating to the role of CSR.  By integrating and merging internal and 
external conceptions of what is considered ‘right’ and how to serve the self-interest of 
others in addition to their own, companies capture wider social movements in an 
attempt to find or construct opportunities to enhance their potential for long-term 
success and sustainability.  If these opportunities mean diverting assets and expertise 
to address social needs, and in so doing, result in tangible (e.g. market entrance) and 
intangible (e.g. motivated workforce) returns on these investments, then CSR becomes 
justified and legitimized by bridging the changing institutional logic.   
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1.  INTRODUCTION 
1.1 Historical Context for the Modern Economic and Business Environment 
1.1.1 Adam Smith – Father of Modern Economics 
 Adam Smith is widely considered the 'father of modern economics' (Hill, 2000; 
Milgate & Stimson, 2009) because of the economic theories he presented in his seminal 
book, The Wealth of Nations (1776).  Smith's theories sought to bring understanding to 
the economic machine (how scarce resources are allocated) that people had created 
and, most importantly, the invisible internal workings that drove that machine.  Smith’s 
theory would serve as a major influence on the various concepts of free market 
capitalism that currently circulate and operate globally.   
 In the 18th century, the study of the economic machine was also known as 
political economy, due to its high level of integration with and control by governments.  
Smith provided two goals of the political economy: 1) to provide plentiful revenues for 
the people; and 2) to supply the state or commonwealth with sufficient revenue for 
public services (Hill, 2000).  According to Smith, the role of the state or government is to 
be an active and strong supporter of the economy, while not impinging on the freedom 
of the individual.  In supporting the economy, government should focus on supporting 
for the common good and not prioritize any particular faction (Smith, 1776; Hill, 2000; 
Milgate & Stimson, 2009).   
 Smith's concept of an 'invisible hand' theorizes that self-interested individual 
economic behaviour will create unintended consequences that will inherently address 
and possibly achieve the two main goals of the political economy: 
As every individual, therefore, endeavours as much as he can both to employ his 
capital in the support of the domestic industry, and so to direct that industry that 
its produce may be the greatest value; every individual necessarily labours to 
render the annual revenue of the society as great as he can.  He generally, 
indeed neither intends to promote the public interest, nor knows how much he is 
promoting it.  By preferring the support of the domestic to that of the foreign 
industry, he intends only his own security; and by directing that industry in such a 
manner as its produce may be of the greatest value, he intends only his own 
gain, and he is in this, as in many other cases, led by an invisible hand to 
promote an end which was no part of his intention.  Nor is it always the worse for 
the society that it was no part of it.  By pursuing his own interest, he frequently 
promotes that of the society more effectually than when he really intends to 
promote it. (Smith, 1776, p. 572)   
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 The previous quote, in combination with others from The Wealth of Nations, are 
routinely used to explain and justify the pursuit of individualistic economic gains 
because of the belief that such actions ultimately benefit the common good; a 
misinterpretation that has drastically influenced economic theory and structure since the 
18th Century (Hill, 2000; Milgate & Stimson, 2009).  The incomplete or selective nature 
of this interpretation of Smith’s theories are discussed in detail, but first, it is important to 
look at the context of when and why Adam Smith was theorizing about the political 
economy. 
 Adam Smith was a Scottish moral philosopher who developed and published his 
economic theories during a time (18th century) when the economic machine in Europe 
was designed and operated by a theory of mercantilism.  “Mercantilism, in this sense, 
was a classic zero-sum game in which trade was effectively to be conducted on a 
warlike footing and understood as politics by another means” (Milgate & Stimson, 2009 
p. 66).  Economic trade was heavily regulated and directed by the state in an attempt to 
keep the state in a constant state of “perpetual readiness for war” (Milgate & Stimson, 
2009 p. 66).  Smith stood in opposition to mercantilism, and Wealth of Nations (1776) 
was both his direct critique of its perceived faults and a presentation of the methods that 
he theorized would operate the political economy more effectively.  
 Additionally, as explained by Hill (2000), Smith's theories were similar to certain 
aspects of those guiding the American Revolution.  The future United States of America 
(USA) sought not only freedom from a distant ruler, but also greater economic freedoms 
for its citizens.  Smith's theories sought to explain how people could have greater 
freedom by creating and using a market system that could fundamentally better the 
common good and do so without an authoritarian or oppressive state controlling it.   
 Rooted in the 18th century, it is important to note that an influential part of Smith's 
work was his acknowledgment and use of religious concepts in his theories (Smith, 
1776; Hill, 2000).  For example, analysis of his work has shown that his economic 
theories were built on a strong moral-ethical-religious foundation (Smith, 1776; Hill, 
2000; Milgate & Stimson, 2009).  Smith combines concepts of freedom and 
individualistic self-interest with religious concepts of justice and concern for the common 
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good.  Additionally, he acknowledges that selfish, unsocial, and social motives are the 
basis for human actions (Smith 1759, 1776).  Therefore, Smith identified a necessity for 
justice within a free market to ensure that the benefits of the invisible hand could be 
more evenly distributed: 
He was certainly aware that individual action could produce unintended good for 
the community.  But his analysis of the role of government, his repeated 
criticisms of actions of businessmen, and his concern for the working classes 
provide an important balance.  Self-interest must be balanced with justice. (Hill, 
2000, p. 114) 
 
 A strong critic of greed and inequality, Smith has been viewed by some as a 
staunch supporter of freedom from coercion and domination in any form, whether by the 
state or other individuals (Smith 1759, 1776; Hill, 2000; Milgate & Stimson, 2009).  
According to Hill (2000), Smith assumed that the costs and benefits of a free market, if 
left unchecked, would be shared unequally by individuals and that certain precautions 
should be taken to both prevent and react to these situations.  As previously discussed, 
Smith theorized that government should have an activist role to ensure an equality of 
justice and that those engaging in self-interested activity should still operate with 
respect to the common good.  Additionally, he believed the free market should have an 
element of fairness; it should reject behaviours that seek to coerce or dominate others 
by using purposeful methods to reduce or prevent competition and/or create substantial 
inequality.   
 Relating to inequality, Smith also criticized people or businesses that obtained 
excessive profits and/or owned disproportionate amounts of property.  He argued that 
these situations could be avoided by entrenching concepts of justice and the common 
good into the operation of a free market-based economic machine (Smith 1759, 1776; 
Hill, 2000; Milgate & Stimson, 2009).    
 In his book, Revolutionary values for a new millennium: John Adams, Adam 
Smith, and Social Virtue (2000), Hill analyzes the influence of Adam Smith and John 
Adams on the American Revolution (1775-1783) and the newly formed United States of 
America.  Hill (2000), along with Milgate and Stimson (2009), argues that over time 
Adam Smith's economic theories have been misinterpreted and even perverted.  The 
result is a system of capitalism (e.g. the US) that ignores or contradicts substantial parts 
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of Smith’s theories (e.g. justice, the common good, and social and political institutions 
as a foundation for the economy), while creating ideology out of others (e.g. 
individualistic self-interest): 
Smith did not establish the priority of the market over the state nor is he 
responsible for the reductions of politics to economics...He is not the champion of 
unregulated competition, nor the moral purveyor of possessive individualism, nor 
the architect of an economic theory of capitalist democracy—not, at least, as 
these ideas are understood today. (Milgate & Stimson, 2009, p. 3) 
 
In effect, American capitalism has undermined civic virtues, which are necessary 
for democracy and, ironically, are also crucial to Smith's type of capitalism. (Hill, 
2000, p. 75) 
 
 Milgate and Stimson suggest this misunderstanding stems, in part, from Smith 
not “presenting a clearly articulated political philosophy or an unambiguously expressed 
set of political principles (p. 13).  Gaps in his views, the use of a different (temporal, 
cultural etc.) lens (e.g. a 20th century one to examine 18th century theories) to analyze 
his work, and selectively using and emphasizing parts of his work while leaving others 
out were among the notable reasons for continuing misinterpretations of Smith's work.  
For example: 
By the early nineteenth century, Americans became aware of Adam Smith's 
Wealth of Nations, but not many actually read that work.  Ironically, many 
Americans learned economics from texts, which had been written by clergy; 
many of these texts distorted both Smith's moral theory and his economics.  
These texts emphasized laissez-faire, a word Smith did not use, and competitive 
individualism, at the cost of the benevolence and justice, which Smith had 
emphasized. (Hill, 2000, p. 140) 
 
 Adding to the misinterpretation of Smith's theories is the perceived gap between 
his two most notable books – The Theory of Moral Sentiments (1759) and The Wealth 
of Nations (1776).  The Theory of Moral Sentiments is based more on concepts of 
morality, conscientiousness, and community than those presented in The Wealth of 
Nations; the latter of which has continually been misinterpreted to advocate for an 
unhindered individualistic pursuit of self-interest.  Confusion arises because a theory of 
individualism or self-interest being in the public’s interest is at odds with Smith as a 
moral or ethical philosopher (Kurtz, 2008; Heal, 2008).  Such confusion is alleviated if 
scholars combined the topics/theories contained in both books rather than treating them 
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as mutually exclusive (Hill, 2000).  What results from a combined understanding of both 
books is that one sees Adam Smith placing self-interest and individualism low on the 
'moral ladder' (Hill, 2000).  Fundamentally, Smith believes that moral considerations 
should rank higher than economic ones (Fitzgibbons, 1995).   
 The compounding misinterpretations of Adam Smith's theories resulted, 
according to some scholars, in the establishment of a “powerful economic justification 
for the untrammelled pursuit of individual self-interest” (Hirschman, 1997, p. 100).  This 
'establishment' has most likely contributed substantially to the economic, social, and 
political theories that guided the late 20th century economic principles that are now 
dominant in the global market.   
 
1.1.2 Milton Friedman and Free Market Capitalism 
 In the latter half of the 20th century, Milton Friedman had a “commanding 
influence in macroeconomics” (Ramratten & Szenber, 2008, p. 24).  In his seminal 
book, Capitalism and Freedom (1962), Friedman details his theory and reasoning for 
laissez-faire economics; a staunch libertarian (neo-liberal or, as he calls it, liberal) 
theory that ties individual freedom to the free market.  He argued economic and 
personal freedom along with minimal government intervention (laissez-faire) were the 
necessary conditions under which 'true' capitalism would flourish.   
 Friedman developed and published his theories during the post-World War II  
(WW2) period.  It was a time when the governments in many industrialized countries, in 
an effort to address social and economic inequality, were in the process of creating the 
modern welfare state, where, for example, tax levels were disproportionally higher for 
the rich and lower for the poor.  Additionally, the 'threat' of socialism, or communism, 
was omnipresent in American life, with the communist USSR representing the only 
other global power.  The USA and the USSR represented two opposing economic and 
political perspectives of what is 'best' for the common good.  As a result, in the ‘West’ 
anything even remotely related to socialism/communism was often demonized in 
American culture (Stiglitz, 2010).  It is more than likely that the political and social 
conditions influenced Friedman’s oversimplified perceptions that comprised his 
argument for the free market in Capitalism and Freedom.   
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 Friedman makes overt linkages across the concepts of free markets, democracy, 
and individual freedom.  Based on these linkages, he proposes an economic theory that 
applies a deterministic logic to argue that a purely free market is the only viable method 
to sustain and grow both markets and democracy.  His book has one main and one 
minor theme: 
Its major theme is the role of competitive capitalism—the organization of the bulk 
of economic activity through private enterprise operating in a free market—as a 
system of economic freedom and a necessary condition for political freedom.  Its 
minor theme is the role that government should play in a society dedicated to 
freedom and relying primarily on the market to organize economic activity. 
(Friedman, 1982, p. 4) 
 
 Following these two themes, Friedman advocates for a seamless and combined 
pursuit of both economic and individual freedom to achieve his view of 'true' political 
freedom.  His socio-economic theory has obvious links to Adam Smith's theories in his 
references to individual self-interest and the invisible hand, but he noticeably leaves out 
the concept of a guiding moral philosophy.  With an amoral foundation, Friedman's 
theory postulates that under his prescribed conditions the market will inherently benefit 
the majority of society economically while also strengthening democracy for all its 
citizens.  However, it appears his argument breaks down as he describes conditions 
necessary for the theory to function – a situation too perfect to be realistic (Stiglitz, 
2010). 
 To further illuminate the extent to which Friedman’s theories deviated from those 
of Smith, a comparison of their seminal works is presented below.  First, Friedman 
perceives the role of government as an instrument for the market: to create and enforce 
the 'rules of the game'.  He demonizes any form of centralized government as overly 
socialist and therefore, undemocratic.  The purpose of government, according to 
Friedman, is not to interfere with individuals' freedoms, and the economic system will 
actually monitor governments to make sure it is sufficiently limited.  Adam Smith also 
suggests that government should create and enforce market rules while not impeding 
individual economic freedoms; but, unlike Friedman, he saw an activist role for the 
government in supporting justice and promoting the common good.  Hill (2000) noted, 
however, that Smith had difficulty explaining how governments would manage the 
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conflicting roles of promoting individual freedom and protecting individuals and/or 
groups since the latter requires some freedoms to be limited.   
 Second, Friedman believed a free market should have unfettered competition, 
and includes, for example, full mobility for workers and companies, elimination of 
monopolies, protection from coercion, and access to complete information – a perfect 
situation.  Analysis of Smith's work shows that Friedman, knowingly or unknowingly, 
selectively chose to advocate a theory that appears to be only half of Smith's economic 
argument.  It acknowledges and adopts Smith's theories of individual economic self-
interest and the invisible hand, but attributes amorality to the economy as a balancing 
factor instead of justice and the common good.  Friedman avoids acknowledging human 
nature by arguing for the infallibility of a perfect or near-perfect, free market, while Smith 
was far more sceptical of his own theories and how they can be tainted by selfish, 
greed-oriented behaviours.   
 Finally, there is conflict between Friedman's perception of freedom and the 
egalitarian undertones of Smith.  Smith argues for a social and political foundation for 
the economic machine, while Friedman identifies all freedoms as originating from a free 
market – a reversal of Smith's position.  Friedman sides heavily with individual freedom 
to a point where he assumes that access and availability is based on the desire of 
individuals.  If the market is running under perfect or near-perfect conditions, then 
anyone who is not able to manoeuvre their way into a profitable or successful position 
has made a conscious decision not to succeed, and therefore, does not require 
assistance because it would violate their freedom to choose.  Smith takes a stance that 
acknowledges that there will always be inequality and opportunities to create more of it, 
and so it is the government's role to balance freedoms for the purpose of egalitarian 
justice.   
 Overall, there is some overlap between the economic, political, and societal 
theories postulated by Friedman and Smith.  However, the differences are most evident 
in the extremely partisan views of Friedman and Smith’s more cautious and more 
neutral view.  Friedman presents an economic theory to shape societal and political 
institutions; a theory presented as deterministically perfect and a necessity to realize 
adequate levels of 'true' democracy.  Smith's theory, albeit somewhat more vague and 
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ambiguous in proposing policies to implement, acknowledges fallibility in the market by 
linking its use to aspects of human nature that he perceives as invariability capable of 
creating negative situations and outcomes.   
 Smith, a 18th century moral and economic philosopher who lived in a time of 
mercantilism and revolution, wrote of how individual self-interest can drive and sustain a 
market if there is active regard given to justice and the common good by individuals, 
businesses, and governments alike.  Friedman, a 20th century economist in a post WW2 
society polarized by communist versus capitalist ideologies, developed an economic 
theory based on concepts of freedom, individual choice, and a minimal role for 
government in order to make an argument for a perfect, free market, which appears to 
be selectively influenced directly or indirectly by Smith's work.  Both theories do overlap 
in descriptions of some situations that should be avoided and might require government 
intervention.  For example, both denounce coercion and uncompetitive practices such 
as monopolies.  However, Smith theorized a laissez-passer economy, not lasses-faire, 
where government plays an active role in the economy to ensure there is justice and 
regard for the common good (Hill, 2000).   
 Friedman finished his book, Capitalism and Freedom (1962), with a quote by 
Adam Smith and a response to it that would set the stage for a deterministic economic 
theory that echoed through the modern incarnation of a globalized market: 
As Adam Smith once said, “there is much ruin in a nation”.  Our basic structure of 
values and the interwoven network of free institutions will withstand much.  I 
believe that we shall be able to preserve and extend freedom despite the size of 
the military programs and despite the economic powers already concentrated in 
Washington.  But we shall be able to do so only if we awake to the threat that we 
face, only if we persuade our fellow men that free institutions offer a surer, if 
perhaps at times a slower, route to the ends they seek than the coercive power of 
the state.  The glimmerings of change that are already apparent in the intellectual 
climate are a hopeful augury. (p. 202) 
 
1.1.3 Friedman, Smith, and 20th Century Globalization: 
 After publishing his manifesto of economic theory in 1962, Milton Friedman was 
appointed President of the American Economic Association in 1967.  Additionally, he 
gained prominent positions within the US government as an economic advisor to two 
Presidents: Richard Nixon and Ronald Reagan.  As a result, Friedman attained a 
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position of power where he could actively advocate for the adoption of his deterministic 
theory of free markets and individuals free of the state’s coercive powers.   
His theories were a direct critique of Franklin Roosevelt’s New Deal economic 
policies that were heavily influenced by the economic theories of John Maynard Keynes.  
In 1933, the New Deal was implemented in the US to spur recovery from the ongoing 
Great Depression that began with the stock market crash of 1929 (Stiglitz, 2010).  
Notably, many of Keynes’s economic theories have probable linkages to the 
moral/economic assumptions of Adam Smith.  Winner of the Nobel Prize in Economics, 
Joseph Stiglitz (2010), explains his perception of the basis of Keynesian economics: 
I believe that markets lie at the heart of every successful economy but that 
markets do not work well on their own.  In this sense, I'm in the tradition of the 
celebrated British economist John Maynard Keynes, whose influence towers over 
the study of modern economics.  Government needs to play a role, and not just in 
rescuing the economy when the market fails and in regulating markets to prevent 
the kinds of failures we have just experienced [referring to the 2008 global 
recession].  Economies need a balance between the role of markets and the role 
of government—with important contributions by nonmarket and nongovernmental 
institutions.  In the last twenty-five years, America lost that balance, and it pushed 
its unbalanced perspective on countries around the world. (p. xii) 
 
 Friedman had originally agreed with Roosevelt’s New Deal and its Keynesian 
influence, but in the 1950’s, he became a critic of what he perceived to be its inherent 
flaws.  Friedman, including other neoclassical (another term to describe libertarians) 
economists (Stiglitz, 2010), sought to persuade decision-makers and his fellow citizens 
about the benefits of a free market unfettered by government.  However, these efforts 
were not very successful until a myriad of crises struck during the 1970s (Saul, 2005).  It 
took a series of crises, involving, war, economics, and foreign policy to send nations 
around the world into a 'vacuum' where economic policy debates heated up.  The result 
was a fundamental shift to a deterministic economic ideology (Saul, 2005) that echoed 
what Milton Friedman had been advocating, but on a global scale and involving free 
trade. 
 Saul (2005) and Bauman (1998) view the vacuum as supporting an aura of fear 
that allows for society to become more susceptible to deterministic viewpoints because 
they are framed by a discourse as the only, best, and inevitable option out of the current 
crisis:  
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Those who held power were simply too busy tinkering in an obscure specialist 
way to talk to us.  And in any case they saw themselves as too sophisticated to 
talk to us in an open, intelligent manner.  The ideologues weren't.  There were 
great differences among those who spoke up, between the intellectual and moral 
sophistication of a Hayek or the careful reflections of a Samuel Brittain as 
opposed to the rather brutal simplifications of a Milton Friedman or an ideologue 
like Robert Nozick, to take just four.  There were also great differences between 
each of the neo-liberals and among all of them as a group versus the simple free 
traders.  But what linked them all was some idea of a possible global balance that 
would be more or less natural, thanks to released market forces.  That in turn 
implied weakened governments, therefore weakened nation-states.  And what 
linked them in turn to the non-communicative technocrats in power was a shared 
utilitarianism.  (Saul, 2005, p. 63) 
 
 Neglecting any notable reflection on the failures of globalized trade in 19th 
Century Europe, there was a shift away from the 'protectionist' economic policies of the 
postwar period to policies that, it was argued, would create greater global growth 
through the globalization of the economic machine.  As it proceeded, globalization was 
intended to reduce the strength of nation-states while simultaneously promoting greater 
democracy—a global free market.   
We define globalization as the process of intensification of cross-area and cross-
border social relations between actors from very distant locations, and of growing 
transnational interdependence of economic and social activities. (Scherer and 
Palazzo, 2008, p. 415) 
 
 The first attempt at global trade occurred in Europe in the 19th century.  However, 
this attempt is perceived to have been deeply rooted in territorial imperialism (Soros, 
2000): 
But because of the way the whole thing works you can never have enough land.  
More colonies means more factories, more factories means more goods and 
more goods means that even more colonies are needed.  The demand isn’t 
driven by ambition or lust for power, but by a genuine need.  But now the world 
had been shared out.  To create new colonies—or merely to prevent the old ones 
being snatched from them by stronger neighbours—it was necessary to fight, or 
at least to threaten to do so.  So each state raised powerful armies and navies 
and kept on saying: “Attack me if you dare”!  The countries that had been 
powerful for centuries felt they had a right to be so.  (Gombrich, 1936/2008, p. 
266) 
 
 Although this form of globalization featured reliance among trading countries, the 
posturing necessary to protect colonial interests and the associated supply lines created 
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a looming aura of hostility.  This form of globalization fostered an arms race between 
countries to maintain and gain influence over colonial regions in Asia and Africa 
(Gombrich, 1936/2008).  An end came to this experiment when countries took sides 
against each other and engaged in large-scale warfare in 1914 (World War 1). 
The second incarnation of globalization began in the 1970s through the 
deliberate political decisions of hegemonic elites (Saul, 2005) as an extraterritorial form 
of imperialism (Soros, 2000).  Its implementation was made possible through earlier 
technological, social, and economic developments (Scherer & Palazzo, 2008).  
Technological advances had increased the mobility of those with the economic 
affluence to use it: 
 Integration and parcelling out, globalization and territorialisation, are 
mutually complementary processes.  More precisely, they are two sides of 
the same process: that of the world-wide redistribution of sovereignty, 
power and the freedom to act, triggered (though by no means determined 
by) the radical leap in the technology of speed. (Bauman, 1998, p. 70)  
 
 It was the intent of these elites that economics and the global free market be at 
the top of the hierarchy of societal decision-making—an economic prism to analyze and 
dictate social and political processes.  Saul (2005) and Bauman (1998) observed that 
the main assertion of globalization was that all civilizations would now be led by 
commerce, which meant perceiving everything, including social and political institutions, 
through an economic prism.  This philosophy adheres to Milton Friedman’s view that 
economics has become a science to direct civilizations.  Essentially, this is a reversal of 
Smith, who considered social and political institutions as the prism through which we 
should view economics.   
 Saul (2005, p. 15) highlights a few of the benefits that were communicated as 
inherent to such a globalist strategy: 
1) Power in global markets would be free of national interest and inhibiting 
regulations, leading to an eventual international economic balances (i.e. out grow 
the historically observed boom-bust cycle in economies); 
2) A broad economic tide of growth will happen—helping everyone including the 
poor in developed and developing worlds alike; 
3) The whole process will empower individuals to overthrow dictatorships in favour 
of democracy; and 
4) Nation-states will hold less power and this, in turn, will result in a shrivelling away 
of irresponsible nationalism, racism, and political violence. 
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Some of the proposed benefits were realized, albeit to varying degrees and fractured 
across nations.  Saul uses the example of Mexico, which, in 1994, was globally hailed 
as one of the most admirable economic successes of globalization, albeit it was short 
lived as its economy collapsed the next year.  However, many scholars question the 
motivations and economic policies that shaped globalization, and cite the multitude of 
benefits that never came to fruition and the negative consequences that resulted 
instead as evidence (Saul 2005; Bauman, 1998; Stiglitz, 2010; Soros; 2000).  As the in 
the case of Mexico in the mid 1990s, the ‘unleashing’ of market forces and the reduction 
of nation-state power resulted in economic, social, and political benefits; but the boom-
bust cycle it was intended to prevent, remained.  In addition, the combination of wealth 
and varying levels of time and spatial constraints created optimal conditions for 
economic inequality (Bauman, 1998).   
 Overall, globalization efforts led to more coercion, dominance, factionalism, and 
inequality, which degraded democracy and individual power (Saul 2005; Bauman, 1998; 
Stiglitz, 2010; Soros; 2000); violating the economic conditions of both Friedman and 
Smith: 
Globalization has given more opportunities for the extremely wealthy to make 
more money quickly.  These individuals have utilized the latest technology to 
move large sums of money around the globe extremely quickly and speculate 
ever more efficiently.  Unfortunately, the technology makes no impact on the lives 
of the world poor.  In fact, globalization is a paradox: while it is very beneficial to 
a very few, it leaves out or marginalizes two-thirds of the world’s population. 
(Bauman, 1998, p. 71) 
 
 What Bauman describes as the reality of the process of globalization, Smith had 
already warned about as a possible outcome of under-regulated free market 
competition: 
Smith assumed that the results of free market competition would be unequal.  
Some would prosper and others would not.  What one earns from one's own skill 
and hard work and cooperation with others, in other words through justice and 
fair play, is acceptable.  But inequality is a vice if it is a result of domination of 
others. (Hill, 2000 p. 115) 
 
This sentiment about human nature and how it can pervert competition is shared 
by George Soros (2000, p. 143): “Collective decision making in contemporary 
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democracies is largely a power play between competing interests.  People try to bend 
the rules to their own advantage.”  However, when scholars and intellectuals warned 
about the need to account for the human nature flaw when designing and operating 
within a free market, their credibility was questioned (Sual, 2005; Stiglitz, 2010).  
Instead, a hybrid economic concept of globalization, free markets, and a reduced role 
for government emerged in the US; referred to as market-fundamentalism by Soros 
(2000).   
 Market fundamentalism as a concept spread globally, with other nation-state 
leaders, such as the UK's Prime Minister Margaret Thatcher (1980), expressing the 
desire to 'unleash' the markets and pull back government intervention (Saul, 2005; 
Ramratten & Szenber, 2009; Stiglitz, 2010).  As a result, an economic movement began 
in the 1970s that included the purposeful weakening of governments, globally forced 
deregulation, and the lowering of corporate and high-earner taxes (Bauman, 1998; Saul, 
2005; Stiglitz, 2010).   
 Upon reflection, however, even Soros (2000), who had previously been an 
advocate for globalization, came to the realization that there were systemic problems 
associated with how globalization was actually occurring: 
Indeed, the main failing of global capitalism is that it is too one-sided: it puts too 
much emphasis on the pursuit of profit and economic success and neglects 
social and political considerations.  This is particularly true in the international 
arena. (p. 179) 
 
Stiglitz (2010) also identified the foundational flaws of an economy guided by a market-
fundamentalist ideology: 
They (market-fundamentalist ideologues) chose to pretend that Adam Smith and 
Friedrich Hayek had had the last word today on market efficiency—perhaps 
updated by some fancy mathematical models corroborating the results—but 
ignored these scholars' warnings about the need for government intervention. (p. 
274) 
 
As a result,  “the disparities are cumulative, and the disadvantages accruing to 
periphery countries resulting from membership in the global capitalist system may 
sometimes exceed the benefits” (Soros, 2000, p. 169).   
 Soros perceives the problem stemming from the flaws in the market mechanism 
and deficiencies in the non-market sector.  Saul (2005), with another perspective on the 
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matter, saw fatal flaws resulting from inadequate regulation and the lack of social policy 
integration.  Stiglitz (2010) reiterates these perceptions in his endorsement of 
Keynesian economics by promoting government intervention in the economy, and he 
adds further that the common good needs to be considered in how we create and use 
the economy.  The economic insights of all three scholars are consistent with Smith's 
desire for social and political institutions as the foundation for the construction and use 
of the economic machine.  According to Stiglitz (2010, p. 275), people shape the 
economy, which implies that it should not be used in reverse, to shape people.  He 
proposes reflection on the current recession to determine the type of society people 
want to live in, and then use that to determine how the economy should be shaped to 
achieve that society—a construct that reflects social values. 
 An important aspect of Friedman's vision of a free market is that it 'naturally' 
leads to the greater promotion and adoption of democracy; but others have disputed 
this claim (Saul, 2005; Bauman, 1998; Hill, 2000; Soros, 2000; Stiglitz, 2010).  Rather, 
the concentration of power from wealth and property creates situations where 
individuals can be dominated and/or coerced, something that Friedman actually wanted 
to avoid, and had assumed an amoral construct (i.e. the free market) would naturally 
counterbalance this tendency.   
 According to Hill (2000, p. 151), Smith's writings are cautionary: 
Note Smith's argument that a free market economy causes deterioration in social 
and intellectual skills, but does not take any steps to prevent or alleviate the 
deterioration.  Furthermore, such problems weaken democracy and the 
government's ability to protect the nation. 
 
 The result of using an economic prism to analyze and direct the functioning of 
nation-states and the rise of a global market was a displacement of the power of nations 
and individuals, shifting it instead toward the hegemonic elite, which includes 
multinational corporations (MNCs): 
The force of Globalism, through trade agreements, deregulation and privatization, 
would seriously weaken the ability of nation-states to act with any political 
independence.  The resulting power vacuum would be filled by the obvious 
modern alternative, the transnational corporation. (Saul, 2005 p. 81) 
 
 Globalization has provided MNCs great latitude and power in choosing the 
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location and legal system in which they wish to operate (Scherer & Palazzo, 2008).  For 
example, freedoms set out by treaties such as the North American Free Trade 
Agreement (NAFTA) and the World Trade Organization (WTO) have given MNCs the 
itinerant freedom to operate and impose their property rights (e.g. patents, trademarks 
etc.) in any member country (Bauman, 1998).  MNCs now have the ability to effectively 
operate in a colonial fashion, where they can easily enter markets, influence the 
regional politics and social structures, and, if necessary, coerce others through threats 
of exiting one market for another (Bauman, 1998).  This has culminated in MNCs with 
more wealth, property, and influence, along with access and infrastructure in parts of 
the world, than most nation-states (Saul, 2005).  As a result, states are increasingly 
more reliant on corporations because the same organizations or treaties (NAFTA, WTO) 
that give increased freedom to corporations, often place restrictions on the ability of 
these states to govern with regard to the common good (Moon & Vogel, 2008).  In such 
situations, corporations have the potential to become the principal moulders of the 
priorities and directions of nation-states: 
In rich and poor countries alike, albeit in different ways, MNCs often enjoy 
decisive powers to shape public policy, to encourage or bar legislative measures, 
to promote or discourage social reforms, and to influence governmental action 
including employment, the environment, and social and civil rights. (Shamir, 
2005, p.92)  
 
The political steering capacity of nation-states continues to erode as MNCs grow in their 
power and realms of influence, which in turn allows them to gain ever more political and 
social power.  
 MNCs have the potential to create high levels of competition and drive economic 
growth and innovation—a situation that has occurred—but the virtually unfettered 
growth of these large entities has resulted in increasingly more effective obstacles to 
competition.  For example, Saul (2005), Bauman (1998), Soros (2000), and Stiglitz 
(2010) claim that corporate mergers and acquisitions represent, for the most part, 
attempts to gain power and market size, which in turn lowers the level of competition.  
With the decline of unhindered (healthy) competition, the perfection necessary for 
Friedman's theory of the free market, in fact, creates situations of inequality, coercion, 
and domination. 
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 The intention is not to suggest that MNCs are purely negative forces in the global 
market; they do play a vital role in economies through such functions as innovation, 
employment, and taxes.  However, if the economy is amoral, then those who use it in 
their own self-interest must still account for the common good, including governments 
that must ensure there is strong element of justice (typically through proper regulation, 
taxation, and public services).   
 As globalization progressed from the 1970s to the present and nation-state 
powers weakened without the anticipated increase in democracy, emerging market (a 
crude term used to describe developing markets that are becoming more globally 
competitive) countries such as China, India, and Brazil deviated somewhat from the 
circulating free market strategy.  They cherry-picked those free market and globalization 
strategies they perceived as best for themselves, and mixed them with internally 
focused strategies to strengthen their power as nation-states (Saul, 2005)—a free-
market/nationalism hybrid strategy.  Saul and Stiglitz observe that these countries use a 
quality of life lens as a measure of success, rather than the purely economic prism 
(associated with gross domestic product (GDP)) used by the Western economies.  
Emerging market governments use increased regulations and other forms of control to 
ensure that they are not sacrificing their potential for growth by reducing their power as 
nation-states.  Although some of these nations have questionable human rights policies, 
their economic strategies are more aligned with the theories of Adam Smith.  By 
extension, they also conflict with Friedman's claims of the free market's ability to 
determine a democratic path.   
 Nearing the end of the 20th century, the cracks or failures in contrast to the 
proposed benefits of globalization were becoming more widely recognized: 
In such an atmosphere, it was only a matter of time before citizens and their 
governments rediscover that they were far stronger than large corporations.  
They are stronger because they can shape events by creating policy through 
choice, as opposed to the transnational corporation, which accumulates power by 
reducing choice. (Saul, 2005 p. 143) 
 
 While Saul (2005) is more circumspect, Fabig and Boele (1999) suggest that the 
exponential growth in non-governmental organizations (NGO) in the late 20th century 
was tied directly to the effects of globalization.  In general, the intended purpose of a 
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NGO is to coordinate the lobbying or to advocate on behalf of a 'cause' for the 
individuals or groups they represent, usually by pressuring businesses and/or 
governments for a response.  'Causes' can include any issue that is perceived as 
important, including, for example, broader categories such as environmental, health, 
economic, and social.  NGOs attempt to apply pressure and create accountability in 
order to influence changes in actions and behaviours that they perceive as negatively 
affecting or not living up to their potential to help their associated cause (Heering & 
Zeldenrust, 1995).  The pressures and calls for accountability that NGOs amplify and 
use are perceived by some as one of the driving forces in the corporate social 
responsibility (CSR) agenda (Fabig & Boele, 1999; Seitanidi & Crane, 2009; Wadham, 
2009).   
 
1.2 History of Corporate Social Responsibility  
 CSR has been researched for over twenty years, with discussions surrounding 
the social responsibilities of corporations dating back to the 1950s (De Bakker, 
Groenewegan, & Den Hond, 2005).  Furthermore, business philanthropy has dated 
back centuries with donations to the arts, as well as other educational and religious 
institutions (Wren, 2005 cited in Carrol, 2008).  It is likely that notions of CSR and 
business responsibilities to society have been continuously discussed since the 
beginning of commercial and corporate life.  For example, in Ancient Greece, Aristotle 
philosophized about businesses being tied to society; consequently, they have an 
inherent obligation to contribute to the common good (Mele, 2008).  There is little 
agreement, however, as to the exact factors and processes that have contributed to the 
development of CSR because of its normative foundations and development as a social 
construct.   
 The following definition of CSR aligns with notions of an integrated relationship 
among business, government, and the common good that a philosopher such as 
Aristotle and economists such as Adam Smith (also regarded as a philosopher), Joseph 
Stiglitz, and George Soros advocated: 
 CSR blends and harmonizes economic operations with human community’s 
social systems and institutions, creating an organic linkage between business 
and society.  The end goal of this relationship is to achieve a balance between 
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the firm’s economic operations and the society’s aspirations and requirements for 
community welfare. (Frederick, 2008, p. 523) 
 
 It appears that a diverse range of CSR actions by businesses that can be 
perceived as somewhat relating to that definition began to occur during the Industrial 
Revolution.  Reformers criticized the factory system, developed during the Industrial 
Revolution, as a main factor in “numerous social problems, including labour unrest, 
poverty, slums, and child and female labour” (Wren, 2005 cited in Carrol, 2008, p. 21).  
Welfare schemes, including bathhouses, profit sharing, and recreational facilities for 
workers are examples of CSR activities carried out by businesses at this time (Wren, 
2005 cited in Carrol, 2008).  According to Carrol (2008), these CSR activities reflected 
an actual concern of these businesses for the well-being of their employees, as well as 
an attempt to increase the production of employees.  The period of expansion of CSR 
during the Industrial Revolution is referred to as the ‘philanthropic’ era (Murphy, 1978 
cited in Carrol, 2008), and continued until the 1950s. 
 CSR, as a distinct concept of expanded business responsibilities, first gained 
broad awareness between the late 1950s and the mid-1960s.  Awareness increased in 
response to societal concerns in Western nations as a response to a perceived lack of 
corporate ethics pertaining to a number of issues, including labour practices, bribery 
and the inability to raise aid for the economically deprived.  This period is referred to as 
the ‘awareness’ era, with corporations pushed to recognize and be accountable for their 
role within society (Murphy, 1978 cited in Carrol, 2008).  Despite growing external 
expectations, discussions and actions about the social conscience or role of a 
corporation were rare within corporate boardrooms, and it was not until the ‘issues’ era 
(1968-73) that Murphy (1978) believes corporations began to focus on socio-political 
issues such as urban decay, environmental problems, and racial discrimination.   
 Since the 1970s, and continuing to the present, “society’s expectations of 
business ethics have been rising” (Lantos, 2001, p. 598).  The ‘responsiveness’ era, 
which reportedly began in 1974 and continued until the 1980s, is supposedly when 
corporations began to make the necessary internal changes needed to respond to CSR 
related issues.  Murphy (1978) and Carrol, (2008) describe these changes as including 
the alteration of managerial and board structures, expanding of corporate ethics, and 
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emergence of social reporting.   
 A different explanation of the emergence and evolution of CSR perspectives and 
engagement is offered by Frederick (2008), who defines the periods of the 1950s-1960s 
as CSR1: corporate social stewardship and the 1960s-1970s as CSR2: corporate social 
responsiveness.  Although the dates are slightly different than the ‘eras’ described by 
Murphy (1978), the overall description and focus are similar.  Frederick extends the 
analysis by including two additional CSR phases: CSR3: corporate/business ethics 
(1980s-1990s) and CSR4: corporate global citizenship (1990s-2000s).  The CSR phase 
of corporate/business ethics focuses on creating a strong business climate for the 
spread and expansion of ethics.  As such, this requires corporations to integrate new 
ethical considerations into the values, beliefs, and culture of the corporation, resulting in 
a normative focused environment. 
The fundamental shift in the corporate mindset that Murphy and Carrol describe 
seems rather optimistic.  After examining the history of economic theory, globalization, 
and multinational corporations, it is doubtful that many companies adopted the 
supposed widespread CSR actions, other than basic philanthropy.  Why would there be 
such a substantial push for CSR by societal forces if they had already been adequately 
addressed?  As a result, these periods of CSR 'engagement' may be better understood 
as changes in the social and political climate.   
 Overall, there is variation in the descriptions of the development of CSR.  
Frederick (2008) explained the variation thus: “individual firms may be positioned at 
different points on the phased trend line” (Frederick, 2008, p. 524).  Additionally, not 
every corporation can proceed through each phase completely or at the same pace, 
and, most likely, at any point corporations might simultaneously represent the focus of 
multiple phases.  Fredrick’s depiction of the modern history of CSR appears to be 
linear.  It is unlikely, however, that the path of CSR for every company would be linear.  
Instead, companies might jump ahead or backwards, skipping trends or even progress 
their CSR strategies along a tangent, straying from those suggested.  A non-linear 
progression of CSR is more consistent with its constantly evolving, normative nature.   
Notably, Frederick’s ‘four stages of CSR’ is specifically derived from the 
development of CSR within the US, while Murphy’s framework, as described by Carrol, 
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was based on both the USA and Europe.  The historical contexts, social norms, etc. of 
each country would have contributed to the development of CSR, creating differences.   
 Most notably, some scholars observe that there is still “strikingly little unanimity 
concerning the actual evolution of this field” (De Bakker et al., 2005, p. 284).  One area 
of agreement is that the concepts comprising CSR among corporations are more than 
just aspects of a temporary business strategy: 
Corporate social responsibility (CSR) has emerged as a global trend 
incorporating business corporations, states, international organizations, and civil 
society organizations. (Sahlin-Andersson, 2006, p. 595) 
 
 In a study carried out by the Society for Human Resource Management (2007 
cited in Fox, 2007) of 431 human resource (HR) professionals, 91 percent indicated 
their company engaged in some form of CSR, and the majority of CSR was in the form 
of volunteer work and donations (philanthropic programs).  Additionally, a recent 
European study found that 73 percent of consumers think that it is a positive attribute for 
corporations to report on their CSR activities (Benett et al., 2009).  In a small number of 
European countries, governments have created regulations to mandate corporate social 
reporting: 
Several governments have sought to promote global CSR by requiring firms to 
report on their social and environmental policies and practices.  Various kinds of 
corporate disclosure requirements have been adopted by Denmark, Germany, 
Finland, France, and Sweden, while the British have issued voluntary guidelines 
on corporate social reporting. (Moon and Vogel, 2008, p. 316) 
 
However, the substance and authenticity of reporting and soft regulation of CSR 
seems to be more of a symbolic step to try to get companies to better address societal 
and political concerns and expectations.  Additionally, simple surveys may be overly 
superficial and subject to respondents giving answers that are perceived to be 'right'.    
Regardless of perceptions of authenticity, it is proposed that CSR is transforming 
the boundaries and relations among business, states, and civil society (Sahlin-
Andersson, 2006) by changing fundamental practices, such that in the future it may be 
necessary to engage in CSR simply to remain competitive (Googins et al., 2007; 
Bennett et al., 2009).  For instance, Sahlin-Andersson (2006) examined the similarities 
of the current CSR trend with previous managerial trends and found there were many 
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commonalities.  The definition of a managerial trend is “they are adopted by 
organizations as a means of appearing legitimate, modern and attractive for potential 
employees, collaborators, customers and others” (Sahlin-Andersson, 2006, p. 603).  In 
accordance with this definition, CSR can be considered a new managerial trend 
because it could be considered a response to social and political forces. 
 
1.3 Pharmaceutical Industry Background – Growth, Prominence, and 
Regulation 
 
 Medicinal products, drugs, or pharmaceuticals, have been developed and 
distributed for thousands of years.  The modern pharmaceutical industry is a clear 
evolution of the discovery, identification, development, and distribution of medicines as 
individuals and companies have adapted to emerging cultural, technological, and 
environmental changes, influences, and opportunities (Dukes, 2006).   
From its original function purely as manufacturer and provider of medicines, the 
pharmaceutical industry has diversified into a wide range of associated activities.  
It has come to function among other things as an innovator, a provider of 
information and even education, a major employer and a significant player in the 
world economy. (Dukes, 2006, p. 10) 
 
 There are two main types of pharmaceutical companies: research-based, or 
brand name, and generic manufacturers.  Brand name manufacturers are the more 
traditional of the two and focus on “innovation programs concentrating on the creation, 
identification, development and marketing of entirely new medicines” (Dukes, 2006, p. 
11).  Historically, the majority of these processes take place in-house or exclusively at 
brand name companies.  However, aspects of these processes routinely occur in 
separate organizations and environments such as academia where a number of 
discoveries are made and then the property rights are frequently acquired by companies 
(Dukes, 2006).  Products developed by brand-name companies are patented, which 
typically provides market-exclusivity for 20 years. 
 Generic companies produce and sell off-patent drugs.  Importantly, the generic 
versions of brand name drugs must be shown to be bio-equivalent and equally safe: 
“Generics are rigorously tested by the FDA and must prove that they are the same 
medicine with the same active ingredient, strength and dosage as their brand-name 
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counterpart” (Canadian Generic Pharmaceutical Association, 2011).  Generic drugs are 
priced at a fraction of their brand-name counterpart due primarily to significantly lower 
development costs.  
The development of both types of pharmaceutical company emerged from 
periods of heavy regulation, the definition of property rights relating to pharmaceutical 
innovations, and a competitive environment that has grown, and is fuelled by, a dual 
role in healthcare and for-profit business.   
 There have been various levels and types of regulation regarding the creation 
and distribution of pharmaceutical-related products since the Roman times, right up 
through the Middle Ages, and into the 20th century (Dukes, 2006).  The combination of 
charlatans, apothecaries, and the rising synthetic chemical industry led to greater 
awareness of the requirement to evaluate and regulate existing and new medicines to 
ensure they are safe for consumption (Dukes, 2006).   
 After World War 2 (WW2), there was an explosion of pharmaceutical innovation, 
a period described as the 'golden age' (Chetley, 1990; Agrawal; 1999).  However, 
without the proper regulation and evaluation of medicines, there was also an increase in 
adverse events.  As additional cases of health disasters resulted from toxic reactions to 
medicines that were either completely avoided or improperly evaluated, regulatory 
bodies were created in Europe and North America in the 1960-70s (Agrawal, 1999).  
The tipping point that created nearly universal agreement about the lack of 
understanding of how medicines operate and the requirement of proper regulation was 
the thalidomide disaster in the 1960s (Dukes, 2006; Chetley, 1990; Agrawal; 1999).   
While the major concern at the time was with the means of ensuring the safety of 
new medicines, there was parallel concern regarding their efficacy, the quality of 
their production and the truthfulness and completeness of the information 
provided on them.  On all these matters, instances had been documented on 
serious shortcomings, and the progressive rise of the clinical pharmacology had 
shown how necessary it as to examine drugs systematically in human subjects if 
their effects were to be properly defined. (Dukes, 2006, p. 107) 
 
After the golden age of pharmaceutical innovation, the decades of the 1960s and the 
1970s were a time of substantial regulatory growth (Dukes, 2006; Chetley, 1990; 
Agrawal, 1999).   
 Dukes (2006) provides three categories that represent a nation's comprehensive 
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approach to evaluating medicinal products’ production and distribution: 1) national drug 
policy; 2) laws; and 3) regulations.  National drug policy serves as the guiding 
foundation for the medicinal-related laws and regulations.  Laws are used to formulate 
the “structures and procedures necessary to assess and license medicines, and deals 
with some closely related issues (such as advertising, adverse reactions and clinical 
research” (p. 109).  Finally, regulations are the detailed network of rules that are used to 
operationalize such laws. 
 Interestingly, Dukes' description of the laws and regulations that govern 
pharmaceuticals included how companies market and sell their products to the public.  
The following explains the rationale for these regulations: 
Few consumers have sufficient technical or medical background to make rational 
and informed choices about therapeutic goods...For this reason, the selling of 
pharmaceuticals is restricted to protect consumers from possible health risks and 
deception.  (Australia Trade Practices Commission, 1992, p. 19) 
 
 Conflicts of interest, and therefore health risks, that may arise from for-profit 
companies being involved in healthcare has likely contributed to further regulations 
beyond the medical effects of products: 
There is an implicit assumption, readily confirmed through experience, that on 
occasion a manufacturer will for commercial reasons wish to maintain or 
introduce a product which is from the public health point of view defective in 
terms of its efficacy, safety or quality, and that in such situations, the authorities 
must be capable of arresting the process until or unless the defect is remedied. 
(Dukes, 2006, p. 113) 
 
 As explained in preceding sections, there have been both positive and negative 
results from the process of globalization, and the pharmaceutical industry has been 
subject to and a force in both.  However, the negative consequences explain why there 
is such a high level of laws and regulations governing the actions and products of the 
pharmaceutical industry.  Furthermore, inequality in the wealth and development of 
nations results in fragmented and/or inadequate laws and regulations and the 
capabilities to enforce them in lesser-developed nations:  
Currently about 20% of countries have well-developed and operational medicines 
regulation.  Of the rest, approximately half have regulation of varying capacity 
and level of development, and 30% have either no or very limited medicines 
regulation.  The reality is that many low-income countries cannot ensure the 
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safety, efficacy, and quality of medicines circulating on their markets.  The 
problems of ineffective regulation transcend national borders and have global 
implications.  Smuggling of medicines is widespread.  Even manufacturers who 
fail to comply with good manufacturing practice (GMP) requirements can still 
produce medicines for domestic use and for export.  Often controls on exported 
medicines are less stringent than for those used domestically.  (WHO, 2004) 
 
Conversely, continuing differences in regulations across all countries are perceived, by 
some, to be causing disadvantages because of varying times of drug availability across 
countries (Agrawal, 1999). 
 Countries are commonly categorized as either developed or developing based on 
subjective and objective assessments of levels of freedom, health, and economic well-
being.  Kofi Annan, former Secretary-General of the United Nations (UN), states:  
A developed country is one that allows all its citizens to enjoy a free and healthy 
life in a safe environment.  And a genuinely developing country is one in which 
civil society is able to insist, not only on material wellbeing, but on improving 
standards of human rights and environmental protection as well. (United Nations 
Information Services, Press Release No. G/05/2000) 
 
 Furthermore, the UN elaborates the reasoning for their classification of 
developed and developing countries: 
There is no established convention for the designation of "developed" and 
"developing" countries or areas in the United Nations system.  In common 
practice, Japan in Asia, Canada and the United States in northern America, 
Australia and New Zealand in Oceania, and Europe are considered "developed" 
regions or areas. In international trade statistics, the Southern African Customs 
Union is also treated as a developed region and Israel as a developed country; 
countries emerging from the former Yugoslavia are treated as developing 
countries; and countries of Eastern Europe and of the Commonwealth of 
Independent States (code 172) in Europe are not included under either 
developed or developing regions. (United Nations, 2010) 
 
 The differences in regulations among countries with similar and differing levels of 
development are a result of country-specific regulation—a process in which countries 
design their national drug policy and its laws and regulations based on their resources, 
capabilities, and the varying interests and influences within their socio-political context 
(Puig-Junoy, 2005).  
 Although Smith and Friedman would agree, albeit to varying degrees, that 
regulation of the pharmaceutical industry is necessary, the levels of regulation created 
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in the 1960s-1970s became widely regarded as too much—an over compensation for 
the preceding crises (Dukes, 2006; Agrawal, 1999).  There was some deregulation in 
the following decades, but the industry remains one of the most heavily regulated 
industries globally.  
  The level of regulation of the industry is a heavily debated topic, with many 
representatives from the pharmaceutical industry and their affiliated associations 
claiming that the high level of regulation stifles innovation and, therefore, should be 
reduced.  However, a 2004 study by the Charles River Group for the European Union 
found that the 45 years of innovative growth coincided with both increases and 
decreases in the level of regulation.  However, they did suggest that serious challenges 
to develop therapies for complex diseases such as HIV/AIDS, and new criteria that 
more strictly define what can be considered a new drug, could be affecting innovation 
levels.  
Pharmaceuticals that have gone through the entire creation and 
commercialization process are generally patented for both the product and the 
production processes involved in its manufacturing, and sometimes also the delivery 
process.  Patents provide exclusive production and selling rights to the owner and, 
typically, they last for a period of 20 years (Dukes, 2006).  The four stages of 
development in gaining approval for a patented drug or product can take over 50 
percent of the 20 years.  As a result, a successfully patented and approved product has 
a relatively short period to earn back research and development (R&D) costs and to 
provide a return to shareholders (profits): “During this time the price can be maintained 
at whatever level its originator has chosen” (Dukes, 2006, p. 11).    
 The monopolistic protections granted by patents are a contested issue.  
According to some, including many governing bodies, the industry, and their affiliate 
associations, patents are necessary because exclusive rights allow these companies to 
conduct business in a profitable manner.  Their view is that such protections are 
necessary if companies are to justify the substantial investments in R&D that are 
necessary to fund the production and development of a drug (Dukes, 2006; Goozner, 
2004).  Furthermore, it is argued that the industry must have this assurance or the result 
of losses is that society will suffer because necessary medications will not be produced 
 
 
26 
and new discoveries may be prevented.   
Most industries view research and development as something they must do to 
stay one step ahead of the competition, just as they must reduce the cost of 
production to maintain profit margins.  If they fail to innovate, they risk 
obsolescence and decline.  “If we don't spend our money on research and 
development, we will die”, I've heard more than one chief executive officer say to 
stockholders at an annual meeting.  The drug industry stood this corporate 
mantra on its head.  “If we don't get your money to spend on research and 
development, you'll die.” (Goozner, 2004, p. 7) 
 
 Monopolies and oligopolies, demonized by Smith and Friedman, are viewed in 
today’s business environment as acceptable in certain circumstances.  Those 
advocating for the patents that create monopolies would argue that it is in the public 
interest (common good) that these companies are granted special protections as an 
incentive to continue to develop innovative pharmaceutical products.  Conversely, 
others believe (e.g. Smith, Friedman, Stiglitz) that if monopolies are allowed to exist, 
then the process that creates the optimal price equilibrium is disrupted because 
competition has been artificially reduced.  Consequently, such monopolies result in 
abnormally high prices for the goods they produce and sell—a situation that exists in the 
pharmaceutical industry and creates substantial social and political controversy 
(Agrawal, 1999; Chetley, 1990; Dukes, 2006; Hawthorne, 2003; Kolassa, 1997; Puig-
Junoy, 2005). 
 One group contesting the pricing power of monopolistic patents are the generic 
manufacturers.  As described earlier, there is a lower cost attributed to the 
manufacturing of generic drugs, in part, because not only are R&D costs lower but they 
also do not tend to widely advertise or promote their products in comparison to brand 
name companies (Dukes, 2006).  As a result of the reduced costs, generic companies 
can price their drugs at a significantly lower amount, approximately 30-80% less than 
those that are still protected by patents (Generics Pharmaceutical Association, 2011), 
while achieving similar returns-on-investment (ROI). 
 The variety of topics discussed in this section will serve as the foundation for the 
critical analysis of the industry and its perceived societal role has become very 
controversial and how society is reacting by pushing the industry to engage in more 
CSR-type activities.  For example, companies with an overt link to the common good 
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(e.g. discovery, production and distribution of medicinal pharmaceuticals) engaging in 
self-serving behaviours that were normalized by the dominating discourse of market-
fundamentalism (Saul, 2005): 
The profit motive can be used as an incentive to bring about desirable social 
outcomes, such as full employment, affordable medicine, or a healthy 
environment, but if the rules that govern industries such as healthcare are 
allowed to be driven by profit, some undesirable social consequences are bound 
to follow. (p. 151) 
 
1.4 Summary 
In the review of the relevant literature, a historical context was provided to create 
understanding about the more influential theories that have contributed to, and 
influenced the construction of, the current economic and business environments.  Most 
notably, Adam Smith in 1776 presented his theoretical insights into how economic 
policy should be created and used.  The acknowledgement of his contribution to modern 
economic theory has resulted in Smith being widely considered the 'father of modern 
economics'.  Although it has been misinterpreted as an amoral approach to self-
interested or individualistic economics, Smith's economic opus was more rooted in 
moral philosophy.  Adam Smith theorized that the economic machine could function 
effectively and with egalitarian side effects if everyone operated in their own self-
interest; however, he perceived many moral-based elements being required for this 
optimal situation to occur.  For instance, government has a difficult role because it must 
ensure justice exists within the market using proper regulations and taxation while not 
impinging on the freedom of individuals.  Additionally, individuals and companies alike 
can operate in their own self-interest, but they must do so with respect to the common 
good.  The important roles of political protection and the common good are central to 
Smith's theory that the economic machine should be built on a foundation of strong 
social and political institutions.   
However, from the beginning, Smith’s theories have been continually 
misinterpreted and/or selectively used by economists, politicians, and others.  Most 
economists, to isolate one group, are trying to create their own preferred version of 
capitalism, how it forms and uses markets and relates to social and political institutions.  
They apply interpretations of theories, historical events, and their experiences to varying 
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degrees to transform or build on what they perceive is the optimal scenario for the use 
of the economic machine.  Should the economic machine be used merely as a tool?  
Alternatively, should it shape how we interact and govern?  Should its principles be 
omnipresent in every aspect of human life?  Can it be used to measure or dictate 
happiness?  The moral components, for the most part, have tended to be ignored and 
sometimes replaced with an almost fundamentalist promotion of individualistic economic 
actions tied to the concept of individual freedom in the current business environment.   
Countries first engaged in globalized economic activities in Europe in the late 19th 
century.  Although it was an attempt to move away from mercantilism to having more 
integrated and therefore interdependent economic relationship across countries, the 
experiment failed with the onset of WW1.  It was not until the compounding economic, 
social, and political controversies of the 1970s that globalization was attempted again, 
but with what seemed to be little reflection on its 19th century failures.  Again, it was 
shaped by the hegemonic elites, but this time it appeared as a form of extraterritorial 
imperialism (Soros, 2000) guided by a deterministic discourse that was heavily 
influenced by a market-fundamentalist ideology (Saul, 2005).  An ideology featuring 
gross misinterpretations of Smith's self-interest and invisible hand theories being 
attached to a scientific use of economic policy and the ‘free market’ to develop and 
shape all other policy, including social and political.  Even Milton Friedman, who 
espoused a simplistic view of perfection in the market, would likely not agree with how 
globalization contributed to the normalization of anti-competitive practices and gross 
inequality.  The startling problem of the deterministic discourse was that it blindly follows 
one path until consequences emerge, then those guided by it ask why no one 
challenged their ideas.  However, it is difficult to challenge a deterministic discourse, in 
this case an economic paradigm, when one would be instantly considered not credible 
for doing so in the first place (Stiglitz, 2010).   
Associated with the rise of globalization is the growth of the multinational 
corporation (MNC).  As markets opened up and became more integrated, companies 
found ways to use the resulting opportunities to exponentially grow in size and 
influence.  As nation-state power decreased, the power vacuum was partially filled by 
MNCs.  However, a missing element of many MNCs’ business practices could be 
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associated with the normalization of self-interested behaviours that appear to disregard 
substantial parts of Smith's desire for the consideration of the common good.  It is not to 
say that what companies did, and continue to do, in their own self-interest is wrong, but 
social and political groups indicate a growing desire for MNCs to adopt additional 
responsibilities to compensate for their new scope of influence and the perceived 
negative effects of their actions and behaviours.  Out of these 'responsibilities' emerges 
the growing field of CSR, which has become a common aspect of business strategy. 
  While the discussions about various explicit and implicit social responsibilities 
that businesses should address have been discussed since the beginning of 
commercial enterprise, its formation as a construct termed CSR has only recently 
developed over the last fifteen to twenty years.  This rapid expansion, along with the 
involvement of many stakeholders (scholars, NGOs, governments etc.), has resulted in 
the notions constructing CSR being pulled in many normative-based directions.  
Regardless of the directions that CSR has and is being shaped, it has become a 
prominent and potentially transformative socio/cultural and economic force.  Rising 
expectations for greater accountability by both business and governments displays how 
global society’s awareness of the negative repercussions created by globalization is 
shaping, in part, the social construction of CSR as mechanism to harmonize the 
societal/business relationship.  However, since it has been theorized that engaging in 
CSR activities may become a requirement to remain competitive in the future (Googins 
et al., 2007; Bennett et al., 2009), it can be assumed that business would also have an 
interest in how the evolving construct develops, including its applications.   
The pharmaceutical industry has gone through substantial growth and 
development during the 20th century.  It went from being based on inexact science that 
was virtually unregulated and, consequently, featured numerous charlatans and 
sometimes-disastrous health outcomes to a heavily regulated global industry that 
generates substantial profits and is protected by monopolistic property rights (patents).  
Throughout this period, the overall health benefits created by innovative medicines have 
been unquestionably enormous.  However, controversies regarding the actions and 
behaviours of companies within the industry have called into question how it manages 
the potential for conflicts of interest that can arise when companies are involved in for-
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profit healthcare.  Continuing and new controversies batter the industry’s already poor 
reputation and, consequently, has resulted in a growing push for greater transparency 
and accountability by pharmaceutical companies. 
The industry’s explicit link to societal interests (healthcare), composition of mostly 
MNCs, and its affiliation with and role in continuing controversies that plague its 
reputation makes it an optimal environment to examine how and why it is or is not 
engaging in CSR strategies.  What has remained unclear is what motivates 
pharmaceutical companies to engage in CSR and what role has external pressures 
played in shaping those same motivations and CSR engagements.  As a result, it is 
important to understand from the perspective of those within the pharmaceutical 
industry as to why and how they engage in CSR. 
 
1.5  Purpose of Study and Research Questions 
 The purpose of my study is to examine CSR within the pharmaceutical industry; 
specifically, to fill the gap in the literature regarding the industry’s perceptions of the 
topic.  To achieve this goal, the following research questions were proposed: 
1) Why do pharmaceutical companies engage in CSR? 
2) How do pharmaceutical companies engage in CSR? 
 
1.6  Research Process 
 Research to examine CSR within the pharmaceutical industry was conducted 
over the last three years using qualitative methods and a conceptual framework 
developed for the project.  Executives and/or managers in the pharmaceutical industry 
with intimate knowledge of their CSR programs were recruited for the study.  Semi-
structured interviews were conducted with those executives/managers agreeing to 
participate.  Collected data was coded, categorized, constantly compared, and further 
analysed in memos and diagrams.   
The research findings will be disseminated through summary reports to the 
participants and the pharmaceutical companies they represent, as well as through 
conferences and peer-reviewed publications. 
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1.7  Organization of Thesis 
 The thesis begins with a literature review of CSR in general, followed by the 
literature specific to the pharmaceutical industry in the US and Canada (Chapter 2).  
The methodological framework and methods used in the research are presented in 
Chapter 3.  Chapter 4 focuses on the results that comprise the substantive theory.  The 
final chapter (5) is an in-depth discussion of the constructed theory, including its 
implications, verification, and how it is enhanced and modified by institutional theory. 
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2.  Literature Review 
2.1 Outline 
The literature surrounding CSR is extensive, and scholars have developed a 
substantial number of concepts, theories, and perspectives that attempt to explain CSR 
and its development and emergence as a global business trend.  There follows an 
explanation of the difficulties associated with defining CSR, the theories that attempt to 
explain it, and its emergence as a global business trend. 
An examination of current CSR consists of perceived responsibilities of CSR and 
how these are associated with various types of CSR practices, the drivers and 
motivators that influence decisions to engage in such practices, and the underlying 
relationship between business and society that is being increasingly emphasized.  To 
illustrate the relationship between these components, a conceptual model of the CSR 
decision-making process is presented.  The general examination of CSR finishes with 
two sections.  The first pertains to the functioning of organizations within the business 
environment and how factors such as history, leadership, and values influence decision-
making.  The second details the current CSR environment in Canada and the USA.  
After reviewing how CSR has developed and operates within the current 
business environment, CSR within the industry is examined to construct an 
understanding of the industry’s self-proclaimed dual role, and the societal expectations 
that result.    
The final two sections of this chapter detail the possible reasons that the industry 
should engage in CSR and the strategies for it to be comprehensive.  In the final 
summary of the literature review, observed connections between CSR and the 
pharmaceutical industry are discussed and, consequently, the gaps within the literature 
are then identified.  
 
2.2 Corporate Social Responsibility (CSR) in the Modern Business 
Environment 
 
2.2.1 Defining CSR 
 Defining CSR is challenging, as there are many, sometimes conflicting definitions 
that attempt to explain its governing concept(s) using normative social constructions 
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that can vary across cultures, regions, etc.  One such governing concept is reflected in 
the following reasoning for CSR: “Economic organizations such as corporations are 
responsible to their shareholders, employees, and stakeholders” (Oketch, 2005, p. 31).  
This reasoning supports the argument that corporations should no longer prioritize 
maximizing profits and shareholder value because they have responsibilities to other 
groups as well.  Instead, it promotes the expansion of responsibilities to include a 
variety of stakeholders (Campbell, 2006; Bennett, Gobhai, O’Reilly, & Welch, G., 2009; 
Googins, Mirvis, & Rochlin, 2007; Frederick, 2008).   
 There are many viewpoints, however, as to whom or what constitutes a 
stakeholder and whether or not they should even be considered in the decisions of the 
corporation.  Furthermore, there are also many potential stakeholders, including 
individuals and groups in the workplace (employees), the marketplace (customers, 
suppliers), government, and the community; as well as non-governmental organizations 
with very specific interests such as the environment, ethics and human rights (Moir, 
2001).   
 The idea of addressing any perceived responsibilities to stakeholder(s) other than 
shareholders by engaging in CSR-type activities is viewed by some as a violation of 
free-market principles.  For instance, Milton Friedman (1970) wrote an opinion piece in 
the New York Times that focused on debunking the validity of companies engaging in 
anything other than strategies that will increase their profits.  He attributed CSR to 
socialism, and therefore deemed it undemocratic and against the basic tenets of true 
freedom: 
This is the basic reason why the doctrine of “social responsibility” involves the 
acceptance of the socialist view that political mechanisms, not market 
mechanisms, are the appropriate way to determine the allocation of scarce 
resources to alternative uses. (Friedman, 1970) 
 
 According to Friedman, businesses and markets are amoral, and as a result 
should not venture into what he considered social policy.  He surmises that issues of 
morality should be dealt with in the political realm.  As far as the market and businesses 
are concerned, as long as everyone is operating in their own best interest, free of 
coercion, and with access to full information, the benefits will balance.  CSR imposes an 
additional tax and constrains the freedom of corporations.  CEOs that engage in CSR 
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are effectively stealing from the shareholders.  Overall, Friedman believed that under 
perfect market conditions, competitive practices to increase profits were the singular 
social responsibility of corporations. 
 However, others argue that, “the amorality of markets makes it all the more 
important that social values find expression in the rules that govern markets” (Soros, 
2000, p. 142).  The purpose of CSR must be, in part, a response to the gaps or the 
absence of social values in those rules because, “rules are made by the authorities, but 
in democracies the authorities are chosen and influenced by the players” (Soros, 2000, 
p. 142).  Improper influence over the social values that govern the rules of the market 
may have contributed to situations where exploitation, abuse, and/or coercion are 
possible.  Soros (2000) finds that the contrast between market values and social values 
is that the former is based on competition and winning, while the latter is about “doing 
the right thing, win or lose” (p. 155), and “if the profit motive is allowed to dominate the 
political arena, society is deprived of any moral basis” (p.157).  
 Examining Friedman's theoretical perspective of the perfect market in 
comparison to those operating in reality, it becomes apparent that it has substantial 
flaws because it hinges on concepts of perfection, which appears to be unattainable 
due to the faults in human nature.  As Soros (2000, p. 145) explains the underlying 
reasoning for such positioning: 
Yet the market-fundamentalist ideology has managed to establish perfection as 
the standard.  It claims that markets are perfect in the sense that they tend 
toward equilibrium or at least correct their own excesses; we should therefore 
rely on the market in our political decisions to the greatest possible extent and 
measure the performance of politics against market performance. 
 
Overall, any failure to create and sustain anything but what can be considered perfect or 
near-perfect market conditions will result in imbalances.   
Externalities, agency problems/costs, and imperfect information (Stiglitz, 2010) 
represent examples of market failures that put into doubt the existence of conditions for 
the perfect market.  Externalities are costs or benefits that affect those that were not 
part of a transaction (e.g. pollution from cars).  Also known as external costs or benefits 
(Frynas, 2009), individuals and businesses alike can either unintentionally or 
intentionally engage in activities that affect parties not directly engaged in the business 
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exchange.  
 When shareholders hire people to run their company, those specific employees 
(executives) become their agents.  One example of an agency problem/costs is when 
inflated and/or improper incentives (e.g. profit-based pay) entice agents to search for 
short-term benefits while disregarding the long-term consequences.  An example of 
such agency problems was the actions of the CEOs and other executives at WorldCom 
and Enron.  These executives instituted the use of a mix of creative and illegal 
accounting practices to produce short-term gains, but, in doing so, caused colossal 
long-term damage when these practices were discovered and the companies eventually 
went bankrupt as a result.  The rippling effects resulted in social and economic damage 
to many people directly involved with company operations as well as the many people 
affected by the loss of their pensions or other moneys invested in the stock market.   
 A perfect market also assumes that everyone has equal access to complete 
information about the scare resources being allocated in the market, or at least if the 
market is slightly less than perfect, then the same applies to information.  Stiglitz (2010) 
found that the latter part of this statement—the focus of which garnered him the Nobel 
Prize in economics—is unrealistic and even a small amount of imperfection in the 
market can lead to substantial information asymmetry. 
 The compilation of the existence of, and potential for, such examples of market 
failure show, according to Stiglitz, Saul, and Soros, among others, that the assumption 
of markets operating under perfect conditions are naturally self-correcting in the face of 
adverse events (e.g. the current recession) is not realistic.  Stiglitz (2010, p. 281), using 
the financial sector as an example, describes what he perceives as the consequences 
for societal-wellbeing by the adoption of market-fundamentalism: 
Economics, unintentionally provided sustenance to this lack of moral 
responsibility.  A naive reading of Adam Smith might have suggested that he had 
relieved market participants from having to think about issues of morality.  After 
all, if the pursuit of self-interest leads, as if by an invisible hand, to societal-
wellbeing, all that one has to do – all that one should do – is be sure to follow 
one's self-interest.  And those in the financial sector seemingly did that. But 
clearly, the pursuit of self-interest – greed – did not lead to societal well-being, 
either in this episode or in the earlier scandals involving WorldCom and Enron. 
 
 How such market failures affect societal wellbeing, and how individuals, 
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governments, and corporations perceive them may be linked to the growing drive for 
acknowledgement of and responses to the various normative concepts comprising 
CSR.  Could the growing realization and therefore public resentment of the resulting 
imbalances, inequalities, and the costs of externalities, agency problems and imperfect 
information, among other market failures, be reasoning for the growth of CSR? 
Externalities and other market failures are not the exception but the rule.  If that is 
the case, it has profound implications.  There is meaning to individual and 
corporate responsibility.  Firms need to do more than just maximize their market 
value.  And individuals within corporations need to think more about what they do 
and the impacts on others.  They cannot get by by saying that they are “just” 
maximizing their incomes. (Stiglitz, 2010, p. 283) 
 
2.2.2   Responsibility and CSR  
 The concern expressed by growing bodies of society is that corporations are not 
meeting their responsibilities as they relate to the common good.  A number of 
responsibilities are identified in the literature include the following examples by Moir 
(2001, p. 19): 
1) Treat employees fairly and equitably;   
2) Operate ethically and with integrity; 
3) Respect basic human rights; 
4) Sustain the environment for future generations; and 
5) Be a caring neighbour in their communities. 
 
Moir appears to be attempting to list a set of universal responsibilities, but 
universal agreement on those responsibilities is not realistic due to normative 
differences.  For example, what may be perceived as a norm in one region and criterion 
for judging the level of responsibility of the actions and behaviours of companies (e.g. 
level of philanthropy) may be not prioritized in another (e.g. level of volunteering over 
philanthropy).  Additionally, scholars generally provided a definition of CSR, from which 
the responsibilities can generally be extrapolated.  As a result, the variance in 
definitions and responsibilities appears to be similar and related.   
A possible result of the normatively based lack of consensus is the fact that there 
is no consistent form of regulation for CSR.  Corporations are free to choose whether or 
not to engage in CSR and the responsibilities they want to endorse (Levis, 2006; Givel, 
2006; Sahlin-Andersson, 2006).  However, a range of conflicts may arise if, for example, 
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they do not engage in CSR or endorse responsibilities that clash with the norms of their 
business environment.   
 While there has been no direct regulation to mandate CSR engagement, various 
European countries have instituted indirect regulations to promote it.  Denmark, 
Germany, Finland, France, and Sweden have all implemented corporate disclosure 
requirements that vary in terms of reporting social and environmental policies and 
practices, while the UK has taken a different route by issuing voluntary guidelines for 
social reporting (Moon &Vogel, 2008). 
From civil society, the Global Reporting Initiative (GRI) has emerged with a CSR 
reporting framework that “can be used to demonstrate organizational commitment to 
sustainable development, to compare organizational performance over time, and to 
measure organizational performance with respect to laws, norms, standards and 
voluntary initiatives.” (Global Reporting Initiative, 2011).  GRI is a non-profit group or 
NGO that relies on a large number of diverse and interconnected stakeholders to 
constantly build and maintain a widely used and sustainable reporting framework 
(Global Reporting Initiative, 2011).  With all of the differences among businesses, 
industries, countries, and cultures, it would likely take a global initiative to create an 
adequate reporting framework; however, it is unlikely that a universal framework could 
account for the variation in differences across industries, regions etc., unless it is 
modifiable and flexible enough to conform to normative differences.   
 Two other CSR promotion strategies are the social labelling of products and 
socially responsible investing (SRI).  Social labelling has occurred in various European 
countries, and involves providing businesses with the option to submit products for 
inspection and certification (Buckland et al., 2006 cited in Moon & Vogel, 2008).  Once a 
product passes the inspection, it can be labelled as produced in a socially responsible 
manner.  SRI refers to the process of using ethical, social, and environmental criteria as 
a guide for pension fund managers and other institutional investors when they make 
investment decisions (European Commission, 2004).  Investors interested in supporting 
SRI are able to identify and support those institutions that use this process. 
 The promotion of CSR rather than its mandatory regulation could represent a 
softer push by NGOs and other groups.  By creating awareness and a discourse of 
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business opportunities, CSR engagement may help influence a greater adoption of such 
practices and policies.  It also has the potential to present viable alternatives to previous 
modes of business. 
 With a range of persistently conflicted perceptions about the inherent 
responsibilities of a corporation, it is understandable that a number of contested notions. 
Doanne (2005, p. 219-221) identifies four such notions:  
1) Voluntary reporting improves performance; 
2) Voluntary codes and management systems change corporate behaviour; 
3) The consumer will drive change; and 
4) The investment industry can provide the strongest incentive for CSR. 
 
 Criticisms of voluntary reporting, voluntary codes and management systems 
include manipulation, self-editing and interpreting of codes, and lack of compliance 
(Sahlin-Andersson, 2006; Levis, 2006).  Basically, if companies are required to report 
on their CSR ventures, they still have leeway to shape and/or withhold information; 
control over transparency still remains at the discretion of companies.  However, 
constructing CSR-related reports, codes, and management systems means that 
companies have to think about the topic and engage in a discourse that has the 
potential to influence future actions and behaviours.  Additionally, volunteer reporting 
using frameworks such as the ones produced by GRI hold companies more 
accountable and leave them with less leeway in what they report.   
 It is a popular belief that consumers drive change.  However, a study of 
consumer spending habits in relation to beliefs surrounding CSR failed to find a strong 
link (Oppewal, 2006).  For example, while survey data show that up to ninety percent of 
consumers consider CSR in their purchase and consumption behaviours, only ten 
percent or fewer actually engage in this behaviour (Vogel, 2005 cited in Smith, 2008).  
The statistics show that there is a substantial difference in stated and actual behaviours.  
Smith's (2008) viewpoint is that this phenomenon is caused by social desirability bias, 
whereby respondents provide answers that they think are the most desirable.  It should 
be noted, however, that actual social movement of consumer demands for greater CSR 
cannot be simply dismissed as not being able to influence the decisions of companies.   
 With regard to the myth of the impact of investments, a sizeable section of the 
investment industry is pushing for ‘green’ and socially responsible investments, which 
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may challenge Doane’s assertions about this contested notion regarding CSR.  
However, it can be argued that sustainable investment indexes such as the Dow Jones 
Sustainability Index (DJSI)(USA), NASDAQ Sustainability Index (Canada), and the 
FTSE4Good Index (UK) most likely react to perceived investor demands to categorize 
and list companies for investment based on CSR-related criteria, such as environmental 
and social practices.  Although these may not be the 'strongest' incentive, they are a 
method, again, to increase the CSR discourse by acknowledging that some investors 
desire this type of benchmarking to inform their investment decisions.   
 Normative differences and contested notions of CSR influences result in an 
extremely varied landscape of CSR engagement, promotion, and regulation, where a 
multitude of forces, including companies, are trying to shape its discourse in an effort to 
strengthen their influence over its trajectory.     
  
2.2.3 Types of CSR  
 There are numerous viewpoints regarding the types of CSR programs and 
policies that should be used in response to different social and environmental issues, 
and whether or not there should even be a response by companies (e.g. Friedman) 
(Lantos, 2001; Carrol, 1979; Porter and Kramer, 2006; Googins et al., 2007).  Lantos 
(2001) proposes there are three types of CSR responses – altruistic, ethical, and 
strategic.  Altruistic CSR refers to helping a group of people or even one person with no 
discernible benefit to the corporation, and involves a financial or another type of 
sacrifice on the part of the corporation.  Ethical CSR seeks to protect those who may be 
harmed, or to support those who have been harmed by the normal operations of the 
corporation.  Strategic CSR, the newest form of CSR to be defined, seeks to infuse 
social responsibility through the overall business strategy of the corporation to create a 
competitive advantage for the business.    
 Whatever the type, CSR can be either proactive or reactive (O'Dwyer, 2002; 
Porter & Kramer, 2006).  Proactive CSR refers to being prepared for probable 
situation(s) by planning CSR programs for the future, while reactive involves adjusting 
and reacting to issues or risks using various types of CSR once a situation has 
occurred.  Altruistic and ethical CSR can be either proactive or reactive in design.  For 
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example, altruistic and ethical CSR programs can be implemented to rectify a problem 
such as recalling a defective product.  As well, both are used to plan for possible future 
problems as a way to mitigate the risk of financial damage or loss of reputation for the 
corporation.   
By its very nature, strategic CSR is proactive, and not reactive, because its 
purpose is to take advantage of possible opportunities through planning.  Based on the 
literature, there appears to be a push for companies to adopt more proactive types of 
CSR as these have the potential to drastically lower negative occurrences in the future, 
while also giving a competitive edge to the corporation.  However, even proactive CSR 
seems to be reflexive in nature, in that it is a response to a perceived future risk—react 
now because it will be harder to do so in the future.  By reacting, companies attempt to 
change or prevent future risks, but may unintentionally create new ones.  
 
2.2.4 Business Theories and CSR 
 Numerous attempts to examine and describe CSR have been carried out using 
established theories.  Moir (2001) uses stakeholder, social contract, and legitimacy 
theories to explore the behavioural reasoning for engaging in CSR.  Stakeholder theory 
looks at the groups to whom a corporation should be responsible: 
Business can be understood as a set of relationships among groups that have a 
stake in the activities that make up the business.  Business is about how 
customers, suppliers, employees, financiers, communities, and managers 
interact to create value.  To understand business is to know how these 
relationships work. (Freeman, Harrison, & Wicks, 2007, p. 3) 
 
Freeman (1984, 2007), advocating and theorizing about the concept of 
stakeholder management, believes there is a link between a successful, sustainable 
business and the proper management of stakeholders; a business strategy that starts 
by moving beyond a single fiduciary duty to acknowledging and using the relationships 
that companies have with their unique set of stakeholders to shape companies 
functioning according to “a different state of purpose” (p.5).  Stakeholder management 
seeks to engage in a plurality of management approaches that have ethics and values 
at its core.  By linking stakeholder management strategy to CSR, Freeman suggests a 
company should recognize a wider set of responsibilities through the identification of 
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societal expectations.  Therefore, the resulting strategy should be executed in the spirit 
of ethical leadership.  
 Donaldson and Preston (1995) evaluated the concepts of Freeman and other 
stakeholder theories.  They concluded, “stakeholder theory is intended both to explain 
and to guide the structure and operation of the established company” (p. 70) and “has 
been advanced and justified in the management literature on the basis of its descriptive 
accuracy, instrumental power, and normative validity” (p. 65).  The three criteria 
(accuracy, power, and validity) that serve as the basis for their evaluation were found to 
be mutually supportive, with the normative base of the theory being foundational for its 
viability.  Overall, the stakeholder theory for a successful, sustainable business appears 
to be an attempt to inject a reflexive morality into the actors that are using the amoral 
economic machine.   
 Social contract theory, in some ways similar to stakeholder theory, contends that 
there is an implied contract between businesses and society.  Both are required to 
respect this social contract or face potentially punitive consequences (Moir, 2001).  CSR 
is a method to ensure that the actions of the company will be viewed as living up to the 
contract.  Notably, the notions that make up the contract are subject to the forces of 
social construction and therefore can vary across space and time. 
 Legitimacy theory requires that the actions and products of an entity (corporation) 
are “desirable, proper, or appropriate within some socially constructed system of norms, 
beliefs, and values” (Moir, 2001, p. 20), and will be discussed further as organizational 
legitimacy theory later in this section (p. 48). 
 Woodard, Edwards, and Birkin (2001), in addition to stakeholder theory, use 
agency theory to explain the relationship between CSR and business.  Agency theory 
centres on the power relationship between a ‘principal’ and an ‘agent’.  Principals are 
the members of society who grant or delegate agents the authority to run and operate a 
business.  Agents are those who take authority from the principal and proceed to 
operate the venture in a manner that is, presumably, in the best interest of the principal 
(Bowie and Freeman, 1992).  However, controversy emerges when agents decide to 
operate the business in their own interests, rather than those of the principal: “Agency 
theorists generally assume that agents seek their own interests, rather than those of the 
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principal” (Salazar & Husted, 2008).  Therefore, shareholders attempt to incentivize 
agent adherence to their fiduciary duty through various forms of compensation (e.g. 
high salaries, stock options etc.) (Salazar & Husted, 2008). 
 In the situation where the agent operates ‘morally’ according to their fiduciary 
responsibility by running the business in a way that addresses the best interests of 
shareholders, there are three motivators to endorse CSR engagement: altruistic, 
coercive, and strategic (Salazar & Husted, 2008).  An altruistic motivator perceives CSR 
as a morally necessary cost that results in a decrease in financial performance, but 
should result in some reputational benefits with stakeholders.  A coercive motivator 
compels engagement in CSR activities to appear more legitimate and compliant with 
societal norms and values.  A strategic motivator for CSR attempts to link CSR 
expenditures to a competitive advantage that will positively affect financial performance 
(Salazar & Husted, 2008).   
 Two types of agency theory that scholars have researched with respect to CSR 
are organizational legitimacy and political economy of accounting theory (Woodward et 
al., 2001).  Organizational legitimacy theory is based on the requirement of a business 
or corporation to disclose its activities to secure legitimacy.  The business must do so 
because there is a tacitly understood social contract between the business and society 
that obligates the company to engage in socially beneficial actions to receive legitimacy.  
The social norms and values construct their perspective of what a business must do to 
receive their mandate to operate (Woodward et al., 2001).  The theory places a great 
deal of importance on a company's ability to be responsive to environmental and/or 
social issues that are affected by their operations.  Additionally, the theory suggests that 
the principals hold the power in their relationship with their agents.  A company 
response to these issues is then communicated or reported to the societal groups and 
the principals who have authority over decisions regarding the legitimacy of the 
company.  Controversies can emerge if there are gaps in the company strategy to fulfill 
their side of the contract (Woodward et al., 2001) 
 Conversely, political economy theory suggests that the agent running the venture 
has the power to set, dictate, and design the agenda, with less reliance on the principal 
to grant legitimacy.  CSR engagement and reporting are used ,therefore, to 
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communicate the perspective of the agent (executives) to the external world in an 
attempt to influence external perceptions.  Rather than the principal requiring the agent 
to be reactive to societal values and expectations, political economy theory suggests 
the agent uses their communicative abilities to proactively re-shape societal 
perspectives and norms (i.e. assimilation rather than accommodation) (Woodward et al. 
2001). 
 In his editorial about CSR (1970), Friedman uses the principal-agent relationship 
as the basis for explaining why it is wrong for companies to engage in any kind of CSR 
other than to increase profits.  The principals (shareholders) have employed their 
agents (executives) to operate their company in a profitable manner.  According to 
Friedman, agents are free to engage in CSR-type activities on their own time and dollar; 
but using the corporation to do so is tantamount to fraud.  However, it may be possible 
for agents to direct their companies to engage in CSR if the purpose of doing so is to 
increase the financial performance of the company.  For instance, CSR is justified, 
according to a Friedman-type perspective, if its attributed socially and/or 
environmentally oriented programs and policies are shown to increase goodwill or 
reduce costs.   
 Another prominent theory as to why and how companies engage in CSR is 
institutional theory (Frynas, 2009).  Similar to organizational legitimacy theory, 
institutional theory postulates that for a company to survive it must maintain legitimacy 
within its business environment to remain socially fit (DiMaggio & Powell, 1983; Frynas, 
2009).  As a result, companies tend to copy the behaviours of others to remain 
legitimate through a process of institutional isomorphism (DiMaggio & Powell, 1983).   
 There are three mechanisms associated with the process of institutional 
isomorphism: 1) coercive – companies are encouraged and sometimes forced by 
regulators and others to engage in certain practices; 2) normative – similar training, 
discourse, philosophy across employees of companies leads to similar actions and 
behaviours; and 3) mimetic – executives and managers attempt to imitate other 
companys’ strategies that are perceived to be more successful (DiMaggio & Powell, 
1983; Frynas, 2009).  Therefore, if the reasoning for engaging in CSR in a region or 
industry becomes institutionalized, it has a higher probability of being adopted by other 
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companies. 
 While exploring the reasoning behind CSR, these authors provide no clear 
evidence of a dominant theory or its relative influence.  Although each theory adds 
perspective on the reasoning behind the behaviours of a company, it has been argued 
that these theories are inadequate because they fail to address the constantly evolving, 
re-defining, and normative nature of CSR (Frynas, 2009). 
 
2.2.5 CSR External Drivers and Internal Motivators 
 When the discussions about the responsibilities, types, and history of CSR are 
placed in the global economic context, it shows a social construction of accountability—
made manifest in organizations such as GRI—that develops into a mix of both internal 
and external reasons to engage in CSR.  Social (e.g. SRI) and political (e.g. CSR-
related regulations) institutions are increasingly seeking accountability by corporations 
for how they have and can influence social and environmental issues.  How 
corporations react to an external discourse that appears to exceed their previously 
singular fiduciary duty (profits for the shareholders) is a matter of great debate.  One 
narrative that appears to resonate with corporations is that there are benefits (profits) in 
addressing these concerns, resulting in their own internal push for CSR.  For the 
purposes of this review, the external and internal ‘push’ for CSR are referred to as 
drivers and motivators, respectively.   
There are growing expectations within global society that corporations, to earn 
their legitimacy as members of the larger society, should be responsible, or 
accountable, for their actions (Oketch, 2005).  It is likely that the majority of external 
drivers for CSR engagement have emerged as balancing factors between MNCs and 
society.  These drivers may be viewed as a reaction to the freedom that corporations 
have to act in their own self-interest.  Even though some of the corporations are global, 
monolithic entities, their increasing scope and power has served only to increase the 
impact of their actions, as well as society’s reaction to them.   
Reflecting the probability that CSR is a response to growing desires for 
accountability by social and political institutions, the external drivers are identified by 
two categories: governance and license to operate (LTO).   
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 Governing bodies or political institutions serve an important role in driving and 
developing CSR.  Moon and Vogel (2008) identified three areas in which governing 
bodies have purposively or accidentally developed drivers for CSR.  First, where 
government assumes a more central role, there is often less adoption of voluntary CSR 
initiatives.  Using the USA as an example, Moon and Vogel explain that government 
with a more retracted role is correlated with greater levels of explicit CSR adoption 
(generally of the philanthropic variety)—a balancing factor.  While in Europe, where 
governments tended to be more centralized, there has been historically more adoption 
of implicit CSR (values, norms and rules integrated into practices of corporations) 
(Matten & Moon, 2008): 
Pasquero (2004) has argued that CSR in the United States is embedded in U.S. 
institutions and culture, particularly in the traditions of individualism, democratic 
pluralism, moralism, and utilitarianism.  We argue that the distinctive elements of 
European CSR are embedded in the European NBSs [national business system], 
such as industrial relations, labor [sic] law, and corporate governance. (Matten & 
Moon, 2008, p. 409). 
 
 Second, the inadequacy or lack of regulations has influenced the creation of 
international and national CSR (Scherer & Palazzo, 2008).  A governance deficit, most 
likely due to a combination of deregulation in some countries and inability to regulate in 
others, has increased because of the process of globalization.  In an attempt to fill this 
void; there has been an increase in the development of “global civil regulation”: 
Much of the growth of global civil regulation is rooted in the perception that 
economic globalization has created a structural imbalance between the size and 
power of global firms and markets, and the capacity, willingness, and ability of 
governments to regulate them. (Moon and Vogel, 2008, p. 309) 
 
Excluding the governments of emerging economies that simply may not have the 
resources or capabilities to impose regulations on large MNCs, the unwillingness of 
governments to regulate may originate from the fear that regulation will reduce 
competition, and therefore negatively affect the economy—a prominent notion within the 
governing logic of the market fundamentalist ideology or neo-liberalism (i.e. dogmatic 
belief in the free market).  Furthering the entrenchment of neo-liberal logic were global 
institutions such as World Bank (WB) and the International Monetary Fund (IMF), which, 
in the 1990s, “pressed for financial-sector deregulation, privatization, and trade 
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liberalization” (Stiglitz, 2010, p. 220).  As instruments of post-colonial control, these 
organizations were especially vocal and influential in developing countries that were 
trying to develop and shape policy in an increasingly globalized world (Stiglitz, 2010).     
 Finally, governments can often confound the process of CSR development by 
displaying contradictory behaviours.  Some governments have created policies or 
legislations to promote CSR through the encouragement of increased responsible 
actions (e.g. soft or hard regulation of reporting, SRI initiatives, partnerships with 
industry to produce voluntary codes, etc.).  As well, international promotions have been 
designed and implemented by both nation-states and international governmental 
organizations (UN, World Bank, OECD, etc.).  However, there has been little hard 
regulation that stringently dictates and enforces CSR engagement.  This may be 
explained, in part, by the normative nature of CSR that makes the universality of hard 
regulations difficult, if not impossible, to apply to a variety of corporations in different 
industries.   
 In addition to government actions, four external drivers, that could shape a 
societal and political argument for CSR engagement, have been identified by the 
Organization for Economic Cooperation and Development (OECD) (OECD, 1999 cited 
in Oketch, 2005, p. 31):  
1) New concerns and expectations from citizens, consumers, public authorities, and 
investors in the context of globalization and large-scale industrial change; 
2) Social criteria increasingly influencing the investment decisions of individuals and 
institutions both as consumers and as investors; 
3) Increased concern about the damage to the environment caused by economic 
activity; and, 
4) Transparency of business activities brought about by the media and modern 
information technologies. 
 
These drivers represent recent external pressures on corporations.  When these 
pressures are combined with the existing drivers, the result is a broad and complex 
network of societal and political factors that somewhat pressures companies to engage 
in meaningful CSR (i.e. beyond philanthropy).  The fourth driver, transparency, stands 
out as a particularily important driver.  The transparency brought about by the modern 
information age via the media, Internet, etc. allows for greater access to information, 
which is a powerful tool to spread ideas and influence the social construction of 
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perspectives.  Albeit, information technologies cannot be considered universally 
accessible, nonetheless, they are still an influential force in the realization and 
communication of social and environmental issues.  
The four OCED drivers can be defined within the umbrella category of license to 
operate (LTO), which refers to situations where corporations require some form of 
permission (explicit, implied, or tacit) from government, communities, or other 
stakeholders to operate unhindered (Porter & Kramer, 2006; Benett et al., 2009).  LTO 
is a somewhat ambiguous term in the literature; but it is a concept shared across 
organizational legitimacy, social contract, and stakeholder theories.   
LTO is viewed by Porter and Kramer (2008) more as an internal motivator, an 
internal reaction to external expectations, but is better classified as a driver due to it 
capacity to initiate a motivating (internal) response by companies.  LTO is the perceived 
need to obtain permission from groups external to the firm, which means that outside 
forces are effectively causing the corporation to act in particular ways.  Each of the four 
drivers, presented by the OECD represent different forms of requirements for a LTO, 
albeit with varying influences on corporate motivations.   
Governance is not included under LTO.  Although the government plays a role in, 
and reacts to, the LTO for a company, the totality of governance has additional factors 
that can drive CSR.  For example, the centrality of a government does not fall under the 
LTO category, but rather a response to the desires of social institutions.   
One possible explanation for the development and expansion of these external 
drivers is that they are a response to controversial actions taken by corporations over 
the last 30-40 years; controversial actions that demonstrate a pursuit of economic 
benefit (profits) in ways that conflicted with basic and widely held social and 
environmental norms.  Some examples include Nike and their abusive labour practices 
in Indonesia; Shell's decision to sink the Brent Spar oil rig in the North Sea; and the 
initial response of the pharmaceutical industry to the AIDS pandemic in Africa (Porter & 
Kramer, 2006).   
In the past, it may have been easier to cover up or hide these actions or to 
rationalize them using the prevalent norms within a market-fundamentalist ideology; but, 
as explained earlier, a side effect of globalization and newer technologies is the 
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development of environmental conditions that support both voluntary and involuntary 
transparency by corporations.  Notably, the high level of public access to information 
technology has resulted in the majority of the push for accountability and transparency 
emerging from more technologically advanced nations.   
With the wide use of information technologies among non-governmental 
organizations, public authorities, and concerned consumers, there seems to be more 
and more eyes watching the actions of corporations.  These groups and individuals act 
as concerned spectators by pressuring corporations to change their controversial 
practices (Shamir, 2005).  The combination of all of these groups and individuals 
creates levels of social awareness and action that have the potential to push 
corporations or even whole industries in a specific direction.  For example, NGOs and 
activists have undertaken both legal and non-legal campaigns to publicly shame 
corporations for their controversial actions (Porter and Kramer, 2006; Shamir, 2005).   
Legal action can also occur if the controversial issue is viewed as violating a 
country’s laws or regulations.  Examples include Royal Dutch Shell being sued for 
conspiring with the Nigerian government against the Ogani people and Coca-Cola being 
sued over claims they should be held liable for the activities of paramilitary units who 
terrorized and murdered union organizers at a bottling plant in Colombia (Shamir, 
2005).   
Outside of judicial systems, campaigns have consisted of “consumer boycotts, 
divestment programs, and popular protest in order to pressure MNCs to adopt 
responsible business practices” (Shamir, 2005, p. 99).  Aiding in the process of greater 
access to information are groups such as Wikileaks, which publicly distribute 
confidential information regarding the actions of governments and corporations.  Most 
notably, communications by the US government with regard to diplomatic cables 
involving both the Iraq and Afghanistan wars were publicly released verbatim, which 
resulted in public outcries against both Wikileaks and the US government (The New 
York Times, 2011).   
 In addition to external factors, internal pressures have created a diverse range of 
motivators that may entice corporations to engage in CSR.  Motivators to engage in 
CSR include the reasons to create new benefits for a corporation, avoid current or past 
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controversies and problems, deal with employee attraction and retention issues, and 
even maintain the status quo.  These motivators can range from dealing with reputation 
issues to basic altruistic endeavours (Porter & Kramer, 2006; Bluestone, Heaton & 
Lewis, 2002; O’Dwyer, 2002; Oketch, 2005; Moir, 2001; Lantos; 2001; Frankentel, 2001; 
Levis, 2006; Bennett et al., 2009; Frynas, 2009; Kurucz, Colbert, & Wheeler, 2008).  
 Reminiscent of other aspects of CSR (i.e. definitions and responsibilities), the 
area of motivators has become saturated, unorganized, and convoluted with concepts.  
In general, categorizing motivators into broad encompassing groupings is not common.  
However, one exception is Porter and Kramer (2006), who identify moral obligation, 
sustainability, license to operate, and reputation serving as the most appropriate 
categories by which to group the fractured listings of motivators within the literature.   
 According to Porter and Kramer (2006), moral obligation is a motivator that stems 
from the idea that corporations should give back to the communities that surround them 
as the right thing to do.  Moral obligation can be illustrated by actions such as 
philanthropy and community volunteering; actions deemed acceptable on an individual, 
but not a corporate level by Friedman.  The issue of morality also ties into the theories 
of Adam Smith; however, his view was that morality should be a factor in how the 
amoral market is regulated to compliment the common good.  What Porter and Kramer 
propose is the supplementary addition of more societal-focused morals and values into 
business operations, almost in reaction to what the company is doing and what it has 
done.   
 Sustainability refers to the corporation focusing on the environment and company 
stewardship to build a strong future for themselves and their communities.  Green 
programs and community development programs are examples of sustainability-
oriented CSR practices.  They show an element of reasoning that companies require a 
healthy environment and community in which to operate if they want to have long-term 
success. 
 License to operate (LTO), as discussed earlier, is more appropriately categorized 
as an external driver of CSR rather than as an internal motivator for engaging in CSR.   
 The final category, reputation, refers to the leveraging of CSR to increase brand 
strength, improve image, and raise morale to increase the profitability of the firm.  
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Reputation is the most commonly discussed motivator for CSR engagement and, at 
times, one of the most morally questionable.  The moral dilemma involves the 
accusation that it turns CSR into a form of public relations (PR) or marketing, rather 
than its intended purpose of addressing social and environmental issues:  
Most CSR is motivated by a desire for an eventual return: a more compliant 
workforce, the smoother granting of planning permission, more amenable 
customers, or in the jargon of today's corporate affairs manager 'gaining a 
license to operate' or 'reputational assurance'. (Franktental, 2001, p. 20) 
 
 This concern is further articulated by Porter and Kramer (2006) because they 
argue that much of the current motivation for engaging in CSR centres on PR purposes. 
For example, tobacco companies use CSR in the form of donations and other 
philanthropic programs to take attention away from the health problems associated with 
their products (Givel, 2006).  Ultimately, such dubious motivators can reduce the 
credibility and legitimacy of CSR, and possibly hinder the evolution and adoption of 
CSR.  One reason for the CSR link to PR is that, “social responsibility has the most 
impact on profitability for companies for which advertising expenditures are large, so 
that they appear to gain most from responsible behaviour” (Heal, 2008, p. 232).  As a 
result, companies with large advertising expenditures may spend more on advertising 
their CSR engagements, and thus, it can be perceived as a marketing tool rather than 
‘honest’ CSR.   
An evolution of the three basic motivators (moral obligation, reputation, and 
sustainability) is adopting a strategic approach to CSR: to integrate CSR into the 
business strategy to maximize benefits and thereby increase financial gains while still 
creating societal benefits (Porter & Kramer, 2006; Lantos, 2001).  In merging CSR with 
business strategy, a more focused approach to CSR develops, which can result in 
better utilization of resources and greater benefits for all parties involved, or a win-win 
scenario.  The merger of CSR and business strategy puts all of the knowledge and 
resources of a corporation into a mutually focused area, greatly increasing the 
probability of success in both financial and socially responsible terms, albeit 
theoretically.  An example of this type of strategy is Toyota and its creation of the hybrid 
engine.  The hybrid engine created a competitive advantage that helped bring Toyota to 
the status of the number one car producer in the world (sales and profit).  At the same 
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time, the firm was able to take an industry leadership role with a proactive approach to 
'green' issues surrounding vehicle emissions. 
Whether the motivators for engaging in, and improving on, CSR strategies are 
moral obligation, reputation, or sustainability, the purpose of each from a corporate 
point-of-view is to increase the realized societal benefits and the financial success 
(profit) of the organization.   
Hanlon (2008) presents two reasons that companies would be legitimately 
interested in CSR as a method to increase profits.  First, managers perceive the act of 
pursuing profit as the socially responsible thing to do; business survives, workers 
remain employed, taxes are paid, governments create social programs, and 
shareholders are rewarded.  Such a perspective of inherent CSR tied to businesses 
acting only in their own self-interest is entrenched in misinterpretations and distortions 
of Adam Smith’s free market theory (e.g. Friedman). 
The second reason is that CSR is the key to opening up future areas for 
businesses.  CSR will become an increasingly important component of overall business 
strategy, which actually implements active use of CSR programs and policies.  For 
example, operating in controversial industries and within developing markets with 
vulnerable populations will require companies to operate with more regard to societal 
constructions of their legitimacy, to reduce potential obstacles.  Competitive advantages 
exist within the opportunities of these future markets, and CSR is a method to mitigate 
conflict and foster diversity with the intention of enhancing a business’s relationships 
with stakeholders and society (Oketch, 2004).  CSR provides companies with greater 
access to potential future opportunities.   
Future business opportunities associated with CSR perspectives create a 
justification, and therefore the rationale, for a business case scenario by which to 
engage in CSR (Frynas, 2008; Bennett et al., 2009; Kurucz et al., 2008; Googins et al., 
2007).  How the business case for CSR translates into specific types of CSR depends 
on the perspective adopted by the corporation.  There are four categories of business 
case scenarios for CSR that have been theorized by scholars (Kurucz et al., 2008):  
1) Cost and risk reduction  
2) Competitive advantage;  
3) Reputation and legitimacy; and  
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4) Synergistic value creation.   
 
 Cost and risk reduction refers to engaging in CSR as a means of reducing or 
removing current or potential risks to the business.  A mix of reactive and proactive, 
simplistic CSR programs would be used as protection for the business.  CSR is likely 
perceived by corporate decision-makers as an additional cost, which results in the 
likelihood that it would be dropped and not used in times when costs need to be 
minimized.  Examples of such programs would be of the philanthropic variety.   
Competitive advantage involves creating and implementing CSR programs that 
can provide or build an advantage for the business while also creating an external 
benefit.  The business is “adapting to its external context in order to optimize the 
organization’s competitive advantage in its respective industry” (Kurucz, 2008, p. 89).  
External expectations identify opportunities to benefit both parties, thereby creating a 
distinct advantage for the corporation.  An example of the type of program implemented 
under this category is creating an environmentally friendly product in a market that is 
typically not environmentally friendly (e.g. hybrid cars).   
The reputation and legitimacy case assumes that the reputation of a company is 
directly tied to its legitimacy within its environment.  Corporations examine their 
stakeholders’ expectations and use a combination of CSR and marketing to create 
programs that can be leveraged to increase their reputation, and thereby indirectly 
enhance financial performance.  Actions and behaviours aligned to the expectations of 
stakeholders can create a competitive advantage for the company by strengthening 
their reputation and ensuring their legitimacy.  An example of the type of CSR program 
attributed to this category is providing better access to expensive but necessary 
products for low-income populations (e.g. increasing access to pharmaceuticals in 
developing countries). 
The synergistic value creation case is complicated in the sense that it layers 
stakeholder expectations onto waves of value (the whole is greater than the sum of its 
parts) that spans and connects multiple layers of benefits for all parties involved—a win-
win-win outcome.  A broad perspective is required to observe and identify the diverse 
expectations of a variety of stakeholders and then create programs with direct and 
indirect benefits that ripple across stakeholders and the company.  The synergistic 
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value creation moves beyond just CSR programs and policies to become a guiding 
philosophy for the company, and is designed to construct value in every internal and 
external interaction.  For the company focused on synergistic value creation, the entire 
business is focused on the interests of its identified stakeholders, under the assumption 
that it in turn make them a more sustainable and financially successful.  
 The perspective of the corporation with regard to CSR is very important in 
determining which strategies and types will be implemented.  A shareholder approach to 
management can be attributed more to the first two categories, while a stakeholder 
approach better represents the latter two (Donaldson, 2008). Each managerial 
perspective has a different mix of motivators for engaging in CSR.   
 Overall, each of the four business cases seeks to leverage the opportunities 
created out of the CSR paradox.  It is interesting that the current use of the economic 
machine has resulted in problems (e.g. externalities) that in turn provide potential 
economic and social advantages to the companies who can capture and strategically 
address the problems they may have had a part in creating.   
As implied throughout this section, motivators to engage in CSR are not simply a 
response to external and internal calls to reduce the impact of harms or prevent future 
harms, but they are also a method to create different social and economic benefits for 
the engaged corporations.  These include additional investing and improved reputation, 
but there are also internal benefits relating to employees, costs, productivity, and 
operational efficiencies (Knox & Maklan, 2004; Peloza, 2006; Frankentel, 2001; Oketch, 
2005; Willard, 2002).   
Akin to motivators, benefits are not isolated in a singular manner.  For the 
majority of these benefits there are overlaps and connections that can result in a chain 
reaction.  That is, an effective CSR program that results in the desired social benefits 
would likely have a ripple effect that generates additional benefits for corporations such 
as increased employee morale.  However, and most notably, it remains contested 
terrain whether or not a direct and positive relationship exists between engaging in CSR 
and financial performance (Orlitzky, 2008). 
 Even though a direct link has not been verified, there appears to be substantial 
indirect benefits that might result in greater financial performance for companies 
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engaging in various forms of CSR.  For example, companies with perceived stronger 
CSR programs experience higher levels of employee recruitment, retention, and loyalty, 
with corresponding increases in workforce productivity (Willard, 2002; Googins et al., 
2007; and Bennett et al., 2009).  Costs are also reduced for companies due to lower 
levels of turnover and less need to train new employees.  Competition for high level 
talent is increasing and has placed the power of choice more into the hands of future 
employees; a new workforce increasingly guided by the CSR-related actions of an 
employer and less by financial incentives (Bennett, et al., 2009).  These newer 
employees are more often attracted to jobs where they can have a flexible work 
schedule, a challenging position, opportunities for advancement, and above all else, a 
vision or mission that is dedicated to helping a wide range of stakeholders (Willard, 
2002; Googins et al., 2007; Benett et al., 2009).   
 Internal motivators for CSR are influenced by, or a direct result of, external 
drivers, and they become incentivized by the potential benefits that the corporation can 
receive from being both socially and environmentally responsible.  Willard (2002) 
describes the “triple bottom line” as companies expand their focus from the strictly 
economic to include environmental and social responsibilities.  In the Sustainable 
Advantage (2002), Willard (2002) identifies seven benefits derived from pursuing a triple 
bottom line (economic, social, and environmental): 
1) Easier hiring of the best talent; 
2) Higher retention of top talent; 
3) Increasing employee productivity; 
4) Reduced expenses in manufacturing; 
5) Reduced expenses at commercial sites; 
6) Increased revenue/market share; and 
7) Reduced risk, easier financing. 
 
 Willard's seven benefits attempt to illustrate the extent to which companies can 
gain by engaging in CSR with a focus on the triple bottom line.  For example, 
developing and introducing environmental-friendly technology into the operations of a 
corporation can create multi-layered benefits that affect the entire organization.  Ray 
Anderson, founder and chairman of Interface Inc., has integrated environmentally 
conscious strategies into the operations of his carpet manufacturing and installation 
company.  Termed sustainability, the strategies, for example, have drastically reduced 
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waste while lowering costs, increasing profits, and building a strong reputation/brand 
(TED, 2009).   
 A possible hindrance to the triple bottom line approach is the considerable 
investment needed to begin these changes, especially for a large corporation.  The lack 
of a direct link to financial performance and the significant short-term implementation 
costs could make it difficult for some decision-makers to justify engaging in the kinds of 
extensive CSR activities proposed by Willard.  However, the potential return on the 
investment in the long-term can be substantial.   
 Overall, the interaction between the external drivers and internal motivators 
provides various notions of routes that can be followed while pursuing a CSR strategy.  
As a result, the various logics that rationalize CSR engagement can be determined by 
how the corporation responds to its internal motivators and external drives that are 
constructed in relation to and interactions with the social and political institutions within 
its business environment. 
 
2.2.6 Implications of a Symbiotic Relationship 
 It has been argued that society and business interdependently operate (Porter & 
Kramer, 2006; Scherer & Palazzo, 2008; Pruzan, 2008; Heal, 2008; Benett et al., 2009).  
The interdependent relationship between business and society has become intertwined 
with drive for CSR: “Where once the interests of companies and the public were thought 
to be antithetical, we can now see more clearly the symbiotic relationship that exists” 
(Benett et al., 2009, p. 17); for a corporation to be successful it needs a healthy society 
around it and vice versa (Porter & Kramer, 2006; Benett et al., 2009; Oketch, 2005).  
Only a stable and prospering society will invest adequately in public 
infrastructure, such as communication, transportation, education and training, 
and health care, which are essential ingredients for successful business growth. 
(Standing Committee on Social Affairs, Science and Technology, 1999 cited in 
Oketch, 2005, p. 38) 
 
On one hand, when a corporation is operating within a society, the health of the 
corporation is dependent on the health of that same society.  For example, companies 
operating within devastated war zones have serious issues with regard to sustainability 
and growth because they simply do not have the environment that is necessary to 
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support their operations 
 On the other hand, a society's development is tied to the state of corporations 
because of the role of businesses in developing and fostering the economy through the 
creation of jobs and the production and sale of products and services.  Without strong 
corporations and other types of businesses capable of developing the economy and 
providing jobs with taxable incomes, a society will be limited in its ability to develop due 
to the inherent limitations created by high levels of unemployment and/or an unstable 
economy: 
Profit is essential for business expansion, leading to the creation of more jobs, 
which in turn lead to increasing savings and better economic times.  Households 
and by extension societies are known to enjoy high levels of cohesiveness when 
they face less economic and budgetary constraints. (Oketch, 2004 p. 6) 
 
The interpretation of a symbiotic relationship can also be made from Smith's 
theories.  According to Smith, individuals do act in their own self-interest, but it is their 
connection to each other through the common good that necessitates the presence of 
justice in how they use the economic machine.   
Connectedness or social cohesion is the “interdependence between members of 
the society, shared loyalties, and solidarities” (Jenson 1998b cited in Berger-Schmitt, 
2000, p. 3).  The symbiotic relationship that exists between business and society 
requires a high level of social cohesion to build an understanding of each other’s 
expectations and interests (e.g. how an individual or corporation’s actions can affect the 
common good): “Connectedness with other people is important for a sense of well-
being, and yet many of the changes in our society (USA) have undermined that sense 
of connectedness” (Stiglitz, 2010 p. 250).  CSR as a responsive, conscious strategy 
towards making connections to and within society is an effective method to strengthen 
the social cohesion between business and society by managing and fostering diversity, 
and reducing conflict (Oketch, 2004).  The costs of externalities associated with the 
operations of businesses can be reduced or mitigated; thereby reducing conflicts and 
supporting greater synergy between business and society.  Social cohesion in relation 
to the influence business has on society revolves around the ability of businesses to 
manage conflicts, and is derived from its perceived legitimacy and trust from society 
(Oketch, 2004).    
 
 
57 
 Based on this symbiotic relationship and the concept of social cohesion, the 
following definition best describes how CSR, as a transformative process, can better 
harmonize the operations of a business with the greater needs of society: 
CSR blends and harmonizes economic operations with human community’s 
social systems and institutions, creating an organic linkage between business 
and society.  The end goal of this relationship is to achieve a balance between 
the firm’s economic operations and the society’s aspirations and requirements for 
community welfare. (Frederick, 2008, p. 523) 
 
The concept of social cohesion and the symbiotic relationship between society and 
business represents the foundation for a conceptual model of the CSR decision-making 
process.  The model presented below (Figure 2.1) provides an understanding for how 
CSR decisions are developed by businesses and how they might affect the symbiotic 
relationship.  In the model, CSR is shown to directly influence the social cohesion 
between business and society.  Social cohesion, in turn, feeds back into the symbiotic 
relationship between the business and society.  The environment that businesses are 
required to consider in their decision-making processes is presented as internal 
(motivators) and external (drivers).  The cycle and points of interaction combine to show 
the multitude of variables that can influence the equilibrium among business, society, 
and their social cohesion.  
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Figure 2.1 Conceptual Model of CSR Decision-making Process  
    
The symbiotic (interdependent) relationship is represented at the top of the 
model by a bi-directional arrow between business and society.  The balance that exists 
from this relationship is both an influence on and a partial result of the CSR decision-
making by corporations.  For example, if a company is already meeting or exceeding 
societal expectations, then there should be less pressure to further engage in CSR.  
The company’s existing perspective of its role within the symbiotic relationship is at 
least in part shaped by the external forces (drivers) that represent its LTO expectations.  
The combination of LTO influences and the internal motivators for CSR develop through 
a business’s decision-making processes and result in a unique strategy that is reflective 
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of their CSR perspective and how it may need to change.  The resulting CSR strategy 
subsequently affects the level of social cohesion.  For example, if a strategy is 
comprehensive and addresses areas of conflict (Oketch, 2004), then it is likely that 
social cohesion will be enhanced, increasing the balance in, and, consequently, health 
of, the symbiotic relationship.   
 
2.2.7 The Link Among Values, Leadership, and Organizational Culture 
 Corporate perspectives on CSR and how these might translate into methods for 
engaging in it require an examination of the factors (values, leadership, and 
organizational culture) that construct these perspectives.  These three main factors and 
how they interplay are discussed in this section of the literature review.  
Values are integral to shaping the way people perceive the world and how they 
act within it.  “Values are concepts people use to make choices, to decide courses of 
action, to explain and justify behaviours, to judge and to be judged” (Baker, 2005, p. 3).  
As the foundation of any culture, including those within an organization or business, 
values can be visualized as the core construct beneath the many layers of what it is 
comprised (Campbell, 2004; Hofstede, Neuijen, Ohavy & Sanders, G.1990).  
Organizational culture exists in the unconscious minds of members and is made 
manifest through the decisions and behaviours of its members (Campbell, 2004; Detert 
et al., 2000; Schein, 1999).  Values also create the underlying ideology (i.e. the core) of 
an organization’s culture (Campbell, 2004 & Hostede et al., 1990).  Each organization 
has its own distinct culture that stems from its own unique hierarchy of values.  
Individuals and groups within these organizations will also have their own distinct set of 
values and subsequent cultures that they will seek to align with those of the 
organization.     
While values are unique to each individual and organization, similarities do occur 
within identified regions.  Across regions, however, differences in values across 
organizations can increase substantially.  For example, 75 percent of companies in 
Asia, 69 percent in Europe, and only 58 percent in North America include CSR in their 
value statements (Kelly, Kocourek, McGaw, & Samuelson, 2005).  Interestingly, the US 
has been argued to be the CSR frontrunners during most of the 20th century, but the 
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previous statistics and other studies find that Europe has progressed ahead of the US 
(Aaronson, 2003; Hartman, Rubin & Dhanda, 2007).  Furthermore, multinational 
corporations (MNC) may influence these statistics as it has been observed that 
headquarters that share core values with their subsidiaries in other nation-states tend to 
be more successful (Buchko, 2006).  Additionally, it is difficult to define an 'exact' set of 
values.  For example, just because a company communicates a set of values there is 
no guarantee that those values are actually directing their actions or employees 
automatically endorse or relate to them.   
According to Buchko (2006), there is a strong link between the performance of an 
organization and whether or not the organization has designed a strong set of 
reinforced values that are embedded throughout the entire hierarchy of the organization.  
A successful organization tends to have identifiable and reinforced values that are 
strongly held by employees and management.  Companies across the globe have 
identified the correlation between strong core values and performance—a connection 
that is possibly reflected in the statistic that 89 percent of companies are reported as 
having written value statements (Kelly et al., 2005).  It is assumed, therefore, that 
values play a strong role in solidifying the social structure of an organization, but their 
presence also influences the functioning of operations. 
In essence, values act as a company’s internal compass, providing a clear sense 
of direction.  Accordingly, core values permeate an organization and are a key 
consideration in major decisions and policies. (Sherman & Gurwitz, 2005, pg. 29) 
 
The effectiveness of values is a function of how well they are embraced, 
presented, and committed to by the members of the organization (Sherman and 
Gurwitz, 2005; Grojen et al, 2004; Kelly et al., 2005).  Therefore, to gain broad 
organizational “buy-in”, leaders must lead by example; reinforcing and confirming the 
core values of the organization by reflecting these values in their decisions and policies.   
While some scholars view the founding leader(s) of an organization as 
responsible for embedding the original values into the organization’s culture, current 
leaders are expected to articulate a clear and compelling vision that expresses the 
desired values of the organization according to the current business environment 
(Grojean et al, 2004).  Regardless, the leader of an organization is an integral part of 
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fostering and maintaining the external and internal trust necessary for the company to 
be successful and sustainable (Bennett et al., 2009).  As a result, a leader must be able 
to back up the behaviours that they have vocalized by making actions that reflect their 
perceived behaviours.   
Globalization has produced additional pressures on organizations and their 
leaders.  Although globalization has increased the scope and power of MNCs, it is also 
linked to increased pressure on companies to conform to LTO requirements.  
Stakeholders increasingly expect company leaders to address issues surrounding 
sustainability, ethics, and culture (Benett et al., 2009).  The combination of expectations 
places greater pressures on the leaders of large companies because they are often in 
the public spotlight where they can be scrutinized about any perceived wrongdoing.  For 
example, Tony Hayward, former chief executive officer (CEO) of British Petroleum (BP), 
faced widespread public and governmental criticism for how he handled the Deepwater 
Horizon oil spill in 2010.  A result of his public mishandling of the oil spill situation was 
his removal as CEO and transfer to Siberia as the director of a Russian-BP joint 
venture.  The decision of the board to replace Hayward was a reaction to societal and 
political backlash over his personal actions during an environmental and social disaster, 
in addition to BPs operational failure in handling the crisis (Macalister & Clark, 2010).   
The increasing awareness of business leaders and their companies of an 
expanding range of expectations from society may help them to identify a business case 
for the adoption and integration of CSR into their companies (Pruzan, 2008).  However, 
it is not as simple as having a CSR conscious leader in place for such a transformative 
process to take place.  Even if the leader(s) are CSR-minded, they may not have 
sufficient justification to pursue it.  “In fact, there is little data to suggest that just 
because a senior manager in a large and complex firm wants to implement a particular 
policy, then it automatically happens” (Mackey, Mackey, & Barney, 2008, p.540).  For 
instance, in a company more or less guided by a shareholder perspective, it would be 
difficult to pursue a large-scale synergistic CSR strategy if the leadership could not 
explain how it would benefit the company’s bottom line.  The difficulties associated with 
CSR as a long-term strategy with indirect financial benefits could be alleviated, 
however, if it had a link to improved short-term cash flow or market value benefits 
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(Mackey et al., 2008).  Since the direct financial benefits are somewhat nebulous, and 
seldom occur, if at all, in the short-term, justifying a strategy as such poses many 
perspective–based obstacles for a company. 
Overall, the values of an organization serve as criteria to judge and guide 
choices about actions and behaviours, making up the core of the organizational culture.  
They are developed by those who also constitute the organization; especially, the 
leaders who are tasked with providing guidance and further articulation of these values.  
The strength of core values and how well they are structured and reinforced throughout 
the company hierarchy are linked to company performance.  The socially constructed, 
relational connection of values, culture, and leadership, form the company perspective.  
Depending on the company perspective and how the drivers and motivators of CSR 
influence it, a business case for CSR engagement can be constructed.   
 
2.2.8 CSR in Canada and the US 
Despite being located on the continent and sharing a border, differences in the 
origins and histories of Canada and the United States (US) have resulted in two 
countries with distinct social, political, and economic perspectives.  The US was born 
out of a revolution and the dramatic rejection of British rule.  Canada did not go through 
a revolution, but rather a counter-revolution arising from negotiations and compromise 
with Great Britain.  These distinctly different origins and other historical differences have 
created paths of influence and choice for each nation (Adams, 2003).  For example, 
each country created a distinct, guiding, and value-laden philosophy: Canada – peace, 
order, and good government, US – life, liberty, and the pursuit of happiness (Adams, 
2000).  These distinct philosophies developed into a set of dogmas relating to what the 
founders (similar to those of a company) perceived as integral to a “good society” 
(Baker, 2005, p. 48).  The historical context of each nation, therefore, can help to 
understand the normative preferences contributing to the current business 
environments and CSR.   
With regard to Canada, there is not a large amount of information on CSR 
practices and the country’s overall business system (Bondy, Matten, & Moon, 2007).  
Based on the information that is available, it has been hypothesized that the reason for 
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the lack of formalized CSR regulations in Canada are the high levels of social capital.  
Specifically, it is suggested that there are higher levels of public trust that corporations 
are acting in an ethical manner and with consideration of the concerns of society, not 
just their financial bottom line (Bondy et al., 2004).  This statement is reinforced by the 
results of the 2011 Edelman Trust Barometer (ETB)—an annual survey of citizens in 23 
countries about trust in business, government, and media—that found that Canadian 
companies continue to be among the most trusted in the world by both Canadians and 
the citizens of other nations (Edelman Trust Barometer, 2011).  The result of these high 
levels of trust may have caused Canadian corporations to be less concerned about 
external stakeholder relationships; focusing instead on building trust and relations with 
employees (Bondy et al, 2004), possibly aligning more with the concept of implicit CSR 
prominent in Europe rather than the explicit in the US (Matten & Moon, 2008).     
Taking into account that Canada has a more centralized government than the US 
reveals a possible link between lower societal expectations for responsibility and a 
business environment that is more heavily regulated.  Despite a strong regulatory 
environment that is more reflective of European countries, Canada has not followed the 
European trend by enacting any sort of CSR reporting regulations.  In addition, 
voluntary adoption of CSR codes is not a prominent feature within the Canadian 
business environment.  Some industries with a larger environmental and social impact, 
and therefore more susceptible to public controversy, such as mining, forestry, 
chemicals, and energy, have created voluntary codes. 
The Conference Board of Canada has stated that the adoption of voluntary 
codes has been slow and not at all universal (Corbett, 2004).  The Canadian 
Democracy and Corporate Accountability Commission (CDCAC) put forth a number of 
recommendations that, if followed, would make CSR engagement mandatory for 
corporations.  Most notably, it would require the expansion of the fiduciary duty of a 
corporation to include the consideration of the business’s impact on non-shareholders, 
customers, employees, and communities (Vallee, 2005).  The push for further regulation 
may also relate to the findings of the ETB in 2011 that 84 percent of Canadians believe 
corporations should create shareholder value in a way that aligns with societal interest.  
In addition, 74 percent thought the government should regulate corporations to ensure 
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they act responsibly.  However, even though it appears the Canadian public wants 
companies to operate in society’s interest (common good), it has not translated into any 
regulations to ensure that it occurs.   
CSR as a concept is widely believed to have originated in the US (Aaronson, 
2003; Frederick, 2008).  Nonetheless, CSR innovation in the US has slowed in recent 
years, leading to the perception that it is lagging behind most industrialized nations 
(Aaronson, 2003; Hartman, Rubin & Dhanda, 2007).  It is further suggested that the US 
government has done little to promote national or global CSR (Aaronson, 2003; 
Hartman et al., 2007): 
The British government has a coordinated and “ambitious” strategy.  CSR 
policies are accepted and supported by business, civil society, and policymakers 
in the legislative and executive branches. In contrast, the United States has a 
wide range of often contradictory and unconnected initiatives.  These initiatives 
lack consistency, coherence, clearly articulated principles, and long-term funding. 
(Aaronson, 2003, p. 309) 
 
An example of the US government’s inconsistency in promoting CSR is its 
interference in lawsuits of MNCs that have been sued because they were believed to be 
violating human rights (Aaronson, 2003).  Aaronson uses the specific example of a 
lawsuit against Exxon Mobil.  It was claimed that security forces hired by Exxon Mobil to 
protect its gas fields in Indonesia carried out murder, rape, and torture.  The US 
government is believed to have dismissed the lawsuit because it could be harmful to 
American interests.  Aaronson suggests that it is not possible to promote CSR while 
carrying out such contradictory acts.  Furthermore, without the government providing 
support for the promotion for CSR, corporations subject to one of the main drivers to 
engage in CSR.   
 Interestingly, the ETB found in 2011 that the US was the only nation surveyed 
that saw trust levels decrease in every category—a period that coincided with the 
current recession (ETB, 2011).  Similar to Canada (82%), US citizens (85%) thought 
businesses should align their shareholder value creation strategies with the interests of 
society, but only 61 percent (74% in Canada) thought it was the job of the government 
to regulate business responsibility (ETB, 2011).  Although there was agreement in both 
countries on companies assuming 
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disagree about the role government should play and whether regulations should be 
used to make it mandatory.   
 Overall, the limited information on Canadian CSR practices is not sufficient to 
compare them directly with the US.  Neither country has the governmental regulation 
and promotion of CSR that is common in European nations.  US-born executives lead 
many Canadian companies, and there is a strong relationship between the Canadian 
business elite and their counter-parts in the US, resulting in the possibility of similar 
business perspectives among Canadian and American corporations.   
 Canada’s high level of dependence on the US market has likely led to some 
economic and policy integration, which is weighted toward the US.  The result may be 
Canadian corporations conforming or aligning to the shareholder perspective that is 
common in the US (Adams, 2003).  In addition, a large number of corporations within 
Canada are subsidiaries or affiliates of US corporations and it is in their best interest to 
share the same core values.  Because Canada has some of the least restrictive foreign 
takeover rules in the world (Saul, 2008), the US and other foreign companies enjoy 
relatively easy access to many sectors of Canada’s economy.  Although both the US 
and Canada are in a deficit when it comes to local versus foreign ownership of 
businesses within their countries, in a seven-year span, starting in 2001, the US sold 
2.1 percent of their domestically owned businesses to foreign-owned companies, while 
Canada sold 12 percent (Smith, 2008 cited in Saul, 2008). 
While there is a great deal of overlap in CSR promotion and policies of the US 
and Canada, a direct link cannot be determined because of the lack of research into the 
area.  The integration of the economies and businesses of the US and Canada has 
likely resulted in some similarity in the business perspective of corporations and how 
they engage in CSR, but each country's historical roots and experiences are different 
and remain extremely influential.   
 
2.3 CSR within the Pharmaceutical Industry  
2.3.1 The Canadian Regulatory Framework – Function and Influence 
The following is a description of the current regulatory process for 
pharmaceuticals in Canada.  The intention is to provide context and understanding of 
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the regulatory environment of one country, and how such regulations might affect 
pharmaceutical company operations in that country.   
In Canada, “the Foods and Drugs Act gives authorization to Health Canada to 
regulate the safety, efficacy, and quality of therapeutic products” (Health Canada, 
2006).  The review process for drugs occurs in the Health Products and Food Branch 
(HPFB) of Health Canada.  The overall purpose of HPFP is to ensure the safety, 
efficacy, and quality of human and animal drugs, natural health products, and medical 
devices that will be sold on the Canadian market.  
 Within the HPFB, Health Canada's Therapeutic Products Directorate (TPD) is 
specific federal authority responsible for the regulation of pharmaceutical products 
(drugs) and medical devices (Health Canada, 2006).  A manufacturer must submit an 
application for a drug and supply scientific evidence that the product meets the three 
requirements set out by the Foods and Drugs Act.  This evidence is further evaluated 
and reviewed by TPD using both internal and external experts.  Additionally, “TPD also 
collaborates with scientists and agencies around the world, such as the United States' 
Food and Drug Administration and Australia's Therapeutic Goods Administration, who 
share our interests and goals” (Health Canada, 2007, p. 2).  This relationship is also 
intended to reinforce the international harmonization of regulations concerning the 
safety, efficacy, and quality of therapeutic products.  Regulatory collaboration occurs 
between countries to better manage the complexity associated with the scope, depth, 
and expertise required to perform these reviews.  For example, comparisons of reviews 
can identify commonalities as well as differences and potential errors made by the 
regulatory agency of a country.  
 The review process includes both pre- and post-market inspections.  The pre-
market inspection, as stated earlier, examines the safety, efficacy, and quality of the 
drugs, to assess whether the risks outweigh the potential benefits (Health Canada, 
2007).  A post-market review routinely consists of three parts: surveillance, inspection, 
and investigation.  Adverse reaction reports from the public, health professionals, and 
manufacturers are reviewed to decide whether any action needs to be taken.  Possible 
routes of action range from public warnings to a recommendation for the company to 
remove the product from the market (Health Canada, 2007). 
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 Regulating the advertising of health products (e.g. pharmaceuticals) also falls 
under the jurisdiction of Health Canada: “Our department is committed to ensuring that 
information in a health product advertisement is not false, misleading or deceptive” 
(Health Canada, 2011).  “Specific regulatory provisions exist to limit the type/extent of 
advertisements of prescription drugs to consumers.  Advertising of narcotic and 
controlled drugs to consumers is prohibited” (Health Canada, 2011).  One example of 
such regulatory provisions is the prohibition against providing both the name of the 
product and its medicinal purpose in the same advertisement for those pharmaceutical 
products requiring a prescription (Dukes, 2006).   
 In Canada, the costs of some pharmaceutical products will be partially or entirely 
paid for by Federal or Provincial governments if they are part of a public drug plan or 
formulary.  Notably, in Canada, there is a patchwork of 16 different provincial, territorial, 
and federal drug plans that “differ in the beneficiaries and drugs that they cover” 
(Canadian Agency for Drugs and Technologies in Health, 2011).  Rather than having 16 
different assessments of each pharmaceutical, the Government of Canada, in 2003, 
created a centralized drug review program, Common Drug Review (CDR), to coordinate 
the applications for drug coverage. 
CDR reviews the clinical and cost effectiveness of the drug compared to 
alternative therapies, looks at whether the drug improves health outcomes and 
provides good value to the health care system. (Canadian Agency for Drugs and 
Technologies in Health, 2011) 
 
The CDR provides this service for every federal/provincial/territorial drug plan, except 
for Quebec (Morgan, 2006).  Importantly, CDR provides only recommendations, and 
each of Canada’s 16 drug plans has final authority over its own decisions, which are 
further influenced by “drug plan mandates, jurisdictional priorities, and financial 
resources” (Canadian Agency for Drugs and Technologies in Health, 2011). 
 Some concerns voiced with regard to the CDR process, include these: it delays 
the listing of drugs on public formularies (drug plans), is a barrier to patients’’ access to 
new treatments, restricts choices patients compared to others countries, controls costs 
and does not recommend expensive drugs, and reviews lack input from relevant clinical 
experts.  The Canadian Agency for Drugs and Technology in Health (CADTH), which 
overseas the CDR, explains that these concerns are myths, and provides statistical 
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evidence to counter the validity of each claim. 
 CADTH does not provide the sources of the myths, but it can be assumed by 
their content that the pharmaceutical industry would be interested in the validity of such 
claims since each can affect patient access to their products; thereby, impacting their 
financial performance.  Listing products on drug plan formularies quickly is very 
important financially for pharmaceutical companies, especially in a country such as 
Canada that limits their ability to advertise.   
It is apparent from the examples cited that Canada’s regulatory framework 
influences the operations of pharmaceutical companies because of the restrictions and 
opportunities that it creates.  For example, restrictions may delay pharmaceutical 
coverage on drug plans, but also opportunities for increased sales when coverage is 
granted.   
Overall, the regulatory environment of Canada represents only one of the many 
that pharmaceutical companies must operate within as MNCs.  Concerns about the 
safety of their products have led to an international web of experts assessing the safety, 
efficacy, and quality of pharmaceuticals.  Assessments continue even after approval to 
report and monitor any unforeseen adverse reactions that may prompt a warning or 
removal, by companies, of the product from the market.  Companies must also adhere 
to regulations about the advertising of their products.  Submitting to each layer of 
regulation contributes to the overall costs of developing and commercializing drugs.  
Particularly relevant for CSR research is how the regulatory framework of a 
country might influence company perspectives on their responsibilities to stakeholders 
and the common good; an intriguing question that remains contested and nebulous.  
 
2.3.2 Perceived Responsibilities and a Drive for Greater CSR Engagement 
 Since the ‘golden age’ of innovation following WW2, the global pharmaceutical 
industry has become hugely profitable.  For example, twelve pharmaceutical companies 
with combined profits of over $65 billion are among the top 500 of America’s largest 
corporations (Fortune 500, 2010).  The profit margins associated with the 
pharmaceutical industry are also substantially higher than average; a situation of 
excessive profits that Adam Smith suggested as an indication of market mechanisms 
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failing and/or nation-states not properly regulating an industry's activities (Smith, 1776).  
For example, in 2009, Wal-Mart had $408 billion in revenue with a total profit of $14 
billion, while Pfizer had $50 billion in revenue with $8.6 billion in profits (Fortune 500, 
2010).   
The pharmaceutical industry has become, and remains even during periods of 
recession and in spite of the controls imposed on it, one of the most profitable 
sectors of commerce.  It sometimes experiences substantial setbacks but these 
tend to be short-lived and confined to certain firms; in the long run, it is only likely 
to grow by adjusting its course as to seize the successive opportunities which the 
health market has always provided and will no doubt continue to deliver. (Dukes, 
2006, p. 7) 
  
 Most of the larger pharmaceutical companies are MNCs that face rising societal 
expectations to give back to society as a matter of a perceived license to operate 
(Shamir, 2005).  However, unlike other sectors, the pharmaceutical industry’s position 
as a collection of MNCs is unique because of its role as provider of healthcare 
(Nussbaum, 2009).   
The role of a pharmaceutical company in a global economy is to research, 
develop, and produce innovative medicines that make a difference to sick 
people’s quality of life, and it is their duty to do so in a profitable way.  No other 
societal actor assumes this responsibility. (Leisinger, 2009, p. 7) 
 
 The pharmaceutical industry has a vital role to play in ensuring the availability 
and accessibility of ‘vital medicines’ because of their innovative and commercialization 
orientations and abilities (Greve, 2008).  The industry’s role in healthcare is also linked 
with the concept of every individuals’ ‘right to health’, considered a fundamental human 
right by the UN Social and Economic Council (Greve, 2008).   
 With regard to pharmaceuticals, availability, accessibility, and affordability are the 
three key issues that should be addressed in support of the ‘right to health’.  The claim 
of Greve and Leisinger that the role of the pharmaceutical industry is linked to a 
perceived right to health implies a situation where people may believe that the common 
good has some claim on the property rights of pharmaceuticals; defined as a form of 
pluralistic property rights (Donaldson and Preston, 1995).  Additionally, it is argued that 
because society provides the industry with extended rights of property (e.g. patents) 
resulting in substantial, possibly excessive, profits, the industry should acknowledge a 
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greater responsibility beyond operating in their own self-interests. 
The TNPC’s (transnational pharmaceutical corporations) conduct can have a 
positive impact on development and the enjoyment of the right to health since 
they have the capabilities, deliverables, knowledge, capacities or resources to 
contribute to better accessibility to vital medicines in a sustainable way.  (Greve, 
2008, p. 493) 
 
The healthcare-related products of the industry can and do directly contribute to 
the health of populations around the world.  Higher life expectancy, lower infant 
mortality, and better disease management are examples where realized social 
responsibilities of pharmaceutical companies have had a substantial impact on society.  
In addition, secondary economic effects can occur as healthier populations are also 
more productive (Djolav, 2008); an effect that is also linked to a country's level of 
development.  For example, in developing countries where right to health issues are the 
most prevalent, the economic benefits from health improvements are substantially 
higher than in developed countries because of the interdependency of poverty and poor 
health (Leisinger, 2009).  
 While the pharmaceutical industry benefits from its image as a healthcare 
provider, its economic role as a for-profit business often creates conflicts of interest that 
have led to substantial criticism (Nussbaum, 2009).  As discussed earlier, some argue 
that patent protection is essential for the industry to make it possible to achieve enough 
financial returns; thereby, funding further R&D to produce more innovative medicines 
(Leisinger, 2009).  Others argue patent laws as they currently exist are ineffectual, and 
that reform is needed to promote innovation and better access to medicines (Angell, 
2005; Bluestone et al., 2002; Saul, 2005; Stiglitz, 2010).  
 While significant, patents are just one of many areas of controversy relating to 
the inherent responsibilities of the dual role of pharmaceutical companies:   
The products the pharmaceutical industry develops, produces and markets are 
related to crucial issues such as health, well-being and poverty, while developing 
these products requires huge investments and is heavily regulated.  These 
diverse characteristics could easily give rise to contradictory interests. (van de 
Pol and de Bakker, 2010, p. 211).   
 
As a result, a ‘battle of perceptions’ emerges between the pharmaceutical industry and 
its complex stakeholder environment of government, media, regulators, patient groups, 
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non-governmental organizations (NGOs), health professionals, and society (Esteban, 
2007).  This battle of perceptions appears to pit social and political perspectives against 
the economic. 
 The battling perspectives, and therefore expectations, involve three issues 
concerning the relationship between ‘right to health’ and pharmaceuticals: accessibility, 
availability, and affordability (Greve, 2008).  Identifying, prioritizing, and addressing 
pertinent expectations from the plethora of stakeholders is a daunting task (Schneider, 
Wilson, and Rosenbeck, 2010) that is only made more difficult by the polarizing 
positions among industry actors, stakeholders, and society.  These positions are 
believed to be stifling the process of seeking a constructive means to address major 
issues (e.g. drug access in developing nations) and, as such, would need to be 
discarded for progress to be made on these issues (Leisinger, 2009).   
Differences in perceptions are not restricted to stakeholder groups; it also 
includes regional differences.  For example, Cheah, (2007) studied the affect that 
product recalls have on shareholder wealth in the United States and the United 
Kingdom (UK) using the Dow Jones Sustainability Index (DJSI) and the FTSE4Good 
Index.  US investors were supportive of companies with product recalls if they were 
listed on the DJSI, while UK investors ‘penalized’ companies with recalls if they were 
listed on the FTSE4 Good index.  Traditionally, the focus on CSR in the US marketplace 
has been explicit (e.g. philanthropy), while in the UK, CSR is a far more implicit and 
integrated aspect of business (Matten & Moon, 2008) and, as a result, the implications 
of product recalls varied between countries.  Therefore, stakeholders on a societal level 
also have varying perspectives of company responsibilities.   
The growth and power of pharmaceutical companies has led to their ability to 
influence the political and social decisions of markets around the world (Saul, 2005).  
Such influence is controversial in its own right, but may be further scrutinized if 
companies, especially those involved in healthcare, use an economic prism as their 
primary lens for decision-making.  Increasingly, social and political groups appear to be 
demanding a greater focus on the common good throughout the entire pharmaceutical 
product cycle, rather than one that is heavily prioritized on creating profits (Angell, 2005; 
Saul, 2005; Stiglitz, 2010).  It is also unclear how Friedman would have reacted to such 
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a dilemma; although he was a staunch believer in the equalizing and beneficial power of 
every economic actor operating in their own self-interest, he also demonized the 
existence of monopolies and coercive practices that prevent perfect conditions in the 
marketplace.  
 Historically speaking, for the greater part of the 20th century, the pharmaceutical 
industry was well regarded, with high levels of credibility and trust with populations 
throughout the world (Parker, 2007).  However, a multitude of continuing incidences, 
perceived as morally and/or ethically controversial by social and political groups, have 
repeatedly tarnished and consistently diminished the reputation of the industry.  Can the 
moral and/or ethical controversies be understood as normative differences between 
companies and stakeholders according to how each perceives how the industry should 
be using their resources and capabilities?  Whatever the reason, such controversies 
have greatly contributed to a declining reputation, and the pharmaceutical industry's 
general standing in countries around the world is now perceived as “next to malpractice 
lawyers, divorce lawyers, and immigration lawyers, the Pharma industry is probably the 
most disliked entity today” (Flaum, 2004, p. 50). 
 Despite erosion of their reputation, the pharmaceutical industry is still valued due 
to their potential to positively affect the health and sustainability of societies around the 
world.  In addition to their primary role, the size, scope and wealth of the industry 
creates inherent responsibilities for the industry not only to supply new, innovative 
medicines, but also to support the provision of existing medicines to the two billion 
people who desperately need better access to them (AMI, 2010).  In effect, legitimacy 
and moral obligation drivers/motivators are pushing the industry to generate profits in a 
more socially responsible manner as a way to enhance the quality of the relationship 
that exists between themselves, as a business, and society (Leisinger, 2009).  But, as 
described earlier, the historically rooted competing interests of the industry's for-profit 
and healthcare roles have resulted in a situation where heavy regulation has been put in 
place in an attempt to adequately address safety and some social concerns (e.g. 
advertising).  However extensive these regulations are, they apparently fall short in 
aspects relating to the original purpose of the industry while also failing to address the 
growing social and political concerns. 
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 Where political institutions are viewed as failing or inadequately regulating or 
promoting action concerning social and political concerns, NGOs have attempted to fill 
some of the perceived gaps.  NGOs have “initiated new alliances amongst themselves, 
created integrated NGOs, and engaged with TNCs (a.k.a. MNCs) to affect the changes 
they desire” (Fabig and Boele, 1999, p. 58).  For example, the Access to Medicines 
Index (2010) provides industry benchmarking by ranking the drug access strategies of 
27 pharmaceutical companies.  The purpose of the index is to “encourage companies to 
act responsibly in this area and play their part in achieving improvements in healthcare 
at a global level” (ATMI, 2010).  Recent examples of strategies that ATMI designated as 
notable methods to secure better access included: GlaxoSmithKline (GSK) reinvesting 
20 percent of the profits made in developing countries back into the health infrastructure 
of those countries; GSK and Pfizer collaborating to create a HIV focused company (ViiV 
Healthcare) that now has seven HIV drugs in its pipeline as candidates to be provided 
at not-for-profit pricing and available for voluntary licensing; and Novartis supporting 
localized R&D in developing countries by collaborating with various regional institutions 
(ATMI, 2010).  Designed to be transparent to its stakeholders, the ATMI benchmarking 
process seeks to identify areas of strength and weakness so that pharmaceutical 
companies might continue to improve their drug access strategies, while also being 
better connected to the expectations of stakeholders (ATMI, 2010). 
 Recent CSR activities of the pharmaceutical industry are not isolated to just 
developing countries, but include a diverse range of programs in developed countries as 
well.  For example, Johnson and Johnson (J&J) has partnerships with professional 
associations, academic facilities, and healthcare systems (Nussbaum, 2009), while both 
Pfizer and Merck have developed or expanded drug access programs in the US that are 
intended to help offset the effects of the recession on people’s abilities to affordably 
access medicines (Wientraub, 2010). 
 To summarize, the recent uptake of CSR by the industry may be a response to 
changes in the economic, social, and political status of the industry so “that the 
pharmaceutical industry, having acquired a position of global power and wealth, has 
thereby also assumed worldwide the moral duties that go with that station” (Dukes, 
2006, p. 266).  What remains contested is whether they have actually assumed those 
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morally related duties or are just strategically responding for various reasons such as 
risk or reputation management.  For instance, the numerous and continual controversial 
actions committed by various pharmaceutical companies challenge the veracity of the 
claim that CSR initiatives are not merely isolated actions, but represent a major priority 
for companies (Nussbaum, 2009).  These controversies may have been or continue to 
be a normative wakeup call for the industry; causing it to act more responsibly with 
regard to both society and their stakeholders.  Companies are now seeking a perception 
of responsibility, justified by the possibility of benefits, to leverage and achieve 
substantial benefits, both internally and externally (Scheider, et al., 2010). 
 
2.3.3 Perceived Conflicts of Interest – Constructed Controversies 
 The unique dual role of the pharmaceutical industry in combination with the size 
and scope of its economic, social, and political influence has led to normative 
expectations from society to prioritize additional responsibilities beyond basic 
development and commercialization of pharmaceuticals.  Contesting this statement is 
the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA 
cited in Roche, 2007, p. 1): “It should be underlined that the pharmaceutical industry's 
primary role and social responsibility is to deliver new, innovative medicines.”  There 
appear to be differing perspectives between society and the industry as to what 
constitutes social responsibility, with the IFPMA, which represents many pharmaceutical 
companies, linking the industry operating in its own self-interest to a natural and positive 
affect on the common good.   
 Societal expectations for greater responsibility appear to relate to the industry 
being more accountable for its actions in five areas of operations, while also fulfilling the 
industry’s self-described ‘primary role and social responsibility’.  The five areas are: 1) 
product recalls; 2) direct-to-consumer advertising (DTCA) and industry-sponsored 
education; 3) pricing; 4) innovation and patents; and 5) drug access.   
 In placing the onus on the industry to meet society’s expectation, there are five 
areas of controversy that display the different perspectives of responsibility between the 
industry and society.  Examples of these controversies are presented to illustrate the 
differing perspectives about responsibilities that, at times, divide the industry and its 
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supportive associations from a multitude of external groups (stakeholders and society). 
 
2.3.3.1 Product Recalls 
In the past decade, the pharmaceutical industry experienced an increasing 
number of product recalls detrimental to both its reputation and financial performance 
(Cheah, Chan, & Chieng, 2007).  In general, product recalls by pharmaceutical 
companies to take defective products off the market are voluntary, both in the North 
America and the United Kingdom (Angell, 2005; Cheah et al., 2007).  In the UK and 
Canada, the Medicines and Healthcare Products Regulatory Agency (MHRA) and the 
Marketed Health Products Directorate (MHPD), respectively, have the ability to remove 
a defective product from the market.  In the US, the Food and Drug Administration 
(FDA) has more limited powers, and can only recommend the removal of a product from 
the market (Cheah et al., 2007).  However, a recommendation from the FDA to 
withdraw a product carries very real consequences for a company.  A prominent 
example is the case of Merck and its popular arthritis pain medication, Vioxx, which acts 
as a nonsteroidal anti-inflammatory drug, or in other terms, a COX-2 inhibitor.  The 
reason Vioxx was removed from market was that post-market surveillance of the drug 
identified an increased risk of heart attacks and stroke for those on the medications 
(Angell, 2005).  The immediate financial and eventual reputational effects of Vioxx’s 
removal to Merck were significant: 
Merck’s stock price fell about one-third on the day of the announcement 
(FDA’s recommendation to remove Vioxx from the market), and the market 
analysts began to speculate gloomily about the company’s uncertain 
financial future and legal liabilities. (Angell, 2005, p. 266).   
 
 In this example, the negative consequences in terms of reputation and financial 
performance were compounded by other actions taken by the Merck.  Although 
recommended by the FDA, Merck was reluctant to put a warning label on Vioxx.  In 
addition, there is evidence that Merck began to suspect there were potentially harmful 
risks associated with Vioxx in 2000, but did not voluntarily pull it from the market until 
2004 (Cavusgil, 2007; Angell, 2005).  Furthermore there were allegations that Merck 
had articles ghostwritten and published in peer-reviewed journals based on Vioxx 
clinical trials that they paid for and ran (Faunce, 2010). During that four-year span, it 
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was estimated that Merck spent $50-100 million a year on advertising Vioxx to the 
public (Angell, 2005).  While Merck has maintained its innocence throughout the course 
of these events, some of the firm’s actions are questionable in light of society’s concept 
of social responsibilities for the common good. 
 Operating in a manner that is overly focused on self-interest rather than the 
patients using Vioxx illustrates a fundamental conflict of interest that resulted in a 
controversy that went beyond original safety concerns.  Controversy that can be 
perceived as an abuse of payers and patients that lack the expertise or experience to 
adequately evaluate the efficacy and safety of pharmaceuticals they are consuming 
(Australian Trade Practices Commission, 1992).   
 The information gap between the industry and the end-users of its products 
illustrates the vulnerable consumer base that is taking pharmaceuticals out of medical 
necessity rather than choice—a vulnerability that is easy to exploit.  Therefore, various 
stakeholders and society, in general, increasingly view a proactive, rather than a 
reactive, response to the unforeseen risks of a product as an action that is more socially 
responsible and accountable: 
In the area of product recalls, constructive responses to product defects 
by recalling defective products could be seen as positive efforts towards 
corporate responsibility and accountability; whereby the existence of what 
could be viewed as socially responsible practices (e.g. recalling defective 
products) could mitigate the adverse reactions arising from product 
recalls, and in doing so, protect the long-term interest of the stakeholders 
of the firm. (Cheah et al., 2007, p. 428) 
 
2.3.3.2 Direct-to-consumer Advertising (DTCA) and Industry-sponsored Education 
 Direct to consumer advertising (DTCA) is the marketing of pharmaceuticals to the 
general population, and from the industry’s perspective, serves to educate and 
empower the end-users of pharmaceuticals (van de Pol & de Bakker, 2010).  There is, 
however, a growing concern about DTCA, including the advertisement and promotion of 
pharmaceuticals in general (van de Pol & de Bakker, 2010; Angell, 2005; Hawthorne, 
2003).  While the information patients receive from DTCA may lead to greater patient 
autonomy and empowerment (van de Pol & de Bakker, 2010), many are concerned 
about ethics of advertising pharmaceuticals in general and the potential effects of what 
is perceived to be biased information contained in advertisements.  Consequences 
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include: inflated expectations, unnecessary demand for pharmaceuticals, higher priced 
drugs because of the inclusion of advertisement costs, self-diagnosis, and pressures on 
the doctor to prescribe certain pharmaceuticals (van de Pol & de Bakker, 2010).  
Therefore, “inappropriate medicalization carries the dangers of unnecessary labelling, 
poor treatment decisions, iatrogenic illness, and economic waste, as well as the 
opportunity costs that result when resources are diverted away from treating or 
preventing more serious disease” (Moynihan, Heath & Henry, 2002, p. 886).   
Although widely employed in the US, the concerns about the negative 
consequences of DTCA have led to it being prohibited or severely limited in its use in 
the EU and Canada.  Of greatest concern is that though there are regulations setting 
standards and guidelines on DTCA, there are often too few regulators to ensure full 
compliance (Dukes, 2006) and there are many ways to exploit its loopholes.  For 
example, US television channels with commercials that feature DTCA of 
pharmaceuticals are easily viewable in Canada where available.  Regulations only 
control DTCA within that country and do not have control over sources originating from 
a different one. 
 Another area of controversy for the pharmaceutical industry is their ever-
increasing role in the education of health professionals, both during and after their 
formal training (Angell 2005).  The ethical boundaries between some faculty members 
and pharmaceutical companies have become blurred, and, according to Angell (2005), 
it is not uncommon in the US for high-level faculty members of a health profession 
school to receive consulting fees from pharmaceutical companies.  The impact of a 
faculty member’s association with pharmaceutical companies on their students is not 
clear and remains contested, but nonetheless this relationship is a focal point of 
controversy.   
 Regardless of whether the cause and effect of such controversial education 
practices has been proved or disproved, some educational institutions have taken 
action against it.  Many prominent US universities have developed strong conflict of 
interest rules for physicians at their respective teaching hospitals to restrict or prohibit 
accepting money or gifts from pharmaceutical companies that engage faculty as 
speakers (Kowalczyk, 2010).  Additionally, there has been concern over the funding 
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provided by companies in the pharmaceutical industry to professional medical 
associations (PMA), and increasing interest to tighten the rules around the possible 
conflict of interest that could arise.  Recent proposals include requiring PMAs to reach a 
goal of $0 funding from the pharmaceutical industry, no collaboration or profiting from 
industry marketing activities, and ensuring all those with higher positions in the PMAs 
are free from any conflict of interest (Rothman et al., 2009). 
 Due to the competitive nature of the industry, it is always looking for new ways to 
promote its products, but such practices may be perceived as unethical.  Regulations 
are a response by governing bodies seeking to curb actions and behaviours that have 
been deemed unacceptable by those with the ability to pressure for or put such 
regulations in place.  What remains unclear is whether the industry itself understood 
that what they were doing with regard to education and DTCA was unethical, or was it 
part of a culture where it was just the way things are done, or were social and political 
norms such that it was socially acceptable at the time that the strategies were 
introduced—an acceptance that was later revoked by society.  Was the public aware of 
the possible implications of such strategies?   
 
2.3.3.3 Pricing 
In both developed and developing countries, the pricing of pharmaceutical 
products has been a significant point of controversy for the industry.  The adoption and 
use by brand name companies of a high risk, high financial return business strategy, 
that is incentivized and stabilized by the global availability of patent protection, has 
resulted in what has been perceived as ‘what the market will bear’ pricing for products 
that are a necessity rather than a luxury good (Hemphill, 2010; Hawthorne, 2003; Puig-
Junoy, 2005).  For example, in the US, from 2006 to 2007 the most commonly 
purchased brand name pharmaceuticals had an average price increase of 7.4 percent, 
which is 2.5 times the rate of inflation over the same time period (Hemphill, 2010).   
All patents create a monopoly, guaranteeing the innovator's exclusive rights to 
use and sell the innovation for a fixed period of years.  The monopoly revenue 
during this period is what provides the compensation for the initial investment.  
Ultimately, the market determines the size of the reward. (Puig-Junoy, 2005, p. 
23)  
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Such a pricing strategy may be considered socially acceptable if it does not 
create undue obstacles to patient access.  Two examples of pricing as an obstacle, and 
therefore issues of responsibility, is the 2001 incident around access to HIV/AIDS 
medications in South Africa and Brazil, and the extraordinary price increases of orphan 
drugs in the US (Hemphill, 2010.) 
The historical factors that led to the incidents in South Africa and Brazil can be 
partially traced to the creation of the World Trade Organization (WTO) that was 
designed to lower trade barriers around the world and further the goals of globalization.  
However, the inclusion of trade-related aspects of intellectual property rights (TRIPS) 
into the WTO framework was seen by some as a method to create a global scheme to 
secure and collect royalties on intellectual property (IP), such as patents (Saul, 2005).  
Even pro-globalization economists were displeased with its inclusion: 
The corporate lobbies [sic] in pharmaceuticals and software had distorted and 
deformed an important multilateral institution, turning it away from its trade 
mission and rationale and transforming it into a royalty collection agency. 
(Bhagwati cited in Saul, 2005, p. 179) 
 
 Saul (2005) describes the two main problems with the use of TRIPS by the WTO: 
1) the developing world saw it as severely limiting their ability to afford high-end western 
products when priced at western levels; and 2) it “creates cliffs of knowledge that 
newcomers to research are legally discouraged from scaling” (p. 179).  Eventually there 
was a backlash to TRIPS because of a perceived purposeful link to the reduction of 
competition; effectively, an attempt to solidify an oligopoly in sectors dependent on the 
use of IP.  For example, in 2001, the US government sought to protect pharmaceutical 
patents by challenging Brazil in the courts of the WTO for breaking patents to deal with 
its rising HIV/AIDS crisis.  However, in the six months following this intervention, 
protests around the world had sufficiently pressured the US government to withdraw 
their complaint (Saul, 2005).  
In addition, in 2001, 39 companies, backed by the US government, lodged legal 
complaints in response to South Africa’s decision to import generic forms of AIDS drugs 
that were still under international patent protection (Shamir, 2005).  South Africa and 
other African nations were importing what was considered by international property law 
as 'illegal' generic drugs as a method to control the high cost of therapy for HIV/AIDS, 
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an issue that continues to be a major health, economic, and social problem for much of 
sub-Saharan Africa.  In 1997, South Africa had amended its Medicines and Related 
Substances Control Act (1965) to allow for the importation of generic drugs; however, 
under international law, these generic drugs were viewed as illegal.  A coalition of 
pharmaceutical companies challenged the constitutionality of the amendment to the Act 
and argued that the new law violated the WTO's TRIPS agreement (Shamir, 2005).    
 International backlash against the coalition's actions by both social and political 
institutions was significant.  Over 250 NGOs joined the cause and they, in particular, 
were critical of the actions of the pharmaceutical industry.  As stated by the NGO, 
Oxfam: “pharmaceutical companies face a major reputation risk if they do not do more 
to promote access to life-saving drugs in the developing world” (Cited in Dukes, 2006, p. 
266).  In response to the backlash, the coalition of pharmaceutical companies conceded 
defeat rather than further jeopardize their reputations.  Did the pharmaceutical 
companies assume it would be socially and politically acceptable to act in their own self-
interest and counter to the common good of the people in South Africa because the 
current laws deemed them to be correct?  In light of South Africa's disadvantaged 
situation and pricing barriers to access, how could companies rationalize a decision that 
would drastically affect a vulnerable population?  Again, it appears as though the 
incidences in Brazil and South Africa are examples of companies analysing a situation 
using an amoral economic prism to understand and influence social and political policy.  
While there may be a lack of transparency about the connection between the 
cost to develop and produce a drug and the price the company will sell it for, there is a 
class of medications for which it is understood that costs will almost certainly exceed 
revenues.  These are referred to as orphan drugs.  In the US, the definition of an orphan 
drug is a pharmaceutical treatment for a disease that affects fewer than 200,000 
Americans (US Food and Drug Administration, 2010; Medicine Net, 2002).  In 2000, the 
European Union (EU) adopted a similar definition, but also included diseases and 
disorders more prevalent in developing nations.  In an attempt to compensate for the 
cost-benefit dilemma associated with orphan drugs, both the US and EU legislations 
provided pharmaceutical companies with incentives to research and develop treatments 
for orphan diseases (Hemphill, 2010 & Dukes, 2006).   
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In the US, incentives include a guaranteed seven-year period of exclusivity after 
FDA approval, 50 percent tax credits for clinical research during the approval process, 
grant funding, the waiving of fees, protocol assistance by the FDA, and availability for 
inclusion in the FDA’s fast track approval program (US Food and Drug Administration, 
2008a,b cited in Hemphill, 2010).  In theory, the combination of all these incentives will 
motivate companies to focus on orphan drug R&D.  Consequently, the products should 
be sold at a lower price because the substantially lowered R&D costs create greater 
opportunity to recoup those costs.  Even with such incentives, however, there have 
been a number of incidents where extraordinary price increases of more than 100 
percent on various orphan drugs have been instituted by pharmaceutical companies: 
An egregious example of such an extraordinary orphan drug price 
increase is Cosmegen, manufactured by Ovation Pharmaceuticals, Inc. for 
a small group of patients afflicted with Wilms’ tumour.  Ovation originally 
priced Cosmegon at $16.79 per dose, but subsequently raised the price 
per dose to $593.75—a 3,436% per drug dose increase. (Appleby, 2008 
cited in Hemphill, 2010, p. 226) 
 
 The social responsibility of such a price increase generates controversy because 
it is easily perceived as a self-serving ‘price gouge’ targeted at a group of patients for 
whom, in this particular case, the drug is necessary to treat a rare form of kidney 
cancer.  Additionally, the dramatic change in pricing also creates an issue of negative 
perception, or at least confusion, among stakeholders.  While there may be legitimate 
reasons, unless properly communicated, such pricing decisions will likely to erode the 
reputation of the company. 
The pharmaceutical industry’s perceived practice of routinely charging what the 
market will bear has resulted in major social responsibility issues.  Two main issues are 
the burden that these rising costs are placing on healthcare systems around the world 
and the inaccessibility of products due to pricing strategies, particularly in developing 
countries and/or poor populations (Dukes, 2006).  If companies are granted 
monopolistic property rights, should they be allowed to price their products at levels that 
would be counter-productive to not only the economic, but also the social purpose of 
patent incentivized R&D?  In addition, if resulting pricing strategies from controversies in 
developing countries still result in pricing drugs that are far too high for average 
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household incomes, then does a response by companies to pricing controversies 
represent just another strategy to protect patents and limit the introduction of generic 
competitors (Saul, 2005)? 
 
2.3.3.4 Innovation and Patents 
In the US, pharmaceuticals go through four key stages before marketing: 
discovery, preclinical testing, clinical trials, and approval review (Pharmaceutical 
Research and Manufacturers of America, 2010).  Only one in 10,000 medicinal 
molecules make it through all four stages.  A new pharmaceutical agent takes 
approximately 15 years to gain approval, and the estimated cost for a pharmaceutical to 
go from discovery to approval is $800 million (Pharmaceutical Research and 
Manufacturers of America, 2010).  The $800 million price tag is, however, an area of 
controversy, and seen by some as an exaggeration that does not accurately reflect 
actual R&D costs (2005, Angell; Dukes, 2006; Goozner, 2004; Light & Warburton, 
2011): 
Thus the mythic costs of R&D are but one part of a larger, dysfunctional system 
that supports a wealthy, high-tech industry, gives us mostly new medicines with 
few or no advantages (and serious adverse reactions that have become a 
leading cause of hospitalization and death), and then persuades doctors that we 
need these new medicines.  It compromises science in the process, and 
consumes a growing proportion of our money. (Light & Warburton, 2011, p. 15) 
 
Additionally, the 15 years’ approval time has been contested by external 
estimations of around 10 years (Dukes, 2006).  Importantly, the revenues of approved 
products must also account for the costs associated with products that failed to go 
through all four stages and gain approval. 
While the costs of development and approval are high, the rate of innovation has 
been declining.  From 1998 to 2002, only 14 percent of newly approved drugs by the 
FDA could be considered truly innovative, and from 2000 to 2004, there were only 32 
truly innovative drugs out of the 314 approved by the FDA (Angell, 2005).  Critics argue 
that the pharmaceutical industry is not providing enough ‘relevant’ innovation to justify 
the pricing and monopolistic property rights provided to them (Dukes, 2006).  
Additionally, “at the same time evidence is advanced to the effect that much of the 
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creativity attributed to research-based industry lies in fact with academic and other non-
commercial institutions” (Dukes, 2006, p. 238).  Saul (2005) describes the industry as 
increasingly reliant on public funded research, which they can purchase, and claim as 
their own through patent transfers.  As a result, the ‘weak innovative pipelines’ of 
pharmaceutical companies are causing share prices to fall, which have partially resulted 
in pharmaceutical companies attempting to create me-too drugs and extend patent 
exclusivity by a variety of means (Angell, 2005).   
The vast majority of “new” agents are classified as “me-too” drugs.  Near-
duplicates of drugs already on the market, these new drugs made up 77 percent of the 
approved drugs from 1998 to 2002 (Angell, 2005), and accounted for 80 percent of R&D 
costs (Dukes, 2006).   
Market reports from industry-oriented journals repeatedly confirm, there is still an 
over-whelming interest to develop products because of the relative ease and 
speed with which “me-too” molecules can be created and brought to market 
where there is a wide willingness to pay high prices. (Dukes, 2006, p. 246) 
 
The proliferation of me-too drugs creates an issue of research appropriateness as a 
reflection of the social responsibility of the pharmaceutical industry (Dukes, 2006; 
Angell, 2005).  Directing the majority of R&D toward duplicating existing drugs that 
target affluent populations, results in less innovation aimed at diseases of minority or 
developing world populations (Dukes, 2006).  However, it does avoid riskier ventures 
into trying to discover and commercialize truly innovative drugs.   
 In the pharmaceutical industry, once the patent expires—typically about 20 
years—generic manufacturers can legally produce and sell an identical version of the 
drug at a fraction of the price due to less spending on R&D.  Brand name companies 
want to be able to continue pricing products at their discretion, creating a situation of 
competing interests between them and generic manufacturers.  This situation has 
resulted in the pharmaceutical industry operating in its own economic self-interest by 
routinely trying to limit competition through various ways to extended patents, while also 
attempting to boost the sales growth of products before patents expire (Hawthorne, 
2003).  Is it socially responsible to limit competition when there could be adverse effects 
that result?  Additionally, shifting innovation priorities to me-too drugs violates their self-
described primary social responsibility of developing innovative medicines.  Many 
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controversies arise, and consequently damage the reputation of the industry. 
 
2.3.3.5 Drug Access  
 In 1948, the United Nation’s Universal Declaration of Human Rights established a 
basic human right that every person has a right to health, with access to medicines as a 
critical component (Dukes, 2006).  Notably, issues of drug access are not isolated to 
developing countries.  As the issues of orphan drug innovation and pricing demonstrate, 
people in developed countries must also deal with issues of access (Leisinger, 2009).  
 The debate about the pharmaceutical industry’s role in securing drug access is 
complex.  Issues around pricing, innovation, and patents have all been perceived as 
playing a role in the development of obstacles preventing desirable levels of drug 
access (Leisinger, 2009; Bluestone et al., 2002).  Playing an important part in the 
provision of healthcare, the industry is thought to have an inherent responsibility to 
provide access to their products to satisfy their ‘role’.  Paradoxically, the pharmaceutical 
industry is both blamed for and sought after as the champion that can cure the problems 
associated with drug access (Leisinger, 2009).  However, these opposing hardline 
views of the industry are unhelpful to the point that they are preventing a multilateral 
approach to a very complex problem involving many stakeholders: 
Sustainable improvements in access to medicines for the poor necessitate 
complex systemic changes and political reforms.  Demands for unilateral action 
focusing on selected elements of the complex problem will achieve little more 
than short-term symptomatic alleviation on the micro-level that will be quickly 
absorbed by extant systemic limitations.  The strength of the ‘solution chain’ is 
determined by the weakest link.  This is – as said before –often the willingness or 
ability of the primary duty bearers to live up to their responsibilities.  
Nevertheless, the private sector has an important role to play.  (Leisinger, 2009) 
 
 The pharmaceutical industry has a history of voluntary and charitable acts with 
regard to drug access (Dukes, 2006; Leisinger, 2009); however, proponents of drug 
access and critics of the pharmaceutical industry are calling for changes to patents and 
R&D to help ensure greater drug access (Bluestone et al., 2002).  The patchwork 
strategies of volunteering and charitable acts are not the systemic changes that 
proponents of greater drug access are promoting.   
With the majority of focus and discussion around access directed toward the 
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pharmaceutical industry, issues of “absolute poverty and powerlessness, lack of good 
governance leading to deficits in health infrastructure, lack of well-trained doctors, 
nurses and pharmacists have taken a back seat” (Leisinger, 2009, p. 9).  Leisinger 
suggests that for progress to be made in addressing these areas of concern, the 
singular blame of one aspect (e.g. the pharmaceutical industry) in the totality of an 
extremely complex problem must be acknowledged and eliminated because it is not 
productive and may actually be stifling progress.   
 As large entities with the ability to discover and commercialize a drug for market, 
the pharmaceutical industry is perceived by many, including social and political 
institutions, to have a social responsibility to increase drug access—a possible license 
to operate (LTO) based on the capabilities on the industry and the incentives provided 
to it.  To use the industry’s own words, if they fail in their ‘primary role’, then they will be 
perceived as failing their social responsibility.  The result of a perception of failure could 
be reputational and financial problems for an industry that is already facing an economic 
downturn.  Examples of failure in the primary role include pricing strategies that create 
obstacles or overly burden healthcare systems; engaging in litigation to extend patents; 
and diverting R&D towards profitable therapeutic areas targeted at affluent populations.  
  
2.3.4  Culmination of Controversies – An Uncertain Future 
 In addition to the presented social responsibility issues, a number of ethical 
controversies coupled with product pipeline, talent, and cost issues create a potentially 
troubling scenario for the future health of the pharmaceutical industry.  The ethical 
controversies are connected with the previously described five areas of company 
operations creating controversy because of perceived self-interest guiding their 
behaviour.   
 The following section details the additional issues troubling the industry and then 
explains how CSR, in a business case scenario, has a substantial role to play to help 
mitigate the uncertain future that it is facing. 
The reputational fallout from social responsibility issues is related to growing 
ethical concerns about the business practices of companies in the pharmaceutical 
industry, and has resulted in litigation and fines by governments, federal trade 
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commissions, and consumer groups:  
In just the past couple years, the pharmaceutical industry has faced a tidal wave 
of investigations and lawsuits brought by federal prosecutors, state attorneys 
general, company whistleblowers, and a host of consumer groups and individuals 
(Angell, 2005 p. 229). 
 
 Litigation associated with, for example, off-label marketing for unapproved uses 
of drugs has been prominent in recent controversies.  For example, Pfizer was required 
to pay $2.3 billion in fines for off-label marketing of 13 different drugs (Associated Press, 
2009).  AstraZeneca recently had complaints filed against it because of accusations that 
it has been promoting a drug, Seroquel, to treat disorders that were not authorized by 
the FDA (Jack, 2010).  In 2009, Eli Lilly settled criminal and civil cases for $1.4 billion 
after allegations for off-label promotion of Zyprexa.  As a result, Eli Lilly overhauled their 
code of conduct for employees in an attempt to prevent similar controversies in the 
future (Sullivan, 2009).  It is not to say that the drugs being marketed off-label would not 
be effective for these conditions.  Rather, the controversy arises from the fact that these 
products did not go through the appropriate safety evaluations by regulatory bodies to 
ensure they are appropriate for these unauthorized conditions.   
 Presently, there is an industry-wide legal investigation looming over the 
pharmaceutical industry.  The Department of Justice (DOJ) and the Security and 
Exchange Commission (SEC) in the US are conducting an international corruption 
investigation into numerous pharmaceutical companies and their payments to doctors, 
clinicians, hospital operators, and regulators in foreign markets (Kirchgaessner, 2010).  
Since these actors tend to work at state-run medical facilities, they are considered 
government employees.  As such, payments to these individuals violates US anti-
bribery laws that state it is illegal to offer items of value to foreign government 
employees for the purpose of making a profit (Kirchgaessner, 2010).  A main area of 
concern for the DOJ and SEC is how these payments may have influenced foreign 
clinical trials that were eventually included in the FDA’s approval process. 
 Social and political institutions appear to be increasingly concerned that the 
business practices of the industry might violate laws and regulations regarding 
influence, coercion, and misinformation.  Laws and regulations continue to be adapted 
to address developing concerns.  Again, a question arises: is it ethical of 
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pharmaceutical companies to engage in practices that might be considered morally 
wrong by society, but do not violate any current laws or regulations?  Based solely on a 
declining reputation and a greater emphasis being placed on ethical codes of conduct, it 
appears that society considers it rather unethical.   
 While profits and margins remain high, sales growth is slowing and share prices 
are dropping (Angell, 2005).  The weak pipeline, in conjunction with a wave of upcoming 
patent expirations, has the pharmaceutical industry facing an uncertain future (Berger 
and Grainger, 2010).  For example, at the end of the past decade, a wave of patents 
began to expire, and this is expected to translate into substantial decreases in revenue 
for the majority of the brand name companies.  For example, Eli Lilly has the following 
four patents expiring: Cymbalta (anti-depressant), Humalog (insulin therapy), Evista 
(osteoporosis treatment), and Gemzar (cancer treatment).  These four products 
represent 40 percent of Eli Lilly's forecasted sales in 2010, and when they expire, the 
level of revenue generated from these will decrease substantially.   
 The dry-pipelines are a signal of the pharmaceutical industry’s business model 
coming under siege.  It is less viable to focus on ‘one size fits all blockbuster drugs’ 
(Berger & Grainger, 2010).  Drug development costs have been steadily increasing, 
while R&D productivity is decreasing in the face of the “low-hanging fruit of evolving 
medical science have already been harvested, and the promise of recent rapid 
advances in pharmacogenomics and genetics has yet to be realized” (Berger & 
Grainger, 2010, p. 916).  To make matters more difficult for companies, there is a talent 
shortage resulting from the departure of executives and substantial lay-offs at most 
major pharmaceutical companies (Neff, 2010). 
 One way the industry is seeking to deal with these issues is through mergers and 
acquisitions (Fai and Morgan, 2007).  In two recent moves to combat pipeline, talent, 
and cost issues (Fai and Morgan, 2007), Pfizer purchased rival pharmaceutical 
company Wyeth for $68 billion, while Merck has merged with Schering-Plough.  The 
takeover gives Pfizer and Merck increased R&D capabilities and access to drugs 
produced currently and new drugs in the pipelines at Wyeth and Schering-Plough, 
respectively (Hall and Krauskopf, 2009).   
 There are issues, however, with whether merger and acquisitions are socially 
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responsible.  While mergers and acquisitions may be necessary to improve the 
sustainability of the companies involved, the resulting layoffs negatively affect the lives 
of many former employees (Esteban, 2007).  Additionally, CSR programs are likely to 
be reduced in total when two companies merge into one entity.  Not including the recent 
mergers and acquisitions, there have also been large-scale layoffs and transition 
periods for many pharmaceutical companies (Angell, 2005).  Most notably, the process 
of merging and acquiring corporations by different corporations has been described as a 
process of purposely reducing competition in an attempt to create monopolistic or 
oligopolistic business enthronements (Saul, 2005; Soros, 2000).    
 The combination of controversies infused with social responsibility issues, an 
unstable financial future, and a tarnished reputation displays an obvious need to better 
respond to the concerns and expectations of society.  Saul summarizes the potential 
backlash: 
The question is simple: How long will a handful of the most profitable joint stock 
corporations in the world, whose declared purpose is well-being, be allowed to 
cause tens of thousands of premature deaths each year in the name of patent 
protection and stockholder interests?  There are growing signs that the answer is 
not much longer. (Saul, 2005, p. 181) 
 
A possible response would be to integrate a CSR-based strategy into the 
pharmaceutical industry to mitigate the uncertain future.  It is suggested, that similar to 
other industries, by thoroughly integrating CSR into the core business strategies, the 
pharmaceutical industry will be better able to identify and prevent present and future 
risks facing the industry.  They could also begin to rebuild their reputation to previous 
levels, provide benefits to those all affected by their CSR efforts (Bennett et al., 2009; 
Googins et al., 2007), and live up to their ‘primary role and social responsibility to deliver 
new, innovative medicines’.  All of this would by accomplished by operating in a way 
that addresses matters of the common good in conjunction with their own self-interest.  
However, it must be noted that CSR is only one part of the solution for pharmaceutical 
companies, and should only be considered as part of a larger, complex strategy that 
seeks to better align the priorities of the healthcare industry with those of the common 
good. 
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2.3.5  Future Strategies for CSR in the Pharmaceutical Industry 
 Although the pharmaceutical industry is actively engaged in CSR practices, a 
range of controversies challenges their approach.  It is unclear if CSR, as it occurs in 
the pharmaceutical industry, is simply a reactive patchwork or a proactive approach to 
address their social responsibilities through a fundamental shift in perspective aligning 
actions with society’s interests.  It also could be mix of both, or neither.   
 A patchwork CSR strategy is generally limited to short-term benefits and is seen 
as lacking accountability and transparency (Greve, 2008).  For example, in the area of 
marketing, Pfizer has begun disclosing payments made for educational purposes to 
private practice doctors (Kirchgaessner, 2010b), while GSK, Merck, and Pfizer are 
looking at new compensation methods for their sales force representatives in an attempt 
to curb any irresponsible practices that were incentivized by sales-based compensation 
(Loftus, 2010).  Examples such as these suggest isolated and reactive rather than 
comprehensive and all-inclusive strategies.  The promises made by engaging in or 
promoting CSR by pharmaceutical companies will remain unfulfilled until the CSR 
strategy is not simply patching up some of the most publicly troublesome areas 
(Nussbaum, 2009).  Many industry observers are advocating more company-wide, 
integrated, and comprehensive approaches to actually address the root causes of the 
concerns relating to issues of social responsibility, instead of a reactive treatment for the 
symptoms of such problems (Angell, 2005; Leisenger, 2009; Nussbaum, 2009). 
 In the following section, four main areas of a successful CSR strategy will be 
presented: 1) CSR unified industry; 2) adoption of a business case for CSR; 3) 
benchmarking and transparency; and 4) the pertinent areas to address in a 
comprehensive strategy. 
 
2.3.5.1  A CSR Unified Industry 
 A CSR-unified pharmaceutical industry with a comprehensive strategy is viewed 
by some as an effective and universal response that will be perceived as authentic by 
stakeholders, governments, and society.   
Owing to the nature of its trade, the pharmaceutical industry is in a sensitive 
position, with its credibility depending on sound business ethics.  Pharmaceutical 
companies thus have an interest to adopt socially responsible business practices.  
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Such actions, if employed by all players, would create a level playing  field 
and dispose of competitive disadvantages CSR-conscious companies might have 
at the moment. (Nussbaum, 2009, p. 75)   
 
 Reputational damage is industry-wide and not focussed specifically on one 
corporation (Esteban, 2008).  As a result, mitigating the damage and dealing with an 
uncertain future are simply too much for one corporation to tackle alone (Parker, 2007).  
To adequately transform their reputation, an industry-wide mutual understanding and 
implementation of a comprehensive CSR strategy should occur (Nussbaum, 2009).  An 
industry-wide CSR plan would unify practices, utilize multiple perspectives to identify 
potential risks and opportunities, combine areas of expertise, and concentrate 
resources to achieve effective and efficient strategies (Nussbaum, 2009).  Most 
importantly, if each company is engaging in similar CSR, there will be a higher 
probability of its normative adoption as a standard aspect of business.  
 The peer pressure exerted through a CSR-unified industry is intended to increase 
the interdependence and social cohesion among corporations.  Unification would also 
resist any free-rider companies that do not properly engage in CSR, but nonetheless 
seek to reap the reputational benefits created by other companies (Greve, 2008).  Even 
with a unified CSR strategy, mistakes will occur (Neal, 2006).  Nevertheless, a unified 
industry would better prevent individual controversies from affecting the overall 
reputation of the industry.  However, the likelihood of this situation developing has to be 
questioned because of the fierce competition among companies and the anti-
competitive practices that have been a major source of their current problems.   
 An example of one pharmaceutical company’s actions serving as the tipping 
point for industry-wide negative effects was the J&J/McNeil recall of a children’s 
medication.  In April 2010, an FDA investigation reported incidents that violated quality 
control standards through the mishandling of materials and inadequately investigating 
consumer complaints about a medication for children that is produced by McNeil, a 
consumer healthcare unit for J&J (Rockoff, 2010).  The ensuing recall was the fourth 
product recall for J&J that year.  Additional claims that the company was stalling 
information requests and that they knowingly misled regulators has spurred many 
criticisms and desires for change by the FDA and the US Congress (Wechsler, 2010).   
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The case could have broader ramifications for pharma companies, as FDA 
moves to step up oversight of drug manufacturing operations and recall 
procedures.  And Congress seems more enthusiastic about enacting legislation 
to strengthen FDA’s enforcement powers, namely authority to mandate recalls, 
impose civil monetary penalties and facilitate access to company records. 
(Wechsler, 2010, p. 14) 
 
The actions by J&J and their subsidiary McNeil demonstrate how a company that 
engages in CSR but has not approached it in a strategically comprehensive and ethical 
way can cause a controversy that may have ramifications that affect the entire industry.   
To better prepare and design a comprehensive CSR strategy, the 
pharmaceutical industry must enhance their dialogue with stakeholders.  The complex 
web of stakeholders around each company is, in reaction to controversies, becoming 
increasingly informed, critical, and active (O’Riordan & Fairbrass, 2008).  As a result, 
the industry must look to broadening stakeholder dialogue and engagement (O’Riordan 
& Fairbrass, 2008).  This heightened level of engagement would aid in identifying new 
opportunities for the industry to help them to proceed in a socially responsive way 
(O’Riordan & Fairbrass, 2008).    
 
2.3.5.2 Adopting a Business Case for CSR—A Win-Win Justification 
 Keeping CSR on the periphery of operations will likely result in diminished 
effectiveness or patchwork strategies because of the lack of priority, and therefore 
resources and commitment.  Based on this logic, CSR should be integrated into the 
centre of operations within a corporation for it to reach its full potential.  This requires 
the developing of a business case for CSR (Esteban, 2008; Bennett et al., 2009; 
Googins et al., 2007).   
 The business case for CSR is the process of developing and implementing a 
CSR strategy as a means to create win-win scenarios between the company and 
targets of CSR policies and programs (Frynas, 2008; Bennett et al., 2009; Kurucz et al., 
2008; Googins, et al., 2007).  Although there is no conclusive link between CSR 
engagement and financial performance, some have qualitatively argued that there is a 
business case for CSR because of the intangible external and internal benefits that 
result (Parisi & Hockerts, 2008).  
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 Kurucz et al. (2008) elaborate on four developed categories of business case 
scenarios for CSR based on the perspective and approach selected by those with 
decision-making authorities: cost and risk reduction; competitive advantage; reputation 
and legitimacy; and synergistic value creation.  In comparing the four scenarios, 
synergistic value creation would likely be the optimal solution for the pharmaceutical 
industry because it details the most complete strategy to finding a balance between self-
interest and the common good.  Using synergistic value creation to develop layers of 
partnerships with stakeholders (e.g. NGOs, governments, academia, health 
professionals patient groups etc.) will help to better identify risks and opportunities, 
utilize a variety of expertise, and inherently become more transparent, while also re-
shaping the industry to become more sustainable (Kurucz et al., 2008; Lee & Kohler, 
2010; Benett et al., 2009; Googins et al., 2007).  
 
2.3.5.3 Benchmarking and Transparency  
 The CSR literature discusses the use of benchmarking to entice CSR-related 
competition among pharmaceutical companies (Leisinger, 2009; Lee & Kohler, 2010).  
A multi-stakeholder approach to benchmarking, such as the Access to Medicines Index 
(2008, 2010) is suggested as having the potential to elevate transparency with regard to 
the strengths and weaknesses of the operations of the industry.  The resulting 
transparency could lead to better and more specific multi-stakeholder strategies that 
address large-scale social responsibility issues in which the pharmaceutical industry 
plays a key role (Lee & Kohler, 2010).  Transparency plays a vital role in providing 
authentic communication of CSR outcomes so that the industry can be credited for its 
CSR accomplishments, while also adding validity to industry CSR reports and the 
voluntary nature of CSR (Nussbaum, 2009).  
 Competitive advantages are likely to result from both the reputational benefits 
associated with higher rankings and the potential increases in investments from socially 
responsible investors (SRI) that use a combination of financial and social performance 
as a filter for investment (Lee & Kohler, 2010).   
 Overall, examining the literature around benchmarking reveals many cause and 
effect assumptions that have not been effectively realized.  Benchmarking might 
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incentivize competition among companies to engage in CSR, but these same 
companies have been shown to find effective means to stifle competition and engage in 
overly self-serving behaviours.  Benchmarking, therefore, has to be considered a 
supplementary method to encourage CSR engagement as it might otherwise incentivize 
further unethical actions if it is not carried out in tandem with more comprehensive and 
normative changes.   
 
2.3.5.4 A Comprehensive CSR Strategy 
 If adequately addressed, six areas of business practices recommended should 
reflect and induce greater social responsibility in the operations of pharmaceutical 
companies.  Adapted from Esteban (2008) and Parker (2007), the six areas include: 
1) Be more transparent and better at communicating their policies and procedures 
for testing and marketing products; 
2) Develop a comprehensive HR strategy around issues like diversity, 
remuneration, and personal and professional development as well as employee 
engagement in charitable activities; 
3) Manage ongoing environmental issues relating to procurement, waste 
management, and the efficient use of key resources like water; 
4) Design new innovation strategies that focus on addressing the needs of 
stakeholders and relying less on industry needs; 
5) Develop an open dialog with stakeholders to help identify their needs and 
expectations; and 
6) Lower R&D costs by increasing outsourcing and in-licensing, resulting in lower 
costs for consumers. 
 
Encapsulated within these six areas are a number of concepts previously 
discussed in this literature review.  For example, the lowering of R&D costs was 
discussed with regard to patents and innovation, and HR strategies regarding 
remuneration policies were discussed as a response to specific controversial practices 
by sales associates.  Overall, the six areas blur and overlap the five areas of 
controversy detailed earlier.  They provide insight into possible strategies to overcome 
practices that have been deemed socially unacceptable by individuals and groups 
around the world.  Used in combination with each other and within a unified industry 
context, companies could potentially develop synergistic business cases for addressing 
all of the six areas using programs and polices considered CSR.  The results of which 
could be validated and communicated externally by benchmarking organizations. 
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 A comprehensive and unified CSR strategy for the pharmaceutical industry would 
need to be complementary to the current business strategy changes that are already in 
progress.  For example, emerging markets are becoming the new source of growth for 
the pharmaceutical industry.  These markets are estimated to make up 70 percent of 
the worldwide growth in the pharmaceutical market, and expanding their presence in 
large markets such as China and India is vital for the pharmaceutical industry (Rockoff, 
2010b).  In addition to entering these new markets, the industry is also beginning to 
develop a more fully integrated pharmaceutical network, where out-sourcing of drug 
development services and trials to the developing world is used to lower R&D costs and 
speed up development times (Van Arnum, 2010).   
 It does appear that the industry is attempting to address some aspects of the six 
areas already, but in what could be considered a more patchwork way.  It is also 
important to note, however, that the CSR-related strategies in this section come from 
the perspective of people outside the industry.  Just as it has been assumed that the 
industry lacks external perspective, those external to the industry may lack an internal 
perspective.  As a result, what is required is an industry-based perspective on these 
matters to better complete the understanding of the strategies currently in place and the 
rationale for past and current decisions by pharmaceutical companies.   
 
2.4 Summary  
There are many players (scholars, business leaders, NGOs etc.) positioning 
themselves in relation to CSR, yet there has been a failure to bring standardization to 
what it can or should entail for businesses and what society should expect in return: 
 The study of CSR has been hampered by a lack of consensus on the 
definition of the phenomenon, unifying theory, measures, and 
unsophisticated empirical methods. (Crane, McWilliams, Matten, Moon, & 
Siegel, 2008, p. 568)  
 
The normative nature of CSR affected by continually changing business 
environments appears to be a major reason for the lack of consensus.  Every person, 
group, culture etc. has different expectations about the role and responsibilities of 
businesses to society, both locally and globally.  As a result, there is a mix of drivers 
and motivators interacting to create reasons, or rationale, for engaging in CSR at both 
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the company and industry levels.   
Seemingly connected to current concepts of CSR is the perception of a symbiotic 
relationship between business and society.  The symbiotic relationship represents the 
interdependence between business and society, where the health of one relies on the 
health of the other.  Recent economic maleficence of Enron or WorldCom are large-
scale examples of how the demise of an integrated and influential MNC can have 
rippling effects, both economic and social, across the lives of individuals.  However, the 
concept of the symbiotic relationship has been discussed for much longer.  Aristotle, for 
example, discussed how businesses are a part of society so they have an obligation to 
contribute to the common good (Mele, 2008).  Therefore, the following definition best 
explains how the process of strategically engaging in CSR brings together the overlap 
between definitions, the normative nature of CSR, and the symbiotic relationship 
between business and society: 
CSR blends and harmonizes economic operations with human community’s 
social systems and institutions, creating an organic linkage between business 
and society.  The end goal of this relationship is to achieve a balance between 
the firm’s economic operations and the society’s aspirations and requirements for 
community welfare. (Frederick, 2008, p. 523) 
 
 In combination with a substantial increase in technology, globalization has 
created greater access to information, albeit unevenly within and across nations.  The 
current drivers for CSR have been influenced by society’s increased access to 
information.  The information provides greater awareness regarding the costs (negative 
externalities of company operations) that individuals are routinely and involuntarily 
subject to as a consequence of market failures in economies heavily influenced by the 
concept that individualism in a perfect market can lead to societal-wellbeing:   
Externalities and other market failures are not the exception but the rule.  If that is 
the case, it has profound implications.  There is meaning to individual and 
corporate responsibility.  Firms need to do more than just maximize their market 
value.  And individuals within corporations need to think more about what they do 
and the impacts on others.  They cannot get by by saying that they are “just” 
maximizing their incomes. (Stiglitz, 2010, p. 283) 
 
Interestingly, it is paradoxical that businesses can be considered the cause and the cure 
for the growing environmental, social, and economic problems (Scherer & Palazzo, 
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2008).   
The employees and leaders of businesses are not separate from the society in 
which they operate.  Increasing numbers of employees are stating a desire for more 
CSR engagement by their prospective employers, and leaders of companies are facing 
greater public pressure to assume more responsibility for the operations of their 
company.   
All of these economic, political, and social factors have contributed to CSR 
becoming a global business trend.  Although it is applied according to a range of 
perspectives and methods, the motivators for engaging in CSR vary greatly.  Both 
Canada and the US feature companies that are engaged in CSR at varying levels for a 
range of reasons.  In contrast to many European nations, neither the government of 
Canada nor the US has made it a priority to promote the adoption of CSR by business.  
Canada’s social safety net and the US economy’s reliance on free market economics 
create two different but often similar business environments with regard to CSR.  
However, proximity, market size, free trade agreements and the greater reliance of 
Canada on the American economy presses the Canadian market to adopt more 
American business perspectives and policies than vice versa.  Therefore, Canada and 
the US, with pharmaceutical companies with operations in both countries, make them 
the desired locations to examine the engagement in CSR within the pharmaceutical 
industry. 
 The pharmaceutical industry has faced persistent and increasing criticism for not 
properly managing the social responsibilities attributed to its dual role, as an integral 
part of the healthcare system with a for-profit orientation.  The industry's history has 
been shaped by its dual role because the regulations designed to protect those using its 
products are applied in combination with others designed to prevent or stop conflicts 
from the dual and competing interests.  As a result, the pharmaceutical industry is one 
of the most heavily regulated industries in the world.   
 Further attributed to the dual role of the industry is a multitude of controversies 
around the industry’s social responsibility.  The controversies are fuelled by a battle of 
perceptions about the industry, its responsibilities, and the changes that many perceive 
to be required to fix systemic problems.   
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Big pharma did help pump up drug spending by pushing the edges of the profit 
envelope.  It used every trick in the law to delay generic alternatives.  It poured 
on DTC advertising to encourage patients to demand expensive new medicines 
rather than generics and over-the-counter products, and then buttressed that 
effort by courting doctors with fancy meals.  It harnessed its clout in Congress 
and state legislators to try to block measures that would restrain the cost of 
drugs, give a leg up to cheaper competition, or—most notably—add a 
prescription drug benefit to Medicare. (Hawthorne, 2003, p. 180) 
 
 A solution to the systemic problems could be the adoption of a comprehensive 
CSR strategy, which includes a CSR-unified industry, synergistic business cases to 
incentivize engagement, changes to six areas of business operations, and participation 
in external benchmarking.  The pharmaceutical industry is a highly competitive industry, 
and it appears that it is still necessary to ensure that it continue to operate in its own 
self-interest as they engage in CSR.  As they take on greater responsibilities to benefit 
others outside their company, it will have to be done in a way that creates benefits for 
the companies as well. 
 External groups and individuals have dominated the discussion about the socially 
responsible actions and behaviours of the industry, perhaps, even to the dismay of the 
pharmaceutical industry.  The poor reputation of the industry leads to authenticity 
including minimal credit for its current CSR strategies.  The battle of perceptions is 
weighted heavily toward those outside the industry, and this may hamper the industry’s 
ability to improve its reputation and justify further engagement in more socially 
responsible behaviours.  As a result, it is necessary to examine the perception of CSR 
from the point of view of those within the industry to better understand how and why the 
industry is currently engaging in CSR.   
 Many questions about the pharmaceutical industry's perspective about the issues 
and strategies are brought up in this review of the literature.  The debate about CSR in 
the industry needs to become better rounded through the inclusion of an internal 
perspective.  Are companies adapting CSR strategies in recognition of external drivers?  
Where are the continual changes with regard to CSR headed?  What internal and 
external obstacles is the industry facing with regard to the development and 
implementation of CSR?  Creating more effective and efficient dialogue among the 
pharmaceutical industry, stakeholders, and society is intended to lead to the removal of 
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polarizing perceptions that are hindering CSR progress.  As a result, the review of the 
literature revealed gaps, which, if examined, would contribute to our understanding of 
how and why the pharmaceutical industry engages in CSR. 
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3. Research Methods 
3.1 Outline 
 The following chapter provides an overview of the research methods employed, 
beginning with my selection of qualitative research as the main method of inquiry.  
Based on this choice, the next three sections explain my epistemological stance, 
methodology, and data methods (collection, procedures, and analysis).  Overall, the 
totality of the research methods aligned for a more fluid and appropriate approach to the 
research topic that I studied.   
 
3.2 Methodological Framework 
3.2.1 Qualitative Research 
 Research can generally be separated into two fundamental approaches: 
qualitative and quantitative.  The distinction between qualitative and quantitative 
research occurs at the level of methods.  Identical epistemologies and methodologies 
can be represented within both types of research, but the selected methods will 
distinguish the two.  However, qualitative and quantitative research does not have to be 
mutually exclusive, and mixed methods approaches are increasingly common (Crotty, 
1998).   
 Qualitative research was selected as the most effective route to conduct research 
into CSR within the pharmaceutical industry.  While a quantitative approach was 
contemplated, it was disregarded due to perceived limitations associated with the depth 
of information that it could obtain.  I believe a sometimes-controversial subject like CSR 
requires a substantial amount of flexibility to obtain adequate and comprehensive data 
for analysis.  As a result, I concluded that questionnaires, commonly associated with 
quantitative research, would not provide the necessary data for the research.  
Additionally, with a relatively small number of large-scale pharmaceutical companies 
operating in Canada and the US, sufficient levels of respondents for statistical analysis 
and generalizability would be difficult.  As a result, qualitative research was selected 
because for its flexibility and depth.  
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3.2.2 Epistemology - Constructionist 
 An epistemology “is a way of understanding and explaining how we know what 
we know” (Crotty, 1998, p. 3).  A “philosophical grounding for deciding what kinds of 
knowledge are possible” (Maynard, 1994 cited in Crotty, 1998, p. 4) is essential to form 
an understanding of what is being researched.  Therefore, my perspective on the nature 
of knowledge is used as reasoning or justification for my methodology and methods.   
The three most prevalent epistemologies are: constructionism, objectivism, and 
subjectivism; each has a different perspective on the nature of knowledge and reality.  
In my research, I chose to use a constructionist epistemology.  To ensure consistency, I 
attempted not to waver too much from constructionist into different epistemologies 
because each is inherently different from others, and shifting back and forth across 
epistemologies would likely result in contradictions within the research findings. 
 Constructionism is the idea that knowledge is constructed through our 
interactions with the world (Crotty, 1998; Burr, 1995); meaning cannot exist without the 
use of our minds.  This is opposite to objectivism, which sees meaning as always 
existing with or without consciousness.  The opposing nature of these epistemological 
assumptions supports the argument that an epistemology should be stated and 
consistently relied upon throughout the research process to avoid possible 
contradictions.  However, my own and participants’ interpretations of participants have a 
subjective element because we are each attempting to understand and place meanings 
onto the actions of others.  As a result, although subjectivism is not the chosen 
epistemology, it did play a factor in the research process and should be noted.  To 
compensate for the levels of subjectivism, I had to consciously reflect on the level of 
subjectivity in my interpretations as to understand how it influences my analysis and 
viewpoint of the other narratives at play.   
Constructionism takes the viewpoint (Burr, 1995, p. 4) “that all the ways of 
understanding are historically and culturally relative”.  This method of conceptualization 
is important when investigating practices in the business world because cultures vary 
from employee to employee, business to business, region to region: each has its own 
history and experiences that can influence decision-making and the construction of 
areas such as CSR.  Based on this information, I think that the complex cultures within 
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and around businesses required an epistemological stance like that of constructionism 
because it is a socio-cultural practice.  Burr (1995) expresses a similar viewpoint in her 
explanation of constructionism: “Each different construction also brings with it, or invites, 
a different kind of action from human beings”.  It is my personal belief, as well, that 
knowledge is constructed through our interaction with the social world. 
  
3.2.3 Methodology – Constructivist Grounded Theory  
Grounded theory was developed by two scholars, Glaser and Strauss (1967).  
The grounded theory methodology was created as a way to deduce insights directly 
from the data to develop a substantive theory (Glaser & Strauss, 1967).  “The relevance 
of a grounded theory derives from its offering analytic explanations of actual problems 
and basic processes in the research setting” (Charmaz, 2000, p. 511). 
The primary concepts driving the process of grounded theory are constant 
comparison and theoretical sampling (Suddaby, 2006).  Constant comparison is the 
process of collecting and analyzing data simultaneously while constantly comparing 
each piece of data, whether they are categorized or not, to identify similarities and/or 
differences that can create new or build upon existing categories in the attempt to 
further construct a substantive theory (Glaser & Strauss, 1967; Suddaby, 2006).  
Theoretical sampling uses the developing theory to identify new and/or old sources of 
data to be collected that can potentially yield theoretically relevant data to help further 
its construction (Suddaby, 2006; McCann & Clark, 2003).   
Constructivist grounded theory accepts that there are multiple realities at play 
during any situation, but these realities are not truths as post-positivists (e.g. objectivist 
epistemology, Glaser and Strauss’s original version of grounded theory) believe 
(Charmaz, 2000).  The realities created through the social interaction of people within 
their personal and societal roles are never one-dimensional and, therefore, settling on 
only one perspective drastically oversimplifies any reality.  Charmaz (2000) explains 
how constructivism “recognizes the mutual creation of knowledge by the viewer and the 
viewed, and aims toward interpretive understanding of the subjects’ meaning” (p. 510).  
The researcher becomes an active participant by interpreting participants’ 
interpretations about their perceived realities.  The researcher plays a role in the 
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construction of realities.  As a result, I had to understand the influence of my 
perspective on the both the collection and analysis of data (Charmaz, 2000).   
Constructivist grounded theory seeks to collect not only facts or figures but also 
the multiplicity of the views and values interacting in any given social situation 
(Charmaz, 2000).  Understanding that there are always multiple perspectives interacting 
in the creation of any phenomenon, I consider my substantive theory open to 
modification through refinement, adaptation, and additional contributions.    
The social world is always in process, and the lives of the research subjects shift 
and change as their circumstances and they themselves change.  Hence, a 
grounded theorist – or, more broadly, a qualitative researcher – constructs a 
picture that draws from, reassembles, and renders subjects’ lives.  The product is 
more like a painting than a photograph (Charmaz, 2000 p. 522). 
 
Based on a constructionist epistemology, I chose to adopt the constructivist 
grounded theory methodology because of how its philosophical undertones and 
methods of developing a substantive theory aligned with my beliefs.  Additionally, it 
features rigorous data collection and analysis methods that are not overly constraining 
but do require a high level of creativity to adequately generate a substantive theory 
(Suddaby, 2006; Charmaz, 2000; Richardson & Kramer, 2006).  Reflexivity is a 
requirement of constructivist grounded theory because, as a researcher, I had to 
constantly analyze not only the interpretations of the participants but also my own to 
understand how they might have affected each other.  The resulting substantive theory 
is embedded within a multi-story narrative, which is the most accessible way to present 
it (Charmaz, 2000; Scott & Howell, 2008).  
  
3.3 Data Collection Methods  
 Although usable under grounded theory, a mixed-methods (qualitative and 
quantitative methods) approach was not adopted because of the potential for 
introducing additional limitations into the research.  For example, if a quantitative survey 
was sent before an interview occurred, it might have resulted in prepared responses to 
my interview questions.  Prepared responses could have hindered my research and, 
therefore, by using only qualitative methods (e.g. semi-structured interview) I removed 
the likelihood of this occurring. Additionally, when theoretical saturation of data has 
 
 
103 
been achieved using grounded theory, then it would be improbable that a post-interview 
survey would yield any new and/or pertinent information. 
 
3.3.1 Semi-Structured Interviews 
 I found that using a personalized interview, as my main data collection method, 
was the most effective way to conduct my research.  While (1994, p. 329) listed four 
benefits noted by other scholars to using a personalized method of interview: 
1) The potential to overcome the poor response rates of a questionnaire survey 
(Austin, 1981); 
2) Well suited to the exploration of attitudes, values, beliefs and motives  
(Richardson et al., 1965; Smith, 1975); 
3) Facilitates comparability by ensuring that all questions are answered by each 
respondent (Bailey, 1987); and 
4) Ensures that the respondent is unable to receive assistance from others while 
formulating a response (Bailey, 1987). 
 
 These four benefits provide further justification for my choice to use a qualitative-
based epistemology (constructionist) and methodology (constructivist grounded theory) 
as a fluid framework for my research.  All four benefits reinforce my rationale for not 
using questionnaires as data collection method, and each provides insight into why 
interviews have the flexibility and depth that I desired.  Specifically, the first, third, and 
fourth benefits explain how I can avoid response limitations with a small sample size, 
ensure all questions are answered, and that the participants are exclusively answering 
the questions.  The second and third benefits relate to the abilities of a personalized 
interview to have great depth and insight into the interpretations of participants.  
 There are two types of personalized interviews: structured and semi-structured.  
Structured interviews follow a set of questions and do not deviate because the purpose 
is to have each interviewee answer the exact same questions.  The reduced flexibility 
limits the ability of the interviewer to explore topics further.  
 The majority of grounded theory research uses interviews as the primary data 
source (Suddaby, 2006; Seaman, 2008).  The use of constant comparison and 
theoretical sampling under the grounded theory methodology is congruent with the use 
of semi-structured interviews.  Constant comparison and theoretical sampling require 
flexibility and adaptability that is inherent to semi-structured interviews.  
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 Two specific benefits of the semi-structured interview method are that it allows 
the interviewer more freedom to probe interesting areas that arise and the interviewer 
can follow the respondent's interests and concerns (Smith & Osborn, 2003).  I used this 
same format to create a strong dialog with each participant with the purpose of creating 
deeper and more fulfilling interviews that generated strong and useful data.   
 Limitations associated with using this method are that it “reduces the control the 
investigator has over the situation, takes longer to carry out, and is harder to analyze” 
(Smith & Osborn, 2003).  I found the latter two limitations were true, but I did not find 
that I lost control during any part of data collection and analysis process because I 
actively attempted to keep interviews on topic but in a way that both the interviewee and 
I were comfortable.  The result was that most interviews ended up similar to a candid 
conversation.   
Semi-structured interviews require a flexible interview guide to keep the interview 
on track and to ensure that all relevant topics have been covered (Smith & Osborn, 
2003).  Charmaz (2006) notes that she does not use interview guides because of her 
experienced and refined interview techniques.  However, she does recommend their 
use for novice grounded theorists that are using interviews as their primary data source.  
The attached interview guide (see appendix A) was used for the purposive sampling 
stage of my research.  During the theoretical sampling stage the content did change 
and this can be observed in the differences among the versions of the interview guide 
included in Appendix A. 
The questions were crafted to foster the participants’ reflections and 
interpretations (Charmaz, 2006).  The interview questions focused on eliciting the 
participants’ views and experiences with a phenomenon.  The interviews proceeded like 
a directed conversation that avoids harshly directed questioning.  “Interviewers use in-
depth interviewing to explore, not to interrogate” (Charmaz, 2006, p. 29).  For initial 
questions I used open-ended questions because it allows the participant to explore their 
experiences and go in different directions with their responses (Seidman, 2006); probing 
or follow-up questions were not always open-ended.  The probes were based on the 
content of answers, and they provided options for possible follow-up questions (Kvale & 
Brinkmann, 2009).  There was intentional over-lap among questions so that interviews 
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produced rich data for comparison. 
The layout of my interview guides was based on the work of Charmaz (2006).  
She provides a sample of an interview guide (2006, p. 30-31), but the focus of its 
questioning is to study a particular individual’s experience.  While the individual 
experience is an important element of my interviews, the organization’s collective 
practices are also of interest.  Based on her recommendations I balanced the two 
factors by laying out the interview guide in a way that would best reflect both the 
organizational practices and individual experiences and views of these practices 
(Charmaz, 2006).   
The interview guide begins with questions oriented to the collective practices of 
the participant’s company.  The purpose of these questions was to create a dialogue 
around the CSR practices of their company, the role of organizational values, and what 
company motivations are for engaging in CSR.  Another function of these questions was 
to generate a rapport that enriched the discussion and answers during the second 
section of questions, which it accomplished. 
 The first section of questions was designed to cause the participants to reflect 
on their involvement and relationship with CSR at their company, which resulted in a 
rich dialogue about their views and experiences with CSR during the second section of 
questions.  The second section of questioning focused on the views of participants and 
their participation in CSR at their respective company.  These questions placed the 
participant and their views into relation with the answers they provided in the first 
section.   
 The final section of questions focused on wrapping up the discussion and 
providing the participant a final chance to reflect on their answers and any developing 
insights.  I used the final section of questions to end the interview on a positive note 
(Charmaz, 2006), allowing for the option of follow-up interviews and networking for 
additional participants.  Although no follow-up interviews were necessary, networking for 
additional participants was quite successful.  To comply with ethical standards, I asked 
the participant to personally correspond with the potential contacts to verify if it was 
acceptable for me to begin contacting them. 
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3.3.2 Role of the Researcher 
 I was an active participant during the research process because the nature of 
constructivist grounded theory is to assume an active and influential role throughout the 
data collection and analysis (Charmaz, 2000).  This role served as the foundation for 
sifting through participant-generated data and interpreting how the participants make 
sense of their own actions and surroundings, resulting in a co-production of meaning. 
 In addition, semi-structured interviews create the need for the interviewer to 
become active in the conversation with the interviewee.  This required me to actively 
participate in the conversation and adapt to the answers that the interviewee provides 
by taking different routes with questions or delving more deeply into topics when it was 
necessary. 
 
3.4 Data Collection Procedures 
3.4.1 Data Sources and Sampling  
 There were multiple data sources used in this project.  Semi-structured interviews 
served as the primary data source, and CSR/value publications from pharmaceutical 
companies were the secondary source of data.  The type of data analysis (Section 3.5, 
p. 128) used on the primary data was applied to the secondary data, but modified 
slightly to account for substantially larger amounts of information.  Keeping the analysis 
similar allowed me to integrate the data using constant comparison.  The following are 
publications that were targeted for analysis: 
1) Sections of websites pertaining to CSR and corporate/organizational values; and 
2) Pamphlets/promotional material detailing CSR policies and programs. 
I found that data saturation was achieved by examining the online content of 
pharmaceutical company’s mission, values, goals, and, most importantly, CSR 
programs and policies.  The availability of CSR reports and annual reports across 
companies was found to be consistent.  Although grounded theory does not require 
uniform collection of information, secondary sources were successfully collected from 
the company websites of participants in the country in which they operate.  
The use of these particular publications as a secondary source was beneficial 
because the available publications were used to help triangulate with the primary data, 
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and constant comparison helped in the development of theoretical sampling.  
Additionally, the gaps in the amount of CSR content on company websites helped to 
understand the CSR perspective of the company and its leaders.  For example, why 
does a company not publish or even produce CSR publications that are commonplace 
in the communications programs of other pharmaceutical companies?  Overall, it helped 
to provide a well-rounded understanding of each company’s values and CSR policies 
and programs through constant comparison with the data collected from interviews.   
 Purposive sampling was used to create a broad but selective database for 
analysis.  There was a near homogeneous sample, in that all participants were of the 
managerial or executive level but had varying levels of personal engagement in CSR 
decision-making and its implementation.  This sampling is considered 'purposive', in that 
the researcher selects the sample from which the most can be learned (Suzuki et al., 
2007).  With approximately twenty large-scale pharmaceutical companies in Canada 
and the US, there was little room to randomly sample. 
  As explained in the next section (3.4.2, p. 125), the data was analyzed and 
collected simultaneously.  This process resulted in there being no lag between the 
collection and analysis of data.  Upon starting the analyses, I began to construct a 
theory from the multiple perspectives and data sources.  The growing theory needed 
additional data to further develop, and through theoretical sampling, in the form of 
instrument development and networking for additional participants, saturation was 
reached, leading to the full construction of the theory (Charmaz, 2006).   
 
3.4.2 Participants and Recruitment 
 In terms of participants, I gained access to executives and managers from 
pharmaceutical companies that have substantial investments in terms of employment 
and infrastructure within Canada and the US.  Most of these companies are US-based 
multinationals with affiliates operating in Canada.  The executives and managers best 
suited for this research had, at a minimum, general knowledge of, and interactions with, 
CSR-related activities at their respective companies.   
 Purposive sampling began and finished with the selection of two groups of 
executives and managers to interview: 1) government, regulatory, patient, and market 
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affairs; and 2) CSR team members (strategy development, implementation and 
reporting).  Each group provided a valuable perspective on their interactions with the 
CSR decision-making process.  The first group dealt with organizations outside the 
company that have been described as drivers for engaging in CSR, and had knowledge 
and experience with their company’s CSR policies and programs.  Although they were 
not directly involved in implementing CSR policies or programs, their perspective was 
valuable because of their interaction with external drivers, CSR programs, other 
employees, and their overall perceptions of company motivations for engaging in CSR.   
The second group, CSR team executives or managers, were knowledgeable 
about the decision-making process for engaging in CSR.  They were responsible for the 
design and implementation of CSR policies and programs; they had roles in translating 
the ranging drivers for engagement into strategies.  The combination of both groups 
yielded a more complete perspective on how CSR decisions are formed from the 
interactions with external and internal pressures/influences.  
 Analysis (Section 3.5, p. 128) of interviews occurred simultaneously with data 
collection, and this provided insight into how to better optimize my interview method.  As 
a theory began to form from the data, it provided guidance toward the theoretical 
saturation of data.  Additionally, the focus of the questions was altered to probe specific 
topics brought to my attention by the forming theory. 
 The recruiting process consisted of sending emails and/or phone calls to various 
contacts from pharmaceutical companies in Canada and the US.  The correspondence 
featured an invitation to participate in research that could be beneficial in understanding 
CSR at their company.  All information attained from research pertaining to the names 
of the participating companies is considered confidential, have not, and will not be 
published. 
 Although there were no guarantees that companies would benefit from the 
research, it was still a way for the companies with a means to explain why and how their 
companies engage in CSR.  Specifically, the benefits for participating corporations is 
that they can communicate their values and intentions, potentially affecting CSR for 
other companies within and outside of the pharmaceutical industry, while becoming 
more informed on the current CSR environment within the industry.  This recruitment 
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process was appropriate because it served as the best means to secure the 
participation of the targeted group of pharmaceutical industry executives and managers. 
 The recruitment process ranged between difficult and easy because, in part, of 
the nature of a manager/executive's job.  Committee members, my supervisor, and 
other faculty helped the recruiting process by providing me access to their contacts 
within the pharmaceutical industry.  After creating a relationship with my initial 
participants, their contacts were used in a modified snowball effect (MSE), resulting in 
more contacts becoming available.  In my research, the modification of the MSE is a 
process to build positive relationships with each manager/executive (i.e. the snowball) I 
interviewed, and then ask those respondents to use their contacts to help me identify 
and gain access to additional respondents (expanding of the snowball).  For example, 
after multiple interviews I asked respondents from pharmaceutical companies in 
Canada to provide me with the contact information for their counterpart at their 
company’s US affiliate or, in one case, global headquarters.  As stated earlier, to 
comply with ethical standards I asked the participant to personally correspond with the 
potential contacts to verify if it was acceptable for me to begin contacting them.  
Additionally, I found it essential that I personally make formal contact with each possible 
participant so I could become better acquainted with him or her before the interview. 
  
3.5 Data Analysis 
 The purpose of grounded theory is to generate a substantive theory (Suddaby, 
2006; Annells, 1996; Richardson & Kramer, 2006; & Scott & Howell, 2008).  The 
complex process of constructing a theory from the data requires constant and iterative 
data analysis (Scott & Howell, 2008).  My data analysis occurred simultaneously with 
the collection of data, leading to concepts and categories developing early on.  Insights 
from early data analysis led to theoretical sampling that helped to focus questioning 
toward the developing theory and data saturation (Suddaby, 2006; McCann & Clark, 
2003a; Charmaz, 2006).  The constant analyzing and re-analyzing during data 
collection kept me immersed in the data and provided me with the ability to use 
developing concepts and categories as areas for probing in future interviews.   
Constant comparison is the main analytical tool used by grounded theorist 
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throughout the process of coding and categorizing data toward the development of a 
theory.  Charmaz (2000, p. 515; Glaser, 1978, 1992) provide a list describing what 
constant comparison entails: 
1) Comparing different people (such as their views, situations, accounts and 
experiences); 
2) Comparing data from the same individuals with themselves at different points in 
time; 
3) Comparing incident with incident; 
4) Comparing data with category; and 
5) Comparing a category with other categories. 
 
Constant comparison of numerous aspects of every piece or chunk of data 
proceeds until theoretical saturation occurs.  It is the guiding analytical tool for the 
coding and categorizing of data (Glaser & Strauss, 1967).  I applied each of the five 
strategies during my data analysis, and the results I found to be enriching and 
enlightening during the construction of my substantive theory.  Evidence of my use of 
the constant comparative method is systemic throughout the presentation of my results 
(i.e. substantive theory).  
 I used the standard process of coding and categorizing data that is typically 
associated with grounded theory.  I used three types of coding: open, axial, and 
selective (Strauss & Corbin, 1990; McCann & Clark, 2003a; Scott & Howell, 2008; 
Charmaz, 2000).  Each type of coding is a step towards the next; however, the process 
of going through each type is not linear.  Bouncing back and forth across the three with 
new and old data was required for constant comparison. 
 To help gain a better understanding of transcript content before coding, I 
personally transcribed 15 interviews verbatim from their audio recordings.  I found that 
transcribing interviews myself was a fulfilling experience that increased my connection 
to and immersion in the data, thereby reconnecting me to the original interview 
experience and enhancing my theoretical sensitivity.  The other seven transcriptions 
were done externally.  However, I still made sure to completely read each of those 
seven transcripts to regain my familiarity with the content before coding them.  Overall, 
20 out of 22 interviews were conducted in person, with two occurring over the phone.  
All of the interviews were tape recorded to ensure accuracy and authenticity.   
 Secondary sources were collected as interviews were conducted.  Prior to an 
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interview, I would browse the website of that respondent’s company, to get a sense of 
its CSR programs and policies.  Coding of such sources was conducted after the 
interviews.   
 McCann and Clark (2003a) provide a detailed explanation of each of the three 
types of coding (open, axial, and selective), which I followed throughout my data 
analysis.  During open coding, I took the raw data, broke it down line-by-line, and coded 
each piece, forcing myself to become extremely familiar with the data.  The purpose of 
open coding was not to create categories but to break down the data into usable chunks 
so that the relationships between them could be highlighted.  Line-by-line (open) coding 
was applied to new data (discussed further in Section 4.1.2, p. 139), but paragraph 
coding was also used to code entire concepts that spanned multiple sentences.   
 Axial coding took the fractured pieces created by open coding and used them to 
identify the commonalities and linkages among the coded data; creating sets of 
categories and sub-categories.  It was important to use constant comparison and 
abductive reasoning to construct the categories because it made me look past the 
surface of the data in order to find deeper and less obvious categories and sub-
categories.  Until categorical saturation was adequately attained, the categories were 
works-in-progress that required refinement. 
 The final type of coding is selective coding, and it resulted in the creation and 
development of the substantive theory.  Selective coding was the process of identifying 
a common or over-arching core category that is directly or indirectly influencing the 
majority of developed categories.  According to McCann and Clark (2003a), a core 
category may not be explicitly present within the categories, and this was the case 
during my data analysis.  Rather, it developed using all three types of coding, abduction 
and constant comparison.  The core category and its relationship with its four sub-
categories that comprise it represent the constructed theory.   
Selective coding and sometimes axial coding led to and inspired theoretical 
sampling.  The resulting selections for theoretical sampling helped collect additional 
data for the developing theory (Cutcliffe, 2000; McCann & Clark, 2003a).  In my data 
analysis, this process continued until I reached theoretical or categorical saturation.  
Saturation is the point where virtually no new data that is pertinent to the developing 
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theory is appearing (Suddaby, 2006; Strauss & Corbin, 1998; Cutcliffe, 2000).  “The 
signals of saturation, which include repetition of information and confirmation of existing 
conceptual categories, are inherently pragmatic and depend upon both the empirical 
context and the researcher’s experience and expertise” (Suddaby, 2006, p. 639).  I 
attained saturation of both my primary and secondary data after the collection and 
analysis of data from 22 interviews and the respective affiliate and headquarter 
websites of respondents.  At the perceived point of saturation, data became overly 
repetitive, so it was deemed that further data collection was not required. 
To conduct the first two stages of coding, open and axial, I used computer 
software, Nvivo versions 8 and 9.  Although Nvivo can be used to extensively code and 
analyze documents, pictures, video, etc., I used it only as an organizational tool for 
coding and categorizing my data analysis.  Using the basic functions of the software, I 
created open codes from imported interview transcripts into the proprietary term ‘free 
nodes’, which I could then title (code) appropriately.  Most notably, I did not use free 
nodes multiple times throughout interviews, and instead I decided to contain the unique 
construction and context of each code within its own individual free node.   
Based on the developing categories, I analyzed the free nodes and then 
clustered them together into ‘tree nodes’.  During and after development, the free and 
tree nodes were constantly compared free to free, free to tree, and tree to tree.  
Additionally, for verification purposes coding of one interview was audited by an 
experienced qualitative researcher – Dr. Jason Perepelkin, Assistant Professor in the 
College of Pharmacy and Nutrition, University of Saskatchewan.  Dr. Perepelkin coded 
one entire interview at the axial level and those codes were then compared to the ones I 
made on the same interview and were found to be very similar.   
Coding of secondary sources proceeded differently than that of primary sources.  
Due to the size and amount of CSR information contained on many of the websites, it 
was not reasonable to break down over one thousand pages of discourse line by line.  
Instead, modified axial coding was conducted to group common themes, forms of 
discourse, and observations.  After axial coding, secondary data was compared to itself 
and primary data to enhance selective coding.    
As a substantial part of my data analysis, I used memoing and diagrams to help 
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organize and track my thoughts (Strauss & Corbin, 1990).  Memos were especially 
helpful as a method to express my inner-dialogue with the data that I was collecting and 
analyzing (McCann & Clark, 2003).  Writing 89 separate memos served as an organized 
way to think abstractly and express the theoretical connections that I was in the process 
of making (Charmaz, 2006).  Sometimes referred to as journaling, memoing helped me 
to look at and examine the data in new ways; thereby, acting as a catalyst for creativity 
(Charmaz, 2000).  Memo topics included my interpretations of social processes within 
and across companies, elaboration of categories, comparisons across categories, and 
theoretical ones aimed at continually adding to my developing theory.  Overall, memos 
served as an extremely effective method to identify and elaborate the abstract linkages 
across categories and codes, to create a tangible core category that would serve as the 
backbone of my substantive theory.  Six examples of memos can be found in Appendix 
B.  The first is an early memo (Charmaz, 2006) that contains some of my more general 
observations of what was going on in the field when I was first collecting and analyzing 
the data.  The remaining five illustrates memos that are more advanced (Charmaz, 
2006), where aspects of my core and subcategories are beginning to develop.  These 
five provide various perspectives, comparisons, beliefs, and assumptions about their 
topics, creating a foundation for my critical analyses and interpretations presented in my 
results and, most notably, discussion sections.  Additionally, the memos are in their 
original, un-edited form.   
Although I made multiple small diagrams during my data analysis, the majority 
ended up combining in an effort to construct a model to visually explain my “Model of 
the substantive theory of CSR evolution within the pharmaceutical industry” (Figure 4.3, 
p. 147).  As the final product of continual improvements to multiple diagrams, it serves 
as a tool to illustrate the complex substantive theory I present in my results section.   
Both diagrams and memos were required because the substantial amount of 
information collected and analyzed generated a massive amount of information to 
process.  Keeping track of thoughts, no matter how small or large, helped the 
development and insight into the developing theory (Strauss & Corbin, 1990).  However, 
the processing and comparing of data continued after memoing was complete, and as 
sections of the results were written, information from memos, diagrams, and open and 
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axial coding were continual compared to further refine the theory.   
A more detailed explanation of how I used and applied the various aspects of 
data analysis to develop my substantive theory is explained at the beginning of the 
results section (4.1.2, p. 139).  It provides further and more specific insights into the 
exact process of taking my two sources of data through the data analysis process and 
how it resulted in the creation a multi-narrative substantive theory.      
 
3.6 Trustworthiness, Rigour, and Triangulation 
Trustworthiness, rigour, and triangulation are intertwined with the grounded 
theory methodology.  Trustworthiness appears to be a more quantitative or positivistic 
(objectivist) term because it denotes the accuracy of a truth.  Constructivist grounded 
theory is not in search of a truth but rather the interpreted, multiple perspectives that 
socially construct the multiple realities of a phenomena (Charmaz, 2000).  However, the 
quantitative version of trustworthiness can be bent in ways to make it usable in 
qualitative research: the trustworthiness of the constructed theory is reinforced by the 
inherent triangulation and rigour associated with a comprehensive approach to 
grounded theory.  
Rigour was required to adequately implement and express all seven key 
elements of grounded theory (McCann & Clark, 2003a, p. 10): 
1) Theoretical sensitivity; 
2) Theoretical sampling; 
3) Constant comparative analysis; 
4) Coding and categorizing the data; 
5) Theoretical memos and diagrams; 
6) Literature as a source of data; and 
7) Integration of theory. 
 
As detailed in the data analysis section (p. 128), the first five elements were 
rigorously carried out during my research, while the sixth was applied during my 
literature review.  The cumulative effect of the application and interaction of the first five 
element led to the creation, modification, and then integration of a substantive theory.  It 
is important to note, however, the sixth elements had a purposely-limited effect on my 
results sections, but is an integral part of my discussion where insights from comparing 
the literature to my substantive theory are discussed.   
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Although McCann and Clark (2003a) recommend it as a source of data, I 
adhered to the more traditional stance of not letting the literature have too much effect 
on my substantive theory until after I had constructed it.  In my discussion, I compare it 
to the literature to further modify and explain my substantive theory.   
 In addition to the development of a substantive theory, the rigorous following of 
these seven elements of grounded theory led to categorical or theoretical saturation.  
The point of saturation provides verification for the research (Suddaby, 2006) because 
virtually no new theoretical data is being collected, resulting in the most complete 
picture that can be created from the data.  The relationships among constant 
comparison, theoretical sampling, and coding and categorizing resulted in further 
verification throughout the entire research process (Annells, 1996).  Verification occurs 
in the sense of triangulation rather than the positivist or post-positivist meanings of its 
quantitative use, which assumes verification only occurs at the end of research.  
Verification in constructivist grounded theory does not seek to use statistical tests 
(positivism) or the falsification of a null-hypothesis (post-positivist) to verify the theory 
and consequently the research (Annells, 1996). 
Triangulation was accomplished through the constant comparison of multiple 
data sources (McCann & Clark, 2003c).  In this context, multiple data sources are not 
only interviews in comparison to company CSR publications.  Rather, the constant 
comparison methods were comparing each piece of an interview to each other, 
publication-to-publication, etc.  Triangulation was based on the rigour of constantly 
comparing each source of data and using theoretical sampling to focus data collection 
towards saturation (McCann & Clark, 2003c). 
The discussion of trustworthiness, rigour and triangulation hints towards the 
evaluation of the constructed theory.  Glaser presented four key criteria to evaluate a 
theory developed using grounded theory (Glaser, 1978, 1992 cited in McCann & Clark, 
2003b p. 26): 
1) Fit – the categories within the theory must directly relate to the data; 
2) Work – the theory should have an explanatory power and be able to interpret 
what is taking place within the context of the theory; 
3) Relevance – the theory is relevant because the researcher allows the core 
problems and processes to emerge from the data rather than attempting to 
impose a preconceived theory on to the area of study; and 
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4) Modifiability – given that the social (or clinical) world is constantly changing, the 
theory must be adaptable and modifiable. 
 
The third criterion does not pertain to constructivist grounded theory because it is 
overtly positivist.  However, the other three illustrate the need for rigour and 
triangulation throughout the grounded theory research process.  Obviously, the 
language within each of the criteria is positivist, but the foundation of the three criteria 
can translate to a constructionist epistemology.  For instance, my categories represent 
the many interactions that shape the participants’ interpretations of their social worlds, 
and my substantive theory compiled those interpretations as the inner-workings of 
categories meant to give them shape.  My substantive theory works to present a 
glimpse into the range of influences of the CSR decision-making process according to 
those with an internal perspective.  Lastly, as a glimpse, my substantive theory is 
therefore modifiable because it acknowledges there is a constantly changing, or 
evolving social world (social context), where it is possible to describe what is presently 
occurring, but a multitude of variables can affect the functioning of the theory in the 
future.   
 
3.7 Summary 
Using qualitative research as a foundation, there is a consistent stream of 
purpose to the adoption of my constructionist epistemology, constructivist grounded 
theory methodology, and the accompanying methods.  From the beginning, I decided to 
use qualitative research as my overarching method of inquiry because I believed that it 
did not share the same limitations of quantitative research and it provided the necessary 
flexibility and depth I required to adequately examine CSR within the pharmaceutical 
industry.  Next, I selected a constructionist epistemology because it best represents my 
own beliefs that knowledge is constructed through our interpretations of the world as we 
interact with it and others.  Based on my two previous selections, I decided to adopt a 
constructivist grounded theory methodology because it aligns with both my conceptions 
of knowledge creation and requirements for flexibility and depth.  As the dominant data 
collection method used by grounded theorists, I wanted to use semi-structured 
interviews as my primary method of data collection.  Additionally, secondary sources, 
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which are also common to grounded theory, were used comparatively with the primary 
data to add more depth and perspective.  Lastly, I used the data analysis methods 
associated with grounded theory to develop a substantive theory that explains why and 
how pharmaceutical companies are engaging in CSR. 
 The data analysis process took a number of different interlocking concepts to 
develop a theory from the data.  Coding and categorizing began during the collection of 
data, and it proceeded in a non-linear fashion, bouncing back and forth, constantly 
comparing and analyzing each piece of data.  The iterative and circular process 
developed into theoretical pathways that required further examining.  Theoretical 
sampling followed the pathways and provided further data with an aim towards 
theoretical saturation.  The cumulative amount of information was daunting, so memos 
and diagrams were used as markers for thoughts and creative tools to further analyze 
the components of the developing theory.  The result is a theory that was constructed 
from multiple perspectives and woven within a multi-story narrative.  “The seamless 
craft of a well-executed grounded theory study, however, is the product of considerable 
experience, hard work, creativity and, occasionally, a healthy dose of good luck” 
(Suddaby, 2006, p. 639) 
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4.  RESULTS – Substantive Theory of CSR Evolution within the 
Pharmaceutical Industry 
 
4.1  Demographics and Introduction 
4.1.1 Demographics 
 Managers from eleven companies (nine brand name and two generic) 
participated in the study (Table 4.1).  In total, 22 interviews were completed, and 
consisted of fifteen Canadian managers, six American managers, and one British 
manager.  Additionally, there were three companies where interviews were conducted 
with managers from both Canadian and American affiliates of the same company. 
 
Table 4.1 – Positions Held by Respondents 
 
 
 
 
 The positions held by respondents within their respective companies included 
those directly related to each company’s CSR programs, and those distanced from such 
programs, but still affected by CSR policies.  The range of perspectives based upon the 
positions held by participants provided an insightful range of interpretations regarding 
CSR within the pharmaceutical industry.   
 Although it was the intent of the study to interview executives/managers from 
more than two generic companies, the ones I contacted from other generic 
manufacturing companies were not willing to participate.  The two interviews conducted 
with executive/managers from two generic companies participating in the study provided 
Company
Vice,
President
Executive,
Director Director
Associate,
Director
Senior,
Advisor
Program,
Organizer
Senior,
Director
Senior,
Mananger
Regional,
Manager
1 1(C)
2 2(C),,1(U) 1(C) 1(U) 1(U)
3 1(C)
4
5 1(C) 1(C)
6 1(C) 1(C)
7 1(C),,1(U)
8 1(C)
9 1(C) 1(C)
10 2(C),,1(U)
11 1(UK)
Total 3 1 10 1 1 1 1 1 2
*,(C),P,Canada,,(U),P,,USA,,(UK),P,England
Positon
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a perspective from generic companies; but I deemed it be insufficient to make overt 
comparisons and distinctions between generic and brand name companies.  However, 
these two interviews are still included because the information they provide makes an 
important contribution to theory development.  
 
4.1.2 Introduction: Constructing the substantive theory – Process and Path 
 The overall goal of my research project was to develop a substantive theory of 
why and how the pharmaceutical industry engages in CSR.  The process of 
constructing the substantive theory was immersive; in that I had to thoroughly analyze 
the information from transcripts and secondary sources to create an understanding of 
the multiple narratives at play, including my own.  Throughout the course of data 
collection and analysis, theoretical insights began to develop until saturation was 
reached after 22 interviews were conducted and analyzed, including secondary data 
sources.  To reach the point of theoretical saturation when the substantive theory could 
be developed, I employed a multifaceted, iterative approach to data analysis that relied 
on three levels of coding (open, axial, and selective), memoing, and diagraming; all 
facilitated by constant comparison and theoretical sampling (see Figure 4.1).   
 The coding of data started my journey towards interpreting how respondents 
understand and manoeuvre within their social context, and within their companies.  As 
well, how they perceive the actions of their companies in response to the constraining 
and enabling forces within the larger macro-environment.  By using open coding, to 
break down interviews line-by-line, the respondents’ interpretations were dissected into 
small, usable, and labelled chunks of data.  The chunks were then constantly compared 
to the other codes and developing categories of that particular interview through the use 
of axial coding, while also comparing it to each level of coding from other analyzed 
interviews.  Although the analysis of the first interview followed a rather linear pathway, 
the addition of more interviews and secondary sources added complexity to the iterative 
comparisons across all three levels of coding.  
 The coding and categorizing process, however, was not sufficient to generate a 
substantive theory.  As a standalone data analysis process, it does not provide the 
insight needed to critically analyze data toward the goal of theoretical saturation 
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because it lacks the capacity to refine the results through constant comparison.  As a 
result, I relied heavily on memoing, including some diagramming, to map out and refine 
the constant comparisons of each interview across the three levels of coding in order to 
achieve theoretical saturation.   
 As a guide for memoing, I relied on the seminal work of Charmaz (2005) in her 
book: Constructing Grounded Theory.  While Charmaz (2005, p.85) provided many 
suggestions, I focused on four specific tips on writing memos for the purpose of 
constructing a substantive theory: 1) stop and think about your data; 2) avoid forcing 
your data into existent concepts and theories; 3) develop fresh ideas, create new 
concepts, and find novel relationships; and 4) develop connections between categories.  
These four tips transformed the act of memoing into a practice reminiscent of a 
research process journal, whereby theoretical generation can be observed from start to 
finish.  As well, these four tips detail how memoing was used to inspire both creativity 
and clarity in the data analysis process and the subsequent development of a 
substantive theory.    
 Throughout the coding process, I focused on creating codes that detailed the 
actions and processes the respondents were attempting to describe.  I wanted to 
preserve them in the narratives of each respondent's interpretations of why and how 
they occur so that they could be compared to the codes both later in that particular 
interview and across other interviews.  Notably, the process of actually comparing 
codes occurred in the narratives I created in memos and diagrams (both to be 
discussed later).   
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Figure 4.1 – C
onstructing a Substantive Theory 
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After open coding (Figure 4.1 – Process B) was completed for an interview, I 
sorted through the codes and identified common categories from which I created axial 
codes that could be constructed to group together related actions and processes, as 
interpreted by myself and the respondents.  At the same time, I was creating modified 
axial codes on the CSR information on websites of the respondents’ companies.   
Upon completion of the open and axial coding (Figure 4.1 – Process C) of the 
first interview, I began to write a series of memos that were intended to detail how the 
actions and processes captured by the codes and categories function (Figure 4.1 – 
Process D).  Included in the analysis of their functioning is my interpretation of the 
respondent’s interpretations as to why and how certain actions and processes at their 
company were happening.   
 As additional interviews were analyzed, I relied increasingly on constant 
comparison to build a theoretical framework that would serve as the basis for presenting 
a multi-story narrative or substantive theory that addressed the topic of CSR 
engagement in the pharmaceutical industry (Figure 4.1 – Process D).  For example, the 
depth of analysis in early memos reflected the limited amount of content from 
interviews.  Topics from memos included: need to focus CSR, motivations, CSR 
measurement, and CSR targeting.  As coding progressed through additional interviews, 
the memos became more focused on the categories that were becoming saturated.  
However, outlier categories and/or codes were still used because they were beneficial 
in detailing alternative perspectives.  At this point, memos focused on theoretical 
insights developed into categories such as: the evolution of CSR as tied to the internal 
and external pharmaceutical environment, emerging interpretations of CSR evolution, 
quick thoughts on the symbiotic relationship, and the leveraging of CSR to enhance the 
win-win scenario (an example of an outlier).   
 The theoretical insights I made using memoing guided me through the process of 
selective coding required to create the core category that would serve as the over-
arching theme for the constructed categories (Figure 4.1 – Process E).  My research 
goal was to identify why and how the pharmaceutical industry is engaging in CSR.  The 
core category that was created and best articulates this goal is the process of ‘CSR 
evolution in the pharmaceutical industry’.  The core category, however, is a hollow shell 
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unless the subcategories that comprise it are focused and detailed enough to explain its 
effects and inner-workings.  As a result, I needed to ensure that within my 
subcategories, all the necessary information can be found to comprehensively explain 
why and how the pharmaceutical industry engages.   
 At this stage, I had created the core category that would serve as the vessel for 
my substantive theory, but I still needed to focus my existing categories into the main 
subcategories.  Memos now included the following: communication requirements for 
CSR success, the influence of drivers on strategies to realize anticipated benefits, 
developing a value-base decision-making process, evolution of CSR in the shared-value 
space, evolution towards CR integration into the business strategy, and CSR strategy 
and the continual improvement process.  It became clear to me that I needed to further 
analyze and interpret the functions and purposes of the range of categories in order to 
transform them into the necessary subcategories. 
 After I had completed the core and subcategories, I moved away from using 
memos for analysis and interpretation to diagramming because I believed that using 
visual explanations to make creative connections across my existing theory would help 
to complete the substantive theory (Figure 4.1 – Process E).  I began this process by 
listing the potential subcategories, and then I used a white board to map out the 
connections among them.  Diagramming provided the additional perspectives and 
insights needed to narrow-down and refine the various subcategories into the four that 
would best articulate the processes and purposes that comprise the core category. 
 It must be noted, however, that even when memoing ceased, its underlying 
process continued as I wrote the substantive theory.  Using information from memos, I 
began writing my results sections, but as I did that I continued to refine the 
subcategories by constant comparison with both sources of data.  As the writing 
process occurred, I identified different or new elements of relationships and gaps in my 
theory that required clarification.  Therefore, the writing process further transformed and 
elaborated the content on memos in a way that is nearly identical to memoing.  
The first subcategory is the social context of the respondents and their 
companies, and it provides a comprehensive description of the relational forces that are 
interpreted as constraining and enabling the actions and behaviours of the 
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pharmaceutical industry.  The second subcategory is comprised of three CSR 
perspectives that detail the evolution of why and how the pharmaceutical industry 
engages in CSR.  To ensure the internal and external context is capable of perspective 
evolution, the third subcategory represents the interdependent elements of the company 
that are continually improved upon to align and shift its capabilities.  Each of the three 
sub-categories operates with respect to the fourth subcategory, the symbiotic 
continuum, that represents the perceived priority alignments between pharmaceutical 
companies and the actors within their social context.   
 Overall, respondents and their company’s websites and CSR reports provided 
comprehensive interpretations of why and how their companies engage in CSR, but 
these narratives needed considerable processing and interpretation to construct and 
articulate a substantive theory.  The process of using constant comparison in 
combination with coding and memoing refined my theoretical insights (Figure 4.1 – 
Process F) to a point where I could use diagraming to put all the pieces together and 
construct a model to articulate the substantive theory (Figure 4.1 – Process G). 
 For further clarification, Figure 4.2 provides an example of the coding process 
using nine selected codes from Interview 20.  My intention is to illustrate, specifically, 
how an open code becomes part of one or more axial codes, how the axial codes are 
theorized and compared to others in multiple memos, and how they contribute to the 
selective codes, or subcategories, that are under construction.  Notably, the axial codes 
are shown as being part of each memo in Figure 4.1, but this is not meant to state that 
each has an equivalent amount of focus in each memo.  Rather, each axial code had a 
role in the process of constant comparison within those particular memos, but the 
amount of focus on each varied according to how it related to the topic of the memo.  
Each stage of analysis depicted in Figure 4.2 is an example of processes B, C, D, and E 
discussed earlier in Figure 4.1. 
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Figure 4.2 – Exam
ple of C
oding Process (Interview
 20) 
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As a result, the theory and its accompanying model present an evidence-based 
framework for the industry’s evolutionary process for CSR (core category) by 
articulating the relationships, interactions, and influences of its four subcategories: 1) 
social context; 2) CSR perspectives; 3) continual development and reinforcement 
process (CDRP); and 4) symbiotic continuum (See Figure 4.3) 
 
Figure 4.3 – Model of the Substantive Theory of CSR Evolution within the 
Pharmaceutical Industry 
 
 
I interpreted that, similar to the different functions of the parts throughout an 
automobile, the subcategories in the model are separate processes that also interact 
and relate to each other to create the conditions necessary for the functioning of the 
core process: the evolution of CSR engagement.  Based on this premise, the following 
four sections detail each subcategory in isolation, as to address its individual function, 
and how they interact with each other in an attempt to drive a larger, core function: CSR 
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evolution within the pharmaceutical industry.   
 
4.2 Social Context 
 Based on the comments of the respondents, the pharmaceutical companies 
appear to operate within a complex social context containing multiple layers of actors, 
each with their own concerns and expectations.  Ranging from highly competitive to the 
unified, the concerns and expectations of these actors construct frameworks of 
evaluation and the consequences of violation.  The constraining and enabling forces 
that result have the potential to influence the actions and behaviours of companies 
within the industry.  Based on the comments of respondents, it would appear that 
companies attempt to navigate the constraining and enabling forces by identifying and 
assessing those with the most potential to impact their business operations, either 
positively or negatively.  The compilation of forces pushing and pulling each company 
within its social context appears to be the major catalyst for the creation and continual 
development of each company’s unique CSR perspective and its resulting strategies. 
 Similarities in the interpretations of their company’s social context and their own 
perspective of CSR were found across the companies included in this study.  These 
commonalities appear to form the foundation for the industry’s social context, and to 
serve as the basis for understanding the CSR decision-making process.  It is important, 
therefore, to explain and understand the social context in which companies operate as it 
provides a glimpse into the maelstrom of constraining and enabling forces that are 
processed and then prioritized during the CSR decision-making process.   
 Based on information collected from the respondents and company publications, 
there are a variety of actors, commonly referred to as stakeholders by both respondents 
and company websites, interacting with the companies and each other within the social 
context of the pharmaceutical industry.  I observed that a substantial part of a 
company's decision-making process is acknowledging that they must better address 
stakeholder expectations or face the negative repercussions.   
 In identifying their stakeholder expectations, respondents referred to an 
intangible threshold called 'license to operate' (LTO) that is mutually constructed by 
stakeholders as a ‘roadmap’ for what is effectively the responsibilities or obligations of 
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specific pharmaceutical companies and/or the industry as a whole.  The LTO with 
regard to CSR is interpreted as being constructed and then translated through the 
interplay of these stakeholders, the business orientation of the industry, and each 
company and its articulated values, to create perceptions of responsibilities.  There is 
often no set point where LTO is violated, but the risk of potentially reaching a point 
where it can be perceived to be violated, creates priorities for the industry to create 
policies and programs (e.g. CSR) to mitigate this possibility.  
 'Soft' risks resulting from some violation of LTO were perceived by all the study 
respondents.  However, based on the information collected and presented below, I 
believe that the most substantial external reason to mitigate risks of violation is the 
threat of further regulation of an industry that is already considered to be one of the 
most highly regulated in the world.  In addition, employees are increasingly aligning with 
elements of the external LTO, reinforcing it internally, to create greater proximity at the 
company to the influences of the constraining and enabling forces.  Providing further 
justification for an evolving response to these forces, shareholders were perceived by 
many respondents as increasingly encouraging them to increase their CSR 
engagement.   
 The results section begins with the how respondents have interpreted the 
business and societal role of their companies and the entire industry, including how it 
has changed overtime.  Next, I will discuss the implied values of companies that reflect 
and reinforce both the perceived role of pharmaceutical companies and how values 
function as a lens to assess and navigate the pressures of constraining and enabling 
forces.  Resulting from company perceptions of their unique role and the accompanying 
values, and how constraining and enabling forces might affect each is their actions and 
behaviours, which can include CSR practices and structures.   
 Stakeholders and shareholders respond to the actions and behaviours by 
developing, maintaining, and changing their concerns for and expectations of 
pharmaceutical companies.  These concerns and expectations form the basis of 
company/industry reputations and an intangible threshold to evaluate the 
appropriateness of their actions (LTO).  Importantly, the interactions of socially 
constructed perspectives have the potential to result in the implementation of soft and 
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hard regulations to curb or shape certain undesirable industry practices.  The combining 
risks and consequences associated with reputation, LTO, and regulation have 
translated into forces that pressure the current role and values of companies toward 
certain actions and behaviours, albeit in varying degrees.  This circular and relational 
process of socially constructed influence is depicted in Figure 4.4, and will be detailed 
further in this section about the social context of the pharmaceutical industry. 
 
 
 
Figure 4.4 – Relational influences in the Social Context 
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4.2.1 Unique Business and Societal Role of the Pharmaceutical Industry 
  Based on the comments of respondents, the products of the pharmaceutical 
industry and how it goes about commercializing those products creates linkages to their 
external environment.  According to respondents and company websites, unlike most 
other industries the pharmaceutical industry produces and commercializes healthcare 
products that serve to cure or treat health-related conditions.  Perceiving a linkage 
between their products and a high level of importance, respondents describe the role of 
the pharmaceutical industry as vital to society and therefore, it has an “inherently good 
purpose” (Respondent 19).  According to respondents, the 'good purpose' originates 
from the industry’s role within the healthcare industry as a provider of innovative 
healthcare products: 
Yes, of course our key responsibility as an innovative pharmaceutical company is 
to conduct research to develop new medicines.  That’s what we do.  That’s our 
core business. (Respondent 10) 
 
 The pharmaceutical industry has a dual role that combines for-profit entities with 
responsibilities to society as healthcare providers.  Based on the comments of 
respondents, all of them think that the purpose of their companies is to create and 
distribute products that reduce morbidity and mortality; but they need to do it in a way 
that is profitable.  Business needs to be sustainable or they will not be able to continue 
to develop additional healthcare products.   
We have a product, medicines are our product, and it is a product that can save 
lives or help people live longer.  We are not a charity, so we are going to make 
money on it, but we are going to do it in a responsible way. (Respondent 17) 
 
 Healthcare products and their inherent societal importance dominate the 
discourse throughout company websites, with discussions about the requirement to 
make a profit or sustainability noticeably taking a backseat.  For example, most 
websites were saturated with healthcare-related imagery and featured written 
communications implying how they help mitigate quality of life issues of people suffering 
from a medical condition.  Financial information tended not to be tied in with healthcare 
discourse.  From this and other comments made by respondents, it appears that there 
is uneasiness about making overt linkages between their products and the requirement 
to make profits.  Instead, they attempt to quell concerns by emphasizing comments 
 
 
131 
about continuing to strive for profits and how it will be done in a responsible way.    
 Although the industry has proven itself successful in developing life-saving 
products, in some of the comments made by respondents, there are issues and/or 
controversies that challenge their ability to continue to develop innovative products and 
sell them in ways that are less ethically questionable.  For example, some respondents 
indicated that the industry is having difficulties with a “pipeline that isn’t producing” 
(Respondent 22), and that the entire industry, and not just individual companies, are 
facing considerable challenges in dealing with a declining reputation: 
We’ve been compared to tobacco companies and we’ve been accused of a lot of 
different things. I think it’s created a lot of soul searching in the company as to 
how did this happen and what can we do to change it. (Respondent 6) 
 
 There appears to be a misalignment of perceptions as to what 'responsibility' 
means between the companies and the individuals/groups that portray the industry as 
having a poor reputation.  While respondents often perceive their companies as 
completing their 'key responsibility' in a 'responsible' way, it is shocking to them when 
controversies do emerge because it is difficult for them to understand what could have 
caused it.  They viewed the normalized practices within their company cultures as ‘right’ 
and deviation from those practices or having them viewed as ‘wrong’ was difficult to 
cognitively process.   
 The industry appears to be generating controversy within their social context.  
They are perceived as failing to fulfill their traditional role as innovative developers of 
medicines while also operating in ways that are considered irresponsible.  However, 
respondents seem to be experiencing a moral dilemma as to why such a misalignment 
of perceptions about responsibilities exists.  This dilemma has created conflict between 
their values as individuals and as employees of companies that are supposed to be 
guided by values. 
 
4.2.2 Values  
 As discussed in the literature review, values are subconscious guides that help 
people make judgments and choices about their own and others actions and behaviours 
(Baker, 2005).  Additionally, the importance of shared and expressed values in the 
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business environment has been being positively linked to performance (Campbell, 
2004).   
 According to the respondents, companies have embraced values by broadly 
expressing and entrenching into their culture those values perceived as important in 
achieving the goals of their business.  An example of this was the reinforcement of 
values during evaluations of employee performance.  However, after examining 
company websites, the values publicized by companies also appear to be a method to 
project a value-infused persona that is intended to create trust by normatively relating 
their values to those of the actors in their social context.  For example, values regarding 
financial performance were absent in comparison to societal/health-related ones on 
websites, but most respondents explained that, as a business, there is also value in 
being profitable.  The result is that each company has a defined set of single-word or 
phrase-based values that are articulated to show their influence, importance, and 
integration into the actions and behaviours of the company.  The values appear to be 
designed to relate to the normative concepts that companies perceive as widely held 
internally by employees and externally by other stakeholders.  To reinforce a perception 
of normative relation, the values are widely communicated both internally and externally 
to stakeholders to increase and shape understanding in the hope that groups will better 
relate with a company's values; a process designed to create alignment of company 
priorities with the perceived priorities among stakeholders.    
 All of the respondents and nearly all the company websites described a long 
tradition of reinforcing and emphasizing the importance of aligned values throughout 
their companies.  Notably, some Canadian affiliates did feature extensive websites but 
the respondents of those companies still described the importance of values.  The 
purpose of values is perceived as providing an intrinsic framework for guidance – one 
that is currently focused on trying to create ethical criteria for the business's decision-
making process. 
What we’ve done is set out our values and if people understand those values and 
what the expectations are around those values, they can then use those to 
inform decision-making that may go outside the sort of strict rule set out in a 
policy. (Respondent 19) 
 
It is that set of values that is supposed to guide our work broadly.  There are 
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echoes of that in the strategic statement we have for our global health programs. 
(Respondent 20) 
 
They (values) interact in everything we do.  (Company A)’s values are inherent in 
everything that we do; they’re the backbone of the organization (Respondent 2) 
 
 What the respondents did not discuss was the communication of their values to 
external stakeholders.  Their perceptions of values revolved around how they interpret 
their use and importance within the organization.  However, respondents did suggest 
that values are communicated externally in the actions and behaviours of the company.  
 Some respondents thought that for employees to understand company values 
and their attributed expectations they need to be effectively communicated and 
reinforced throughout the hierarchy of the organization.  
We have a set of four core values that are the foundation of our brand, and it’s 
something that we have spent a lot of time training and educating our employees 
on.  (Respondent 18) 
 
Based on position, some respondents were evaluated and educated on values, while 
others were responsible for the evaluating and educating other employees.  Regardless 
of position, all the respondents were routinely exposed to the company's expressed set 
of values.  
 According to the respondents, company leaders are identified as the main source 
of articulation and guidance as to the purpose and integration of values and how they 
should reflect and/or shape the company’s vision and its priorities.   
We have a book, an approach that really looks at (Company A) values and its 
updated on a frequent basis every 2 years, 3 years, et cetera, and what that book 
really talks about our core values of the organization and then specifically talks 
about what are the implications.  (Respondent 3) 
 
Additionally, most respondents perceived the leaders of their company as attempting to 
align the company values with their personal vision.  An important part of this process is 
creating motivation for the vision by encouraging greater value alignment among 
employees: “Our president certainly sets the tone and has clearly articulated the 
importance of our values and the importance for us to really be focused on ethics” 
(Respondent 5). 
 The single-word values that the leaders continue to shape through articulation 
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have gained an almost iconic status within many companies, and it appears to be quite 
rare for the communicated set of values to change.  Indeed, most of the respondents’ 
companies still subscribe to the same single-word values that the founder of the 
company first articulated.   
These are probably the three values that have been articulated since the 
company was started.  Embedded within those concepts, though, are a great 
many things.  (Respondent 21) 
  
 Value reinforcement not only occurred in the communications from leaders to 
employees, but in the recruitment and retention process and the promotion of actions 
that demonstrate the application of values.  Respondents often commented on how 
those seeking employment are increasingly interested in finding a workplace where their 
individual values aligned with those expressed by the company.  Companies are 
motivated, therefore, to communicate their values and use tools such as their websites 
to publicize their values to sustain or create a positive reputation with people searching 
for work. 
I just think that the kind of profile of individuals that (Company A) hires brings in 
people who want to give back and want to give back both through their work, and 
in the form of improved health.  As well, I really haven’t run into anybody who 
doesn’t want to be involved in the community and (doesn’t) have a sense of 
purpose bigger than their own life. (Respondent 22) 
 
 The retention of talented employees who embrace the company values was also 
important to respondents.  Although not stated openly, it was implied by many that value 
alignment could add predictability to actions and behaviours of employees.  This is 
especially important if companies are trying to curb certain actions and/or behaviours 
that they perceive to be detrimental or risky to some aspect of company performance.  
In effect, employees are embracing the values of the organization.  For example, 
respondents described values assessment as a part of their overall employee 
evaluations: 
In our evaluations and our objectives every year there is a section called being 
responsible, being ethical, and living the values.  We’re actually rated and 
evaluated on them – every single person that works for (Company B).  So, 
although it comes from the top, the bottom is in agreement that this is the right 
way to do it and many of us wouldn’t work here if we didn’t feel the culture was 
like that. (Respondent 11) 
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 In the above quote, the respondent describes two-way expectations between the 
leadership and the other employees of the company.  In the quote, the respondent uses  
'responsible' and 'ethical' with reference to living the values.  I perceived this to be a 
product of the relationship between the leadership articulating the values and 
employees adopting but also influencing them.  Not only are the values being used to 
inject these two words and their accompanying meanings into the consciousness of the 
company culture, but they are also a response to expectations of that culture.  There 
appears to be an expectation to be responsible and ethical that originates from both the 
leadership and the employees.  
  
4.2.3 Stakeholders 
 Consistent with the CSR/business literature, respondents perceived stakeholders 
as groups or individuals with a claim to some level of non-monetary investment in the 
operations of the company (Freeman, 1984; 2007), from which they create concerns 
and expectations of how companies should conduct business.  Respondents explained 
that it is important to address stakeholder expectations.  From these acknowledgements 
and other statements from the respondents, I presume stakeholders are increasingly 
gaining the ability to influence company and/or industry decision-making.  
Acknowledging and then responding to stakeholders appears to be a difficult balancing 
act for companies because of the size and scope of companies has created a diverse 
range of stakeholders and for most companies the broadening of stakeholder dialogue 
is still in its early stages.  As a result, I interpreted a common theme that suggests 
individual companies have neglected some of their stakeholders’ concerns and 
expectations.  This neglect has subsequently transformed the concerns and 
expectations into constraining and enabling forces with increasingly greater influence on 
pharmaceutical companies to adopt a wider set of responsibilities to both specific 
stakeholders and society in general.  In an apparent response to these forces, 
companies are attempting to increase their perceived levels of responsibility through 
programs and policies categorized by them as CSR, or some variant of that label.   
 As they interpreted the variety of sources creating constraining and enabling 
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forces, respondents identified the following groups of internal and external stakeholders: 
patients, governments, employees, NGOs, local communities, and the media.  Although 
categorically separated, shareholders represent the most explicitly influential 
stakeholders.  As owners, they represent the group with the greatest financial and 
legally recognized stake in the company.  Each of these seven (stakeholders and 
shareholders) groups will be presented to show how they play both unique and 
interdependent roles in driving the growth of the forces that are trying to influence 
companies to enhance their responsibilities with regard to stakeholder concerns and 
expectations.   
 
4.2.3.1 Patients 
 According to respondents, patients represent individuals and their supporting 
groups that require the medicines and other healthcare products produced by 
pharmaceutical companies to alleviate single and/or multiple health-related conditions 
(the core purpose of the industry).  Discussions with respondents about patients 
revolved around how it is of the upmost importance that the concerns and expectations 
of patients are adequately addressed.  Most respondents thought that it was required of 
their companies to put the patient before profits, and if this is done then profits will 
follow.   
I think it starts with the patient.  I think what we’ve decided as an organization is 
that they kind of go hand-in-hand: why we’re successful as a business is 
because of what innovative medicines we bring to patients. (Respondent 6) 
 
 A patient focus that leads to profits suggests an industry seeking to achieve a 
unique balance of its dual role as healthcare providers and for-profit entities.  However, I 
perceived this view presented by respondents as somewhat idealistic.  Although the 
company is oriented around the development of healthcare products, reputation issues 
resulting from controversies raises questions as to how consistent is their application of 
this principle.  If strategies were authentically designed to put patients before profits, 
then would the concerns and expectations for more responsible actions by companies 
exist? 
 My interpretation of the patient focus is that it is an interesting dynamic from a 
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business perspective.  In most developed countries, the patient is not the major payer; 
therefore, companies are actually focusing on the end-user rather than the payer in 
many circumstances.  Additionally, respondents indicated that patients typically have a 
selective recognition that prioritizes pharmaceutical product names over the name of the 
manufacturing company.  Patients routinely remember the name of the medicinal 
product they are taking, but do not make the connection between the product and the 
company that produces it.  If this is true, why do patients have so much ability to 
influence decisions?  One explanation is that patients are the origin of all stakeholders’ 
concerns and expectations of the pharmaceutical industry.  If patient needs are 
adequately addressed, then the other stakeholders may have less reason(s) to develop 
and use forces to influence company decision-making.  As a result, even though their 
natural business operations attempt to address the main expectations of patients - the 
production of safe and useful medicines - the focus on a wider range of patient needs 
continues to develop, in part, because their expectations are not as basic or influential 
as previously assumed. 
CSR is an approach to corporate strategy that incorporates a lot of what 
previously would have been considered externalities, which is both how the 
broader world that a company operates affects the material impact and 
operations of the company and also how the company itself has a much broader 
impact on the broader world.  (Respondent 4) 
 
 To partially address the range of patient expectations, I believe the prioritization 
of the patient has transformed into a prioritized focus of CSR at the pharmaceutical 
companies represented by the respondents.  The majority of CSR revolves around 
improving the health of patients and, depending on the company, it has evolved to 
broaden the definition of a patient from those exclusively using the medications 
developed by that company to public health in general.  “I think it’s intrinsic, that 
corporate responsibility in terms of the public health mission that we all carry with us” 
(Respondent 22).   
 Whether it is through donations to patient groups or partnering with them, aiding 
the development of health infrastructure, or knowledge transfer programs, the 
pharmaceutical industry has increasingly directed their CSR programs both directly and 
indirectly toward their corporate missions; which was described by respondents as 
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revolving around patient and public health.  Respondents observed this process as a 
response, both reactively and proactively, to the 'social needs' of patients.   
The need for the, let’s say, the diabetes patient; so we do put a lot of money with 
the diabetes patient that will help them and support them.  It will help them in 
their day-to-day life, but it will always be seen, at the end of the day, that we do 
that for our own benefit because, at the end of the day, these are our customers. 
(Respondent 15) 
 
Other stakeholder groups are offshoots of this main priority because benefits generated 
from targeting patient and public health with CSR programs and policies may result in 
indirect benefits for other stakeholders and the company. 
 
4.2.3.2 Government 
 According to all respondents, governments represent one of the most influential 
stakeholders in the pharmaceutical industry.  Not only do governments tend to be the 
largest payer for pharmaceuticals in most countries, they are also charged with the duty 
and ability to develop, monitor, and enforce the regulations (Section 4.2.6, p. 177) that 
attempt to control the actions of the pharmaceutical industry.  Based on the 
respondents’ comments about governments, I believe that the combination of influences 
from their roles as payers and regulators creates a scenario where it is necessary for 
companies to acknowledge that they must respond in some way to the expectations of 
governments:  
Government is a big one (stakeholder).  They’re the ones who foot the bill for a 
lot of the medicines, so their actions and words are important.  If they’re saying 
things like, “we value innovation” and “medicines are a cost-effective way to 
deliver healthcare”, that’s good.  If they look at us or say, “they’re overpriced”, 
“they’re unsafe”, “you need to do more homework”, “you need to lower your 
prices”, then obviously we have opposing views on this and we have to find a 
way to find the middle ground or a mutual purpose. (Respondent 6) 
 
 How the government perceives the industry, whether they are a necessary or 
unnecessary cost, for example, shapes how they will use their powers of influence to 
constrain or enable certain actions by the industry.  Governments have the ability to 
make decisions that affect the bottom line of the companies, either positively or 
negatively.  As well, in the preceding and following quotes it is implied that governments 
also filter public opinion, including those the stakeholders described in this section, 
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when making decisions that can affect the pharmaceutical industry. 
It (crisis of rising healthcare costs) means that they (government) have to make 
decisions sometimes that will have an impact on us, which is not necessarily the 
best decision because we are an easy cost to target and people generally don’t 
like us. (Respondent 15) 
 
If this is the prevailing public opinion as the respondent claims, then it makes it more 
socially acceptable for governments to take actions against pharmaceutical companies 
because it is likely to benefit other stakeholders, including themselves.  
 Based on discussions about the role of government, I observed a difference in 
the perception of government influence between respondents from the Canadian and 
American affiliates of their respective companies.  Canadian employees were more 
critical of the government’s influence and actions as the major payer of 
pharmaceuticals, whereas American employees focused more on the government’s 
regulatory influence.   
A Canadian perspective: 
 
The governments are also in an economic sort of squeeze, I guess; so, we are 
constantly challenged from a cost perspective.  It is very difficult to be in a world 
where you are seen as a cost and not necessarily as a solution. (Respondent 14) 
 
An American perspective:  
 
Europe is another critical example where they’re not shareholders but we need to 
work closely with them.  Not only do they approve products but increasingly they 
determine how much we are going to be reimbursed for our products, and the 
same with Canada, obviously.  In the US, we haven’t done as much with the 
government specifically on CR, but I think it’s because the US is a little bit behind 
in CR. (Respondent 17) 
 
 It is interesting that Respondent 17 perceives her country as lagging in CR.  Her 
history in the area of CSR and her interaction with other CSR representatives from 
different pharmaceutical companies and industries—both of which she implied had 
shaped her perspective of CSR—could have heightened her awareness regarding 
regional CSR differences and how her country of origin and operation lags behind.  It is 
an awareness that could add a political element to CSR: where her and the company 
she works for try to shape the public and private discourse of CSR in light of areas for 
improvement.    
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 The experiences of different nations or regions also appear to affect their view of 
pharmaceutical companies, including their products and services.  This in turn will 
shape how and why companies apply pressure on governments to address certain 
concerns and expectations.   
 Given the industry's complex and influential relationship with governments, 
respondents suggest that it is important to strengthen ties through partnerships and 
collaborations.  Such a strategy is intended not only to ensure a positive reputation with 
governments by working together to close some of the drug access gaps, but to 
enhance the expertise and capabilities of both.  For example, each company has 
programs in place in Canada and the US to help enhance drug access to those lacking 
adequate coverage for the costs for pharmaceuticals.  However, respondents stated 
that they would prefer to collaborate with governments to find a more suitable and 
equitable solution.  I think these 'solutions' to mutually expressed issues are also 
methods for pharmaceutical companies not only to strengthen relationships with 
governments, but to leverage partnerships so they can engage in such programs on a 
less philanthropic basis.  They desire to create multiple wins for the companies, which 
also provide themselves and governments with gain public recognition for the services 
provided.   
 Respondents also indicated that relationships with governments in emerging 
markets are increasingly important.  These regions are perceived by respondents as the 
main markets of future growth; featuring governments that are quite interested in what 
companies can offer in addition to their pharmaceutical products.  Specifically, emerging 
market governments are concerned about how companies can provide social, medical, 
and economic benefits to the health of their citizens.  This level of concern has 
translated into a willingness to place barriers—suggested by Respondent 17 in the 
quote below as including patent and payment issues—in the way of companies that do 
not use business strategies to address them.  As a result, it appears that the potential 
market growth is in part motivating companies to respond to the forces placed on them 
by the governments of emerging markets.  For example, Respondent 17 discusses the 
requirement for partnerships with India’s (classified as an emerging market by the 
respondent) government:  
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They (India’s Government) are interested in how are you contributing to India’s 
economic development.  There it was more about the taxes we pay, the amount 
of people we employ in India, the clinical trials we are conducting in India which 
are giving Indian doctors experience, and that’s going to help us.  I mean, we 
want to be a partner with the government of India not only because India is a 
purchaser of our products for their people but because we need to have a good 
relationship.  They’re the ones who grant patents for our products.  They approve 
our products obviously to even sell them in their country. (Respondent 17) 
  
 Reputation is also becoming increasingly important in managing the 
company/industry/government relationship: 
We are an industry that in the past sometimes government relations has meant 
yelling at government, and I think we are probably ahead of the curve when it 
comes to actually identifying the importance of creating solutions to share 
problems together. (Respondent 14) 
 
One of the things that CSR is integral to is reputation, and in the world in which 
we operate, government plays an increasingly important role.  As you know from 
the way a drug is brought to market, there are numerous stages in different 
companies.  Countries are different, but the role of regulatory agencies, the role 
of health agencies, the role of public payers, the role of regulators, and all those 
sorts of things, play a significant role in kind of determining are you getting the 
product approved.  Are you going to get a product listed?  Are you going to get a 
product reimbursed?  All these kinds of fundamental questions. (Respondent 4) 
 
 Concerns over how they are perceived by governments (i.e. their reputation) in 
combination with government's ability to turn their own and other stakeholder concerns 
into regulations suggests a need for companies to make their case to governments that 
they are an important and necessary part to the healthcare system: 
I think that this is also our corporate responsibility: to sit and to convince 
government that we are not a cost; we are a partner. We are as important in the 
healthcare system as the doctors, the pharmacists, and the nurses.  You take 
one of us out of the equation and we are in trouble. (Respondent 15) 
 
 Based on respondent comments, the industry appears to have made the 
connection that an effective use CSR as a response to constraining and enabling forces 
of stakeholders improves their relationship with government.  CSR targeted at improving 
patient or public health can create 'talking points' with governments, and it can serve as 
a common goal that will strengthen partnerships with governments, and help build trust 
and reliance by way of an enhanced reputation.   
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 Government appears to be the hub for the reputation of the pharmaceutical 
industry, with many of the concerns and expectations of stakeholders coming together 
to be processed.  If governments are concerned with the economic, social and medical 
health of their citizens and have to ability to regulate the actions of companies that may 
be adversely affecting them, then, according to the connections implied by respondents, 
they will likely attempt to include and understand, or process, the concerns and 
expectations of their citizens prior to making a decision to act or not (e.g. whether or not 
to further regulate the industry).  Additionally, during the decision-making process, 
governments respond to a variety of their own constraining forces (e.g. the sustainability 
of healthcare costs).  As a result, respondents, regardless of their country of 
employment, appeared interested in developing collaborative partnerships with 
government as a way, from my interpretation, to bolster reputation, reduce costs, and to 
gain or strengthen access to markets.   
 
4.2.3.3 Employees 
 “Employees are critical stakeholders” (Respondent 5) because they have the 
closest proximity to the company and they make up the body of the company to form its 
culture and talent base.  Respondents all discussed the important role that employees 
have on the overall direction and focus of the company.  Focusing on the respondents’ 
comments about employee importance, it appears the companies must be conscious of 
the concerns and expectations of employees as they, much like external stakeholders, 
can to influence the company's decision-making processes.  Companies often use value 
alignment for its predictive qualities as a way to hold off or control such forces, but they 
also may be used to re-align predictive behaviours after a shift in the strategic direction 
of the company (Section 4.4.3, p. 216).   
 These same forces, however, could also push company leadership to re-
articulate values.  For example, each company has strategies for recruiting employees 
with values that align with those expressed by the company and policies designed to 
reinforce the same values among the current workforce.  
 In reference to current and potential employees, respondents commented on a 
“new” or “younger generation” of employees entering the workforce, who expect or even 
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demand more of a CSR-oriented perspective by their prospective employers: 
I think the management team, to some extent, deserves some of the credit, but I 
think the employees that we hire now—the 20 somethings, the 30 somethings—I 
think they come in with a much broader view of their role in society and I think 
that’s healthy.  I think people that say, “we’ve got to be more than just a job in 
our, in our life and I want to be more than my title”, and I think that’s a good thing. 
(Respondent 6) 
 
I think younger employees are looking at a number of things in companies before 
they make a decision to join.  Corporate responsibility efforts are clearly one, and 
why is that?  I am not an expert, certainly, but I think younger individuals have a 
stronger understanding and appreciation of environmental issues.  I think they 
have an appreciation of value that goes beyond a pay cheque, and that’s 
important. (Respondent 20) 
 
I believe these two quotes are reflective of some of the major changes in the social 
context of the companies, in that they have decided to pursue potential employees and 
to align existing employees in accordance with emerging internal and external concerns 
and expectations.  Such forces within their social context are thus pushing companies to 
increasingly prioritize enhanced responsibilities in more and more areas of their 
business strategies.   
 The acknowledgment by respondents of an employee role in the way that a 
company constructs and implements CSR strategies demonstrates what I interpret as 
an employee-centric design.  Using a combination of employee empowerment and 
participation, companies increasingly engage in CSR activities that not only address the 
external expectations of enhanced responsibility, but also boost morale and align 
employee values.  Growing empowerment provides employees with a vehicle not only 
to express their concerns and expectations, giving them a stronger voice, but also to 
address those concerns as well:     
You are also going to get some of the message coming this way (points up) 
because if employees are coming up with practices, those practices are going 
drive upwards.  Then you’ve got the CEO coming back down and saying, “we 
have a corporate social responsibility policy”; the messages meet in the middle. 
(Respondent 16) 
 
 Overall, employees play a key role in the forces pushing for CSR, including its 
design and implementation.  In fact, I believe employees have the most dynamic role of 
all the stakeholders because they can act as a bridge between the company and the 
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expectations and concerns of society. 
 
4.2.3.4 Non-Governmental Organizations (NGO) 
 The non-governmental organizations (NGO) described by respondents are a mix 
of not-for-profit groups with an expressed stake in the operations of pharmaceutical 
companies.  NGOs range from groups with a direct stake (e.g. patient groups) to the 
more indirect (e.g. advocacy and/or multipurpose groups).  According to the 
respondents, most of the influence comes from NGOs with a direct stake.  Patient 
groups, for example, target companies that produce the medicines that address the 
health needs of their constituency.  A cancer-based patient group would advocate for 
assistance from companies that have a larger presence in the development and 
commercialization of cancer-related medicines.  Similar to governments, the patient 
groups focus the concerns and expectations of patients to form a larger advocacy 
argument that pressures company strategies. 
 Other NGO groups also advocate or exert pressure on the pharmaceutical 
companies but have a broader focus.  Although not generally concerned with 
pharmaceutical company operations, their size and scope of influence can be 
formidable.  For example, the Gates Foundation was routinely brought up by 
respondents as a model and advocate for successful public health intervention, and is 
one example of the “sophisticated entities that want us to take this kind of approach 
(Shared-value Approach, Section 4.3.4.1, p. 194)(Respondent 20). 
I am very impressed by the Gates Initiative, many aspects of it, obviously, but 
one, if I understand it right, is that he (Bill Gates) wants to eradicate polio off the 
earth.  That’s cool.  That’s an aggressive goal, but it’s clear: let’s get rid of polio.  
We can do it.  We have the capabilities.  Let’s go do it. (Respondent 21) 
 
By advocating for pharmaceutical companies to adopt sustainable CSR strategies as a 
way to maximize benefits for themselves and stakeholders, the foundation seeks to 
create mutual and sustainable benefits. 
 The validation and promotion of such strategies by the Gates Foundation, the 
globally- based NGO with the highest level of funding, provides both pressure and 
justification for shifting to a stakeholder approach that emphasizes CSR as a method to 
increase multidirectional sustainability.   
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 Another example of a global, advocate NGO is the Access to Medicines Index 
(ATMI), “which is a ranking of pharmaceutical companies’ commitment to improving 
access to medicines in the developing world” (Respondent 18).  ATMI uses 
benchmarking to rank pharmaceutical companies according to standardized criteria for 
access to medicines – a substantial CSR-related activity that many stakeholders believe 
company resources should support.  Although some respondents did express difficulties 
with conforming to an external set of criteria (including one respondent from a company 
that ranked quite high), every company but one provided all the information requested 
by ATMI.  I believe some respondents may not have wanted to participate for various 
reasons (e.g. being judged on a sensitive matter by an NGO) but understood that it was 
necessary to avoid the possible damage to their reputation of being labelled non-
participants. 
 Although some respondents thought that there were limitations in the ATMI 
feedback, the rankings were perceived as promoting better performance in this 
particular area: 
But what we do is we use a lot of this as benchmarking because you can see 
where you stand.  You take a look at the questionnaire from last year to this year 
or over several years.  You cannot see what other companies have done, of 
course, because that’s confidential, but at least they give you an idea of where 
you stand in the rankings and then you can say, “well we need to look at this 
particular aspect and really become better in that particular aspect.” (Respondent 
16) 
 
It appears that external benchmarking organizations, such as ATMI, play a role in 
providing information to companies about how they sit in comparison to others, where 
and how they can improve (based on the assessment criteria), and identify a range of 
current societal concerns and expectations.  According to the respondent, however, 
each area of information and the entire process is not without its limitations.  Overall, I 
believe ATMI provides companies with an opportunity to compare their CSR-related 
strategies with other pharmaceutical companies even if it is only superficial, and then 
companies can use this information to act and reflect upon.  As well, the information 
may provide some level of normative recognition for companies with regard to their 
stakeholders. 
 In addition to efforts to increase CSR activities, NGOs are attempting to create 
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partnerships with companies that are designed to target various 'social needs' 
associated with patients and public health.  I contend that some NGOs do not want to 
be limited to the role of advocate.  They also seek a collaborative role in the delivery of 
CSR programs.  Some companies have recognized this desire and have responded 
with efforts to engage in such partnerships.  For example, to best address a mutually 
perceived 'social need', some respondents described how complementary partnerships 
are designed to use companies to cover the gaps in an NGO's expertise and 
capabilities.  These companies appear to be comfortable entering into collaborative 
partnerships with NGOs: 
There are some charities or organizations that are really driving the whole cause 
and they come to us for a certain aspect where they need help, and that’s fine 
too. (Respondent 21) 
 
 As well, the companies also appear to understand that to be successful in some 
CSR ventures they need to find external expertise to fill their own knowledge gaps.  The 
United Way and the Red Cross were two common examples of NGO partners because 
of their networking capabilities to direct donated funds or medicines to intended targets.  
Additionally, when entering new markets, companies often develop local partnerships to 
become more knowledgeable about the area, its expectations, opportunities, etc.  This 
strategy suggests that they are becoming aware, comfortable, and experienced with 
both entering into collaborative partnerships and using them to create multidirectional 
benefits. 
 
4.2.3.5 Local Communities 
 All of the respondent companies have global CSR initiatives; however, they also 
indicated the importance of CSR programs for the communities within which their 
facilities were situated.  Respondents described a tradition of interest in their local 
communities.  As the place where the company operates, their employees, and their 
families live, it appears to be important to companies that they are perceived as active 
members of those communities.  Although it may be interpreted as a strategy to 
minimize any potential risk(s) or barriers, I got the impression from respondents that 
companies think that caring for employees should include being a positive force in the 
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community.  Although respondents did not overtly state that there are pressures to 
conform to local norms, I believe that the established tradition of local, employee-centric 
CSR suggests that they not only want to relate to local norms but they also want to 
enhance their operational locales.  By having a healthy and vibrant community in which 
to operate, companies benefit through happier and more motivated employees, stronger 
infrastructure, and greater ability to recruit talent.   
 It can also be interpreted that companies engage in substantial local CSR due to 
significant constraining and enabling forces placed on them by both their local 
communities and their employees living in these communities.  The result is CSR 
approaches that attempt to bolster the overall health of the community (economic, social 
and medical).  Strategies can include partnerships, volunteering, and charitable 
donations based on therapeutic and employee expertise, either alone or in combination, 
to address the social needs of the community.  
 
4.2.3.6 Media 
 Respondents suggested the media as a stakeholder has an indirect influence on 
the pharmaceutical industry because of their ability to shape perceptions of the industry:  
Media is very important, so whether we like it or not, they tend to be the objective 
conscience of society and…health care reporters at the major papers and in TV 
are very quick to find a story and how they position that story is very important.  
Again, if we get contacted for interviews we’d like to have our side of the story 
heard. (Respondent 6) 
 
 I interpreted the industry/media relationship as different from that of other 
stakeholders because the media does not have the typical 'stake' in the operations of a 
business.  Rather, they have a stake in reporting the actions of companies to society, 
and therefore influence other stakeholders’ perceptions of pharmaceutical companies.  
Respondents generally saw the function of the media as necessary, but that they would 
like more input into the content that is communicated about them.  Based on this, I 
perceive that some respondents have an issue with the lack of control they have over 
the media's communications; in particular because of its substantial influence on 
societal perceptions.   
 While respondents understood the media have an important role to play in the 
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communication of their actions to society, some respondents thought that the media 
often portrayed them unfairly, and this has contributed to their decline in reputation:   
The media is very quick to portray the pharmaceutical industry in a negative light, 
and so I think there is societal pressure because the pharmaceutical industry is 
still viewed, now I can’t speak for all of society and I think it varies region to 
region, the pharmaceutical industry is viewed very poorly.  I think it is media 
driven largely.  (Interviewee 8) 
 
In this respondent's portrayal of their 'unfair' treatment, it is suggested the media is not 
being objective.  I believe this opinion demonstrates a desire by some within the 
industry to lay partial blame for their poor reputation on those external to the company. 
 Further highlighting this struggle for control of the media's message, respondents 
explained that there is difficulty in trying to get their perspective across in the media, 
and that the acknowledgment(s) they should receive from their positive actions like CSR 
programs are adversely affected by media scepticism.  Some respondents even went 
so far as to suggest that the perception of the industry is mostly positive among those in 
general society, and that any negative perceptions are mostly due to their portrayal by 
the media.   
 According to respondents, the industry’s CSR is focused on patient and public 
health, and is not intended to be directed towards the media.  However, I observed 
some respondents perceived CSR as a way to overcome the negative image portrayed 
in the media; possibly as a way to pull some of the control of content to their side by 
winning over sceptics (Respondent 22).  Therefore, even though it was not the stated 
main purpose of CSR, if successful, companies might anticipate their CSR 
engagements resulting in positive media coverage and improved reputation.  
 
4.2.4 Shareholders 
 The company’s shareholders are its owners, and their interests represent the 
traditional priority of executives, to make as much profit as possible for shareholders 
(Friedman, 1962).  Therefore, issues might arise if company leaders chose to respond 
to the concerns and expectations of other stakeholders in ways that could result in 
losses or less profits for their company's owners.  Not surprisingly, it was important to 
respondents that CSR-related responses to stakeholders be justified by way of 
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shareholder approval. 
 As stated previously (Section 2.3.3, p. 86), controversies have emerged about 
the actions of pharmaceutical companies when the dual role of the company is 
perceived as shifting too much toward profits, a traditionally shareholder-based priority, 
and away from their expected duties as a healthcare producer and provider, an 
increasingly influential stakeholder priority.  The majority of respondents described their 
values as based on the concept of patients before profits, with profits that will naturally 
follow if the patient is prioritized.  For some respondents, the contradiction among stated 
values and some of the industry's actions considered controversial by stakeholders was 
often demoralizing for employees, and that the perspectives that may have normalized 
such actions are no longer credible: “I think in this day and age you can no longer just 
get by on just sort of shareholder value alone” (Respondent 4).  This quote is 
particularly helpful in illustrating how the previously held shareholder perspective was 
accepted as 'normal', but changed over time in response to transforming norms to 
include a wider set of stakeholders.   
 As employees of companies have changed their perspective of the 
shareholder/stakeholder dynamic, respondents perceive shareholders as acting 
somewhat similarly.  The traditional perspective of making investments in companies 
with the intention of receiving a financial return is being transformed.  Respondents 
observed shareholder expectations of both profits and CSR from the companies in 
which they invest:  “Our shareholders demand it (CSR); globally shareholders are much 
more educated these days” (Respondent 13).  It is interesting that this respondent 
would use the term 'educated' to describe current shareholders as it could be 
interpreted to mean that past shareholders did not understand or have the knowledge to 
identify the possible benefits of engaging in CSR, or how to actually 'put patients before 
profits'. 
 Respondents described the influence of progressive shareholder expectations in 
the competition that exists among companies listed on the Dow Jones Sustainability 
Index (DJSI).  “Launched in 1999, the Dow Jones Sustainability Indexes are the first 
global indexes tracking the financial performance of the leading sustainability-driven 
companies worldwide” (DJSI, 2010).  The sustainability aspect is assessed using a 
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questionnaire filled out by a company and information that relates to the same company 
from the media and stakeholders, both of which are continuously monitored.  The stated 
purpose of DJSI and similar indexes provide a framework by which current and potential 
shareholders can judge companies while also providing public acknowledgment for the 
desire to invest in socially and environmentally responsible (CSR) companies.   
 Obviously, not all shareholders are overly concerned with CSR.  Based on 
respondents’ comments, however, even those shareholders who may be dissatisfied 
with pharmaceutical companies engaging in greater CSR will come to accept its use if it 
can be justified by the benefits (revenues) outweighing its costs. 
 
4.2.5 License to Operate (LTO) 
 The foundation of the stakeholders’ influence is a web of concerns and 
expectations with regard to various actions and behaviours of pharmaceutical 
companies.  Attached to these forces is the widely held perception that negative 
repercussions can result for companies if they are not addressed adequately; termed by 
some respondents as a license to operate (LTO).  Based on the comments of 
respondents, I interpreted LTO as a series of subjective thresholds of expected 
responsibility.  The thresholds that make up the boundaries of the LTO are created by 
stakeholders based on their unique concerns and expectations formed from their 
various experiences and interactions within their own social context.  Companies secure 
a LTO (ability to conduct business unhindered) through tacit approval from various 
stakeholders.  At the same time, however, it is also understood that a company would 
not automatically lose its ability to operate simply because it violated superficial levels of 
the conditions set by its stakeholders to secure a LTO.   
 Identifying the threshold where tacit approval is revoked and actions (hard or 
soft) by stakeholders may be taken against the industry appears impossible to pinpoint.  
The complex web of varying forces expressed by the mix of stakeholders that 
comprises the LTO shifts and changes with an evolving social context.  Trying to identify 
the possible effects would be like standing on a beach and trying to predict the pattern 
and force of waves crashing onto it.  Companies can only prepare for what they 
perceive may be coming or react to what has already happened.  Based on respondent 
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discussions about stakeholders and LTO, I believe that they have perceived—albeit in 
varying degrees—a series of ‘waves’ that are pushing them to integrate more 
responsibilities in their overall actions and behaviours.  Companies appear to address 
the LTO issue by engaging in greater levels of what they define as CSR.  What they are 
now reacting to is a very large wave that, if they do not address, will have substantial 
repercussions for the industry.  As one respondent explained, “if we are irresponsible in 
the way we run our business we will just increase the legislation and control around our 
business” (Respondent 19).  As a result, stakeholder influence is being increasingly 
acknowledged as important, and companies are taking action to address it.  Even 
though “they’re not a shareholder, we increasingly see the relevance of developing and 
working and engaging with stakeholders” (Respondent 17).  By working with 
stakeholders, companies are able to better understand what the concerns and 
expectations are and why they are important to stakeholders.   
 In part, I believe the lever of action to address, and even use, the constraining 
and enabling forces is the re-articulation of values and the subsequent CSR programs 
and policies.  Combined with a focus on enhanced ethics, the articulated values and 
CSR programs and policies are used to address stakeholder concerns and expectations 
that make up the current LTO:   
I think that we all realize collectively that in order to operate in a community, a 
country, et cetera, you need to obey certain rules and you need to give 
back.  That principle I think is what drives it (CSR). (Respondent 11) 
 
The resulting drive to engage in CSR is constructed, transmitted, and reinforced through 
the use of value articulation within companies.  
 Although companies must obey existing laws and regulations, they are 
increasingly conscious of potential risks of further regulation—a situation perceived as 
placing unnecessary costs on the industry: 
Now, company behaviours are always going to be aligned with legal 
requirements.  We go absolutely out of our way to make sure that we don’t 
deviate outside regulations and legal requirements.  But there’s an element of 
responsibility that takes us beyond just complying with the law and there are 
some areas where we’ve had to pay more attention to what the external 
expectations are, the way those expectations are developing, and making sure 
that as a company we understand that and integrate those expectations into the 
way we run our business. (Respondent 19) 
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(Company D) is not going to survive as a company, or any company wouldn’t, if 
they don’t pay attention to this; they will lose their license to operate.  
Consumers, to the extent that they can in our industry, will not want to take our 
products; if a doctor has a choice, they will consider prescribing another product 
if they feel better about that company.  If we don’t pay attention to these things 
the risks will increase and those risks will eventually have a bottom line impact.  
On the flip side, there are opportunities in terms of selling more products.  The 
other thing that I think the pharma industry needs to do a better job on the 
opportunity side is: how do you create products that speak to social needs? 
(Respondent 17) 
 
 I interpret from the above quotes that respondents are trying to understand the 
changing expectations pressuring the industry to act in certain ways (e.g. enhancement 
of responsibilities).  CSR appears to be the main method of reaction to the forces 
comprising the current LTO.  As a result, CSR is becoming more pronounced as 
respondents and their companies increasingly perceive it as the best approach by which 
they can align aspects of their business with identified social needs, and thereby, 
strengthen the company.  It is a strategy further justified by both internal and external 
perceptions that mutual growth and sustainability for companies and stakeholders can 
be achieved by using elevated levels of CSR to integrate greater responsibility into their 
business practices.    
 The second quote also includes examples of softer actions by stakeholders and 
others in society if the LTO is violated: doctors may prescribe rival drugs and people will 
not want to take their products.  Going beyond the soft actions are hard actions, which 
are the introduction of new laws and regulations to control certain actions and 
behaviours of pharmaceutical companies.    
 
4.2.6  Regulation 
 A country’s legislative bodies create regulations designed to govern the practices 
of business and punish when standards are violated (Dukes, 2006).  Across business 
sectors there are national laws that are universal and designed to govern basic aspects 
of business, but there are also industry specific rules or regulations that are created to 
curb or control actions that are perceived by governments, who enacted the legislaion, 
and society, who often advocate for it, as harmful to others.   
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 There are specific regulations to ensure safety and efficacy of the products that 
companies are producing in the pharmaceutical industry.  A partial result of the 
controversies that have developed from a perceived unbalance in its dual role and the 
industry's healthcare orientation is that it has become one of the most heavily regulated 
industries in the world: 
Because within this industry various types of activities interact, intersect, and 
need to be taken into account, differing interests need to be weighed against one 
another and some novel ethical problems and conflicts of interest can arise. 
(Dukes, 2006, p. 8). 
  
 Interestingly, other than attributing it to higher costs of doing business, which is 
significant, respondents did not state anything else that was overtly negative about the 
high level of the regulation.  However, I interpreted that they did perceive regulations as 
a motivator to curb certain practices, resulting in the companies promoting those that at 
a minimum would ensure compliance with these regulations: 
We make that very clear and we give a lot of training to our employees to ensure 
that they are familiar with and that they understand, first of all, how important it is 
to act ethically and, second, that they understand the parameters of the different 
legislations that govern what it is that they do. (Respondent 10) 
 
The respondents appeared to understand that they are at a point where it is better to 
embrace the regulations rather than fight against them; that to do the latter could result 
in prosecution, fines, and the introduction of more regulations.   
 Unlike the subjectivity associated with a LTO, regulations have explicit 
expectations and rules that are expected to be enforced if they are violated.  
Respondents were better able to identify or pinpoint the thresholds of regulations where 
violation and subsequent enforcement could happen, and has resulted in company-wide 
strategies to reinforce employee understanding of the 'parameters of the different 
legislations'.  However, with regard to recent controversies, it can be assumed that while 
companies may be able to pinpoint the threshold for enforcement, some have at times 
overstepped this threshold. 
 Referring to the previous quote, Respondent 10 continued this discussion to 
include integration of ethics into the workplace: “It’s part of the social fabric of the 
company; we talk about it often.  We talk about ethics, we talk about compliance, and 
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we are the most heavily regulated industry in Canada.”  Weaving ethics into the social 
fabric of the company as a method to ensure compliance with regulations was 
commonplace among the respondents and their respective companies.  The phrase 
“above-the-board” was commonly used to describe the dedication to ethics that is 
promoted among employees.  As a result, ethics, and variations on that word (e.g. 
ethical behaviour or decisions), was associated with the company processes designed 
to ensure compliance at a minimum with regard to regulations.   
 None of the respondents suggested CSR was intended to reduce or mitigate 
current regulations; rather, they perceived that it would help prevent the addition of 
future regulations.   
If we are irresponsible in the way we run our business, we will just increase the 
legislation and control around our business.  Now, the pharmaceutical sector is 
highly regulated.  We have regulations coming out of our ears; every step we 
take is regulated.  It’s in our interest to work in a way that keeps the regulation 
where it is and we don’t have significant regulation around even more factors 
because we have behaved well.  Because increased regulation just increases the 
cost of business, it is much better for us to do it in a voluntary way and behave 
responsibly, and have all the other advantages of that.  (Respondent 19) 
 
 It appears that the underlying motivation for operating in accordance with 
regulations and LTO was to avoid further regulations; perceived as adding costs and 
unnecessarily constraining to the actions of companies.  Respondents stated they 
would rather voluntarily address LTO themselves to avoid further regulation. 
 Overall, a common theme emerges.  The constraining forces are pushing 
companies to act and behave more responsibility through fear of soft (e.g. product 
boycotts) and hard (e.g. regulations) repercussions that result from not securing a LTO.  
The enabling forces provide them with opportunities to create benefits for the company 
through compliance that is beyond expectations.  Using the enabling forces illustrates 
company attempts to voluntarily address the concerns and expectations of stakeholders 
to avoid further regulation. 
 CSR is, then, a method to enhance the level of responsibility in the actions and 
behaviours of companies.  However, what also emerges as an important factor is the 
image, or reputation, of the industry, according to stakeholders.  The connections 
respondents made about the use of soft possibly leading to hard regulations implied that 
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a poor reputation with some stakeholders could be used as justification for others to 
also introduce repercussions.  Consequently, CSR is motivated by a perceived potential 
to build a more positive image of the company to stakeholders and society in general.  
 
4.2.7  Reputation 
 The use of CSR to address risks associated with LTO violation appears to be in 
part driven by a desire to improve company and industry reputations.  In theory, by 
creating a better reputation with stakeholders, a company demonstrates that it has 
taken actions to address some aspects of its stakeholder concerns and expectations; 
thereby, eliminating or drastically lowering the repercussions associated with LTO 
violations.  Since LTO has no observable framework for evaluation, the perception of a 
company's reputation becomes a powerful force to sway stakeholder opinions. 
 Respondents differed in their opinions as to whether or not the pharmaceutical 
industry has a poor reputation.  Perceptions varied from the admission that ethical 
violations or controversies have contributed to a poor reputation to outright denial of 
anything but a positive reputation.  The respondents that perceived an entirely positive 
reputation focused their arguments on basic contributions to health care that is created 
by their streams of innovation, while the others acknowledged the complexities of both 
the workplace and social environment and that conflicts of interest do arise and have 
contributed to declining reputation.   A battle of perceptions is occurring not only 
between companies and their stakeholders but within companies as well.   
Some people (employees) are still criticizing that we did that (product recall), but 
we certainly are a company that can demonstrate that we make decisions based 
on what’s best for patients even though it might have a bad impact on our bottom 
line. But we are very serious about doing the right thing. (Respondent 10) 
 
 Regardless of their perceptions about the reputation of the industry, however, 
respondents all described internal and external forces that constrain and enable their 
actions as to encourage, sometimes demand, engagement in CSR. 
 Contradictions also emerged over the course of the interviews.  At the beginning, 
some respondents stated that there are no reputational benefits from engaging in CSR, 
but over the course of the interview all conceded or alluded to reputational benefits.  
Some attempted to clarify their position by specifying that reputation is not the primary 
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motivation or driver but may be a major catalyst for the current period of CSR evolution: 
Yeah, I mean we’ve been compared to tobacco companies and we’ve been 
accused of a lot of different things. I think it’s created a lot of soul searching in 
the company as to how did this happen and what can we do to change it.  
(Respondent 6) 
 
 Some respondents, however, did overtly state throughout the interview that there 
are reputational benefits.  Nevertheless, most perceive it as a flawed and inauthentic 
strategy to engage in CSR for purely reputational reasons, with the hope that it will 
deflect from their negative actions: 
I have mixed feelings that it (CSR) has become an instrument to try to deal with 
some of our public image issues.  I want to do it because it’s the right thing to do.  
That’s probably naive and a bit idealistic, but I really think everybody does it 
towards that end because it’s just the right thing to do.  And the fact that we are 
now spinning it to show that we are socially responsible against some of the 
actions that, frankly, we have to be accountable for…we’ve not always behaved 
in other ways socially responsible. (Respondent 22) 
 
 The two preceding quotes suggest a process of recognizing the constraining and 
enabling forces that have been constructed by stakeholders.  The 'soul searching' that 
followed is the social disturbance of and reaction to these forces.  In part, this has likely 
contributed to engagement in CSR and promotion of greater levels of ethical behaviour 
to employees by companies to both avoid further controversies and to rebuild or 
maintain morale.  However, as this process occurs, some employees have become 
troubled by a possible connection between CSR use and its reputational benefits.  As 
concerned as these employees may be about a CSR/reputation link, CSR does appear 
to be a response to pressures from stakeholders and their abilities to impose soft and 
hard controls on companies. 
 Overall, the majority of respondents were comfortable with reputational benefits 
as an indirect benefit as long as CSR focused primarily on the patient and their health.  
Yes, you can develop a reputation, an image, using traditional tools such as 
advertising and promotion; I guess we’ll call it that.  But the truth of the matter is 
that in this day and age what you really want to do is build relationships, and 
building relationships you do that through CSR activities really well.  We partner 
a lot with all kinds of stakeholder groups.  They benefit from the relationship and 
we benefit from the relationship as well because we share common objectives of 
ensuring that patients have access to medicines. (Respondent 10) 
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4.2.8 Summary – Social Context 
 The pharmaceutical industry, like every other industry, operates within its own 
unique social context.  For-profit entities that are also providers of necessary healthcare 
products, the industry has faced continually shifting expectations and concerns from a 
wide array of stakeholders.  Having a 'stake', either directly and/or indirectly, these 
groups use their influence to evoke a response from companies.  The continuum of 
concerns and expectations forms a subjective and intangible license to operate (LTO).  
As such, LTO is a nebulous set of thresholds that can be used to judge the actions and 
behaviours of companies.  If stakeholders perceive a threshold is violated, it can 
potentially result in the introduction or increase of various soft (e.g. consumer boycotts) 
and/or hard (e.g. regulations) forms of repercussions for companies.  While each 
stakeholder group is capable of its own form of soft repercussions, only government is 
capable of instituting hard repercussions.  The result of this dynamic situation is 
government acting as the hub for other stakeholders to voice their concerns.  As a 
result, the desire by companies to avoid the risks associated with LTO violations 
appears to result in responses to some of the stakeholders’ constraining and enabling 
forces.  As such, the risk avoidance mentality provides weight to the stakeholders’ 
ability to influence.   
 According to respondents, stakeholders are continually pressing for the adoption 
of more responsibilities, a substantial part of which is using their capabilities to help 
alleviate various social/health needs.  Companies appear to be responding through the 
expansion of a practices and policies called CSR.  The enabling forces have also 
presented opportunities for companies to further their own sustainability using CSR as a 
response to stakeholder expectations and concerns: 
I think in this day and age you can no longer just get by on just sort of 
shareholder value alone.  It’s just sort of the Friedman theory versus the 
stakeholder theory.  There are too many influences that act on companies to feel 
that the only duty of managers is to prioritize quarterly earnings at the expense of 
everything else.  It’s [CSR-Stakeholder perspective] an integrated approach to 
running an operating company.  It’s a sustainable approach to running a 
company because at the end of the day every industry and every company has 
sort of a social life to operate, and government reinforces and establishes that 
through regulations and policies. And so ensuring that you’re around as a 
company – not just in four quarters but in four years or forty years – is about 
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actually thinking about that long-term perspective.  You can’t do that in an 
accurate and comprehensive way unless you’re looking at the broader world in 
which you operate.  (Respondent 4) 
 
 An important variable in this process is the shareholder, the owners of the 
companies, and how they perceive CSR as a response to stakeholder forces.  
Respondents appear to be under the impression that the majority of shareholders agree 
with their CSR strategies, resulting in the justification for CSR engagement.  
Additionally, if CSR actually has the potential to assist companies in realizing how to 
more effectively put patients before profits in a manner that will actually benefit them 
and their stakeholders, then shareholders that only prioritize profits should be satisfied 
as well.   
 Overall, the current social context provides the insight into the operational 
environment of the industry, one where companies are under increasing pressure to 
respond to stakeholders’ concerns and expectations regarding the adequacy of their 
support for perceived responsibilities, and this has resulted in the expansion of CSR.  
Although the reasoning for why contextual actors are influencing CSR is evolution is 
presented as rather clear (e.g. greater health, social and economic outcomes for 
themselves or the group they represent), companies and their respective employees 
process the meaning of these forces and the response to them from perspectives based 
on the organizational context within their company and their own personal experiences, 
making the resulting possibilities more complex and pluralistic.  
 
4.3 CSR Perspectives 
 My analysis of respondent interviews and company websites is mapped out as a 
structured series of interpretations to explain the various forces within the social context 
that companies are responding to by engaging in CSR.  The result of the various 
responses was the development and evolution of three interconnected perspectives on 
CSR: 1) Traditional; 2) Expanded; and 3) Integrated. 
 Figure 4.5 illustrates the relationship among the three CSR perspectives as an 
upside down pyramid; where the traditional perspective serves as the bottom, or basis, 
expanded as the middle, and integrated as the top.  The programs and polices 
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associated with the traditional perspective of CSR at the bottom stage serve as the 
foundation to guide and build upon as perspectives evolve.  The large purple arrows 
symbolize the incremental, but not deterministic process of perspective evolution from 
the traditional to the integrated.  The smaller red and orange arrows represent the 
possibility of changes in the social context (e.g. the constraining and enabling forces 
direction and strength) that may influence the perspectives of employees and 
companies to regress or even digress into a new direction.  Finally, the arrows to the 
unknown (illustrated by question marks) that are above the integrated and below the 
traditional perspectives represent the uncertainty about perspectives that might evolve 
in the future, or existed in the past, but could not be identified based on the information 
provided by respondents and their company websites.  Overall, the purpose of the 
figure is to illustrate how these three perspectives, which will be discussed in this 
section, influence and relate to each other and the potential for change and divergence 
from the current trend of perspective evolution. 
 
 
Figure 4.5 - Evolution of CSR Perspectives 
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 Based on information collected, there appears to be a process of evolution from 
the traditional to the integrated perspective.  However, specific companies do not 
perfectly align with any one perspective per se; rather, they display features of multiple 
perspectives such as a blend of CSR programs and polices, some with more integrative 
construction (e.g. reinvestment of profits into health infrastructure) and others that are 
remnants of more traditional practices (e.g. monetary donations to a social cause).  In 
addition, the movement through the perspectives is not a linear progression that is 
deterministic; therefore, it is not an automatic and straightforward progression.  
Transformation can occur in various directions and speeds due to differences in values, 
history, experiences, etc. that influence the perceptions and choices of companies.  
Evolution of perspectives towards integrated is not automatic, and can be observed in 
how the companies represented by the respondents are evolving at different speeds 
and developing unique characteristics.  However, based on respondent comments and 
company websites, I believe that these three perspectives of CSR best represent the 
historical influences and goals that are driving this period of CSR evolution in this 
industry. 
 The following section will first detail the respondents’ ideas about why CSR has 
recently been evolving and from where it has evolved.  Next, the three evolving 
perspectives are explained to provide insight into how the respondents and companies 
are in a process of changing conceptions of the CSR role and purpose within and 
outside their company. 
 
4.3.1 Emergence of CSR 
 According to respondents, engagement in CSR has had a long existence in the 
operations of pharmaceutical companies.   
 It’s (CSR) a long tradition.  It’s been there for a long time and it’s an example of 
how everything we do is dictated by a sense of ethics and responsibility and a 
focus on helping out patients. (Respondent 10) 
 
I think it’s (CSR) in the DNA of who they (employees) are and what they want to 
be a part of, and so I don’t think it’s surprising that if you go back over the history 
of the company that CSR has been there from day one.  It may not have been 
under that title, but it’s certainly a part of what the company is about. 
(Respondent  22) 
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 Although it is believed by respondents that there is a long established history of 
CSR, the industry appears to be in the middle of a period of rapid CSR evolution.  An 
increase in the development and influence of stakeholder-created forces appears to be 
a major catalyst for CSR evolution.  However, companies are not isolated to their own 
social context and respondents discussed how controversies from other industries also 
influence their choice to further engage in CSR: 
I began working in sustainability in 2000, and we developed at that time shorter 
reports.  A lot of it started with health, safety, and environment.  Requirements 
were forcing us to report, but then, overtime companies felt that voluntarily we 
needed to speak to all three performance areas: the economic, social and 
environmental.  You could see how things were happening; environmental 
disasters like Bhopal and Exxon Valdez, then Enron happened, and the 
responsibility aspect became an issue.  CSR has become very important within a 
10-year timeframe; it’s being taught in MBA courses. (Respondent 16) 
 
 Respondent 16 explains that the rising societal importance of CSR as a response 
to business-based controversies in different industries highlights issues regarding 
business responsibilities and how they are interpreted as a warning.  What is interesting 
is how Respondent 16 describes growing CSR engagement as a choice, heading off 
regulation by responding voluntarily.  It is also notable that the respondent did not 
categorize the pharmaceutical industry as one of the companies involved in 
responsibility related controversies.   
 Within the pharmaceutical industry, it appears the companies have chosen to 
enhance existing aspects of their business perceived as related to CSR. 
I think it’s probably been a crescendo-effect in the last twenty years.  I have been 
in the business for twenty years, certainly not closely on corporate citizenship 
(CSR), but I’ve seen it evolve, like I am sure you have seen it evolve too, in the 
right direction. (Respondent 11) 
 
Respondent 11, like most of the respondents, identified the evolution of CSR as 'in the 
right direction,’ describing how the use and understanding of CSR is still changing, but 
in a way that employees perceive that as responsible and justifiable: 
Some of our efforts for access to medicine are selling products at not-for-profit 
pricing that may not be essential for the long-term survival of our business but it’s 
the right thing to do and we have to look at what I can only describe as a contract 
with society. (Respondent 19) 
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4.3.2 Traditional Perspective 
 A traditional perspective of CSR in the pharmaceutical industry was evident to 
respondents as they reflected on the histories of their companies.  They suggest that 
throughout the history of these companies, their 'natural' role as developers and 
commercializers of pharmaceuticals and other healthcare products has served various 
public health needs.  In addition to their 'natural' CSR role, respondents argue that the 
companies were traditionally engaged in a number of internal and external arms-length 
programs and policies that, upon reflection, can be defined as CSR.  As the historically 
dominant perspective, traditional is an approach to engaging in CSR programs rooted in 
philanthropy, community support, and employee health and safety (Respondent 16):   
Until the past ten or twenty years or so most companies had, or at least large 
multinational ones like ours, a function known as environmental health and 
safety.  That function was part of the manufacturing operations part of the 
company and it was focused on things like ensuring a safe working environment 
in terms of lost time, accident rates, and exposure to potentially hazardous 
chemicals and things like that.  It is sort of a compliance driven type of approach.  
Often other silos that are sort of separate somewhere else in the company would 
be a philanthropic organization of some kind, a not-for-profit fund or a grant-
making organization or some hybrid that provided support to civic, community, 
and cultural initiatives that the company felt were important.  This idea of being, 
you know, a good neighbour, a good citizen, a company where if it was viewed 
as a premiere employer where people would want to work and so forth. 
(Respondent 18) 
 I believe that constraining forces resulting in a ‘compliance driven approach’ 
drove the traditional approach to CSR.  Companies responded to the enabling forces 
with basic, 'silo' programs that were designed at the local level to boost their reputation 
to both attract talented employees and gain local approval.  It appears the constraining 
forces were not perceived as placing enough pressure or having enough influence on 
the company to cause them to innovate how to better use the enabling forces to create 
a more dynamic approach to engaging in CSR.  The companies could not or would not 
identify alternatives to what they were doing already.  Therefore, the traditional 
perspective of CSR is one where companies find it satisfactory to engage in limited 
CSR activities as a way to supplement their 'natural' CSR role of healthcare producer 
and provider.  These minimal CSR activities are based on a foundational concept that if 
communities and employees are happy and the company is an attractive workplace, 
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then it will retain and recruit a more talented and dedicated workforce: 
We really base our CR approach kind of going all the way back to that (beginning 
of the company) and we’d done, I think, a very traditional corporate responsibility 
for a long time that was mostly philanthropic…I think in the past it was driven 
mostly by reputation in some ways, that we wanted to be seen as a good 
neighbour or a good employer. (Respondent 17) 
 
In those days (Company D) was just making donations, lots of donations, but it 
was philanthropy, pure philanthropy.  We give money and there we go, but 
millions of dollars, and I thought we were pretty good. (Respondent 9) 
 Examples of CSR practices related to the traditional perspective include a 
combination of employee and philanthropic efforts such as matching the donations of 
employees to registered charities and community volunteering programs.  By matching 
employee donations, the company empowers employees to choose a charity of their 
choice while also showing support for philanthropic ventures.  For example, 
respondents commented that they have routinely volunteered outside of company 
hours.  However, through company volunteer programs they can combine their 
volunteer efforts with other employees, and in some cases, be paid to do it during work 
hours.   
 Upon reflection by respondents, the process of providing philanthropic donations, 
grants, etc. was considered a basic transaction: “I think the first is that if you’re 
operating as an ATM, if you’re writing cheques to people, but you’re not actually sort of 
putting any meat behind it then it’s a transaction, not a relationship” (Respondent 4).  It 
appears that Respondent 4 seems to acknowledge that what was traditionally 
normalized as a successful method of CSR engagement is now perceived by some to 
be an insufficient response. 
 Based on the descriptions of respondents, I interpreted that within the traditional 
perspective, CSR programs and policies operate on the periphery of the organization 
where it is more of an add-on strategy, which can be reduced or discontinued during 
times of budgetary constraint:  
The true criticism will be is when times are tough what’s the first thing to go?  My 
guess is things like corporate social responsibility; I think the donations would 
probably decrease in tougher times. (Respondent 12) 
 
The preceding quote also illustrates the fact that some respondents had reservations 
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about their companies’ dedication to CSR and its long-term sustainability.  I believe this 
gives credence to an interpretation that most companies’ perspectives on CSR continue 
to be in transition and that it takes time to create and respond to cultural shifts through 
strategic realignment (Section 4.4.3, p. 216). 
 
4.3.3 Expanded Perspective 
 While the traditional perspective on CSR may have the longest history in the 
pharmaceutical industry, in recent years there appears to have been an evolution of this 
perspective by some companies in response to the forces attributed to stakeholder 
concerns and expectations:  
Over the last few years, I think a lot of leading companies have started to bring 
together this thinking that used to be grounded in that EHS function on the one 
hand and in the philanthropic in the other, and try to bring it together in a much 
more holistic fashion and also make it much more proactive where we are 
listening to and engaging with stakeholders and then developing systematic 
programs and processes to address stakeholder issues and concerns. 
(Respondent 18) 
 
 In this example, the company’s response was to evolve, from a narrow CSR 
perspective of CSR placed on the periphery of the company to one that acknowledges 
more stakeholders through dialogue and a diversification of CSR programs and policies.  
It appears the companies began to understand that the forces combining in their social 
context needed to be better acknowledged as credible risks to the companies.  As a 
result, simplistic programs of philanthropy and volunteering were increasingly seen as 
insufficient as methods of CSR engagement.    
 I believe that when companies begin to address the rising concerns of their 
stakeholder-constructed LTO, a response of expanded CSR engagement results in a 
better understanding of the opportunities that can be constructed.  The simplistic 
philanthropy and volunteer programs are then used as templates to improve upon for 
future CSR strategies.   
I interpreted this process as companies attempting to respond while trying not to 
re-invent the wheel, but rather to transform their current wheel into one that may be 
more effective within their current environment.  For example, respondents discussed 
the use of philanthropy in knowledge and technology transfers to developing or 
 
 
165 
emerging countries.  The transfers require a substantial investment of time, money, and 
expertise to ensure they are functioning properly and the protocols for manufacturing 
are strictly followed.  Additional funding is also provided in combination with 
manufacturing capabilities so that other countries or groups can purchase or have 
access to needed medications.  As a result, the complexity of programs also increases 
with the company’s expanding perspective and subsequent use of CSR.   
 In addition to the increasing complexity, respondents suggested that as CSR 
evolved in their companies it became more oriented towards benefiting the business, 
creating a business case or win-win strategy for engaging in CSR.  The creation of a 
business case for CSR can be interpreted as part of the evolutionary process not only to 
address the concerns and expectations, but also to go 'above the board' strategically to 
create business opportunities.  
Let’s face it, the environment is changing, it’s becoming more difficult, and there 
are just so many ways that a company can engage with their constituents.  The 
responsibility activities are certainly a very good way and a win-win for everybody 
involved. (Respondent 10) 
 
We really think that the unique demands that society places on healthcare 
companies are also opportunities for sustainable growth and development.  Not 
only sustainable business growth for us, but also for sustainable growth for the 
markets we are in the process of entering, and so we really think there is a great 
synergy between our citizenship (CSR) strategy and our business goals.  One of 
the things that we have really been emphasizing in recent years is our expansion 
into so-called emerging markets. (Respondent 18) 
 
 Respondent 18 identifies the link between the demands put on them as a 
healthcare company and how there are opportunities for sustainable growth and 
development.  As companies and their employees start to identify a connection between 
CSR and company sustainability, it can lead to further justification of its use.  This 
connection also provides incentive to create new opportunities and/or enhance current 
ones – a dynamic period of transition and choice.  
 Furthermore, Respondent 18’s comments on emerging markets provides a clear 
example of how companies are using CSR as a toolkit of methods to address the 
business constraints they attribute to entering markets that are not as wealthy as 
Western markets.  I believe these companies are trying to gain access to markets 
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where their traditional perspective of business strategy, including CSR, is viewed by the 
new stakeholders as normatively insufficient, and an evolved perspective is seen as 
helping to provide a clearer understanding of how to operate in different environments:  
You’ve got these vast populations that don’t have access to our products 
because our products are expensive.  Well it is in our interest as a business to 
improve access and thus improve the volumes we sell, and so it is a win-win. 
(Respondent 19) 
 
What they found was that in a lot of very impoverished countries, patients they 
would be willing to buy medicines.  They could afford to buy them, but the 
problem is they had to walk or travel to the pharmacy, which is quite a ways 
away, and they’d get there and they would be out of stock.  So what they did is 
they developed a program where with a cell phone they could actually program in 
tell them whether or not there is stock in the pharmacy to actually get their 
prescription filled.  By closing that loop, you are actually helping a patient get 
well. (Respondent 21) 
 
 The expanded perspective appears to be associated with both the 
acknowledgment that LTO risks are sufficient to warrant a response by companies to 
use CSR and that there are also opportunities for mutual benefit or win-win scenarios 
when strategically engaging in CSR.  Overall, the majority of respondents were from 
companies that have CSR and business strategies that would be considered as aligning 
with an expanded perspective.   
 In some interviews, respondents discussed the use and function of CSR in ways 
that may suggest a personal perspective that is evolved beyond the expanded.  
However, these personal perspectives do not appear to have been widely adopted by 
their respective companies.  Company websites of the same companies reinforce this 
perception because CSR is being communicated as an important part of the business, 
but it was still separated from the main business priorities.  Additionally, the evolution of 
CSR perspectives appears to be a slow process where aspects of programs and 
policies tend to blur in their representation of traditional, expanded, and integrated 
perspectives.   
 
4.3.4 Integrated Perspective 
 The integrated perspective results in a business strategy that attempts to better 
address stakeholder concerns and expectations by using CSR and the principles 
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perceived to be associated with it as the guiding philosophy for its business.  This 
response to stakeholder forces provides companies with ample incentive to create 
business-wide opportunities through the innovative use of enabling forces.  An attribute 
of an integrated perspective is the justification for CSR engagement that is more tacitly 
understood.  The result is less hesitation about shaping a company's business 
strategies with evolving concepts of CSR.   
 Based on discussions with respondents and the information on company 
websites, I interpreted two notable features of an integrated perspective: 1) shared-
value approach to CSR programs and policies, and 2) developing value-based decision-
making.  These two features appear to emerge from, and lead to, the merging of CSR 
strategy with the overall business strategy of the company.  To fully explain an 
integrated perspective of CSR, the following section will first details the two features and 
then the merging of business and CSR strategies.   
  
4.3.4.1 Shared-value Approach to CSR Programs and Policies 
 The term 'shared-value' is used to explain the process of companies innovating 
business opportunities found in the relationship between constraining and enabling 
forces, to develop strategies that use their assets and expertise to address the social 
needs of stakeholders while creating benefits for themselves.  According to one 
respondent, and implied by others, having an integrated perspective of CSR allows the 
company to identify overlap among business opportunities, assets and expertise, and 
social needs.  That information is then used to create CSR strategies designed to 
benefit all parties involved: 
There is really of things that you can think of as ‘three-ringed Venn diagram’.  
The phrase in academia is shared-value, and shared-value really is that space 
where you have overlap of social need, business assets and expertise, and 
business opportunity.  When organizations like ours can identify those locations, 
we really believe that we can have meaningful impact on individuals.  We can 
produce a sustainable corporate responsibility model that could ultimately just 
blend into being part of the business.  In sum, it’s a long definition, but it’s a 
definition of evolution, and (Company A) is just now stepping into that shared-
value space. (Respondent 20) 
 
Most notably, Respondent 20 also acknowledges that although his company has 
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identified the benefits of prioritizing CSR engagement in the area of overlap, it is only 
beginning to take strategic steps toward actually carrying it out.   
 Entrance into what would constitute a shared-value space would incorporate a 
stronger focus on business opportunities than the other CSR perspectives, causing 
discomfort for some respondents.  
But what I think that the key things is – this is what I was pointing out yesterday 
to some of our folks – as we become more comfortable that there may be kind of 
synergistic areas.  I also think that it is very important that we put firewalls around 
where that is so that where the social responsibility stops and where the 
business starts we don’t get into things where people are saying, “Hey, you’re 
just doing this for the business”.  I think there are potentially some blurry lines 
there, so I think companies need to think a little bit about how they do that. 
(Respondent 21) 
 
Although Respondent 21 works for the same company as Respondent 20, there is a 
divergence in how each perceives CSR, with the former being more idealistic and the 
latter attempting to merge idealism with business strategy.  Both noted the need to 
engage in CSR as the “right thing to do”; however, Respondent 21 is concerned about 
the reputational problems of being perceived as engaging in CSR more for business 
purposes than because it is the “right thing to do”.  However, at least one company, on 
websites and CSR reports explains the business case for entering a shared-value 
space: doing so can be of great benefit to all those involved if it is done responsibly. I 
interpreted these differences as a reflection of the cultural and value-based struggles of 
a changing CSR perspective at a company comprised of tens of thousands of 
employees, with an even wider range of perceptions. 
 Other respondents indicated that the benefits of the shared-value space far 
outweigh the possible negative perceptions that could result, and that the general trend 
is driving companies in this direction.  It is an assumption that implies that idealistic 
concerns can be satisfied by the use of shared-value approach to CSR. 
Increasingly we are looking at corporate responsibility not only as an opportunity 
to do good and to hold that up externally, but as a way to drive revenue.  I think 
in the past we said, “Uh, that doesn’t sound right, we shouldn’t be doing 
corporate responsibility to make money”.  But I think increasingly you are seeing 
companies like GE, Nike and Nestlé that are saying, “that’s exactly what your 
corporate responsibility is: it’s to be responsible to your shareholders and making 
sure that your company is sustainable in the future”.  But you should be doing it 
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in a way that also benefits society, and I think the pharma industry is such an 
easy way to make that case.  You know when we have a product – where 
medicines are our product – and it’s a product that can save lives or help people 
live longer.  We are not a charity, so we are going to make money on it, but we 
are going to do it in a responsible way. (Respondent 17) 
 
 Respondent 17 also touches on an important incentive, or reason, for engaging 
in shared-value CSR: there are highly regarded and influential not-for profit 
organizations that are placing pressure or encouraging companies to move toward the 
shared-value space: 
Places like Gates that we have talked about are eager for us to do this (shared 
value CSR) kind of work.  The Access to Medicines Foundation, who produces 
the Access Medicines Index, is interested and observant of us doing this kind of 
work.  I think the time is right because there are organizations that are eager for 
us to do this.  I feel an increasing feeling of eagerness internally to do this and I 
am positioning the company to pilot some of these programs over the next year.  
(Respondent 20) 
 
 I interpreted these organizations as being important and influential for the 
following reasons.  First, they hold high status with positive reputations, and second, 
because they provide insight and guidance as to how companies can successfully 
engage in shared-value CSR.  With CSR reports and the websites of companies, all had 
sections describing their partnerships and/or collaborations with NGOs that attempt to 
address specific and more general social needs of groups around the world.    
 One region where it appears that the shared-value approach provides the best 
incentive to companies is in emerging markets: 
…Improved healthcare means improved economic activity; it all goes around in a 
virtuous circle.  But it is not just about that, it’s about coming down and accepting 
that where the real business in these markets is in the vast middle class 
population rather than the wealthy upper class, and therefore, we should be 
pricing to enable sales in this sector of the market, accepting that margins might 
be lower, but our increased volume of sales will compensate for that. 
(Respondent 19) 
 
A shared-value approach to CSR becomes a justifiable alternative to traditional 
business practices in the emerging markets because companies can more readily 
identify a link between enhanced social/economic responsibilities and a potential 
increase in sales volumes.  Therefore, some respondents perceive a shared-value 
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approach to CSR as a response reducing barriers and opening up these markets for 
future growth. 
 
4.3.4.2 Value-based Decision-making  
 The specific values communicated by the respondents' companies have 
remained relatively constant in title; however, whether they have achieved their 
intended purpose (outlined in their articulation) to guide all the employees’ actions and 
behaviours remains an area of much debate.  For example, Respondent 10 stated that 
a decision to pull a product from market that posed unexpected health risks is still being 
criticized by some employees within the company.  Criticism that would appear to run 
counter to the patient oriented values supported by the company.  Furthermore, some of 
the respondents acknowledged that the industry has a poor reputation and that it is 
connected to public perceptions that some actions were negligent of expected 
responsibilities and therefore controversial.  I believe the contradiction of values 
observed around recent controversies, involving not only the pharmaceutical industry 
but other industries as well, has contributed to the voluntary establishment of stronger 
codes of conduct within the industry.  Additionally, these codes of conduct are routinely 
revamped and consistently reinforced across the employee hierarchies—Respondent 3 
stated that his company’s handbook regarding conduct is updated yearly and 
employees are continually assessed on how they adhere to its policies.  In fact, most 
respondents discussed the rising importance of ethics.  However, some respondents 
perceived limitations to the complex layering of conduct policies that has resulted.  For 
example, codes of conduct and other internal regulating polices may become obstacles 
to decision-making if there are too many, or if they do not sufficiently cover every 
possible situation; either there is too much ‘red tape’ or too little guidance. 
 Reflecting this view, Respondent 19 explains how her company seeks to move 
beyond rules or policy-based governance to value-based decision-making that uses the 
aligned values of the company and its employees to provide tacitly understood criteria 
for decisions. 
Actually, what we want to do is get people to accept that, yes, we do have 
policies that set out a framework, but actually to move much more towards a 
values-based organization rather than a rules-based organization.  When new 
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issues come up, we want to ensure that the people we’ve got in the organization 
have got the right values such that they make good judgments about what line to 
take or what approach to take.  So they are not constantly having to go back to a 
rule book and say, “well because there’s not a rule in there I can do whatever I 
want”.  We don’t want that sort of behaviour; you want people to make a 
judgment that is around our values as an organization. (Respondent 19) 
 
At its core, this is an attempt to hasten decisions and create a business that can swiftly 
react to a changing social context in ways that will be perceived as socially acceptable.  
Triangulating her statement, examination of her company’s website and CSR report 
discussed the importance of all employees sharing a more integrated perspective of 
CSR but also still featured sections of the standards and code of conduct that 
employees are expected to adhere to—showing that the company is likely in transition 
like the respondent explained.   
 If CSR is the response to stakeholder forces in the industry's social context, then 
it is possible that engagement in CSR programs and policies will reinforce skills and/or 
values that would be considered socially acceptable:  
I think one of the reasons why CSR is so important is because the kind of 
mindset it imparts and the skills that it emphasizes are those kinds of skills of 
empathy, of curiosity, of innovation, and of collaboration that are actually going to 
be the same skills that are going to lead to our success or lack thereof going 
forward. (Respondent 4) 
 
…we help our employees recognize that the company supports activities that 
allow them to expand and deepen their thinking, touch the world in ways they 
might otherwise not, and allow them to find effective ways to improve their 
expertise.  Those things engage and inspire employees. (Respondent 20) 
 
Respondent 4 observed a connection between the skills and values associated with 
engaging in CSR and the success of the organization in the future, framing constraining 
forces into enabling ones for company and stakeholder sustainability. 
 A value-based framework for decision-making and how to really accomplish it 
remains unclear.  Although the respondents commented on it, none of them stated that 
their companies have implemented it.  It remains more of a theoretical strategy hinting 
toward a future form of CSR in the pharmaceutical industry.   
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4.3.4.3 Merging Business and CSR Strategies 
 In discussions about entering the shared-value space and implementing a value-
based decision making process, some respondents described the necessity of merging 
the business strategy with a company’s CSR strategy as a foundation for its 
sustainability: 
CSR is saying the scope of action and the scope of influence is bigger than we 
have ever thought before, and an intelligent approach to CSR is to say we’re 
going to reframe our [business] strategy to factor in both of those proactive and 
reactive influences. (Respondent 4) 
 
Respondent 4 frames CSR engagement and its integration into the business strategy as 
the response to a changing social context that is telling the pharmaceutical industry that 
their impact on society is much larger than they previously thought.  The majority of 
respondents commented that CSR should be more integrated into the overall business 
strategy of the organization, and that is where CSR is evolving. 
 Even though respondents perceive it to be a natural step forward, I interpreted 
the idea of CSR and business strategy integration more as a desired than a realized 
goal.  One respondent, however, stated that her company has integrated CSR/business 
strategies, evidence for which was observed on their company website, where the 
company explicitly discusses and promotes integration as the primary method of 
business, and in external measures, where they ranked quite high (specific measure 
and ranking absent to maintain confidentiality):  
We don’t have a CR strategy, we have a business strategy and we build 
responsibility into all our activities.  So we don’t have a separate CR strategy 
because what that’s saying is that CR is a standalone activity and it’s not.  You 
can’t use animals in research and then have a separate strategy in doing that in 
a responsible way.  If you are generally going to be a responsible business you 
have to build it into every policy you’ve got. (Respondent 19) 
 
In support of Respondent 19's comments, her company was highly regarded as the 
leader in CSR engagement by respondents from other companies.  Additionally, her 
company’s website and CSR report explicitly detailed the integration of CSR into the 
overall business strategy and the benefits that would result.  Based on these comments 
and observations, it seems as if this company was serving as a role model for other 
companies with regard to CSR since it was noticeably more progressive and vocal 
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about its strategy. 
 Although Respondent 19 stated that it is still a future goal of their company to 
implement a truly value-based decision-making system, they already had a business 
strategy featuring a high level of CSR integration.  The intention is to integrate higher 
levels of responsibility into every action of the company.   
The overall purpose of this strategy is evidently to integrate their response to the 
influential forces from concerns and expectations into the overall business strategy.  In 
this way, they would be capable of quickly analyzing and taking action when new 
opportunities are identified.  This entire process appears to happen while the company 
attempts to strengthen its reputation by aiming to exceed stakeholder concerns and 
expectations.  Overall, it appears this strategy is a method to boost company 
reputations and sustainability by utilizing normative opportunities.  It is an attempt to find 
modern methods to actually put patients first in ways that will make the company more 
successful.   
 
4.3.5  Summary – CSR Perspectives 
 The evolution of the CSR perspectives may be depicted as responses to the 
continually changing forces, both constraining and enabling, within the social context 
pharmaceutical companies operate.  It seems that the perspective shift (traditional-
expanded-integrated) is a gradual process; it takes time to normalize the evolving 
perspective within the companies.   
 The traditional CSR perspective appears to have been the dominant method of 
engagement until a combination of industry changes (e.g. attempts to enter emerging 
markets) and a rise in the influence of stakeholders’ drove companies to change their 
perceptions of, and, therefore, approach to CSR.  Based on comments from the 
respondents, it seems that ethical controversies from within and outside the industry 
played a substantial role in giving the concerns and expectations more prominence, 
changing the power dynamics within the social context.  As a result, the industry 
interacts with a variety of stakeholder forces in deciding whether or not to respond, 
including what a potential response would entail.   
 Changes in the social context have led to stakeholder forces with enough 
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influence to garner responses by companies.  Such responses appear to be based on 
insights into possible alternatives to their current, normalized actions and behaviours.  
For instance, the traditional perspective was thought by respondents to be an effective 
way to engage in CSR.  However, once stakeholder forces had enough influence to 
pressure for insight into alternatives, the evolution of the CSR perspective started to 
gain momentum.  In responding, companies built upon traditional CSR strategies as a 
foundation for future engagement.  
 The evolution and adaptation of CSR perspectives can also be observed in how 
companies label or name their CSR programs and policies.  Interviews and websites 
suggested that programs expanded from philanthropy to CSR, sustainability, and/or 
triple-bottom-line, as reflecting a perspective to address and articulate greater 
responsibilities with regard to social, economic, and environmental issues.  Yet, over 
time some respondents stated that themselves and their company identified limitations 
associated with these descriptions, which, according to Respondent 16, makes it 
appear that the company is prioritizing environmental issues over social ones.  CSR, by 
contrast, appears to prioritize social issues instead.  What I observed is that as 
respondent companies expanded their perspectives toward integration, they addressed 
the perceived limitations of the title of their respective responsibility practices by 
changing it to corporate responsibility (CR).  According to respondents, this title is 
meant to convey their desire and commitment to enhance levels of responsibility 
throughout all their corporate actions and behaviours and not only one specific area. 
 Movement through the three perspectives is not deterministic because 
companies have choice in how they will respond to forces from their social context, just 
as they had choice to engage in actions that should be considered unethical.  However, 
most companies appear to be evolving toward a more integrated perspective of CSR.  
Whether the respondents’ companies will change their strategies to reflect the 
integrated perspective held by some of their employees is unclear.  Re-alignment of a 
company's culture and strategy to reflect a selected alternative to traditional and/or 
expanded practices and policies appears to be a complicated process.  I believe that 
the stability of the social forces will play a significant role in whether it continues to 
promote CSR evolution.  If the forces lose influence or shift in another direction, it could 
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result in the CSR perspective regressing or digressing (as shown in Figure 4.5, p. 185)  
 
4.4 Continual Development and Reinforcement Process (CDRP) 
In the previous section, the evolution of the three perspectives of CSR was 
presented to explain how approaches to and understanding of CSR by pharmaceutical 
companies are shifting in response to the social forces.  The shifting of CSR perspective 
does not appear to be a simple process.  Companies must be active in making 
decisions to develop and reinforce elements of the company so that it is prepared for 
the strategic changes and challenges that accompany a shift in their CSR perspective.  
The continual development and reinforcement process (CDRP) relies upon four 
evolving and interdependent elements that are critical for a pharmaceutical company 
wishing to effectively respond to the forces of its social context.  These four elements—
creating authenticity and transparency (CAT), measuring outcomes, cultural shift and 
alignment (CSA), and CSR programming—are in dynamic relationship that may 
reinforce progress or delay or even prevent progress. 
 The conceptualization of the four elements of the CDRP is based on my 
interpretation of the perceptions of respondents as to how and why CSR engagement 
has evolved at their respective companies, including how it functions both internally and 
externally.  I analyzed the commonalities and differences among the respondents and 
identified the four elements of the business that appear to function as both the engine 
that causes CSR to evolve and constructs how it is perceived.  The following section is 
structured around these four CDRP elements. 
 
4.4.1 Creating Authenticity and Transparency (CAT) 
 According to study respondents, an important and growing part of CDRP is 
authentic and transparent communication of the intent and reasoning behind business 
decisions, including CSR.  Respondents commented that it is important to ensure that 
all stakeholders, including employees, understand the direction of the company.  They 
want to ensure stakeholders perceive the actions of the company as appropriate 
responses to their concerns and expectations.  If executed properly, the reputation of 
the company should improve and constraining forces diminish.   
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 The current era of CSR evolution in the pharmaceutical industry has evolved at a 
rapid pace, and it appears that the link between the influence of the LTO and the 
industry's reputation has heightened the importance of communications both internally 
and externally.  Through authenticity and transparency, companies seek to create a 
synergy of understanding about their CSR response to stakeholder concerns, including 
the purpose, use, and outcomes of CSR.  This first element of the CDRP appears to 
function by communicating information regarding the purpose and results of the other 
three CDRP elements to relevant stakeholders in a ways that will construct or reinforce 
perceptions of transparency and authenticity.  The intention of CAT appears to be an 
attempt to engage stakeholders to create authenticity that will ultimately alleviate LTO 
obstacles and barriers and in some cases create mutual benefits by strengthening 
relationships.   
 However, the concept of transparency can be extremely subjective.  Others may 
not perceive what one person or group views as transparent communication.  It appears 
the companies are trying to cope with this issue of subjectivity by focussing their efforts 
on business practices that are key points of concern for their stakeholders (e.g. 
concerns about access and affordability by most stakeholders).      
 Communication appears to be the main method to create authenticity and 
transparency.  Some respondents thought the industry had done a poor job in the past 
in externally communicating its perspective on decisions, such as pricing, product 
recalls, marketing, etc.  They were of the opinion that the substantial gaps in external 
communications created issues with authenticity because of the perceived lack of 
transparency, and have contributed to the poor reputation of the industry.  As a result, 
companies have chosen to expand and modify their communications: 
There is a lot of movement to open up the black box a little bit and to help 
government, patients, consumers, and new media, just help people outside the 
company better understand the different risks and benefits, and the different 
decision points that get weighed inside a company.  And sort of how, why and 
when different products come to market or how, when and why different 
geographic expansions are made or not made.  Just a better understanding of 
what’s going on inside the company so that there is a more holistic 
understanding of performance in the market place. (Respondent 18) 
 
We now talk about the way we run our business, where previously we didn’t have 
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active communications around, “this is how we are doing it”, now we do have 
that. (Respondent 19) 
 
 The focus on improving transparency in communicating with external 
stakeholders is a transition from a perspective where it was considered acceptable to 
limit external communications, to one that focuses more on stakeholder dialogue, which 
was observable on company websites were most discourses were constructed to inform 
interested external audiences and explicitly detail their prioritization.  Based on 
comments by respondents and company websites, examples of such attempts at 
transparency include public disclosures of clinical trials, code of conduct violations by 
employees, and payments made to physicians.  Each of these attempts represents a 
modification of the communication strategy to better respond to stakeholder concerns 
and expectations.  When once it may have been more acceptable to be less 
transparent, companies now perceive that they should respond to the demands for 
greater transparency by stakeholders.   
Some of that (industry backlash) has been put on us because of issues we’ve 
had in not being transparent; some regulations have been put upon us.  But I 
think what has really been impressive is (Company A) has led the whole 
transparency initiative, which I think, again, could fall under the umbrella of CSR 
because it’s saying we are going to be a good corporate steward and really be 
transparent in how we run our operations. (Respondent 22) 
 
 In addition to providing reasoning that a company should respond to LTO risks 
(e.g further regulation), the preceding quote shows that the respondent perceives 
transparent communications as being tied to their CSR perspective evolution.  It 
appears that this respondent considers it an act of social responsibility to operate the 
company in a more transparent way.  Respondent 22 also talks about his company 
being the leader in their response to 'industry backlash'—a position that the respondent 
perceives as truth but also reflects a communication strategy to reinforce an identity as 
a leader rather than laggard in one area of CSR engagement. 
 Repeatedly discussed by respondents and company websites was the 
importance of transparency as an integral part of operating in a social context that 
increasingly emphasizes greater stakeholder dialogue: 
That’s the whole problem: you need to be very transparent.  You need to be 
transparent with your stakeholders and with your customers.  I mean all of your 
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stakeholders.  How many stakeholders do we have?  Loads of stakeholders. 
(Respondent 16) 
 
 Respondents also suggested that communications should not be unidirectional, 
recognizing that stakeholders have useful perspectives that can assist companies in 
identifying business risks and opportunities:   
We talked about the requirements of a successful CR approach; we talked to 
them about how we got to our CR priorities by talking to a lot of different 
stakeholders; and then this is the approach that did get approved last week 
where we said that the obvious nexus between our shareholder’s interest and 
society’s interest as a healthcare company is access to health.  (Respondent 17) 
 
 I interpreted the comments of Respondent 17 as implying their company is 
responding to stakeholder and society interests by finding the opportunities within their 
LTO.  These opportunities focus on creating a convergence rather than a divergence of 
priorities in their dual role—an approach that could satisfy both shareholders and 
stakeholders.  
 Previously, non-constructive dialogues with critics were seen as contributing to 
the poor reputation of the industry.  To address this issue, some respondents stated that 
their companies included dialogue with supporters and critics alike in an attempt to 
encourage mutual education.  I interpreted this process as intended to assist the 
development and reinforcement of an authentic external perspective of the industry: 
I’ve had an individual on my staff developing kind of a fairly rigorous approach to 
finding who are our stakeholders as it relates to corporate responsibility, and that 
stakeholder list should include organizations who consider us allies and 
individuals and organizations who would be considered critics.  We need to have 
a conversation with those individuals.  We shouldn’t have those conversations 
with the belief that we are going to fundamentally change their thinking on these 
matters, but we should approach them with a fundamental notion that we may be 
able to improve our understanding of their issues and we may be able to improve 
their understanding of our issues.  Success will be measured in maintaining that 
open dialogue. (Respondent 20) 
 
 I believe the pursuit of transparency in the communication strategies of the 
companies is guided by the desire to be perceived as authentic in their actions.  
Respondents viewed authenticity as achievable by transparently communicating their 
actions and behaviours to all their stakeholders, including employees.  Based on 
comments by respondents, I would suggest the authenticity and transparency dynamic 
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is guided by the philosophy that the company and its employees must ‘walk-the-talk’ to 
prove to stakeholders that CSR policies and procedures are an actual response and not 
just rhetoric that lacks substance: 
It is important for us to develop a good reputation, but it’s important to walk-the-
talk.  When we go talk to our customers, talk to our payers, we are telling them 
how important it is for the patients to get access to the drugs and we have to 
make sure that we do everything that we can to make sure that patients have 
access to the drugs that they need. (Respondent 10) 
 
 Respondents thought it hypocritical to be promoting elevated levels of 
responsibility if also involved in ethical controversies such as product recalls and 
questionable marketing practices.  Furthermore, they commented that employees 
tended to be the most critical of authenticity because of the insight provided to them by 
a more transparent perspective of company operations and a desire to be proud of their 
workplace: 
If you are internal you are much more critical of it (increased responsibilities) than 
external people will be because you can see what is going on.  So you 
completely undermine trust with your workforce if you don’t walk the talk.  
Employees will spot very quickly a gap in the external rhetoric and what we are 
actually doing internally.  Actually, the messaging needs to be the same 
externally and internally.  You can’t differentiate between them because we have 
a company of (tens of thousands) people.  You can’t sort of compartmentalize 
that. (Respondent 19) 
 
 Employees, as stakeholders, have the greatest proximity to the actions of the 
company, which also provides them with higher levels of transparency.  Since 
companies rely on their workforce to operate, the ability of employees to spot gaps 
between their company's rhetoric and actions increases their ability to question and 
influence company decision-makers.    
For these companies, the pursuit of authenticity with employees appears to be 
tied to the education, promotion, and reinforcement of the currently articulated values of 
the company.  If companies are articulating their values in response to the perceived 
normative priorities within their social context, then doing so also creates a frame of 
reference from which employees can judge the authenticity of their actions and 
behaviours.  Employees may then attempt to hold the company accountable for actions 
and behaviours they perceive as not living up the values that employees are constantly 
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being told to observe. 
 The combination of employee influence and the perceived benefits of CSR 
activities appear to have resulted in various methods to educate employees about CSR 
strategies.  These include CSR opportunities, motivating engagement, encouraging 
discussion about CSR experiences, and empowering employees to help guide CSR-
decision-making.  An example of one such method is that some companies created 
internal website forums where employees can discuss their CSR-related experiences 
with other employees. 
One of the tools is going to be almost like a Facebook-like conversation 
capability, where if an employee goes through this volunteer program, or they are 
in (specific program), or they did something on the (specific program), they can 
provide their thoughts and input, they can put pictures up, they can do video 
blogs, they can do written blogs, they can open up chat rooms, and find a way to 
have some longevity to the experience and to increase the breadth of the impact 
of the experience. (Respondent 20) 
 
Opportunities for CSR engagement are also communicated to employees in a variety of 
ways; with customized notifications sent by email to employees based on their 
preferences.  
 Overall, focusing transparency and authenticity efforts on employees appears to 
be part of a larger strategy to ensure the companies can recruit, retain, and motivate 
employees, not just with regard to CSR.  By attaining some level of cultural alignment 
with employees and the articulated values, the company can use employees to judge 
the levels of transparency and authenticity of the company responses to the concerns 
and expectations of stakeholders.   
 While the industry appears to be shifting toward increasingly open 
communication, some companies are having difficulties with transparency and 
authenticity, even as their CSR perspective evolves.  For example, the following quote 
by Respondent 9 reveals a gap in CSR understanding between top management and 
other employees.  
More and more I see now it’s important for them (executives and management) 
to start leveraging our community involvement and the good that we do.  Like I 
said, here in (affiliate location) it is difficult about the whole CSR because, to be 
honest, I don’t think that our top management necessarily comprehends what the 
whole CSR thing is.  When I talk about the big umbrella, which brings in the 
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ethics and all this, I think for our upper-management all these are independent 
and not under one umbrella. (Respondent 9) 
 
These comments illustrate how communication gaps can result in uneven levels of CSR 
understanding among employees, and how the evolution of CSR is an uneven process.  
However, I observed that the majority of CSR communication gaps among company 
employees were the result of differing levels of tacit understanding embedded in 
position-based differences.  For example, I observed that respondents positioned within 
a company’s CSR team tended to have a wider and more progressive understanding of 
CSR in comparison to those in positions further away from the CSR decision-making 
responsibilities (discussed further in Section 4.4.3, p. 216).  
 Communications was a term used frequently by respondents and it seems to be 
the preferred method to generate and reinforce levels of transparency and authenticity.  
Companies 'talk' about what they think is valued and what they intend to do about it, but 
they also have to do what they said they would to complete the respondent-described 
formula for transparency and authenticity—walk-the-talk.  The walk aspect and how it 
relates to and reinforces communications through promotion of interactions and other 
arenas for discourse is discussed further in the following sections.  
 
4.4.2  Measuring of Outcomes 
 In the previous section, respondents placed a great deal of importance on the 
concept of walk-the-talk.  An important part of which is the reinforcement of CSR 
communications with evidence of what is being done, who is doing it, and what it is 
achieving.  Measurements of CSR engagement outcomes results in the further 
development and reinforcement of authenticity with stakeholders. 
 However, most respondents indicated that measuring these outcomes is very 
difficult because social and economic outcomes are not easily isolated from the medical 
outcomes achieved by their products.  The challenge of creating valid outcome 
measures is the focus of this second element of the CDRP; outcomes that include 
internal as well the external benefits of engaging in CSR. 
 Measurement of CSR in the pharmaceutical industry focuses on the outcomes of 
programs and policies.  Respondents claim that their companies want to know if the 
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time and resources provided to create and staff CSR programs are creating a return on 
investment (ROI).  However, respondents also indicated that the traditional view of ROI 
(strictly linked to a monetary value) is neither appropriate nor possible when measuring 
CSR: “I am not going to tell you that we would measure it looking at a return on 
investment because that is definitely not realistic” (Respondent 10).  The general 
perspective provided by respondents is that CSR is focused primarily on the patient and 
improving their lives, implying other benefits are of secondary importance.  Although 
respondents for companies with an expanded or integrated perspective of CSR 
suggested there is a business case for CSR, there was also a strong sentiment that 
programs and policies should not be oriented to improve the business if it meant 
sacrificing the goals of the other stakeholder groups.  For these respondents, such a 
strategy would contradict the values and principles that were meant to guide the CSR 
engagement strategies of their companies.   
 Respondents expressed an understanding of the role of measurement in both 
reinforcing the purpose and perspective of CSR to stakeholders and identifying the 
strengths and weaknesses of programs and policies.  I believe companies are engaging 
in the measuring of CSR outcomes not only to reinforce their transparency and 
authenticity with stakeholders, but also to continually assess what is or is not functioning 
properly.  Additionally, as the companies evolve to incorporate CSR into their business 
strategy, it becomes increasingly important to be able to assess whether their integrated 
business strategy continues to be justified.   
 The range of different measurement strategies discussed by respondents 
reflected the evolving perspectives depicted in the last section.  For example, 
companies, with a more traditional perspective of CSR, often relied on simple 
input/output measurements that were considered by other respondents as superficial. 
In the past, we’ve talked a lot about simple inputs and output measurements, as 
an example.  We said we were going to donate 10,000 vials of insulin and we 
donated 10,000 vials of insulin.  Simple input/output kind of a measurement, but 
it shows no social impact whatsoever. (Respondent 20) 
 
Respondents from companies with a more expanded or integrated perspective of CSR 
discussed their desire to customize measurements according to each of their CSR 
programs.   
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 In the preceding quote, Respondent 20 describes the limitations of simple 
input/output measures: they are unable to measure social impact.  If simple input/output 
measures do not measure social impact, then why are they used at all to measure CSR 
outcomes?  I believe most likely there are three contributing factors: 1) it makes for easy 
reporting; 2) companies have long histories of using quantitative scorecards or metrics 
for measuring performance; and 3) complex social impact measures are difficult to 
create, collect, and report.  
  Based on my observations, the simple measurements alluded to by Respondent 
20 are based on easily quantifiable aspects of CSR programs, such as the number of 
employees that participate in a particular program, funds provided for disaster relief, or 
medications provided through access to medications programs.  These measurements 
are considered overly simple by some; but, nonetheless, important to all respondents.  
Not only are they the easiest outcomes to measure, but also these quantified measures 
or statistics are also easy to report and understand.  Various company websites, most 
commonly those in the US, consistently followed a pattern of presenting a social need 
(e.g. a medical emergency in a developing nation), what the company was doing to 
address that need (e.g. provide specific medications and/or monetary donations through 
an NGO), and then presenting quantified measures of what they had achieved (e.g. how 
much medicine or money was sent).  Regardless of their CSR perspective, it appears 
that these companies still place importance on simple input/output measurements.  
Quite possibly, it is because these measures are a quick and easy way to report some 
evidence of outcomes from CSR engagement.  Particularly attractive is the fact that 
these measurements require minimal resources, but can still influence the perceptions 
of stakeholders. 
 Similar to how companies use existing CSR programs and policies as the 
foundation of their evolving CSR perspective, they take the historically dominant 
methods of quantitative measurement and apply them to CSR.  For example, most of 
the respondents explained how their companies have applied their traditional use of 
metrics as scorecards to assess progress and success with CSR.  
The key things in terms of measurement, I would say, is an increasingly robust 
system of metrics and key performance indicators that is then monitored globally, 
and so we report in through that. (Respondent 5) 
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 The preference for simple and quantitative methods is reinforced by the fact that 
social outcomes are incredibly difficult to measure: 
However, our goal now is mostly trying to measure because I think to get real 
value of one of your investments you need to be able to make or bring social 
change.  So how do you bring social change?  It is very difficult to measure, 
right? (Respondent 9) 
 
Well you know, for example, we donate a lot of medicines, but we can’t track 
those people that we’ve donated to so I don’t know the outcome. (Respondent 
13) 
 
 Confounding variables and obstacles to measurement create a difficult scenario 
for measuring social impact, which is actually the combination of not only social but also 
economic and medical outcomes.  Some respondents displayed a clear understanding 
of these difficulties, while also stating that their companies are trying to figure out 
methods to overcome such obstacles: 
So we are trying to figure how we measure lives saved, which is really hard to do 
because can you say, “well somebody in Africa didn’t die of diabetes just 
because they got our medicine”, or is it because the government also has a really 
good program to make sure that they’re eating right and exercising. (Respondent 
17) 
 
 Respondent 20 discussed how his company is trying to develop customized 
measures to assess the social outcomes (clarified as a combination of social, medical 
and economic outcomes) created by specific programs.  For example, tracking and 
measuring patients who received greater access to medications as to whether their 
health (medical) has improved and if it has, did it also increase their quality of life 
(social) and ability to generate income for their families (economic).  This measuring 
strategy involves a mix of qualitative and quantitative measures with the intention of 
reducing confounding variables so they can accurately correlate a CSR program’s 
intervention with specific outcome(s).  However novel this approach to measuring may 
be, I believe that its complexity brings up a major issue about the amount of time and 
resources that will be required to measure outcomes, especially since some global CSR 
programs are large and designed to help out thousands to tens of thousands of 
patients.  The combination of this dilemma and availability of easier, although simpler 
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measures presents a difficult choice for companies that must also manage costs and 
the bottom-line.   
 A deciding factor that could influence the decision to pursue complex measures 
is the current effort by pharmaceutical companies to expand further into emerging 
markets.  The governments in these markets are especially concerned with the positive 
outcomes companies can bring to their countries: 
So we just had a delegation of parliamentarians from India last week, and you 
know they’re not so interested in all of our philanthropic programs we are doing in 
Africa; they are interested in how are you contributing to India’s economic 
development. (Respondent 17) 
 
 Difficult as it may be to measure the three types of outcomes (social, economic, 
and medical), companies are being pushed by stakeholders to address them; most 
notably by the governments of emerging markets.  With the potential for significant 
barriers to entry and/or operation to develop, the incentive will increase for companies 
to engage in and assess whether strategies can effectively measure these outcomes. 
 As stated previously, the company of Respondent 19 has integrated CSR into its 
business strategy, but, even though it represents the most progressive CSR, it also 
acknowledged that some aspects of CSR could not be measured: 
Some pieces are easier to measure than others, but, no, there’s a lot of it that 
cannot be measured.  But my favourite saying is that not all that counts can be 
counted and not all that can be counted counts, which I think Einstein said, and I 
think it is so true, just because we can’t count something doesn’t mean it isn’t 
important.  And so we can measure something, but a lot of our information is 
qualitative rather than quantitative stuff. (Respondent 19) 
 
Respondent 19 and her company acknowledge that parts of CSR cannot be measured 
but the ability to measure should not affect their drive to implement such programs.  It is 
possible that the result of their integrated perspective is a tacit understanding that CSR 
efforts will inherently benefit the company, reducing fears about not being able to 
measure some aspects of CSR engagement.  Additionally, Respondent 19 makes the 
distinction between not being able to quantify some outcomes and the desire to collect 
qualitative data.  The search for qualitative rather than complex quantitative measures 
suggests an evolving perspective on what and how to measure CSR. 
 In addition to measurements conducted internally by companies, participating in 
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externally verified measurements was a common practice among the respondent 
companies.  The two main external measures discussed were the Access to Medicines 
Index (ATMI) and the Dow Jones Sustainability Index (DJSI).   
We also participate in the Access to Medicines Index, which is a ranking of 
pharmaceutical companies’ commitment to improving access to medicines in the 
developing world, and that is another externally verified rating that we participate 
in. (Respondent 18) 
 
The DJSI is used worldwide and ranks companies, for both current and future investors, 
according to their ability to integrate economic, social, and environmental awareness 
into their overall business strategies, while still being financially successful.   
Both external measures act as forms of benchmarking, so any audience can see 
where companies rank in comparison to each other while also assisting companies to 
identify their own areas of strength and weakness.  Additionally, I believe companies 
participate to mitigate possible reputation repercussions associated with not 
participating in an external measure that assesses critical components of their 
stakeholders' concerns and expectations.  Depending on their perspective, respondents 
displayed a mix pride and a sense of obligation to participate in them. 
 Overall, the measurement of CSR was thought by respondents to be important in 
identifying evidence that the time and resources the companies are investing in CSR is 
resulting in social, economic, and medical outcomes.  Some respondents, however, 
placed greater importance on measuring CSR to identify how it is benefiting the 
company, while others tacitly understood its internal benefit and, therefore, were more 
focused on the external outcomes.  Also important for companies was that measuring 
outcomes assisting them in demonstrating to stakeholders that their CSR actions met or 
exceeded their communicated intentions (i.e. evidence to support walk-the-talk).   
 
4.4.3 Cultural Shift and Alignment (CSA) 
 According to respondents, the leadership is largely responsible for the culture of 
companies.  In response to the opportunities and threats associated with their social 
context, leadership must ensure company culture is properly aligned with its 
stakeholders.  The following section examines the relationships and interactions within 
the workforce that are acting as an engine to both shift the culture of companies and 
 
 
187 
realign employees to the changing culture through processes designed to avoid 
conflicts and maintain or develop smooth corporate functioning.   
Respondents reported that the leaders or executive are mainly responsible for 
guiding and driving CSR throughout the company.  As stated previously, support for 
CSR from the top is seen as essential to an authentic walk-the-talk culture.  The 
following two quotes provide examples, respectively, of leaders articulating the 
philosophy to guide company culture. 
I think the tone has been set from the top and I think that’s absolutely critical, and 
I think that there has been a real drive to really embed it in business practice, 
right.  If you’re talking about sort of the philosophy, the philosophy certainly 
emanates from the top. (Respondent 5) 
 
We also have a great deal of personal involvement from our chairman and CEO 
in overseeing a number of our philanthropic programs, particularly in sub-
Saharan Africa where we have a lot of infrastructure building that we have done 
and partnerships with local governments.  Our chairman/CEO has personally 
visited all of those sites and has been quite involved in the design and 
development. (Respondent 18) 
 
 Employees acknowledge their reliance on leadership for guidance, since all the 
respondents emphasized that support from the top is important: 
I think an essential requirement is support; not just support, actually, it’s got to be 
driven from the top.  If you don’t have a CEO and a board that really believes that 
this is important, then I think that we are really stuck.  It’s really hard to make any 
progress because people in the business just won’t feel comfortable driving 
change. (Respondent 19) 
 
 Respondent 19's comment is interesting because it has been stated repeatedly 
that employees, as stakeholders, are able to influence the decisions of their companies.  
I believe employees do influence the decisions of the company, but still look to 
leadership to analyze and shape a response and then guide the company with regard to 
that decision.  
 The leadership of the company responds to social context forces by choosing the 
overall direction and focus of CSR, and then place personnel in charge of designing and 
implementing the strategy.  I suggest that there are currently two main evolving roles 
associated with leadership: 1) developing an authentic walk-the-talk response to help 
drive and articulate CSR reasoning and priorities; and 2) placing the proper personnel in 
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positions so that their goals and objectives can be achieved:  
I think one of the things that a CEO does is to identify a few really big priorities 
and then build the team around them, below them, who can sort of operationalize 
those and actually allow them to happen.  (Respondent 4) 
 
 According to respondents, the ‘CSR team’ came in many forms and sizes.  CSR 
teams ranged in size from a single employee to more than ten and this variance was 
attributed to the CSR perspective of the company.  I observed that at a company with a 
more traditional perspective, CSR duties are given to an employee in addition to their 
regular job, while an expanded perspective has a dedicated person or small team.  
These individuals and teams tend to operate on a full-time basis to develop, organize, 
implement, and report on CSR.  Respondents from the latter discussed their desire for a 
global-based, higher level executive CSR position.  For the integrated CSR perspective, 
the size of the team actually declined to a few employees that focused almost 
exclusively on CSR reporting.  Since CSR was integrated into the overall business 
strategy, I assumed that all high level executives are expected to prioritize the 
application of CSR like an umbrella over the entire company.   
 In reflecting on the evolution of CSR perspectives from traditional to integrated, I 
became increasingly cognizant of a stream of awareness and motivation that runs 
through the workforce, relating to the variety of benefits that CSR engagement can 
produce for participating employees and, in turn, for the company as a whole.  The 
combination of the reliance on employees to implement and operate not only CSR 
programs but also all of a company's operations and its growing strength as an 
influential stakeholder has created an employee-centric approach to CSR engagement.  
By being perceived as authentically engaging in CSR at a normatively approved level, 
the company not only elevates the morale of its employees, but also increases its ability 
to recruit and retain employees.   
Employee engagement, attraction and retention of talent, while not the primary 
focal point of our work, is another outcome that is worth mentioning.  
(Respondent 18) 
 
I just can’t imagine that we would keep the quality of people if we didn’t engage 
in it (CSR). (Respondent 13) 
 
So in other words: to keep talented people in our company we have to be good at 
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corporate social responsibility. (Respondent 6) 
 
 In effect, CSR is perceived as appealing to a new generation of employees who 
want to use their skills and abilities, not just to earn a paycheque but to contribute to 
society in a meaningful way.  It appears that companies are realizing that they have to 
respond to this desire by offering appropriate CSR programs, which are designed to be 
perceived as authentic.  If they do not, it could influence the quality of talent they are 
able to attract and retain.  As the previous quotes illustrate, respondents routinely talked 
about the use of authentic CSR as a method to secure the top talent they desire.   
 I believe that, as leaders of companies are attempting to engage in CSR as a 
response to the forces of stakeholders, they are both consciously and unconsciously 
shifting the culture of their organization.  They create programs and policies, re-
articulate values, and place personnel in positions to design, implement, and operate 
programs and policies, but the same culture they are shifting applies new pressures on 
the culture to continue to shift: 
I think it (CSR engagement) really plugs us in and grounds us because sitting 
here in the Ivory tower of the corporate centre one can kind of get immune to 
what’s going on around us.  And that was the huge benefit for me, was just 
grounding me, and, Oh my gosh, just within a couple miles of this beautiful 
campus, there are homeless people walking the street and what are we doing 
about that? (Respondent 22) 
 
 As companies identified the employee benefits attributed to direct interaction with 
CSR programs and policies, they expanded their CSR programs to better promote 
opportunities for further employee empowerment and engagement.  I saw this as part of 
the response to what Respondent 22 had stated—companies realize they have to get 
more and more employees engaged in CSR activities because it helps to align the 
culture to the strategic direction of the company.  The employees gain normative insight 
into CSR and they in turn push the company to further engage in CSR; the process 
continually builds incentives, fuelling the evolution of the company’s CSR perspective.   
 For example, to sustain perceived employee benefits attributed to direct CSR 
engagement, some respondents describe how their companies are creating forums of 
communication between employees to share and discuses CSR experiences.  
Additionally, to further motivate employees to engage in CSR, companies use a variety 
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of methods designed to empower employees so that they feel more connected with the 
decision-making aspects of the CSR strategy: 
Unless we get our employees to places that expose them to the realities of 
healthcare delivery in other locations, they won’t have the skills to be able to 
think in a way that helps them make decisions that align back to our strategy and 
reflect the global nature of our company and the global nature of healthcare 
issues.  I think the third and final thing is that we want our employees to be 
inspired and engaged.  We think that by offering an array of things like 
appropriate pay, appropriate benefits, a work environment that provides a culture 
that’s supportive of innovative thinking, and we help our employees recognize 
that the company supports activities that allow them to expand and deepen their 
thinking, touch the world in ways they might otherwise not and allow them to find 
effective ways to improve their expertise, that those things will engage and 
inspire employees. (Respondent 20) 
 
 The cultural shift and alignment element of the CDRP focuses on how leaders 
respond to the forces of stakeholders by making strategic decisions that tended to 
require a shift and then realignment of the company’s culture.  This process is intended 
to ensure the company has the skills and expertise to follow through with its responses 
to stakeholder forces.  I interpreted the culture shift and realignment process as 
comprised of methods to encourage employee participation in CSR as a way to 
reinforce cultural alignment.  It was perceived by most respondents that this strategy 
affected employees by inspiring motivation and enhancing their skills and expertise 
through a close proximity to CSR engagements.  However, by exposing employees to 
CSR engagements and promoting a culture that is increasingly broadcasting the 
benefits of a CSR mindset, employees, as stakeholders, gain influence to further shift 
the company culture.  As leaders and employees align to a culture that pushes for 
further CSR engagement, I believe it will justify and incentivize additional CSR 
perspective evolution—a self-reinforcing, circular process. 
 
4.4.4  CSR Programming 
 The following section will explain how programs are developed and implemented 
at the local and global levels to align with the evolving perspective of CSR.  
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4.4.4.1 Local and Global Program Dynamics 
 Respondents perceived the CSR framework as coming from the executives in the 
global headquarters of the company.  The executive committee was observed by 
respondents as creating the overall focus for CSR strategy, which the leaders at 
affiliates articulated and implemented a CSR strategy.  Analyzing the observations of 
respondents, I interpreted that the executive committees are currently attempting to 
create umbrella CSR strategies to make sure that their strategic response to 
stakeholder forces is consistent across their companies, which are comprised of tens of 
thousands of employees.  It appears to be a process of clarification and control.  
Therefore, CSR programs of each company were broken up between global and local 
efforts, with the global framework guiding both: 
I think what you, the way I would divide it up at least in a large company, is you 
are going to have purely local CSR initiatives, you’re going to have, some could 
be regional but probably not a lot, and then you are going to get some global 
efforts. (Respondent 21) 
 
 Based on respondent discussions of local and global programs, it was evident 
that the differences exist because of the unique forces at each level.  Global programs 
addressed larger, trans-national concerns and expectations, while local programs 
responded to the desire to be a positive force in the communities in which they 
operated.    
 For example, global CSR efforts tended to be substantially larger and more 
complex, and they often required more resources as a result.  The majority of such 
programs at the global level were referred to as ‘flagship’ programs and seen by 
respondents to globally symbolize the level of commitment and authenticity the 
companies had for CSR and the values they communicate, such as removing barriers to 
healthcare, creating greater availability of products, and implementing regional pricing 
based ability to pay.  I interpreted this as a global response to larger issues affecting the 
entire pharmaceutical industry.  
One example of a flagship program would be a program of one company to 
research and develop a drug to cure or to treat a neglected disease where substantial 
investments are needed to produce the product, which is then sold at not-for-profit or 
low profit prices.  A high sales volume often compensates for lower profit pricing so 
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companies can still make a profit while providing a necessary medicine to a 
disadvantaged population.   
The transparency of flagship programs is promoted on company websites by way 
of the previously described formula: explaining a social need, what the company can do, 
how they do it, and the results to date.  A company's flagship programs appear to 
manifest from concerns about violating the global elements of their LTO.  In some 
cases, these programs might represent a method to be above board with regard to one 
or two of the concerns they have prioritized.  Through flagship programs, companies 
can promote their authentic commitment to the social needs of stakeholders at a global 
level.  If there is a connection between LTO and reputation, then flagship programs may 
be viewed as a strategy to improve the reputation of a company.  
 At the local level, CSR programs are generally designed on a global strategy 
framework but customized to meet community level concerns and expectations: 
Regionally, or locally, it’s really an affiliate, an individual affiliate decision.  It 
could be just a couple of employees getting together and saying we want to 
spend some time on Habitat for Humanity, OK?  That’s very simple applied stuff.  
It could be an entire affiliate getting together and saying, “we want to participate 
in the Terry Fox cancer run”, and we do that quite a bit in a few places.  That’s a 
local decision. (Respondent 21) 
 
 Respondents often took great pride in the CSR programs designed for the local 
setting because they wanted the company to be perceived as a contributing member in 
each of their operating locales.  These CSR programs tended to be relatively basic 
programs that offered the maximum opportunity for employee inclusion and 
empowerment.  The perception of the respondents was that their company wanted to 
embrace employee desire to live and work in a healthy and prosperous community.  In 
addition, Respondent 21 suggested that employees wanted not only to be part of the 
efforts to help local communities, but also to have the opportunity to shape the 
programs that were initiated in their communities.  These companies appear to be 
motivated to contribute to their local communities in no small measure because of the 
presence of their employees in these communities.  The employees have a more 
personal stake in how the company operates in the same neighbourhoods where their 
families live.  The long tradition of local initiatives seems to reflect leadership 
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understanding of employees wanting a healthy and strong community in which to both 
work and live, and of business benefits that can result.   
 
4.4.4.2 Evolution of CSR Programming 
 It has been suggested that companies are growing in their understanding of how 
to construct a business case or a win-win scenario as they develop and reinforce their 
CSR engagement.  Companies attempt to transparently communicate this 
understanding down through the employee hierarchy to create a perception of 
authenticity that should motivate and enlighten employees as to the potential benefits of 
CSR engagement.  To complete the authenticity of CSR communications, programs 
need to be created to reflect what is being communicated and measurable to provide 
evidence of the company walking-the-talk.  Based on the comments of respondents, 
companies are increasingly trying to ensure communications about CSR programs are 
manifested in actual programs.  It appears that, as the perspective of CSR evolves, so 
too do the associated communications and programs of the company.   
 For example, referring to a more traditional CSR perspective, respondents 
described programs that are more basic in design and relatively easy to implement.  
Simple philanthropic ventures such as contributions to charities, matching programs for 
employees, disaster relief, drug donations, some volunteer efforts, and prioritizing 
health and safety for patients and employees.  Most respondents described the focus of 
these CSR programs as not being well aligned with business priorities of a company, 
described one as a “shotgun technique” (Respondent 1).  That is not to say that 
respondents thought these programs were ineffectual; but they tended to believe that 
these programs had limitations—limitations understood only as the process of CSR 
perspective evolution provided a lens for self-reflection (e.g. some concepts of CSR 
evolved out of the occupational health and safety area (Respondent 16)).  Therefore, as 
perspectives evolve, one-way transactions are no longer perceived by those within the 
company as an effective means for making up the totality of CSR programs (see 
Respondent 4 quote, p.190).  Some respondents suggested, however, that these types 
of programs continue to exist because employees take pride in them and, I assume, 
that stakeholders continue to see benefit from receiving them.  In addition, these 
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programs are the most inclusive of employee participation because they offer the most 
direct opportunities for participation: 
What happens is that we have sort of traditional campaigns where every year we 
would collect donations for charities and collect presents under the tree and we 
still do that, but you know we began to sort of look at how we could be more 
effective. (Respondent 5) 
 
 As a company's perspective evolves, however, I suggest they analyze programs 
to look at how they can be used to enhance partnerships and relationships with different 
stakeholders to produce better outcomes in a two-way flow of resources: 
Over the last few years, I think a lot of leading companies have started to bring 
together this thinking that used to be grounded in that EHS function on the one 
hand and in the philanthropic in the other, and try to bring it together in a much 
more holistic fashion and also make it much more proactive, where we are 
listening to and engaging with stakeholders and then developing systematic 
programs and processes to address stakeholder issues and concerns. 
(Respondent 18) 
 
 The improvements to achieve the change in focus that respondents described 
results in a diversification of CSR programs.  Newer programs build on the existing 
ones, but are modified to better align the assets and expertise of the business with the 
current concerns and expectations of stakeholders to become more strategic in their 
CSR focus.  One way I observed this process was that in addition to donating funds or 
finished products, companies are beginning to transfer their assets and expertise to 
build and strengthen relationships.  The following are two examples of how companies 
are modifying traditional programs to better represent an evolving CSR perspective.  
First, in locations where the companies have limited operations, there are transfers of 
the knowledge needed to produce the products or the expertise and equipment needed 
to directly manufacture the products to governments or capable local companies.  The 
second is investing money and expertise-related resources (volunteers) to improve the 
healthcare infrastructure of emerging or developing nations.   
 The companies of respondents were also described by some as seeking out 
expertise from other groups or organizations to channel the combination of expertise 
from both parties in an attempt to create greater social outcomes.  I saw this as 
companies acknowledging the limitations of their own expertise and the benefits of 
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collaborating with others to combine areas of expertise to fulfill their commercial goals.  
For example: 
We are going to be developing other commercial partnerships with distributors in 
some of these countries in sub-Saharan Africa where we don’t have offices.  We 
don’t know the local distributors, so we right now couldn’t really do a great job 
selling our products throughout Sub-Saharan Africa, but we know that there are 
companies, small companies, that do that in these countries.  So we are going to 
be developing relationships with them. (Respondent 17) 
 
 What begins to emerge is that CSR programs based on expanded and/or 
integrated perspectives are being designed and enhanced to create strong relationships 
with stakeholders across the world.  The intention of these relationships is to provide 
positive outcomes that address the pertinent social needs of stakeholders while 
enhancing the sustainability of the business.  I see this as evidence of an evolution of 
their response to stakeholder concerns and expectations—a process incentivized by the 
identification of business opportunities.  Respondent 20 describes the process of 
evolution from an internal, business perspective: 
Sitting here in this museum is one of the examples of (Company A)’s first 
philanthropic efforts, and they were truly philanthropic.  It was providing monetary 
gifts or product gifts to organizations or entities in need and whose mission was 
aligned with the corporation’s areas of focus, but it was the most simple of 
corporate responsibility.  It was writing a cheque or giving a product.  I think over 
time, (Company A) has sought to evolve its corporate responsibility to be more 
aligned with its assets and expertise.  So in addition to monetary donations and 
product donations, how can we leverage our unique assets and expertise in 
research and development, in manufacturing, in distribution, in marketing, in 
patient outcomes to provide clear, improved patient outcomes in areas that we 
would focus?  I think today the definition that we would crystallize our corporate 
responsibility work around is really one where (Company A) is identifying areas 
of social need, areas where we have unique assets and expertise to bring 
against that social need, and where there maybe business opportunity.  
 
  By identifying methods to develop benefits for both the stakeholder and the 
company, a snowball-effect gains as the company evolves closer to an integrated 
perspective of CSR.  According to Respondent 19, CSR programs are no longer 
referred to as programs because such terminology would make it appear that CSR is 
mutually exclusive from other business strategies: 
We don’t have a CR strategy, we have a business strategy and we build 
responsibility into all our activities.  So we don’t have a separate CR strategy 
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because what that’s saying is that CR is a standalone activity and it’s not.  You 
can’t use animals in research and then have a separate strategy in doing that in 
a responsible way.  If you generally are going to be a responsible business you 
have to build it into every policy you’ve got.  We just don’t have a separate CR 
strategy. (Respondent 19) 
 
 According to Respondent 19, when a company merges its CSR and business 
strategies the programs that were previously considered CSR are now the methods of 
doing business: “I think it’s about the way we do our business.  So, it’s sort of the how 
we make our money rather than how much money we make” (Respondent 19).  This 
suggests a guiding philosophy that the company can become more successful and 
sustainable by focusing on their CSR perspective and embedding it into their entire 
business strategy.  I believe a number of these companies have identified that 
conditions now exist that make it justifiable and even beneficial to operate their business 
in a symbiotic way with stakeholders.  
  
4.4.4.3 Summary – CSR Programming 
 CSR programming at pharmaceutical companies is the method by which they 
manifest the observed pressures from their stakeholders of their social context in CSR 
programs and policies.  In relation to the elements of the CDRP, and to be viewed as 
authentic, CSR programs must transparently communicate the goals of the company.  
Once created, the programs interplay with the other parts of the CDRP.  For example, in 
transparently communicating the CSR perspective, CSR programs are measured to 
determine whether the outcomes achieved align with company and stakeholder goals.  
In this way, evidence of success will reinforce to stakeholders that the company is 
authentically doing what they are saying they are doing. 
 The CDRP is occurring at all levels of CSR programming.  This is because there 
are differing stakeholder forces present within each level.  As a result, global programs 
mostly represent a response to international stakeholder concerns and expectations, 
while local programs are designed to reflect what is perceived as a positive force or 
need in the community.  The global strategy acts as the dominant framework for all 
levels of programming because respondents indicated that company leaders are looking 
for consistent strategies across affiliates as a method of control and predictability.  As a 
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result, this strategic approach is used to align various programs to the CSR perspective 
of the company.  
 During the process of CSR perspective evolution, programs are continually 
improved upon, and programs are created to address newly identified opportunities or 
risks.  Beginning as a basic one-way transaction, their CSR perspective appears to be 
leading to the diversification of programs to better align assets and expertise with social 
needs while moving towards integration with standard business operations.  
  
4.4.5  Summary – CDRP 
 As the CSR perspective of companies evolves, an internal process (CDRP) 
comprised of four elements (CAT, measuring outcomes, CSA, and CSR programming) 
operates as an internal engine to power the processes guiding the evolution.  
Reflexively, the results from the CDRP also fuel further perspective evolution, feeding 
back into the company to add further incentive for CSR engagement.  The overall 
CDRP creates an environment for justifying the evolving CSR perspective to both 
leaders and stakeholders, and the result is a complex web of interactions that appears 
to be constructing further opportunities for companies.   
 It appears that management of the four elements is necessary to create an 
environment where it is possible to evolve, and as a way to inspire or provide insight 
into pathways of further evolution.  To add complexity to the CDRP, there is a high level 
of interdependency between the four elements.  For instance, executives of a company 
initiate most substantial business strategies because they are the leaders of planning 
for the company’s future.  The leaders seek to shift and align the culture according to 
the values, actions, and behaviours that they perceive should be normalized to 
maximize the potential for the successful implementation and operation of their 
strategies.  The purpose and function of the strategies are then communicated 
throughout the company in an increasingly transparent way to help support and sustain 
a perception of authenticity.  At this point, the CSR strategy, or program, is a vaguely 
defined idea requiring individuals or groups within the company to turn it into a clearly 
understood concept or plan.  CSR designated employees then design programs that 
follow the communication strategy and set in place the appropriate personnel for 
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implementation.  The CSR program’s purpose and opportunities for inclusion are 
communicated across the organizational hierarchy to encourage engagement and 
understanding.  The outcomes of such programs are measured for results, which are 
used to provide evidence to various stakeholder groups to judge company commitment.  
The combination of each element of the entire process creates justification for the 
company's response to their social context while also, depending on the success of their 
strategy to create authenticity, supporting greater insight into opportunities to further 
incentivize the entire process of evolving their CSR perspective. 
 Overall, I perceive the CDRP as a behind the scenes process of internal 
evolution that makes it possible to shift the strategies of the company to adapt to an 
evolving perspective.  This does not mean, however, that the CDRP is a predictable 
cycle that will lead each company along the same path.  How companies respond to the 
concerns and expectations that form the LTO, whether or not they will even 
acknowledge stakeholder influences, and their differing histories, experiences, and 
values can all contribute to a divergence of strategies.  Although I observed that the 
majority of pharmaceutical companies have been following this path, it does not mean 
that they will continue to follow it to the same end, or that there is a simple end point.  
They may veer off in a new direction based on a perception of different risks and 
opportunities.  Some may choose to stay where they are because it is perceived to be 
sufficient, or there could be a change in social context that could result in the regression 
of their CSR perspective.  Whatever the future, the current tendency in the 
pharmaceutical industry is to translate their unique healthcare/for-profit nature of the 
industry to increasingly construct a response to LTO concerns by finding opportunities 
to better understand their relationship with society and to focus on the creation of 
mutual benefits for the purpose of sustainability. 
 
4.5 Symbiotic Continuum 
 The intention of this section is to summarize my substantive theory in an attempt 
to identify and explain the evolving response interacting with the CDRP in creating an 
evolution of CSR perspectives to a more integrated and symbiotic relationship between 
companies and society.   
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Based on my interviews with the 22 respondents and my analysis of the company 
websites, I have interpreted the current evolution of CSR in the pharmaceutical industry 
as spiralling process through three distinct yet interrelated CSR perspectives (Section 
4.3, p. 184).  As a company’s CSR perspective evolves, it can be thought of as moving 
along a continuum that represents the relationship between the company's priorities and 
those of globalized society.  As the three previously described components of the 
substantive theory (Social Context, Three CSR Perspectives, CDRP) are seen as 
analogous to the interdependent parts of an automobile, the symbiotic continuum is 
analogous to the reference points on a directional map.  In the case of CSR in the 
pharmaceutical industry, however, it may also provide additional insight into the 
reasoning for the transformative social process of companies responding to their social 
contexts through continual development and reinforcement.  I believe this process is 
resulting in an evolving CSR perspective that is moving toward further embracing a 
symbiotic relationship with not only local communicates but global society.  As 
Respondent 19 explains, her company's process of interpreting and responding to their 
social context and the resulting insight should lead to the integration of societal 
expectations with those of the company:  
We go absolutely out of our way to make sure that we don’t deviate outside 
regulations and legal requirements.  But there’s an element of responsibility that 
takes us beyond just complying with the law and there are some areas where 
we’ve had to pay more attention to what the external expectations are, the way 
those expectations are developing, and making sure that as a company we 
understand that and integrate those expectations into the way we run our 
business. (Respondent 19) 
 
  Respondent 20 explains a similar concept of CSR evolution: 
When organizations like ours can identify those locations, we really believe that 
we can have meaningful impact on individuals.  We can produce a sustainable 
corporate responsibility model that could ultimately just blend into being part of 
the business.  In sum, it’s a long definition, but it’s a definition of evolution, and 
(Company A) is just now stepping into that shared-value space. (Respondent 20) 
 
 The current trend of CSR evolution appears to be incited by societal notions of 
awareness and desire for more responsible and socially oriented practices by 
pharmaceutical companies.  As stakeholders gain greater influence, it raises company 
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awareness that a response is necessary to avoid repercussions.  For most companies 
this response has evolved into the identification and/or creation of opportunities to 
further business interests in tandem with those of stakeholders.   
 My analysis suggests the traditional CSR perspective is more attractive to 
companies that are internally focused, reflective of a silo or narrow perspective that the 
company held about its relationship to society, which tended to greater weight to local 
responsibilities; however, even those responsibilities were narrow in scope (e.g. local 
philanthropy and volunteering).  The company interacts with society on a daily basis 
through simple transactions but its perception of the totality of its impact on society and 
vice versa is minimal.   
Whereas if you have a more traditionalist CEO who says at the end of the day it’s 
more about selling products, it’s more about kind of the basics and fundamentals 
of a business, than the way it was 20 years ago, so many things are changing, in 
that sense it probably would be that the corporate social responsibility team in a 
company like that may feel more constrained. (Respondent 4) 
 
 My analysis also suggests that as companies undergo the CDRP that fuels and 
responds to their evolving CSR perspective, they perceive a more inclusive relationship 
with society.  In effect, the symbiotic continuum references the approximate location and 
direction of the company's perspective of their relationship with global society.  Once 
started, the process of CSR evolution becomes increasingly justified, creating further 
incentive.  As these companies continue to improve and construct CSR/business 
strategies towards shared-value creation, they also develop skill sets to better identify 
and create further opportunities.  For some companies, this process may eventually 
result in a desire for the merging of CSR and the overall business strategy. 
 My interpretation is that as a CSR perspective evolves, it ties together the 
sustainability of the company with an understanding of how the company relies on 
globalized society just as much as society relies on the company.  The strongest 
example of this among the companies whose members participated in the study is an 
attempt to create mutual sustainability through business strategies that appear to be 
emphasizing a symbiotic relationship; CSR is the strategic vehicle to achieve this goal.  
It’s part of that reputation that you don’t only want to be seen as a business; we 
want to be seen as part of the community. (Respondent 1) 
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But to me it’s all about sustainability.  (Company D) is not going to survive as a 
company, or any company wouldn’t, if they don’t pay attention to this; they will 
lose their license to operate.  Consumers, to the extent that they can in our 
industry, will not want to take our products; if a doctor has a choice, they will 
consider prescribing another product if they feel better about that company.  If we 
don’t pay attention to these things the risks will increase and those risks will 
eventually have a bottom line impact.  On the flip side, there are opportunities in 
terms of selling more products.  The other thing that I think the pharma industry 
needs to do a better job on the opportunity side is: how do you create products 
that speak to social needs? (Respondent 17) 
  
 The ties created through connecting and interacting with a variety of stakeholders 
bonds the business and society together, which can be further strengthened by utilizing 
the potential for shared benefits within a symbiotic relationship.  As a result, a growing 
priority of CSR is to create mutual sustainability: 
We are very much committed to building sustainable and replicable models 
where rather than just providing a cheque to an organization, we are helping that 
organization build infrastructure, build capacity, and learn to operate in a 
sustainable way that will continue long after our footprint is gone. (Respondent 
18) 
 
 The perception of many respondents was that it is far more difficult for a 
company to fail if society not only relies on the company’s products (goods and 
services) but also perceives it as having an important and interconnected role to play 
within that society.  Therefore, rather than operating under the assumption that the 
responsibilities of business and society are mutually exclusive, I believe companies 
within the pharmaceutical industry are evolving from a traditional perspective to one that 
is more symbiotic and incentivized by mutual sustainability.  
 Currently, the best example of this response in the pharmaceutical industry is 
various attempts to use symbiotic strategies to gain entrance into emerging markets.  
Different respondents stated that their companies have identified the emerging markets 
(India, China, Brazil, and Turkey) as the major sources of market growth in the future, 
and not the traditional western markets (European Union and North America).  
Economic pressures combining with industry change and a growing influence of 
stakeholders are necessitating some form of response by companies to address these 
issues or face a range of repercussions.  Respondents explained that traditional ways of 
conducting business are contested in these regions, which, in combination of their 
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financial importance, has challenged business to adapt their business strategies.   
The way we as a business are going to grow is to essentially optimize our 
business in emerging markets, and we are not going to do that if we continue the 
previous practice, which was just to sell just to the top echelons of society, to the 
wealthy people.  You’ve got these vast populations that don’t have access to our 
products because our products are expensive.  Well it is in our interest as a 
business to improve access and thus improve the volumes we sell, and so it is a 
win-win.  We improve our business and we improve access to medicines at the 
same time.  That is mainstream business. (Respondent 19) 
 
In a citizenship point of view, the same places where we are looking to create 
new markets are also the places where there is a need for meaningful and 
sustainable employment opportunities for the population.  The idea of the bottom 
of the pyramid  for us is a business opportunity to find ways to reach people at 
the bottom of the pyramid and a development opportunity to help people at the 
bottom of the pyramid achieve economic growth and productivity, and it’s also an 
opportunity to improve the state of health care at the bottom of the pyramid. 
(Respondent 18) 
 
 The symbiotic continuum provides a road map for how the CSR evolution at 
pharmaceutical companies is affecting their relationship to a globalized society.  
Therefore, the current trend of CSR perspective evolution is resulting in wider 
perspectives that emphasize a more inclusive relationship with all of society as a means 
to create a more successful and sustainable business. 
 
4.6 Summary of Results 
 Based on data collected and analyzed from 22 respondents and their respective 
company’s online CSR disclosures, I developed a substantive theory of why and how 
engagement in CSR is evolving in the pharmaceutical industry.  The goal of the theory 
is to explain the variety of social and organizational forces, constraining and enabling, 
that influenced pharmaceutical company decision-making processes.  Additionally, I 
sought to determine how CSR perspectives continue to evolve the creation of 
snowballing opportunities that are increasingly directed towards matching stakeholder 
concerns and expectations with those of the business for the purpose of mutual 
sustainability.   
To better explain my theory, the complex processes of each component, and how 
they interact with each other, I developed a visual tool or model of the substantive 
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theory of CSR evolution within the pharmaceutical industry (Figure 4.3, p. 145).  This 
model compiles and articulates the four main components of the substantive theory into 
an active, three dimensional spiral design to show their interdependency in the process 
of CSR evolution.  As explained earlier, the theory and model represent a glimpse into 
CSR evolution.  Such CSR evolution should be understood as a dynamic process, this 
model and any other representation are open to modification.   
 Encompassing the entire model, the social context of the pharmaceutical 
companies acts like a web of influence that is shaped by their business orientation, 
values, and experiences, in combination with a variety of constraining and enabling 
forces stemming from the concerns and expectations of increasingly influential 
stakeholders.  The LTO constructed by internal and external stakeholders is perceived 
as having various methods and levels of repercussions if violated.  The complex 
navigation of variously weighted influences comprising the LTO creates a nebulous 
series of decision-making pathways.  The various responses navigating companies 
through these pathways have resulted in a continual, socially based evolution of CSR in 
the pharmaceutical industry, where company and employee relationships with each 
other and stakeholders have reshaped he meaning of CSR and the role it should have 
within the operations of companies. 
 Represented by the spiralling structure in the model, I positioned the three 
evolving, interconnected CSR perspectives to reflect changing philosophical outcomes 
and their tangible formations that result from the responses generated through the 
decision-making process.  Being foundational, each perspective builds upon and 
applies the changes to already constructed versions of programs and policies to make 
them more reflective of the evolving perspective.  As a result, companies tend to blur 
across the three perspectives as they evolve. 
 I observed that respondents are able to foresee only the third (integrated) 
perspective, but that does not mean that the evolution of CSR perspectives will halt 
upon its realization.  Moving into this perspective will most likely create new insights into 
future routes.  In contrast, if companies do settle into the integrated perspective there 
can still be continual changes to how this perspective manifests in company operations.  
It seems unlikely, therefore, that a company’s overall approach to CSR will become 
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stagnant.  Additionally, changes in the social context and/or justification for CSR 
engagement could lead to a response that alters the CSR perspective, or possibly 
sends it into another direction.  That is why this theory explains the current response 
and resulting strategy, and it is not a guaranteed roadmap for the future of CSR in the 
pharmaceutical industry.  As a result, within the model a chevron symbol on the 
spiralling perspectives is used to show the possibilities of both progression and 
regression.   
 In the model, the continual development and reinforcement process (CDRP) is 
represented by circles with rotating arrows around them, to symbolize a continual 
motion.  These arrows are located within the spiralling structure of evolving perspectives 
because I interpreted the four elements as the interconnected parts comprising the 
engine of the entire process.  The purpose of the CDRP is composed of four 
elements—creating authenticity and transparency, measuring outcomes, cultural shift 
and alignment, and CSR programming—that combine to create functionality from the 
alignment of resources, policies, and perspectives to achieve a company’s CSR 
objectives and goals.  The four elements are interdependent and constantly interact with 
each other, making the entire CDRP process more effective and efficient in manifesting 
and reinforcing the company’s CSR perspective.  However, the CDRP is not merely a 
reactive component of the evolution of CSR.  Not only can the outcomes generated 
within it help to achieve CSR objectives and goals, but they can lead to the identification 
and construction of new opportunities that further justify and add incentives for CSR 
engagement.   
 I created the model such that the spiralling perspectives wrap around to 
symbolize the continuum of a company's perceived relationship to local and global 
society.  It ranges from a perspective of the relationship between business and society 
as almost separate (e.g. connections tend to be isolated to the local level) to symbiotic 
(e.g. understanding the interconnections of globalized society), where mutual health and 
concern flourish.  In the model, the traditional CSR perspective is located closer to the 
bottom of the symbiotic continuum (represented by sporadic or scattered pixilation in the 
continuum) because this is where I interpreted companies to be expressing a smaller or 
narrow relationship with society.  As the evolution of the three perspectives occurs, 
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movement up the continuum results.  Therefore, the integrated perspective is 
associated with companies perceiving a more symbiotic relationship with society on a 
global scale rather than just locally, which they can use to create greater levels of 
mutual sustainability.  In addition, and similar to the chevron arrows in the spiralling 
structure, the continuum has multi-directional arrows.  These were added to symbolize 
the concept that changes in the multitude of forces affecting company decision-making 
could cause companies to revert to previous perspectives or shift directions to new 
perspectives of their relationship to society.   
 Overall, the intention of the model is to articulate the interdependent functioning 
of the four main components making up the substantive theory of CSR evolution in the 
pharmaceutical industry.  Originally, the way that the four main components interacted 
with each other was described as similar to the separate parts of a car.  Although they 
function somewhat separately, they require each other to effectively and efficiently carry 
out their intended purposes.  Most importantly, if all parts are properly functioning, then 
the car, or theory, can proceed with fewer interruptions as it heads towards its 
destination.  Like a symbiotic relationship between business and society, the 
components rely on the health of each other to be able to operate at their full potential. 
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5. DISCUSSION  
 Using a grounded theory approach, I constructed a substantive theory to explain 
why and how CSR is evolving within the pharmaceutical industry.  The theory contains 
four main components (social context, CSR perspectives, a process of continual 
development and reinforcement, and symbiotic continuum).  A relational model of the 
components illustrates how they interact to function as an engine to drive CSR evolution 
(Section 4.1, p. 141).  Although some aspects of the theory appear to depict a 
deterministic path toward an integrated perspective of CSR, the relative stability of 
changes in perspective is questionable because of the availability of alternative 
pathways and the uneven progress of companies along the continuum.  Signs of 
heterogeneity, and the freedom to choose, challenges the assumption that each 
company will follow the same path.   
 Based on primary and secondary data collection and subsequent analysis, the 
substantive theory is purposely designed to provide an informative glimpse into: 1) how 
respondents and companies are making sense of the pressures they face within their 
social context; 2) how evolving responses circulate and are continually reinforced; and 
3) how such changes alter company relationships with society.  The theory was 
developed using grounded theory, and as such is distanced from the theoretical 
literature by relying almost exclusively on primary and secondary data sources (some 
organizations discussed by respondents required some use of literature for explanation 
purposes).  I believe, therefore, that it is acceptable to modify and further articulate the 
model by identifying how it overlaps with the framework of different organizational 
theories.  Although a number of theories used to analyze CSR were presented in the 
literature review, I eventually came to the conclusion that two theories were particularly 
suitable in providing further insight in to my findings: institutional theory and stakeholder 
theory. 
 Initially, I considered stakeholder theory as the best lens to examine my 
substantive theory, but upon further reflection, I came to view it as too limited in its 
theoretical scope.  Stakeholder theory does provide a philosophical argument to explain 
why companies should be responsive to the pluralistic expectations of stakeholders who 
influence or are affected by the operations of companies (Freeman, et al., 2007).  The 
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theoretical foundation is “managerial and recommends the attitudes, structures, and 
practices that, taken together, constitute a stakeholder management philosophy” 
(Donaldson & Preston, 1995 p. 87).  Research into this area examines the empirical 
evidence as to whether or not a stakeholder-oriented strategy is viable and successful 
over the long-term (Donaldson & Preston, 1995).  Additionally, studies using this 
approach attempt to assess the relative influence that stakeholders have on company 
operations; whether they can change the flow of resources to a company or limit how 
they can use such resources to effect change (Yang & Rivers, 2009.) 
 Based on my substantive theory, stakeholders do have an important role in 
constructing and applying pressure for changes in company/industry behaviour, which 
includes further engaging in CSR-related activities.  However, I believe that, while a 
stakeholder perspective is an important element of what is changing in the industry, it is 
only an indication of objective result rather than an analytical framework.  
Finding stakeholder theory insufficient as an analytical framework, I considered 
the suitability of institutional theory.  According to Scott (2008, p. 48), “institutions are 
comprised of regulative, normative, and cultural-cognitive elements (pillars) that, 
together with associated activities and resources, provide stability and meaning to social 
life”.  “Institutions as social construction, produced through meaningful interaction, are 
central to institutional theory” (Phillips & Malhotra, 2008, p. 713).  They comprise the 
taken-for-granted behaviours that are mutually held and reinforced through interaction 
between institutional actors, and provide the necessary meaning to be self-reproducing; 
thereby, establishing and maintaining social order (Greenwood, Oliver, Sahlin & 
Suddaby, 2008).   
On the surface, it would appear that many scholars have approached the study 
of institutions as a method of analysis to understand why companies within the same 
organizational field tend to become more similar over time, both in structure and 
practice (DiMaggio & Powell, 1983; Frynas, 2009).  However, the scope of institutional 
theory goes far beyond a simplistic analysis of similarity by explaining how institutions 
are created, maintained, and changed, and the effect these have on the behaviours of 
companies.  Specifically, institutional theory can be used to examine the micro and 
macro social constructions of meaning that constrain and enable access to and 
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understanding of strategic alternatives (Greenwood, et al., 2008; Scott, 2008; DiMaggio 
& Powell, 1991).   
Encapsulating all of these elements is the institutional logic: “the socially 
constructed, historical patterns of material practices, assumptions, values, beliefs, and 
rules by which individuals produce and reproduce their material subsistence, organize 
time and space, and provide meaning to their social reality” (Thornton & Ocasio, 1999, 
p. 804).  Furthermore, “the criterion for legitimacy is encoded within institutional logics.  
Therefore, legitimating an organizational form that does not fit a prevailing logic involves 
modifying or displacing that logic in order to establish new legitimacy criteria” (Suddaby 
& Greenwood, 2005, p. 36).  Institutional theory, therefore, provides a strong foundation 
from which to understand the micro and macro workings of organizations as to why the 
institutionalization of new, prevailing logics and related practices and structures do or do 
not occur.  Overall, I believe it is the most appropriate theoretical framework from which 
to analyze my substantive theory because, unlike stakeholder theory, it analyzes the 
journey or process of change more than it does the result and, importantly, there is a 
“social constructivist thread” running throughout (Phillips & Malhotra, 2008, p. 705). 
In the following discussion, I will explain how I conceptualized the many facets of 
institutional theory as a framework to analyze the substantive theory emerging from my 
results.  The purpose is to accurately articulate why and how CSR is evolving in the 
pharmaceutical industry using a theoretical framework that is comprehensive and aligns 
with my epistemological foundation.  In the end, I am seeking to build an analysis using 
institutional theory that is progressive and loyal to my constructionist epistemology, 
thereby furthering the theoretical implications and clarity of both.   
My discussion consists of four sections.  The first is an examination of the two 
main environmental factors that led to the opportunity for institutional change regarding 
CSR: 1) the aggregate changes and challenges to the legitimacy and technical 
efficiency of the pharmaceutical industry, and 2) employees as conduits of institutional 
differences, both internally and externally.  The second probes how institutional 
entrepreneurs and their resources have captured and framed an argument to promote 
and advocate for greater adoption of integrated CSR.  The third analyzes how the 
transmission of the framed or theorized argument and other ideas regarding CSR occur 
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and how they are translated and edited if imitated.  The fourth illustrates the ongoing 
process of institutionalization, featuring cognitive legitimacy of integrated CSR and how 
companies and employees are both unconsciously and consciously engaged in 
reinforcing and shaping its progress.  Each of the four sections is intended to lay the 
foundation for the next as to build a social constructivist, comprehensive, and 
substantive portrait of institutional change that explains why and how CSR is evolving in 
the pharmaceutical industry and whether such changes are inevitable and stable.   
 
5.1 Aggregate Changes and Challenges  
A ‘battle of perceptions’ regarding the actions and roles of pharmaceutical 
companies was detailed in the literature review (Section 2.3.2, p. 79).  Roles are 
“conceptions of appropriate goals and activities for particular individuals or specified 
social positions” (Scott, 2008, p. 55), pieced together by society as judgments for 
previous and expected future industry actions, and the literature explained how external 
notions about the roles of the industry intertwine with prevailing arguments for expanded 
social responsibility.  Juxtaposed internal and external interpretations of industry roles 
have fuelled conflicting perceptions of the appropriateness of company/industry 
behaviours.  The epicenter of conflict and tension occurs in the duality of 
pharmaceutical companies as for-profit entities delivering healthcare.   
Five areas of duality-related controversy—patents/innovation, product recalls, 
direct-to-consumer advertising/education, pricing, and drug access—illustrate how 
societal constructions of expected responsibilities are consciously or unconsciously 
neglected or avoided by companies.  It is argued that such negligence is done in pursuit 
of growing financial returns over expected social responsibility (Saul, 2005)—an 
accusation that most respondents reject.  Additionally, the broader societal push for 
CSR overlaps with industry specific social movements for transparent adoption and 
prioritization of responsibilities to the ‘common good’.  Negative externalities (implied by 
the five controversies) of companies involved in healthcare are more publicly 
pronounced (Leisinger, 2009), which increases the societal desire for action to remedy 
them.  For example, the health necessity of pharmaceutical products are subject to the 
monopolistic powers of pharmaceutical companies to select and prioritize which 
 
 
210 
molecules are eventually commercialized—including a strong say in how they are 
priced, the quantity produced, which markets they are sold in, and how they will be 
marketed.   
Negative externalities associated with these choices can broadly affect the health 
of individuals around the world.   
Yeah, well the expectations of the public at large are changing.  I mean there is 
less tolerance, I guess, for people who’d be perceived as having a negative 
influence or a negative impact.  (Respondent 10) 
 
Frederick (2008 p. 522-523) provides a conceptualization of CSR that unifies its 
broader societal constructions as well as those specific to the industry (e.g. integrated 
CSR): 
CSR occurs when a business firm, through decisions and policies of its executive 
leaders, consciously and deliberately acts to enhance the social well-being of 
those lives affected by the firm’s economic operations.  In this way, CSR blends 
and harmonizes economic operations with a human community’s social systems 
and institutions, creating an organic linkage of business and society.  The goal of 
this relationship is to achieve a balance between the firm’s economic operations 
and the society’s aspirations and requirements for community welfare. 
 
This definition of CSR action provides insight into its use for injecting and then 
harmonizing social/economic duality into business operations; a ‘conscious’ and 
‘deliberate’ act to minimize negative externalities.  It highlights the direction of a growing 
CSR discourse that theorizes potential of business/society symbiosis.  Over time, if 
changes toward such a goal occur and remain stable, thereby becoming institutionally 
solidified, it should become an unconscious, taken-for-granted way to conduct business.  
However, the logic encapsulated in this discourse, which has been traditionally external 
to the industry, must contest and displace the currently dominant industry logics.   
 Frederick (2008) describes a conception of CSR as integrated with business 
strategy, which is a concept that should be a logical ‘fit’ in the pharmaceutical industry 
because, as respondents repeatedly stated, it is inextricably linked to the health and 
betterment of society by its very nature.  Even with respondents and society showing 
overlap in their understanding of the industry’s role, stated controversies display a 
difference in its interpretation.  Even when nested within societal logics (Thornton & 
Ocasio, 2008), the industry’s conception of CSR differs from those prominent in societal 
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discourse.  The industry’s tradition of passive reliance on the health benefits of the 
products they select to commercialize (IFPMA cited in Roche, 2007) contrasts with the 
more comprehensive and active integration of greater societal welfare that is advocated 
by societal actors.  However, in isolation these exogenous pressures for evolution from 
expanded to integrated CSR are insufficient to cause the institutional change that is 
occurring.   
Uncertainties relating explicitly to the technical efficiencies of companies within 
the organizational field appear to prompt greater receptivity to institutional pressures 
(Hardy & Maguire, 2008; Dacin, Goodstein, & Scott, 2002).  “We see more and more 
pressure from healthcare financing, we see more and more pressure on our bottom line, 
and a pipeline that isn’t producing” (Respondent 22).  Changes in how companies in the 
pharmaceutical industry operate as a result of innovation difficulties, patent expiration, 
market changes (e.g. emerging market growth over Western markets), movement away 
from in-house production of pharmaceuticals, and socio-political sentiments involving 
regulation and healthcare costs combine together with social movements for increased 
and more comprehensive CSR in aggregate to place significant pressure on the 
traditionally dominant institutional logics of companies. 
Interestingly, it seems that the industry has previously managed to distance or 
isolate similar institutional pressures, resulting in a relatively long period of stability.  The 
repercussions of this isolation, however, are believed by respondents to be contributing 
to society’s negative perceptions of the industry as a whole: 
As you know for sure, the pharmaceutical industry, when you look at these kinds 
of surveys about reputation and trust, pharma is very close to the bottom, right 
above oil companies and tobacco companies, and I think a lot of it has been 
because we have been such a secretive industry. (Respondent 17) 
 
The industry history of being perceived as secretive illustrates, first, the 
candidness of the respondent to acknowledge controversial past behaviours and, 
second, how being so secretive has negatively affected the industry’s reputation.  In 
addition, Respondent 17 identifies, quite succinctly, the link between the described 
aggregate pressures and the perceived role of the pharmaceutical industry as affecting 
its legitimacy within its social context.   
Regarding legitimacy, there are three forms described by Suchman (1995): 
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pragmatic (based on interest), moral (based on evaluation), and cognitive (based on 
comprehensibility and taken-for-grantedness).  The declining legitimacy of all three is 
represented by societal assumptions that the industry operates primarily in its own self-
interest, which is in conflict with prevailing norms and values; all of which challenges the 
taken-for-grantedness of the industry’s role in society.  
As companies interact with the social world, legitimacy agents (e.g. regulators), 
mediators (e.g. media), and guidelines (e.g. rules, norms, and values) interact to 
construct individual and societal conceptions of legitimacy, as well as reputation 
(Deephouse & Suchman, 2008).  Reputation, which has been exceedingly negative for 
the industry over the last 20 or so years “is a generalized expectation about a firm’s 
future behaviour or performance based on collective perceptions (either direct or, more 
often, vicarious) of past behaviour or performance” (Deephouse & Suchman, 2008, p. 
59). 
As described in my results, perceptions of company and industry reputations 
have begun to influence technical efficiency.  For example, there is a growing reliance 
on collaborations and partnerships to operate effectively in a globalized marketplace, 
and a positive reputation acts as a gateway to gain, maintain, or repair access to such 
relationships (similar to how legitimacy operates).  I believe the following two quotes 
illustrate this link:   
We see in many cases opportunities to grow and advance our business by 
partnering with non-governmental organizations and civil society organizations to 
offer news ways of working with patients that we may not have reached before, 
who can open new doors for us in working with local governments in countries 
around the world. (Respondent 18) 
 
If we are irresponsible in the way we run our business, we will just increase the 
legislation and control around our business.  Now, the pharmaceutical sector is 
highly regulated; we have regulations coming out of our ears—every step we 
take is regulated.  So, it’s in our interest to work in a way that keeps the 
regulation where it is and we don’t have significant regulation around even more 
factors because we have behaved well.  So, because increased regulation just 
increases the cost of business it is much better for us to do it in a voluntary way 
and behave responsibly and have all the other advantages of that. (Respondent 
19) 
 
 The first quote (Respondent 18) explains the increasing importance and reliance 
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on relationships to effectively work with governments that have the ability to control 
regulations and their enforcement and the second (Respondent 19) explains how 
irresponsible action(s) can lead to further regulation, which negatively affects a 
company’s technical efficiency.  Furthermore, respondents explained the importance of 
accessing emerging markets, where societal actors actors express desires for greater 
social and medical contributions to the region rather than solely economic benefits.   
The traditional logic associated with Western markets (primarily using an 
economic lens to assess value) (Bauman, 1998; Saul, 2005; Stiglitz, 2008), at least in 
this regard, appears to be not as prevalent in emerging markets.  Respondents 
emphasized this point in discussions regarding governments in emerging markets.  
These governments have different perceptions of the responsibilities that 
pharmaceutical companies should adhere to if they want to operate in their market.  As 
potential barriers to access, it would be an unacceptable consequence to bear since 
future market growth is seen as coming largely from the emerging markets:   
They are interested in how are you contributing to India’s economic development.  
So, there it was more about the taxes we pay, the amount of people we employ 
in India, the clinical trials we are conducting in India which is giving Indian 
doctors experience, and that’s going to helps us.  I mean, we want to be a 
partner with the government of India not only because India is a purchaser of our 
products for their people but also because we need to have a good relationship; 
they’re the ones who grant patents for our products, they approve our products 
obviously to even sell them in their country. (Respondent 17) 
 
 Respondent 17 explains how companies have to be aware of the condition of its 
relationship with governments in emerging markets such as India because of their 
regulatory abilities.  By having a stronger, more connected relationship, which now 
involves the strategic use of CSR, companies can be perceived as a need in the 
country, possibly preventing future regulation or influencing other decisions (e.g. 
approval of products for sale).  Furthermore, Saul (2005) discussed how markets such 
as India, China, and Brazil have broken from the strict neoliberal policies that have been 
so popular among Western nation-states by each adopting their only unique version of 
protectionist mixed with free market policies—arguably, a strategy that most nation-
states follow, albeit to a lesser extent.     
It should be noted, however, that the emerging markets described by 
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respondents are countries (e.g. India, China, Brazil) that feature a growing middle-class 
and have far greater capabilities to regulate the actions of TNCs than lesser-developed 
countries.  Although there are CSR programs designated for lesser-developed 
countries, which includes transfer of knowledge and technology programs, the current 
regulatory ability of these governments is presumed to be lacking in comparison to 
Western and emerging markets (Dukes, 2006), which demonstrates that the regulatory 
avoidance specific to a country is not the singular reason to engage in regional CSR.  
Rather, globalization might have also globalized reputation, especially for TNCs (e.g. 
global backlash over pharmaceutical companies crackdown on patents in South Africa 
in 2001).  
Overall, I believe the aggregate sum of the described institutional pressures from 
the external environment suggests an exogenous shock that is assisting in dislodging 
the prevailing logic, thereby providing the possibility of institutional change (Fligstein, 
1987).  However, the ability of employees to act as conduits across company and 
societal institutions and discourses, to effect change through conflict and contestation 
with existing institutional logics, plays a substantial and more endogenous role in 
institutional change.  
 
5.1.1  Role of Employees 
I observe that the respondents were somewhat reflective regarding how they are 
portrayed by those external to the industry.  They acknowledge and interpret growing 
external expectations of healthcare companies, or any company for that matter, to be 
more socially responsible.   
I do believe that corporations and other major institutional players have an 
obligation to ensure that at the very least they are not harming their environment. 
And by environment, I am speaking of it in the macro sense.  Ok?  So, the 
physical environment and the communities in which they operate; more than that, 
to really be a catalyst for improving their surroundings. (Respondent 5) 
 
As institutional conduits, employees in the pharmaceutical industry transfer their 
interpretation of ideas and meanings constructed in their interactions within the external 
social worlds into their companies, which can result in a somewhat porous institutional 
barrier.  Employees not only interact to socially construct company institutions, but they 
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are also part of the same processes externally.  Unless companies and employees 
operate in a vacuum, then it is reasonable to assume that strands of differing logics, 
some conflicting and containing ambiguities and contradictions, are pulled, consciously 
or unconsciously, into companies as employees attempt to make sense of multiple 
social worlds and logics within which they interact.  The relative durability and 
dominance of organizational-based logics, therefore, affects the ascendance of contra 
logics (Suddaby & Greenwood, 2005, p. 39). 
Respondents observed normative and cognitive differences in the younger 
generation of employees entering the workforce:   
I think younger employees are looking at a number of things in companies before 
they make a decision to join.  Corporate responsibility efforts are clearly one…I 
am not an expert certainly, but I think younger individuals have a stronger 
understanding and appreciation of environmental issues.  I think they have an 
appreciation of value that goes beyond a paycheque; that is important. 
(Respondent 20) 
 
Traditional conceptions of work and an employee’s identity had changed to include a 
desire for a greater role in adding value to the common good.  Dacin et al. (2002) 
highlights the institutionally disruptive potential of these and other new employees:  
New members with backgrounds and experiences that differ from existing 
members bring different interpretive frameworks and social definitions of 
behaviour to the organization that act to diminish consensus and unquestioning 
adherence to taken-for-granted practices. (p. 47) 
 
Although respondents can be conduits for external discourses regarding 
expectations, and thereby identify opportunities to address social needs, a translation 
and editing process highlight how their interpretations are conducted according to their 
institutional logic.  Conceptualizing the role of CSR and how it applies to their 
organization occurs through the lens of their changing institutional logic:   
Yes, well of course our key responsibility as an innovative pharmaceutical 
company is to conduct research to develop new medicines.  That is what we do: 
that is our core business.  This being said, however, we understand that you 
can’t do that in a silo.  We understand that we have to go beyond that and we 
have to have a responsibility to behave in a way, which will be responsible of 
course for the environment where we do business. (Respondent 10) 
 
 Overall, in isolation, I believe that these three factors—societal pressures on 
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legitimacy, changes in technical functioning, and employees as porous conduits across 
institutions—have a low probability of catalyzing institutional change.  However, when 
aggregated, they interact to create a situation within the organizational field where 
companies and their employees face substantial uncertainty, and that this uncertainty 
results in the possibility of competing logics to become dominant, as part of a response 
to mitigate the perceived precipitous risks associated with such a situation.  
 
5.2  Institutional Entrepreneurs – Framing and Mobilizing Resources  
The amplified institutional pressure due to the legitimacy/technical efficiency link 
has culminated in a climate within the organizational field that is susceptible to the 
agency of institutional entrepreneurs.  “Institutional entrepreneurs are the agents that 
create new and modify old institutions because they have access to resources that 
support their self-interest” (DiMaggio, 1988 cited in Thornton & Ocasio, 2008, p. 115).  
They work to infuse new logics, including subsequent, self-reinforcing practices and 
structures, into the organizational field in an attempt to gain, maintain, and repair 
legitimacy (Wooten & Hoffman, 2008, p. 136).  The opportunities for institutional 
entrepreneurs and acts of entrepreneurship (DiMaggio, 1988; Suddaby & Greenwood, 
2005) to exist illustrate how the binding nature of institutions is, under some 
circumstances, permeable to change by those with the ability and resources to shape, 
promote, and drive it (Hardy & Maguire, 2008).  
Within the pharmaceutical industry, the self-interest associated with the 
entrepreneurial framing of integrated CSR theorizations appears to be a mix of 
pragmatic idealism and financial acumen that is intended to reshape a business’s 
strategy by promoting mutual sustainability endogenously and exogenously.  The 
following quotes from Respondent 19 depict how the modification of dominant logic to 
include integrated CSR, and, therefore, also the business strategies, needs to occur 
throughout the organizational field to repair pragmatic and moral legitimacy, which will 
solidify a societal perception of the industry as a taken-for-granted, global necessity:  
We believe it’s in our interest that all pharmaceutical companies operate in a 
responsible way because we are interested in the reputation of the industry as a 
whole and people trusting the pharmaceutical sector.  If you’ve got companies 
that are behaving in a way that are perceived to be irresponsible that reflects 
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badly on (Company C) as well, so we are not immune from the impact for how 
other companies are behaving. 
 
If we want society to want to have a pharmaceutical industry, then we have to be 
seen as stepping up to the plate when there are global health crises, and so it’s 
only right that an organization has the capacity to support, for example, some of 
the access to medicine activities that we support, should do that.  So, we see it 
as part of our societal payback. 
 
Using the opportunities for institutional change created by delegitimization 
(pragmatic, moral, and cognitive) (Hardy & Maguire, 2008), institutional entrepreneurs 
continue to frame and promote previously unforeseen alternatives (responses) as the 
logical and innovative solution to the maelstrom of pressures facing the industry.  This 
process involves altering the criteria used to assess legitimacy that underpins the 
institutional logic by displacing the prevalence of the dominant logic, thereby making it 
open to change (Fligstein, 1997; Suddaby & Greenwood, 2005).   
Based on the discussions I had with respondents, it became clear that one 
particular company fit the criteria of an institutional entrepreneur—as an actor 
attempting to reshape institutional logics, practices, and structures (Maguire, Hardy & 
Lawrence, 1990 cited in Wooten & Hoffman, 2008, p. 136).  Respondent 19 represented 
a company with a distinct progression of integrating CSR into its core business strategy 
and vocal in advocating others to do the same—an institutional entrepreneur in form 
and function: 
Now, within (Company C) it is pretty well integrated, so I am not busy doing 
corporate responsibility at the center.  I think it’s mainly out; it’s happening in the 
business where it needs to be.  But I think in other organizations where it’s a bit 
less well embedded, I think over the years it will become more like the (Company 
C) approach. 
 
The respondent explained that there was still room for further integration of CSR, 
but suggested that there was no need to continue pushing for CSR at the center of the 
organization; that it was sufficiently embedded into the company culture to a point that it 
was increasingly taken-for-granted. 
Reinforcing my assertion that the company was an example of an institutional 
entrepreneur, multiple respondents from different companies explained CSR at their 
company relative to Company C.  For example, Respondent 20 identified Company C 
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as an example of progressive CSR integration and strategy: 
I think that there are organizations who are ahead of us in this work.  I think 
(Company C) is an example of a company who is working well in the shared-
value space.  I think that their chief executive officer has been vocal on issues. 
 
Respondent 20’s remarks also provide insight into the effect that rhetorical strategies 
(e.g. effective use of language to communicate the benefits of shared-value or 
integrated CSR) (Suddaby and Greenwood, 2005) used by institutional entrepreneurs to 
build legitimacy and justify the necessity a change in logic at his company.  
Furthermore, Respondents 16 and 13 identified Company C as having the financial 
“clout” and “voice” to promote the virtues of CSR integration.  Many respondents agreed 
with the theorized discourse of CSR as creating sustainability through its integration.  
However, the level of integration, as evident from the CSR practices and structures 
within these companies, was noticeably trailing in comparison to Company C.   
Respondents holding CSR-specific positions were especially vocal about an 
obvious logic for integration, which was probably inherent to how their positions 
necessitate closer proximity to various discourses involving CSR.  The lack of 
integration as manifested in ongoing practices and structures of the same companies 
illustrates a contradiction or gap in logic between these employees and the companies 
for whom they work.  At the same time, those with a greater cognitive belief in the 
usefulness of integration seem to act as micro-institutional entrepreneurs within their 
own companies, mobilizing resources and discourses to promote change internally 
(discussed further in Section 5.4.1, p. 282).  
 While ahead of other pharmaceutical companies, it is inaccurate to consider 
Company C as alone in conducting institutional entrepreneurial activities.  Company C 
conducts its entrepreneurial activities in relation, purposely or not, to other actors 
interested in promoting mutually sustainable business strategies (e.g. 
socialeconomic and companystakeholders).  These groups act as resources, 
with societal and business interests, to further advocate the potential and viability of the 
institutionalization (Hardy & Macguire, 2008) of integrated CSR.  Four groups of such 
actors identified by various respondents included: NGOs, governments, consultants, 
and industry associations.   
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 The Gates Foundation and the Access to Medicines Index (ATMI) were two 
specific NGOs that have been actively framing and advocating for CSR integration as 
sustainable for all parties involved, thereby building pragmatic and moral legitimacy 
associated with its adoption. 
And these are things that are reflective of the shared value, more sustainable 
approach.  Places like Gates that we have talked about are eager for us to do 
this kind of work.  The Access to Medicines Foundation, who produces the 
Access to Medicines Index, is interested and observant of us doing this kind of 
work.  So, I think the time is right because there are organizations that are eager 
for us to do this. I feel an increasing feeling of eagerness internally to do this, and 
I am positioning the company to pilot some of these programs over the next year.  
(Respondent 20) 
 
In addition, Respondent 21 stated that institutional actors do not always perceive 
the pressures exerted by such NGOs as positive.  While the benchmarking capabilities 
of ATMI appear to inspire some respondents’ understanding of CSR meaning within 
their institutional context, others distinguish it more by its soft-regulative properties (e.g. 
comparative ranking of product access strategies). 
Governments have varying approaches to the promotion and regulation of CSR 
engagement.  As detailed in the literature (Section 2.2.8, p. 72)—using Canada, 
Europe, and the US as comparative examples—some countries explicitly encourage 
corporate uptake of some CSR practices and structures (e.g. mandatory CSR reporting 
in European countries), while others restrict regulation to somewhat vague and 
sometimes contradictory promotional strategies (e.g. US and Canada).   
When CSR is placed within a pharmaceutical context, however, it becomes more 
widely promoted because of global society’s growing normative understanding that it is 
the ‘right thing to do’ (Leisinger, 2009).  At the same time, how CSR should be 
conducted remains a matter of serious debate (Leisinger, 2009).  For example, the 
combination of the recent recession, rising healthcare expenditures, and expansive 
regulatory hurdles relating to safety and ethical controversies are placing governments 
and pharmaceutical companies increasingly in an adversarial relationship.  Such a 
relationship is socially constructing different conceptions of the industry’s role: “It is very 
difficult to be in a world where you are seen as a cost and not necessarily as a solution.  
So, that is very challenging for industry right now, not just (Company D)” (Respondent 
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16).  This is in contrast to the past, when it appears companies had greater behavioural 
leeway to operate without fear of being delegitimized: 
We are an industry that in the past sometimes government relations has meant 
yelling at government and I think we are probably ahead of the curve when it 
comes to actually identifying the importance of creating solutions to share 
problems together. (Respondent 4) 
 
Emerging markets and their governments play a significant role in bolstering the 
legitimacy and justification of CSR integration as a logical and viable alternative.  These 
markets represent where most future sales growth will occur, and their governments are 
inquiring about CSR-related activities as ‘payment’ to legitimize company access to the 
market.  At the minimum, this link provides significant weight to engage in integration as 
a sustainable risk management strategy—a business case for CSR.  
Some respondents in CSR specific positions did discuss the use of consulting 
firms to educate and assist them regarding potential CSR strategies, including 
communications strategies (Sections 5.2.1, p. 258 and 5.4, p. 277).  Consultants 
provided this service to individuals from a variety of industries.  These CSR-focused 
workshops provided participating respondents access to a social arena where 
circulating ideas, practices, and structures are discussed, and thereby, influenced CSR 
perspectives.  Unfortunately, the discussions regarding consulting firms did not go into 
detail about the relative influence it had on their company.  However, the use of 
consulting firms in the first place suggests that some companies and employees 
required assistance to formulate their meaning and use of CSR at the company.   
Industry associations were also discussed as encouraging member companies to 
adopt CSR structures and practices, but more as a method to repair pragmatic and 
moral legitimacy:  
Our industry association for research based which is called Rx&D, I don’t know if 
you have heard about them.  They just started last year asking their member 
companies to start reporting on community investment (CSR). (Respondent 9) 
 
But now corporate social responsibility is there partially, not fully but partially, to 
improve the perception of the industry, and that’s why probably Rx&D is asking 
their members to report that. (Respondent 12) 
 
 In Canada, Rx&D is the brand name pharmaceutical industry’s professional 
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association, and mainly focuses on advocacy for its member companies and their 
employees (Rx&D, 2011).  Rx&D promotes the actions of brand name pharmaceutical 
companies and operates as a unifying force, when necessary, to challenge legislation 
that may affect companies.  Similar associations also exist in Europe (European 
Federation of Pharmaceutical Industries and Associations) and the US (Pharmaceutical 
Research and Manufacturers of America), with the International Federation of 
Pharmaceutical Manufacturers & Associations (IFPMA) serving as the global 
representative for most pharmaceutical companies and national associations.   
 The Canadian Generic Pharmaceutical Association (CGPA) represents the 
manufacturers and distributors of generic pharmaceuticals in Canada.   Similar to the 
brand name associations, the CGPA is an advocate for interests the companies it 
represents, which most notably includes promoting the cost effectiveness and medicinal 
equivalence of generic pharmaceuticals in comparison to those create by brand name 
companies.  Additionally, it has a code of conduct for its members, but it does not 
explicitly promote practices associated with CSR (Canadian Generic Pharmaceutical 
Association, 2011).   
 On company websites, mention of industry associations’ influence or involvement 
was mostly absent, with only one company commenting on their participation in a 
product access program promoted by PhRMA in the US.  Other US affiliates of 
companies participated in this same program, but did not discuss its link to PhRMA.   
 Discussions about the role of brand name associations in CSR were limited to 
the promotion of CSR communication and reporting, and did not include its integration.  
However, the notion that part of the stated role of Rx&D is to challenge government 
legislations in some cases displays a paradox regarding its promotion of CSR: how can 
an organization challenge legislation, which is presumably made in the best interest of 
citizens, while also promoting aspects of CSR to member companies?  Do they 
conceive CSR merely as a business tool, or is its historical role as political advocate 
conflicting with prevalent notions of CSR?  Either way, I believe it represents an avenue 
for future research; as to determine CSR perspectives of professional associations and 
the role they play in the evolution of CSR within the industry.   
 As advocates of varying levels and types of institutional change, these four 
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groups of actors—NGOs, governments, consultants, and associations—represent 
relational resources for institutional entrepreneurs to align the commonalities in 
discourse to exploit contradictions in traditional logics (Fligstein, 1997; Suddaby & 
Greenwood, 2005) by specifically framing their theorizations to further the adoption of 
alternative logics.  The potential institutionalization, and, therefore, cognitive legitimacy 
(Suchman, 1995; Greenwood, Suddaby, & Hinings, 2002; Suddaby & Greenwood, 
2005) of such alternative logics is reinforced by the validation of growing moral and 
pragmatic legitimacy by way of explicit and implicit recognition from benchmarking, 
rankings, and partnerships and collaborations.  
 What remains unclear, however, is whether the one company example of an 
institutional entrepreneur mobilizes these groups as resources to effect change, or 
simply relies on them passively to help justify and legitimize institutionalization, or a 
combination of both.  It is also unclear why and how Company C developed into an 
institutional entrepreneur?  Were elements of their historical institution more aligned 
with conceptions of CSR and, therefore, more open and better able to identify to self-
interested pathways of change?  Regardless of the causal specifics of origin, the 
dynamics of interaction and reinforcement among actors assuming various 
entrepreneurial roles demonstrate a powerful motor to effect change in the industry’s 
current institutional context. 
 
5.2.1  Framing 
A significant part of being a successful institutional entrepreneur includes building 
and maintaining legitimacy for the changes being promoted (Wooten & Hoffman, 2008), 
and the compounding challenges facing the industry provide an environment of 
uncertainty that can be leveraged to promote those changes.  The risks and 
uncertainties regarding entrance into important emerging markets, the changing 
dynamics of production, ethical, economic, and legal crises, and changing societal 
movements are selectively framed as best addressed by the integration of CSR; the 
logical and best option for a successful, sustainable, and morally inclined industry 
future.  Framing, as such, is a purposely designed schematic of interpretation (Scott, 
2008) that is used—in this particular case by entrepreneurs—to create common 
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theorizations of meaning among actors in the organizational field by bridging the 
previous conflicted elements of the dual role of the pharmaceutical industry.   
 According to such framing, by being more socially responsible in every business 
action—thereby reshaping product, marketing, pricing, and distributions strategies to 
improve medical, economic, and social outcomes across global locales—it will result in 
mutual sustainability for all parties involved.  Regardless of conceptions of the dual role, 
it should permeate individual and company pragmatic and moral motivations (economic 
and social) to garner the necessary ‘buy-in’ for institutionalization.  Indeed, one 
respondent suggested that traditionally simplistic economic/management theories are 
no longer sustainable in the current business environment and that integrated CSR 
better prepares a company to more fluidly navigate and balance its economic and social 
aspirations: 
I think in this day and age you can no longer just get by on just sort of 
shareholder value alone.  I mean it’s just sort of the [Milton] Friedman theory 
versus the stakeholder theory, and there are too many influences that act on 
companies to think that the only duty of managers is to prioritize quarterly 
earnings at the expense of everything else.  So, it’s [CSR] an integrated 
approach to running and operating company; it’s a sustainable approach to 
running a company cause at the end of the day every industry and every 
company has sort of a social life to operate, and government reinforces and 
establishes that through regulations and policies.  And ensuring that you’re 
around as a company—not just in four quarters but in four years or forty years—
is about actually thinking about that long-term perspective, and you can’t do that 
in an accurate and comprehensive way unless you’re looking at the broader 
world in which you operate. (Respondent 4) 
 
As discussed previously, emerging markets represent the future markets of 
growth for the industry, but they also represent significant and interrelated 
disadvantages in comparison to Western markets: disproportionately higher levels of 
poverty, disease, and inadequate health infrastructure (Leisinger, 2009).  Based on 
these factors, an important part of framing is the promotion of a trickle-up strategy 
based on creating benefits for the most disadvantaged sectors of the population, which 
will eventually bolster widespread economic capabilities by way of helping to build a 
healthier population.  The socio-economic strategy is to generate sales revenue based 
more on volume, rather than price.   
Well, yes, but it is not just about, you know, improved healthcare means 
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improved economic activity means, you know; it all goes around in a virtuous 
circle.  But it is not just about that, it’s about coming down and accepting that 
where the real business is in these markets is in the vast middle class population, 
rather than the wealthy upper class.  Therefore, we should be pricing to enable 
sales in that sector of the market; accepting that margins might be lower but our 
increased volume of sales will compensate for that. (Respondent 19) 
 
Overall, the changing dynamics of industry production (e.g. out-sourcing aspects 
of drug development and commercialization) in combination with pressures from the 
social movements constructed by crises originating within (e.g. patents, pricing, drug 
access, etc.) and outside (e.g. recessions, inequality, health and environmental crises, 
etc.) of the industry has increased the amount and awareness of reliance that 
companies and stakeholders have on each other.  Whether it is for the sake of, for 
example, financial success, patient health, or the fiscal constraints of governments, 
collaborations and partnerships are viewed by respondents as providing opportunity to 
use CSR-reinforced relationships and close proximity to build pragmatic and moral 
legitimacy in order to gain stakeholder and societal trust, which I interpreted as cognitive 
legitimacy. 
But the truth of the matter is that in this day and age what you really want to do is 
build relationships, and building relationships you do that through CSR activities 
really well.  We partner a lot with all kinds of stakeholder groups.  They benefit 
from the relationship and we benefit from the relationship as well because we 
share common objectives of ensuring that patients have access to medicines.  
So, it just makes sense for us to partner with a lot of charitable organizations. 
(Respondent 10) 
 
 CSR is being framed as a strategy that strengthens industry connectedness to 
stakeholders and operational locales.  I believe it is taken as a given by many within the 
industry that such a level of connectedness is meant to grow and then maintain 
sustainable linkages in order to influence future social constructions of meaning 
regarding the industry’s role in society, and to improve levels of legitimacy by partnering 
or collaborating with organizations that are more reputable (LaFrance & Lehmann, 
2005).  Respondent 10 provides a translation of such framing in the following quote: 
Yeah, well the expectations of the public at large are changing.  I mean people 
are, there’s less tolerance, I guess, for people who’d be perceived as having a 
negative influence or a negative impact, and the traditional marketing/advertising 
is certainly not as effective as it use to be.  So, it’s about building relationships 
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now, and CSR is just the perfect mechanism to do this in a win-win fashion. 
 
Since some traditional methods of manipulating external pragmatic legitimacy are no 
longer effective (e.g. failure of traditional marketing/advertising) in preventing the loss of 
moral legitimacy, companies are attempting to compensate to prevent distortion of their 
reputation and the subsequent loss of power and control (e.g. freedom of movement, 
patent protection, etc.) that might occur.  It is a strategy that some have observed as a 
method to demonstrate that companies are committed to CSR policies (i.e. walk-the-
talk), expedite entry in new markets (e.g. emerging markets), and create a relationship 
with governments that can affect the design, implementation, and enforcement of 
regulations (Bitzer & Glasbergen, 2010; Giovannucci and Ponte, 2005; Reed & Reed, 
2009).  
Over the course of this section on framing and institutional entrepreneurs, I used 
quotations from respondents not affiliated with the company that I classified as an 
institutional entrepreneur.  Doing so demonstrates how the idea of integrated CSR, and 
how it is being framed, has spread across discourses throughout the organizational 
field.  Although overall, most companies have yet to adjust their course completely in 
the direction of integration, CSR-designated employees theorize, carry, and spread 
ideas that advocate for such movement.  Their comments, therefore, provide insight into 
their developing understanding of integration as the logical way to conduct business in 
their company/industry. 
In summary, my interpretation of the framing interactively constructed by 
institutional entrepreneurs is that CSR integration is an approach to business that builds 
and maintains mutually sustainable relationships for the social and economic benefits of 
the parties involved.  It is theorized as a justifiable solution to industry problems and 
concerns (Tolbert & Zucker, 1996) that can repair and maintain all three forms of 
legitimacy by addressing the plurality of concerns and expectations within the social 
context.  Attainment of such legitimacy is proposed as morally and financially beneficial 
for companies—a win-win scenario.  Simply making an argument that theorizes the 
benefits of integrating CSR, however, is not adequate to delegitimize aspects of existing 
institutions in favour of a previously unforeseen alternative.  An institutional climate 
wrought with uncertainty presents foot holes to agentic actors, such as entrepreneurs, 
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to use in order to gather the necessary resources to plant and grow seeds of 
understanding within company institutional actors, thereby displacing or modifying 
dominant logics (Fligstein, 1997; Suddaby & Greenwood, 2005).  Within companies, 
employees and, most importantly, leaders are continuing to construct meaning based 
on transmissions containing institutional pressures (internal and external threats to 
legitimacy) and the solutions and responses meant to mitigate these pressures.  
Therefore, it is important to understand the mechanisms contributing to the transmission 
of institutional materials.    
 
5.3  Mechanisms of Transmission 
 CSR perspectives (Figure 4.5, p. 185) is depicted as an upside-down pyramid to 
illustrate the evolution of company perspectives toward greater integration of CSR.  It 
purposely contained arrows, some linear (similar to chevrons) and others that were 
divergent, to explain how the evolution of CSR is probable but not necessarily 
deterministic.  My findings avoid previous conceptions of institutional isomorphism as 
exclusive to factors depicting why companies in an organizational field tend to become 
similar in practice and structure (DiMaggio & Powell, 1983).  “Conformity is one 
response to isomorphic pressures, but not the only one, because institutional processes 
are themselves conflicted or because they combine with other forces to shape structure 
and action” (Scott, 2008, p. 153).  This realization led me to the more recent focus on 
why heterogeneity exists across organizations in the same field, rather than 
homogeneity (Greenwood, et al., 2008; Boxenbaum & Jonsson, 2008).  In addition, how 
isomorphic pressures are translated and edited to form imitations that feature variation 
in practice and structure, but motivated for a similar behavioural result (Sahlin & Wedlin, 
2008; Djelic & Quack, 2008).  The following section will examine the mechanisms of 
transmission that create isomorphic pressures for imitation, as well as how the 
pressures are translated and edited to fit differences between companies.   
[Mechanisms of diffusion] are usefully considered as explaining motivation 
for adoption.  Coercive isomorphism occurs because organizations are 
motivated to avoid sanctions available to organizations on which they are 
dependent.  Normative isomorphism occurs because organizations are 
motivated to respect social obligations.  And mimetic isomorphism occurs 
because organizations are motivated by their interpretation of others’ 
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successful behaviours (Greenwood, et al., 2008 p. 7)   
 
I use the term transmission instead of diffusion because the latter suggests the 
transfer of ideas, practices, and structures to passive recipients (Sahlin & Wedlin, 2008; 
Wooten & Hoffman, 2008).  I found that companies are interactive with institutional 
pressures; therefore, it is not accurate to oversimplify this complexity by assuming 
change is passive, albeit some actors may be unreflective during the process of 
change.  The process of institutional isomorphism is active and open to agency, and is 
better understood as a motivated process of imitation, which allows for the translating 
and editing of transmitted ideas, including practices and structures (discussed further in 
Section 5.3.1, p. 274).   
  Although the three mechanisms of transmission (coercive, normative, and 
mimetic) were observed in discussions with respondents, the underlying elements of 
each in their entirety were not present in every interview and corresponding websites.  
However, there was a large amount of repetition of each element, leading me to believe 
that even though a respondent did not comment on one, within their large globalized 
company, there is a high probability it does occur.   
 Notably, this section serves as a bridge between what has been discussed in the 
previous two sections.  Institutional entrepreneurs’ theorization and resulting framing of 
CSR as a justified solution/response to the various conflicts and challenges to 
company/industry legitimacy and technical efficiency has resonated with respondents’ 
companies because of its relative synergy, resources, and circulation by the 
mechanisms of transmission.  Potentially, the mechanisms of transmission represent a 
categorized framework of the points of interaction with circulating ideas, practices, and 
structures that contest and pressure for the modification of the traditional logic of 
company institutions.  
 The coercive mechanisms of transmission were the most explicitly communicated 
by respondents.  Acting as hubs for public sentiment, governments in developed, 
developing, and emerging markets, each having their own perception of the role of the 
industry, were perceived by respondents as potential risks because of their ability to 
implement regulations and/or create barriers to market access.  For example, the 
governments of emerging markets are explicitly telling companies to address the 
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medical, social, and economic problems of their lower economic classes if they wanted 
to operate within their market.  Governments in developed markets, on the other hand, 
are facing a growing crisis of rising healthcare costs that is further complicated by the 
financial strain of the current global recession.  Governments attempt to manage this 
situation while trying to be responsive to public sentiments regarding the industry as 
well.  According to respondents, how governments process these factors and make 
subsequent decisions will affect their relationship, positively or negatively, with 
pharmaceutical companies.  Relationships range from the more adversarial, where 
companies are perceived by governments as a cost to be cut, to the collaborative, 
where they work together to tackle complex problems, such as drug access. 
Furthermore, the growing number of organizations that engage in CSR-related 
benchmarking represents a coercive form of soft regulation.  Different forms of external 
CSR benchmarking that respondents discussed as areas of pride and competition 
included the Access to Medicines Index (ATMI), Sustainability Asset Management 
(SAM) group, Dow Jones Sustainability Index (DJSI), and FTSE4Good Index.  Notably, 
the SAM group uses its corporate sustainability assessment tool to measure companies 
according social, economic, and environmental performance and provide that data to 
DJSI where it is used as inclusion/exclusion criteria, and also to other SRI persons or 
groups.   
While ATMI is specific to the pharmaceutical industry, the others represent 
measures of differing CSR criteria (social and environmental performance), as well as 
financial performance, as an empirical method to inform investors, shareholders, stock 
exchanges, etc. about companies from a wide range of industries: 
More recently, several indexes have emerged to rank and list companies 
according to socially and environmentally responsible investing criteria.  The 
rationale for this “best in class” approach is to identify and reward the 
sustainability leaders in any given industry. (Robinson, Kleffner, & Bertels, 2011, 
p. 495) 
 
Taken together, the results of studies looking at whether socially responsible 
companies actually perform better in the market have been positive (Doh, Howton, 
Howton & Siegel, 2010).  For instance, studies have shown that firms listed on the DJSI 
have a sustained increase in share price (Robinson et al., 2011) and that investors 
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penalize (e.g. lowering of market value) larger firms with lower levels of corporate social 
performance (Lourenco, Brance, Curto & Eugenio, 2011).  Therefore, there is a benefit 
to ranking higher on these benchmarking indices, and beyond the financial, the 
possibility of intangible benefits to relationships with stakeholders such as government 
and NGOs.  However, the criteria, appropriateness of weighting, and substance and 
authenticity of the data and measures used by the DJSI, and others such as 
FTSE4Good Index, have been questioned: “The result is a jumble of largely 
meaningless rankings, allowing almost any company to boast that it meets some 
measure of social responsibility—and most do” (Porter & Kramer, 2006, p. 81). 
 Regardless of the substantive issues with such organizations, benchmarking is 
described as a coercive mechanism that, intentionally or not, places companies in 
competition with each other and as an external verification of whether they have 
achieved internally and externally created goals.  Importantly, the competition and 
assessment place companies into the broader CSR context, where they are further 
exposed to many of the discourses similar to those captured in its theoretical framing by 
entrepreneurs.  It encourages further CSR engagement as a way to avoid possible 
reputational loss and delegitimizing aspects of company behaviours in the minds of 
concerned investors, NGOs, governments, patients, etc.—even if the criteria for 
inclusion are relatively low and available for manipulation.  For example, respondents 
detailing how it is fundamental that companies are authentic in their support of 
communicated objectives, goals, values etc. illustrated that engagement cannot be 
superficial and without substance, because employees will point out inconsistencies.    
“Norms specify how things should be done and provide legitimate ways of 
pursuing valued ends” (Phillips & Malhotra, 2008, p. 710).  The normative mechanisms 
creating isomorphic pressures appear to originate from the points of institutional 
overlap, where historically stable institutions of the industry face moral delegitimization 
due to both external and internal pressures regarding conceptions what is the ‘right 
thing to do’ in the context of competing and conflicting meanings of their dual role.  The 
overlap represents the porous conduits in the institutional context that I discussed 
earlier; the meeting point of societal norms and values, with those embedded into 
existing company institutions.  Employees have been shown to have attributes of both. 
 
 
230 
Personal and professional relations describe the observed normative 
mechanisms.  Respondents routinely told stories about their experiences within 
professional and personal networks, and how those reinforced or altered their 
understood meanings of ‘the right thing to do’ as both a company and an individual.   
Some of our efforts for access to medicine where we are selling products at not-
for-profit pricing that may not be essential for the long-term survival of our 
business but it is the right thing to do and we have to look at what I can only 
describe as a contract with society. (Respondent 19) 
 
Respondent 11 details the isomorphic pressures resulting from attempts to 
address normative expectations: “If we are all trying to do the right thing then we are all 
probably doing something similar, which is a good sign”.  Congruent understanding of 
how the industry can engage in CSR to address normative expectations, according to 
the respondent, should lead to similar, though not necessarily identical, practices.  I 
postulate that the formation of a congruent understanding of the ‘right’ types of CSR is 
happening through commonly experienced exposure and proximity to various societal 
institutions and discourses.  Specifically, traditional and evolving CSR practices and 
structures, professional groups, participation on boards of not-for-profit organizations, 
and migration of talent between companies, are the prominent mechanisms of 
transmission for normative isomorphic pressures: 
As we get into certain segments and pockets of society we will better understand 
some of the issues that are in those areas and perhaps realize that we have 
solutions to help address their needs.  But unless you are touching those people 
you’d not ever know that. (Respondent 21) 
 
Traditional and evolving CSR practices (Section 4.3, p. 184) provide 
opportunities for employees to gain proximity to societal institutions and discourses 
where many concerns and expectations of company and industry practices are forming.  
While companies control the option of company-related participation in such programs, 
exposure to and participation in societal institutions and discourses appear to turn 
employees into carriers of societal norms and values, transmitting them back into the 
company institution through their interactions with other employees: 
So, I think it really plugs us in and grounds us because sitting here in the ivory 
tower of the corporate center one can kind of get immune to what’s going on 
around us, and that was the huge benefit for me, was just grounding me.  And, 
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oh my gosh, just within a couple miles of this beautiful campus there are 
homeless people walking the street and what are we doing about that? 
(Respondent 22) 
 
 Respondents in CSR-specific positions discussed meeting and talking about 
CSR with consultants and others from other companies within and outside the 
organizational field that had similar job descriptions.  Whether it is education on ‘best 
practices’ (Respondent 9) or getting together with CSR personnel from other 
pharmaceutical companies to push for a global reporting initiative (GRI) sector 
supplement (improves reporting and benchmarking capabilities through industry 
customization) (Respondent 16), socially constructed norms and values related to CSR 
are transmitted across companies as employees engage in, and contribute to, the 
ongoing formation of its discourse.   
 Similar to CSR practices, many employees, especially those at the manager and 
executives levels, participate on boards/committees of not-for-profit organizations:  
I sit on the board there, and I’m sort of active on a number of volunteer 
committees.  And for me, my sort of personal values reflect what I think at a 
corporate level as well: we have an obligation to give back.  Right? (Respondent 
5) 
 
According to multiple respondents, participating on external boards has provided 
respondents with direct experiences of acting in an altruistic role with different 
institutions and actors than their own companies.  I believe the resulting external 
perspective that is provided by such experience affects an employee’s construction of 
the norms and values used to evaluate the moral legitimacy of behaviours, practices, 
and structures within their own company.  Based on those evaluations they might 
identify contradictions in the dominant logic and use their influence through position 
and/or relation to other employees to pressure for institutional changes at their 
company.   
The last element of personal and professional relations is the migration of talent 
among pharmaceutical companies.  It was stated earlier that a younger generation of 
employees is associated with new norms and values, and they carry these with them 
when they join organizations.  Older, more experienced generations of employees, on 
the other hand, bring conscious and unconscious understanding of the institutions from 
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one company to another when they migrate.  Whether in a position of authority to effect 
change or not, migratory employees have the potential to be carriers of differing norms 
and values, which also includes other institutional elements (e.g. taken-for-granted 
assumptions).  Respondent 12 provided an example of employment across three large 
pharmaceutical companies, each with similar sentiments regarding CSR: “I have worked 
in three companies now and all three strongly felt that it was our social responsibility to 
give back”. 
The final mechanism of transmission is mimetic, which represents, as stated 
above, motivation from the interpretation of the successful practices and structures of 
others, as well as the opportunity and availability of theorizations and models necessary 
for imitation purposes.  Personally, I do not believe that mimetic forces should be 
described as a process of duplication because it is not logical to make an exact 
duplication of a program or policy that was designed for an environment that has 
different features.  Rather, it is the logical opportunity to translate and edit practices and 
structures perceived to be successful to create a customized imitation.   
Building off the pragmatic legitimacy generated by addressing coercive 
mechanisms and constructing a perception of technical superiority (e.g. enhanced 
reputation or financial success), as well as the moral legitimacy created by better 
alignment with the normative expectations of stakeholders and society (Suchman, 
1995), entrepreneurs and other successful actors transition the CSR theorizations 
encapsulated in their framing into models increasingly perceived as institutional 
imperatives (Strang & Meyer, 1993; see also Greenwood et al., 2002) 
Understandably, Company C, viewed as successful by multiple respondents, 
including those who worked there, has implemented progressive and successful CSR 
strategies.  Respondent (20) even said that their company is trying to adopt similar 
strategies for the integration of CSR—based partly on what they understand through 
observation of Company C.   
Mimicry of CSR programs, however, is not isolated to those delivered by 
Company C.  Some respondents, whether it was the result of direct observation, 
second-hand knowledge, or migratory experiences, were candid about their respect for 
the programs of companies other than Company C, and how they were planning to 
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introduce similar programs.  For example: 
I know (Company B) has a very solid employee-volunteering program where they 
take one day and they go work in the community for a day.  We are trying to 
organize that for the first time this year.  We are trying to develop that.  Our 
competitors were ahead of us on this one. (Respondent 10) 
 
Introducing the concept of cross-company observation brings up a number of 
contradictions that occurred during interviews.  A few respondents routinely stated that 
their companies did not observe the CSR practices and structures of other companies, 
but most of those same respondents had either worked at multiple pharmaceutical 
companies, made references to benchmark rankings and/or criteria, or stated that their 
company was differentiated or a ‘leader’ in one or more aspects of CSR engagement.  
Most respondents identified CSR differentiation from their competitors as important, 
coupled with a desire to be perceived as a leader: 
But apart from that we believe we can set ourselves apart by saying we have a 
global access to health strategy for all of our products, in every country in the 
world.  And we are in the midst of developing that strategy, and it doesn’t exist—
no other pharma company has done that.  So, we definitely think that we can 
differentiate ourselves through access to health and we will be positioning 
ourselves as a leader. (Respondent 17) 
 
In addition, there was motivation for differentiation because of a perception that it 
would help companies be more successful in capturing the intrinsic benefits attributed to 
CSR engagement that are increasingly objectified during the process of transmission 
(Berger & Luckmann, 1967; Tolbert & Zucker, 1996) and legitimization (Suchman, 1995) 
by them and other actors: 
We really think that differentiation of social responsibility and citizenship enables 
us to win customers, it enables us to attract and retain employees, and it enables 
us to form more collaborative and respectful relationships with a wide range of 
stakeholders including both the governments of countries where we do business 
and the civil-society, non-governmental organizations who are concerned with 
healthcare issues. (Respondent 18) 
 
To differentiate or surpass the CSR strategies of other companies, respondents 
and their companies will be exposed to the transmissions of entrepreneurial framing, as 
well as other actors interacting in their social context.  Mimicry of other companies in an 
attempt to be perceived as leader, therefore, does not mean simply copying but a more 
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complex process of translation and editing others’ strategies perceived to be successful 
as a basis for customization, improvement, and, occasionally, innovation.  It appears to 
be an evolutionary competition with conceptions of leadership used to project an image 
of success to build and maintain trust.  “So, this is our corporate responsibility—to act 
as a leader, to convince people that we are a partner, that we should sit with them and 
build a program that will better manage the patient” (Respondent 15).   
An example of mimicry that details some of the reasoning for customization 
comes from the identification of successful CSR practices outside the pharmaceutical 
industry.  Many respondents brought up examples (e.g. Google, Toyota) of storied or 
publicized successes by TNCs from different industries to better explain how they relate 
broader conceptions of CSR to their companies and the industry.  Respondents realized 
that these examples do not directly fit with how most pharmaceutical companies 
operate, but they do, based on my observation, add to the objectification of CSR as an 
institutional imperative: 
I mean it might not be the supply chain in the purest sense, but for organizations 
like Starbucks and Nestle, their opportunity for shared value is early in the supply 
chain.  It’s at the producer, right?  For us, our issue is at the end of the supply 
chain; it is the user.  And because our programs are so much closer to the end 
user, we have to be even more thoughtful about how we develop programs in 
that trio of facts (business opportunities, assets and expertise, and social needs) 
that we have been talking about.  And so, what we do will by definition look and 
feel different.  Nestle, Starbucks their issues are at the beginning of the supply 
chain, our issue is at the end of the supply chain. (Respondent 20) 
 
Even though the role and weighted influence of the three mechanisms of 
transmission and their respective institutional pillars (regulative, normative, cognitive) 
have been challenged throughout the modern institutional theory literature (Greenwood 
et al., 2008), I have observed an important role for the interdependent influence of each 
mechanism in building legitimacy for the theorizations making up entrepreneur framing.  
Doing so has led to greater objectification of CSR integration, thereby increasing its 
cognitive legitimacy, as a social reality or institutional imperative.   
Whether or not the relevancy of all three mechanisms provides evidence of a 
three-pillar foundation to institutions, addressing that aspect of institutional theory 
specifically is not the purpose of this discussion.  What I do propose is that there is a 
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substantive, dynamic relationship among the three mechanisms regarding CSR in the 
pharmaceutical industry.  First, neither coercive nor normative mechanisms provide a 
framework as a response to the potential consequences of institutional conflicts and 
contestation, but they do add pressures for change—a source of opportunity for 
innovation by entrepreneurs.  For example, there is fear that CSR engagement could 
become mandated through regulation; that, respondents explained, would lead to 
increased costs of doing business by requiring companies to conform to standards 
created without their contribution.  Second, relational networks within and outside 
companies provide greater context for why there are regulatory threats through 
experiences constructed during close proximity to differing societal institutions and 
discourses.  Finally, the mimetic mechanism is a cognitive process where the potential 
consequences (coercive), social context for obligations (normative) and the practices 
and structures of competitors (mimetic) converge and are translated through the lens 
the company’s existing, albeit potentially changing, institutional logic.  The result 
appears, in part, to be manifested imitations as the result of attempts to catch up or 
innovate further to capture and/or maintain legitimacy, until a point where 
institutionalization has occurred and integrated CSR becomes taken-for-granted. 
 Building off the framework of others who appear more successful and technically 
efficient—especially those considered institutional entrepreneurs—assists companies 
by providing a motivational foundation from which strategies of differentiation 
(leadership) continue to evolve.  The following illustrates this process even more 
simplistically: coercive (a problem or a institutional contradiction with consequences)  
normative (understanding the contextual roots of the problem)  mimetic (the evolving 
response as a solution to the problem).  However, as institutional change occurs, there 
is room for the relationship to be iterative and far less linear or unilateral.   
From this study, I observed that implementing new CSR practices and structures 
in turn leads to a closer proximity with societal institutions and discourses.  Exposure to, 
and participation in, the social construction of regulations and norms in turn influences 
greater understanding of the plurality of institutions and the possible ambiguities and 
contradictions within and between them.  Respondent 4 encapsulated this process: 
I think at the end of the day we all realize that you operate in communities.  You 
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live in communities, we have impact in communities, and I think if you feel that 
the operations of your business kind of stop and start at the front door you miss 
incredible opportunities, especially as the world becomes more collaborative; as 
working with cross-sectors and across silos is more and more important.  And I 
also think that you’re less in tune to risks as they come across the horizon, and 
you’re going to become much more myopic and much less successful. 
 
Furthermore, the role of institutional entrepreneurs in the industry is best 
understood as agents of change that captured the “precipitous jolts” (Greenwood et al., 
2002, p. 60) that make available the possibility of institutional change, thereby 
identifying and using the contradictions within competing logics at an early state to 
frame a solution (i.e. innovation) that is in their own self-interest.  In the case of CSR, 
however, self-interest is seen to align with society’s best interest as well—a built in 
foundation of moral legitimacy.  As framing became more prominent in the institutional 
discourse and more justified and legitimate, companies began to cobble a strategy 
together using selective understandings of mechanisms, historical experiences and 
other elements (values, norms, symbols, etc.) of existing institutions in a process of 
bricolage (Glynn, 2008) that has further contributed to the way CSR integration is 
framed and translated by actors.  Bricolage is the process “where organizations 
incorporate cultural meanings, values, sentiments and rules into their identity claims”; 
therefore, “identities can thus be bricolaged or cobbled together from shared cultural 
elements and symbols and it is in this way that they can come to resemble each other” 
(Glynn, 2008, p. 424).  As a result, the process of bricolage does not begin and end with 
entrepreneurs.  The actors interacting in the institutional context translate and edit the 
information packets (ideas, which include, but are not limited to, practices and 
structures), framed or otherwise, which in turn alters them.  Those alterations are 
transmitted back through the mechanisms to other actors, continuing the cycle of 
interaction that can change institutions.   
 
5.3.1  A Process of Imitation: Ideas, Translation, and Editing 
 The discussion of transmission in the previous section underlines a critical 
component of institutional change: the circulation of ideas (Sahlin & Wedlin, 2008).  
Ideas encapsulated by language and models present opportunity for circulation through 
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the previously described mechanisms, but also in everyday interactions among 
employees.  In the discourse communicated by respondents and websites, CSR is 
prominently represented by a variety of buzzwords that correlate with how it was 
framed: sustainability, win-win, innovation, walk-the-talk, leadership, integration, mind-
set, and think-outside-the-box.  Models take form as the CSR practices and structures 
are (re)produced through customization and/or innovation.   
Providing insight into institutional change and the role of ideas, Sahlin and 
Wedlin (2008 p. 221) note four important factors: 1) ideas as triggering for institutional 
change; 2) ideas as impossible to pinpoint to their origin; 3) ideas as becoming more 
powerful as they circulate; and 4) some ideas as becoming popular not because of their 
properties, but, because of who transports them, how they are framed, and their timing.  
I believe respondents try to makes sense of the circulating CSR ideas by 
overlaying its framing onto their socially constructed worlds, which, according to Sahlin 
& Wedlin, 2008, consist of their interest, identities, resources and abilities.  In addition, 
companies appear to be responsive to a growing number of circulating CSR ideas, as 
evident in changing perspectives, practices, and structures (Section 4.3, p. 184).   
Objectifying the opportunities communicated in the circulating pressures and 
ideas, companies are increasingly justifying and legitimizing the framing of integrated 
CSR as a timely solution to an uncertain future, which highlights the growth in its 
discursive popularity.  For example, companies appear to be interpreting seemingly new 
ideas that are circulating within their relational networks.  Within those ideas can be 
various components of a logic, including values, norms, beliefs, experiences, decision-
making rationale, etc.  Using familiar components of their own institutional logic, 
respondents and their respective companies translate circulating ideas and then edit 
them to form imitative responses, if deemed necessary.   
Furthermore, in the context of business, I believe the purpose of editing is to 
better the chances of being technically effective and efficient by aligning it with their own 
assets, expertise, business opportunities, and understanding of social needs and 
expectations.  Respondent 20 depicts his company’s translation process as it tries to 
implement a shared-value or integrated approach to CSR (acknowledged earlier in the 
interview as following in the footsteps of Company C): 
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Shared value really is that space where you have overlap of social need, 
business assets and expertise, and business opportunity.  And when 
organizations like ours can identify those locations we really believe that we can 
have meaningful impact on individuals.  We can produce a sustainable corporate 
responsibility model that could ultimately just blend into being part of the 
business. 
 
Another important reason that the translation and editing process occurs is that 
each of the companies is a transnational corporation (TNC).  They operate across the 
world in a diverse range of distinct social and institutional contexts (Djelic & Quack, 
2008).  Respondents acknowledged this both directly and indirectly during the 
interviews.  They explained that companies have to adapt somewhat to each social and 
institutional context they operate within to ensure technical efficiency (e.g. emerging 
markets) and legitimacy.  Using incomplete information to guide action might lead to 
improper, or conflict-inducing strategies.  Therefore, interacting with, and purposely 
trying to understand, local regulations, norms, and taken-for-granted assumptions might 
cause varying cross-institutional transmission.     
 One manifestation of this adaptive process is the seemingly umbrella-like global 
CSR strategies of every company, and yet, how each is open to regional customization 
by subsidiaries (Section 4.4.4.1, p. 221).  The global strategy is translated and edited 
according to the previously described process, and this process is repeated locally to 
address a more specific context.  However, it is not strictly a global-to-local approach 
because numerous respondents described how locally constructed practices are 
adopted globally and require further editing to customize them accordingly.  
 To summarize, circulating ideas are similar to playing a game of telephone—
transmissions are translated and then edited according to understandings of the 
prevailing institutional logic, including the possible contradictions that may dislodge or 
modify it, and the social context, thereby altering the original ideas.  Therefore, further 
transmission can result in further alteration.  However, the growing CSR discourse 
provides buzzwords/phrases as symbols of meaning, which, I believe, improves the 
clarity of framing for the translation of circulating ideas.  Similar objectification of 
meaning can provide a wider circulation of language, models, values, etc. contained in 
the ideas promoting CSR integration as a legitimate and justified solution.  Greater 
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circulation, appropriate timing, and legitimized framing continue to create isomorphic 
pressures to evolve CSR perspectives, practices, and structures toward its integration 
into the overall business strategy.  Rather than fragmented and distorted results due to 
continuous alteration, framing has helped to stabilize an isomorphic stream through a 
common understanding of social reality that connects the ongoing institutionalization of 
integrated CSR at companies.   
Nevertheless, in this institutional context the isomorphic pressures illustrate a 
scenario of institutional change that appears to be path dependent, or deterministic.  
However, the reinforcement and stability of the ongoing institutionalization of integrated 
CSR needs to be examined before that conclusion can be made.    
 
5.4  Institutionalization of Integrated CSR  
There has been an established history of CSR engagement by companies; but, 
upon reflection, I believe respondents perceived most of them as loosely coupled to 
core business functions.  I avoid using the term decoupled because it denotes that such 
practices and structures have no point of attachment to the company; whereas loosely 
coupled insinuates minor, non-prioritized attachment (Palmer, Biggart & Dick, 2008).  
Simple philanthropy and volunteering represent loosely coupled CSR practices that 
could be considered acts that are more ceremonial, separate from core efficiencies, and 
done to gain or maintain legitimacy (Boxenbaum & Jonsson, 2008; Scott, 2008).  
Currently, an expanded use of CSR and its perspectives has become relatively common 
(Section 4.3.3, p. 190), and located in a position closer to the core and less on the 
periphery in comparison to traditional practices and structures.  Based on the comments 
of respondents and their company websites, continuing to change the institutional logic 
in this context requires fostering cultural modification and an acceptance of shared 
meanings of CSR that snowballs using pathways of discourse in relational networks to 
become increasingly more taken-for-granted as the natural way to do things.   
The process of institutionalization that I observed aligns with Berger and 
Luckmann’s (1967) three phases in the construction of common meaning: 
externalization, objectification, and internalization.  Externalization is a social 
construction of meaning that begins to be shared by actors.  Objectification occurs when 
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a shared meaning takes on state of external reality as experienced commonly among 
others.  Internalization is the process of retroactively injecting the external reality “into 
consciousness in the course of socialization” (p. 61).  This process illustrates the 
ongoing social constructions highlighting the varying progress toward gaining cognitive 
legitimacy (internalization) of CSR integration.  The staggering of progress and stability 
of change relates to how individuals, and therefore companies, move through this 
process, and if changes become institutionalized or just a temporary fad (Greenwood et 
al., 2002).      
I believe these companies are using purposeful socialization to capture the 
growing objectification of CSR in order to internalize it into the prevailing logic because 
as this occurs it is being increasingly understood as an institutional imperative.  
Observed socialization strategies consist of manipulating two types of texts contributing 
to company discourses: symbols and relational networks.  Symbols, such as values, 
encode the ideas being circulated into a form that will be decoded through theorization 
by other actors to construct meanings (Strang & Meyer, 1993; Scott, 2008).  Relational 
networks are arenas of social interaction and discourse where companies become 
porous with employees, groups, and organizations creating conduits that carry 
institutional materials (Scott, 2008).  The leaders of companies use both to reinforce 
preferred socialization as to promote the internalization of a changing institutional logic 
that they have come to identify as an institutional imperative. 
 Leadership by executives, and the company as a whole, are powerful platforms 
from which to use symbols to carry and transmit institutional materials.  For example, 
respondents discussed how executives, especially CEOs, provide regulative, normative, 
and cognitive guidance on why and how the company engages in CSR and in what 
direction it is headed: 
Ultimately, if you want corporate responsibility to be part of the fibre of the 
corporation it has to be appreciated, articulated, and reinforced by the senior 
leadership of the company because employees look to the senior leadership to 
define among all the options.  What are the important things and how do I, as an 
employee, interpret what I am supposed to do day to day based upon what the 
company strategy is based upon what the executives are saying is important, and 
how do those things filter down to their direct supervision. (Respondent 20) 
 
While employees carry ideas across institutional boundaries, they look to the 
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leadership (who are also carriers) of the company, in part, to filter alternatives and 
provide guidance.  It seems to be a method of employees assuring themselves in some 
cases that what they are thinking and doing is legitimate within the organization and its 
institutional boundaries.  I observed respondents constructing their personal meaning of 
CSR in relation to other employees and linking to the framing of ideas by leadership, 
present and past.   
Respondents routinely cited examples of the leadership ‘walking-the-talk’ by not 
only communicating the importance of CSR to the business and society but also by 
engaging in it themselves: 
We also have a great deal of personal involvement from our chairman and CEO 
in overseeing a number of our philanthropic programs; particularly in (location) 
where we have a lot of infrastructure building that we have done and partnerships 
with local governments.  Our chairman/CEO has personally visited all of those 
sites and has been quite involved in the design and development. (Respondent 
18) 
 
In addition, CSR-related stories of previous leaders and founders of companies were 
recalled to establish historical precedence and authenticity—a temporal stream of 
cognitive legitimacy (internalization).  Some stories are also intended to establish a 
perception of CSR leadership by the company, which acts as a symbol to carry and 
circulate a sense of pride while also providing historical context and legitimacy to 
changing meanings of CSR.   
Yeah, well Company D historically speaking has definitely been at the forefront of 
CSR.  I mean the (Drug Name) program that is something that started 20 years 
ago by the CEO at the time.  You have to factor in the fact that nobody was 
giving drugs back then; it was completely a novel idea. (Respondent 10) 
 
 As explained in section 4.2.2 (p. 153), another important function of executive 
leadership was to articulate company values: to provide their meaning in the current 
context.  The values have become symbols of meaning that provide not just normative 
but regulative and cognitive guidance for employees.  They form a basis for what is 
considered the ‘right’ behaviours within the company culture—a basis for governance 
and decision-making for leaders and employees alike.  Values are intended to construct 
similar meanings of what is right and what is wrong, to point, in some cases, where the 
taken-for-granted meanings symbolized by reinforced values unconsciously guide 
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employee decisions.  The intended meaning of values, therefore, is also used as a 
symbolic framework of governance to control and assess employee behaviours.   
So what we’ve done is set out our values, which are about (specific value set), 
and if people understand those values and what the expectations are around 
those values they can then use those to inform decision-making that may go 
outside the sort of strict rule set out in a policy.  (Respondent 19) 
 
 This individual may be from the company considered an institutional 
entrepreneur, but the overall use of values as symbols to construct and carry meaning 
as well as a method of control and governance was evident in discussions with all of the 
respondents.   
We have a set of four core values that are the foundation of our brand, and it’s 
something that we have spent a lot of time training and educating our employees 
on.  Those four values are [specific value set].  And we think that the citizenship 
strategy fits nicely into all of those buckets.  (Respondent 18) 
 
The dominance of rearticulating values, instead of changing the symbolic 
words/phrases, provides a historical bridge of legitimacy by preserving the recognizable 
face of those values.    
 Relational networks also provide both a source of reasoning for institutional 
change and a method to reinforce it.  As explained in the mechanisms of transmission, 
employees come in contact with other institutions via a variety of interactional pathways, 
both prior to and during employment at their current company.  At this point, leaders 
tend to implement or encourage access to specific relational networks that are providing 
exposure to, and experiences with, institutions and discourses that champion the 
institutional features they now envision for their own company.  Isomorphic pressures 
emerge as companies become motivated to imitate successful behaviours, practices, 
and structures.  
 Relational networks and symbols can become mutually reinforcing toward a goal 
of desired institutionalization (internalization/cognitive legitimacy) by establishing 
internal and external legitimacy (pragmatic and moral).  In this case, the ensuing 
alignment strengthens the possibility of stability in the institutionalization of a modified 
logic and its accompanying practices and structures that are self-replicating.  Adding 
stability to institutionalization will increase the probability that it moves from being a 
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process into a stable state of internalized reality.  Respondents and company websites 
provided ample evidence of this process of shaping the institutional discourse to better 
embed particular meanings, thereby promoting the institutionalization of a logic where 
CSR integration is taken-for-granted as the natural way to conduct business. 
 
5.4.1 Reinforcing and Shaping the Institutionalization of CSR 
The preceding sections constructed an argument for why CSR is evolving and 
consequently changing institutions.  The purpose of this section is to detail how 
companies, having already expanded CSR practices and structures, are controlling and 
shaping its continuing evolution in response to isomorphic pressures for integration.   
Reinforcing symbols and relational networks using discourse, including internal 
and external rhetoric, represent attempts at controlling aspects of socialization; thereby, 
influencing how actors within the institutional context construct their understanding of 
the social world.  Companies seek to gain and maintain legitimacy among employees 
and stakeholders alike through a combination of close proximity, communication, and 
measured examples to build ‘buy-in’ or ‘trust’ in a reputation that conforms to, or 
surpasses regulation and addresses normative sentiments of each group.  The result is 
a snowballing institutional logic rooted in translations of the integrated CSR theories 
framed by entrepreneurs and other sources of societal discourse.   
Companies used language to imbue symbols with desired meanings that should 
resonate with and align institutional actors; however, there are difficulties with such a 
strategy.  With tens of thousands of employees at each company there is variance in 
how each subscribes to the institutional logic.  Yet without this variance, the social order 
produced by an institution would likely create an ‘iron cage’ (DiMaggio & Powell, 1983), 
preventing institutional pressures and contradictions from gaining salience:  
I think most people want to participate (in CSR programs) and want to give their 
time, and think it is a good thing.  You always have a few naysayers, but I think in 
general everybody understands it’s just the fabric of what (Company A) is, who 
we are and the kind of the attitude that everybody brings to their day job. 
(Respondent 22) 
 
As detailed earlier, mounting conflict and contestation can contribute to the 
delegitimizing of company behaviours, thereby destabilizing the logic and opening up 
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opportunities for change:   
Yeah, I mean we’ve been compared to tobacco companies and we’ve been 
accused of a lot of different things. I think it’s created a lot of soul searching in the 
company as to how did this happen and what can we do to change it? 
(Respondent 6) 
 
A situation such as this serves as a destabilizing distraction to the company 
culture, and might disrupt social order as well as affect technical efficiency.  However, it 
also serves as opportunity to realign the culture through the application of rhetorical 
strategies using framing and supportive historical sources to somewhat control the 
internal and external processes of socialization through “interest-laden discourse” 
(Suddaby & Greenwood, 2005, p. 40).   
 Predictably, the dominant umbrella for rhetorical strategies used by 
pharmaceutical companies revolves around the use of language to build and maintain 
trust; especially, trust in companies as living up to expected roles within healthcare and 
society.  Buzzwords/phrases, as exemplarly symbols of the rhetorical strategies, such 
as authenticity, transparency, walk-the-talk, sustainability, innovation, commitment, 
collaboration, partnership, and leadership, are commonly used to build an aura of trust 
around company intentions and behaviours.  Websites (regardless of the level of 
specific CSR content) and CSR reports were laced with imagery of health and 
happiness, featured the repetitive use of buzzwords, usually accompanied by measured 
supporting evidence (e.g. simple quantitative measurements, employee and stakeholder 
testimonials), and other related phrases regarding company commitments to achieving 
general (e.g. healthcare) and specific (e.g. lowering the rates of one disease) goals, to 
construct and communicate the role and intentions of companies (e.g. we are this, so 
we do this).  Injection of these phrases into the institutional context appears to be 
intended to display that companies are addressing the interests of stakeholders 
(pragmatic legitimacy), while providing evidence for evaluation that they are doing the 
right thing (moral legitimacy). 
The use of historical referencing represents an important rhetorical strategy used 
by respondents and their company websites.  It reflects Blomback and Brunninge’s 
(2009, p. 413-414) seven proposals regarding the role of its usage in the construction of 
corporate identity: 
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1) References to corporate history in marketing communications affect corporate 
brand image among external audiences. 
2) References to events and/or people in the corporation’s past strengthen the 
recognition of a company’s uniqueness. 
3) References to history are a means to leverage on age. 
4) References to company history in corporate communications affect conceptions 
of the firm’s identity held among internal audiences. 
5) References to company history create stability along historical development lines 
that can turn into inertia when external changes create a need for change in the 
firm. 
6) Change in firm becomes more likely when owners and managers selectively 
draw upon historical events that legitimize ideas for change 
7) Change is more likely in forms where owners and managers are able to infuse 
historical events and labels with new meanings.   
 
Respondents routinely used historical references relevant to proposals 3-7 to 
communicate how they perceive their company and its actions.  When the external 
pressures, taken together, were sufficient to create a need and availability for change, 
companies and employees used historical references for legitimacy purposes by making 
it appear to be “a natural extension of the company’s existing core mission” 
(Respondent 22).  Rearticulating historical references and events such as values, 
products, and services by linking them to growing conceptions of CSR serves to 
establish the institutional legitimacy of each.  For example, respondents providing 
stories of a value-laden past made manifest in CSR achievements and leadership 
illustrates an important component of how employees legitimize institutional change by 
retroactively constructing it (similar to that of internalization).  I believe this is done, in 
part, to avoid the need to acknowledge aspects of previous institutions no longer 
considered legitimate by some (e.g. social movements) by constructing an image of 
change as a natural expansion or modification of previous behaviours, while also 
overcoming the impact to employee morale from ethical and legal controversies.  If 
employees are somewhat bound by their institutional logic as they seek to make sense 
of the growing conflict and contestation against it, then it seems reasonable and 
effective to promote a previously unforeseen alternative as understandable using 
historical reflection. 
In addition, historical references are interwoven throughout websites in a similar 
manner to those discussed by respondents.  These references can be further explained 
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by proposals 1-4 (Blomback & Brunninge, 2009, p. 413-414).  Companies actively 
sought to construct a corporate identity with internal and external audiences as a leader 
in addressing relevant concerns and expectations (e.g. expanding conceptions of 
responsibilities), and how its historical actions and behaviours, including age, contribute 
to its continuing commitment to CSR engagement. 
 Therefore, to bridge the perceived requirements of building and maintaining 
pragmatic and moral legitimacy, companies use websites as platforms for rhetorical 
strategies to construct and reinforce an interpreted identity and the roles associated with 
it.  Importantly, companies used four psychological attributes—personnel, 
anthropomorphism, ordinary language, and visual identity—to construct its 
communicated identity (Bromley, 2001, p. 317-319).  While Bromley described these 
attributes as how people construct their impressions of companies, I observed 
companies using these attributes in an attempt, or possibly instinctually, to better 
resonate constructed company identities with internal and external audiences.  First, on 
websites and in CSR reports, each company was discussed using the term ‘we’, the 
first-person, plural personal pronoun.  This term frames companies more as social-
cultural, or human-based organizations that are shaped and driven by its collective 
individuals, thereby creating a social connection for stakeholders and other external 
audiences to better relate to the company.   
Second, companies are described using human attributes (e.g. being driven, 
good, caring, and committed), even though each is a non-human entity.  It is unknown if 
pharmaceutical companies use of this communicative framing has always been the 
norm, but in the current business environment it likely serves to humanize company 
identities, while also reinforcing collective notions associated with the previous attribute.   
Third, the language throughout websites is non-technical, simple, and focuses 
more on social and psychological factors.  The language is obviously intended to reach 
a broad audience that has various levels of education and experience with corporate 
terminology.  Brief explanations of social needs, company responses, and outcomes as 
well as company values, morals, and codes of conduct are just a few examples of how 
the social and psychological elements of the company identities were communicated.  
For example, after selecting a subject heading (e.g. corporate social responsibilities), it 
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is discussed briefly to build a case for why and how something such as the local 
community is supported.  Then, bullet points are used to highlight specific examples and 
measurements of its commitment to that area, which commonly includes the option to 
read more on the topic by accessing a link on the webpage. 
Fourth, the visual identity of each company was deeply rooted in the health 
component of their dual role.  As stated earlier, websites were laced with healthcare 
imagery, which included emphasizing the overall mission or vision of the organization as 
well as support for statements, events, and people detailed.  For example, pictures of 
patients combined with a narrative that describes their experiences, needs and/or 
achievements, reinforce the ‘health’ and ‘care’ elements of company identities.  
Furthermore, to add a personal ‘feel’ to the legitimacy of what companies are doing, 
stories based on employee involvement in a socially responsible behaviour were 
routinely used.  Notably, stories were not restricted to employee engagement in 
company-created programs, but included charitable work outside of the company during 
personal hours. 
Correspondingly, such rhetorical strategies correlate with the framing of 
integrated CSR.  For example, the following are coded examples from websites and 
CSR reports of commonly used rhetorical phrasing within the industry: 
• Commitment to health of patients and communities; 
• Commitment to culture of strong ethics and values; 
• External verification (benchmarks) as evidence of commitment;  
• Historical references to commitment; 
• Transparency to build trust; 
• Importance of collaborations and partnerships with various organizations; 
• Sustainability in environmental, social, and economic areas; 
• Strive for innovation; 
• Understanding of social expectations through stakeholder engagement; 
• Changing industry (e.g. drug development, emerging markets, etc.) 
• Reinforced culture of values that reflects societal expectations; and 
• Evidence of walk-the-talk using social need—response—outcome formula. 
 
Despite the common rhetoric, there is not complete homogeneity in imitations, 
and companies progress at different speeds and directions through institutional change 
(see Section 4.3, p. 184), and so differences in communicated discourse invariably exist 
among companies.  For example, the relational flow of information across each section 
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within websites did vary across companies and regions, with the global/US websites 
having better flow and greater amounts of information overlap than the Canadian 
affiliates.  Furthermore, the Canadian affiliates routinely had far less CSR content than 
their counterparts in the US.  Notably, multiple respondents involved directly in CSR at 
Canadian affiliates stated that they are in process of aligning their communications 
more with their global or US websites.   
The similarities noted above, however, express a mutual understanding of the 
features institutional entrepreneurs used to frame integrated CSR.  The websites and 
CSR reports from companies or affiliates with more traditional CSR strategies had little 
or no usage of the above examples.  I believe that is because the integration of CSR is 
far less discussed and theorized by employees, especially leadership.  The result is 
they do not understand they have yet to subscribe to the dominant framing and, 
therefore, have not imitated the associated rhetorical strategies, albeit imagery of 
healthcare participation was present regardless of the level of CSR engagement.   
Analyzing responses by the respondents and company websites/reports does 
display, however, a progression of understanding that takes the fragmented strategies 
used to address the above areas of rhetoric and synchronizes them by shifting the 
overall business strategy.  Rhetoric first builds legitimacy in the minds of employees and 
stakeholders for each fragment.  These are then leveraged together as a framework for 
further institutionalization toward internalization of integration—a guided process of 
change that uses reinforcement of established legitimacy to promote it as logical and 
viable.   
The external use of rhetorical strategies with websites also provides a basis of 
judgement for employees.  Respondents described walk-the-talk as the main method of 
evaluation to judge the substance of the rhetoric being communicated.  Straddling 
internal and external elements of institutions, respondents believed employees were the 
best judges of whether the company and leadership were actually doing what they said 
they would.   
You completely undermine trust with your workforce if you don’t walk-the-talk.  
Employees will spot very quickly a gap in the external rhetoric and what we are 
actually doing internally. (Respondent 19) 
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To reinforce their rhetorical strategies, companies use guiding values, hiring 
practices, and relational networks in an attempt to saturate commonality of meaning 
across the workforce.  This process appears to cause the snowballing effect with 
employees increasingly sharing in the mutual construction and, therefore, internalization 
of meaning.  The resulting self-replicating behaviours manifest the walk aspect of walk-
the-talk.  Eventually, employees may come to perceive CSR as the way to conduct 
business, eventually turning them into reinforcing ambassadors of this logic: 
I mean our employees need to be aware of what we are doing and we want them 
to be our ambassadors.  And most companies will do that, and not only that, if 
you’re an employee, think about it, if you’re an employee of a company that 
believes in corporate social responsibility wouldn’t you want to work for them. 
(Respondent 16) 
 
Values and their alteration have been already detailed in section 4.2.2 (p. 153), 
highlighting how they can be used to govern behaviour but also retroactively construct 
legitimacy.  Respondents and websites alike discuss the importance of values, how they 
relate to the company/industry’s role in society, and how it is necessary to educate and 
evaluate employees on them.  Values in this scenario are more than just a normative 
construct, and include understanding of regulative boundaries and rationale for 
decision-making—an outline for the institutional logic.  However, this observation is with 
regard to the current glimpse of the pharmaceutical industry and, therefore, may not 
translate retroactively.  The use of values as symbolic vehicles to generate and 
reinforce legitimacy and the rationale for change as a natural extension of historic 
practices and structures could be a new method to reduce conflict and re-solidify social 
order.   
Hiring practices are used as a method to enhance what values are attempting to 
achieve: consensus for, and alignment with, a changing logic.  Some respondents (4,5, 
and 12) were hired, in part, because of their social advocacy backgrounds, and other 
respondents talked about executives at their companies having similar 
experiences/histories.  Furthermore, placing these individuals in positions where they 
are charged with ‘championing’ CSR at the company provides them with the opportunity 
to introduce and monitor conceptions of, and participation in, CSR.  In addition, the 
younger generation of employees, as explained by respondents, want a workplace that 
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is aligned with their values, including a desire to engage in CSR practices.  Current 
hiring practices appear to be a method to inject CSR-minded individuals into the culture 
of the company.  Such hiring practices not only reflect Dacin’s (2002) assertion that new 
members can weaken the adherence to dominant logics, but also that in a period of 
institutional contest they can affect the result of the institutionalization process by 
promoting certain discourses over others.  
Relational networks are used to encourage participation in CSR-related activities 
and exposure to discussions relating to the experiences of others.  Instead of reducing 
access to networks that can cause exposure to elements of different institutions, 
companies promote access to certain ones that are understood as reinforcing the 
institutional direction that company leaders are seeking.  Beyond hiring practices, those 
without CSR-related backgrounds are provided with the opportunity to construct their 
own experiences in social arenas that consist of others engaging in the same activities.  
Volunteering locally and globally, helping to select targets of philanthropy, and lending 
expertise to assist in building health infrastructure in developing and emerging markets 
are a few examples of the CSR practices in which employees are encouraged to 
participate.  This is an example of the purposeful socialization of common meaning 
among individuals.  For example, respondents discussed the personal gratification and 
professional importance of volunteering to serve on the boards/committees of non-profit 
organizations. 
To foster reflection, reduce the degradation of the experience, and share 
experiences, most companies have created global intranet sites.  Some also built chat 
rooms and other electronic venues (arenas of discourse) to post stories and discuss 
their CSR-related experiences within those sites.  It is a process of sustaining and 
sharing socially constructed experiences and meanings, and, in this particular case, 
those experiences and meanings appear to reinforce the goals of company leaders; 
goals that are increasingly aligned with the framing of integrated CSR. 
Overall, what could have been perceived previously as sources of conflict and 
contestation for company institutions, is now being embraced as a source to gain, 
maintain or repair legitimacy (pragmatic, moral, and cognitive), and as a bridge to 
external information that will keep companies prepared and competitive: 
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I mean corporations are increasingly facing more cynical stakeholders and from 
socially responsible investor groups.  I mean at a global level because I know 
that globally we have consultation with stakeholders.  But if you think of some of 
the debacles of the last decade or so with corporate greed front and center, and 
even in the US there are always stories about ethical or lack of ethical 
promotional practices. So, I would certainly say that that has been one of the 
drivers externally, but I think parallel to that there’s sort of the recognition that 
really to ensure long-term success you have to meet the needs of a variety of 
stakeholders. (Respondent 5) 
 
 Instead of maintaining barriers, companies are reinforcing a greater external 
presence because they believe it will provide them with an aligned and motivated 
workforce and the external linkages or sense of connectedness to sources seen as 
important to future success.  As a result, companies hire, educate, encourage, and 
promote opportunities to employees to bring stability and unity around the changing 
institutional logic prioritized as the most critical to attaining their goals. 
 
5.5 Summary of Discussion 
In my discussion, I sought to rearticulate my substantive theory according to 
institutional theory.  Wading through the changing and contested waters of institutional 
theory provided me the necessary insight to understand how my theory articulated its 
more socially constructive elements.  I explained how employees and companies 
construct their identities, the roles they attribute to themselves and others, and how their 
socially constructed realities relate to frames and other actors with which they are 
interacting.  Moreover, I explained how this process translates into the evolution of 
institutions: 
In other words, institutions arise when groups of people come to understand 
some activity in a certain way and that understanding becomes shared across a 
group.  From their perspective, institutions are cognitive constructions and the 
process of institutionalization is a process of social construction. (Phillips & 
Malhotra, 2008 p. 706) 
 
By applying institutional theory, my social context became the institutional context 
in which concerns and expectations, and subsequent influences, of stakeholders are 
translated into institutional pressures.  Beyond reputation and license to operate, 
legitimacy and delegitimacy in three forms—pragmatic, moral, and cognitive—provides 
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context of effect for such pressures.  Combined with wider societal movements and 
changes to technical strategies and efficiencies, uncertainty created the opportunity to 
expose contradictions or failures in the prevailing logic, which, in turn, were leveraged to 
modify those logics and, consequently, practices and structures within the industry.  
Institutional entrepreneurs captured a stream of consciousness through identifying such 
contradictions and failures, and the resulting framing of their innovative theorizations 
was evident in the observed evolution of CSR perspectives (logics).  Mechanisms of 
transmission (coercive, normative, and mimetic) created carriers of circulating ideas and 
meanings of CSR, thereby increasing the legitimacy (pragmatic and moral) and 
justification of its further engagement.  As companies developed common meanings, 
reflected in similarly evolving perspectives, they attempted to reinforce the growing 
cognitive legitimacy of CSR through the purposeful promotion of its related and 
preferred discourses.  As this process occurred, the circulating ideas of CSR legitimized 
the framing of CSR as integrated or a philosophy (logic) for how business should be 
conducted, thereby traditionally loosely coupled practices were, and continue to be, 
altered in response to, and the reinforcement of, the institutionalization of a modified 
logic.   
The evolving role of CSR in the pharmaceutical industry is tied to the preceding 
and concurrent socialization of common meanings regarding the purpose and 
understanding of CSR.  It is no longer just a pragmatic/moral strategy to gain, maintain, 
and repair legitimacy, albeit superficially, using loosely coupled practices and structures.  
Reinforcement though discourse of logical connections and framing has constructed its 
identity as an umbrella business strategy that can universally resonate and create 
greater connectedness with operational locals through customization.  Subsequently, it 
can be used to mitigate risks and uncertainties, and foster a motivated and controlled 
workforce by reinforcing the internalization of desired meanings relating to the role of 
CSR.  By integrating societal conceptions of what is right and how to serve the self-
interest of others in addition to their own, companies capture wider social movements in 
an attempt to find or construct opportunities to enhance the potential for long-term 
success.  If those opportunities mean diverting assets and expertise to address social 
needs, and, in doing so, result in tangible (e.g. market entrance) and intangible (e.g. 
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motivated workforce) returns on these investments, then it will be done, and eventually 
it could become a taken-for-granted way to conduct business.  
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6.  CONCLUSION 
In the introduction of my thesis, I presented the following quotation as a 
progressive definition of CSR: 
CSR blends and harmonizes economic operations with human community’s 
social systems and institutions, creating an organic linkage between business 
and society.  The end goal of this relationship is to achieve a balance between 
the firm’s economic operations and the society’s aspirations and requirements for 
community welfare. (Frederick, 2008, p. 523) 
 
 I selected this definition because it aligns with notions of an interdependent 
relationship among business, government, and the common good that have been 
proposed by philosophers such as Aristotle and economists such as Adam Smith (also 
regarded as a philosopher), Joseph Stiglitz, and George Soros, and social 
commentators/theorists such as John Saul, and Zygmunt Bauman.  Notably, the socio-
economic theories of the latter four focused on the critiques they have made while 
observing the actual effects of the current form of globalization:   
We define globalization as the process of intensification of cross-area and cross-
border social relations between actors from very distant locations, and of growing 
transnational interdependence of economic and social activities. (Scherer and 
Palazzo, 2008, p. 415) 
 
Placing the definition of CSR into the context of globalization—which includes 
growing concerns regarding inequity, market failures, and externalities—it appears to 
balance out and harmonize the relationship between business and society by 
emphasizing flexibility, reflexivity, and responsiveness to contextual pluralities. 
 Although this relationship appears to be symbiotic, it is only one perspective of 
CSR and how it relates to the functioning of society.  For example, some ways the 
perspectives of CSR have been theorized include examining the various forms of 
business cases justifying its engagement (Kurucz et al., 2008), if and why companies 
engage in it implicitly and/or explicitly (Matten & Moon, 2008), and which generations of 
CSR and the complementary codes of ethics are supported in company 
communications (Stohl, Stohl & Popova, 2009).  Furthermore, perspectives are a 
reflection of the range of notions regarding how companies relate to the functioning of 
society, which includes the previously described role of, and relationship among, 
business, government, and the common good.  
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  The dual role of pharmaceutical companies as for-profit health care producers 
and providers have been contextualized and interpreted by groups and individuals 
within and outside companies, resulting in conflict and contestation.  According to the 
literature, ethical and legal controversies involving the actions and behaviours of 
companies have led to degradation of reputation, which is further declining due to 
continuing and compounding controversies.  It has become clear that society interprets 
a role for pharmaceutical companies with greater responsibility to the common good 
than what has been interpreted by observing their recent actions and behaviours (e.g. 
fines, lawsuits, off-label marketing, etc.).   
Interviews with employees of pharmaceutical companies and the examination of 
their company websites and CSR reports provided the internal perspective that was 
missing in the literature.  Summarizing my results, I created a multi-narrative theory that 
constructs the reasoning for why and how the industry engages in CSR.  It features 
evolving CSR perspectives (traditional, expanding, and integrated), what forces are 
driving change (stakeholders) and from where (social context), how changes become 
reinforced and normalized (CDRP), and how it all relates to changing notions of 
business/society relationship (symbiotic continuum).   
To enhance the substantive theory, I re-analyzed it using institutional theory.  
The results of which included greater understanding of the aggregate pressures on 
dominant institutions to change; how contradictions and failures in logics are leveraged 
for change by entrepreneurs; how the subsequent framing and actors actively and 
passively shape and promote changes; how justified and legitimized changes are 
transmitted and imitated; and, how the whole process leads toward institutionalization 
by using discourse as a method to reinforce the probability of attaining and stabilizing its 
cognitive legitimacy.  
Overall, it was observed that the taken-for-grantedness of traditional business 
structures (e.g. industry secretiveness) and methods of conducting business (e.g. 
universal pricing of products) have been publicly contested as irresponsible and even 
harmful in some instances (e.g. legal battles involving patents fro HIV/AIDS drugs in 
South Africa).  Internal and external contestation of, and conflict with, established 
institutions and associated logics of pharmaceutical companies has gained traction to 
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instigate change.  As a result, companies appears to be in transition regarding their 
perspective of their role(s) within a globalized business environment (e.g. transnational 
interdependency and pluralities) and a rapidly changing industry (e.g. patent expiration, 
innovation pipeline issues, and shifting market dynamics).   
One of the main ways changes in perspective and, therefore, institutional logics, 
are reflected and reproducible is in CSR practices and policies of companies, which 
currently appears to be increasingly directed toward merging notions of CSR with both 
the local and global strategies of companies.  Companies are evolving, or changing, 
from a perspective that was can be considered more neo-liberal and equates the 
inherent good of their products (medicines), operating in their own self-interest, and 
obeying the laws and regulations of the nation-states as natural and sufficiently 
responsible, to ones that better understand the globalized socio-political and economic 
environment and the growing conceptions of greater responsibilities attributed to TNCs 
that operate within it.  As this process occurs, CSR strategies are developed on a global 
scale, while also retaining local customization.  Furthermore, the changes in types of 
programs reflects a paradigmatic shift relating to notions of business sustainability, 
leadership, communication, transparency, and, therefore, the determinants of 
legitimacy.  Consequently, at the furthest point of evolution that I observed (i.e. 
integrated), the traditional paradigm of CSR—featuring an economic view of companies 
and an instrumentality view of CSR programs and policies (Scherer & Palazzo, 2008)—
was fading and being replaced by a more socio-economic viewpoint of CSR as the lens 
through which to develop strategies.   
The existence of institutional change and its relative uncertainty both come from 
a similar source: the pluralism existing within the institutional context.  “Institutional 
pluralism is the situation faced by an organization that operates within multiple 
institutional spheres” (Kraatz & Block, 2008, p. 243).  Even though the contextual 
pluralism was previously observed as a reason for ceremonial or loosely coupled 
strategies (Greenwood et al., 2008), in the case of the pharmaceutical industry, it now 
provides not only an opportunity for a comprehensive strategy but significant challenges 
for its success and stability.   
 Operating as a TNC in a globalized world exposes companies to a range of 
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institutional contexts (Djelic & Quack, 2008), with which their own company must 
interact.  So, how do companies hope to achieve legitimacy in each context?  They 
have adopted diverse strategies to minimize the difficulties associated with contextual 
pluralities (Kraatz & Block, 2008).  Global CSR strategies with local customization 
compartmentalize operational pluralities, not only to demonstrate some level of 
institutional alignment (legitimacy for social fitness), but as a method to understand local 
dynamics for opportunistic purposes.  What is interesting about this entire process is 
that as companies respond to forces and the institutional pluralities that are challenging 
their legitimacy, a process of evolution ensues—including subsequent transmission and 
reinforcement (e.g. historical referencing, rhetorical strategies)—whereby successful 
programs and policies are imitated and sometimes further innovated.  However, what 
appears to be a somewhat purposeful side effect of this process is the absorption, and 
subsequent promotion, of societal notions of responsibility and interdependency into the 
contesting logics.  Much of the reinforcement during institutionalization, therefore, is 
necessary to build and maintain pragmatic and moral legitimacy in order to support 
cognitive legitimacy, thereby mitigating the conflict and contestation that originally 
instigated the possibility of change.  By doing so in relation to influential actors (e.g. 
stakeholders, entrepreneurs, and other companies) and in a competitive context that 
places importance on being leaders, there appears to have created a race-to-the-top 
(e.g. reputational legitimacy) in the industry that requires strategic changes (e.g. CSR 
programs and policies), which necessitates paradigmatic modification of logics (e.g. 
traditional to expanded to integrated) that retain some historical elements. 
While it appears that this is a somewhat deterministic path toward integrated 
CSR, the limitations of my study prevented me from making that broad assertion with 
great confidence.  First, what I examined in my study was a moment in the institutional 
change occurring in the pharmaceutical industry.  It did not predate the change, nor is it 
a point where institutionalization has stabilized into a solidified state.  Based on 
interviews and websites alone, I cannot precisely predict the future stability of the path 
toward integration.  I added the possibility of divergence in my substantive theory, and 
the same applies to my discussion because institutions appear to be in a state of flux as 
modifications are contested.  Disruptions (e.g. global economic depression, financial 
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and regulatory difficulties for companies, failed attempts at CSR, etc.) could eliminate 
progress and cause logics to revert to previously stable ones.  Furthermore, the 
substantiveness of programs and policies remains unknown, as it was not evaluated as 
part of this study.  Therefore, I believe my conclusions remain open to modification as a 
theory that is currently exhibiting path-like tendencies but is not deterministic.    
 Second, the process of imitation through translating and editing runs counter to 
the concept that the isomorphic pressures will result in homogeneity.  Analysing 
websites, for example, shows similar progression and use of rhetoric associated with 
movement toward integration.  Nevertheless, it is rhetoric that is aligned with the 
prevailing framing, which itself is designed to provide an umbrella solution to industry 
pressures and uncertainties.  It becomes a superficial image of homogeneity, which 
provides a unified industry front.  Under the surface, differences in histories, 
experiences, employees, products, operational locales, etc., socially construct, through 
bricolage, distinct spheres of culture within each company.   
 
6.1 Areas of Future Research 
Since my research is based on a momentary glimpse into the functioning of the 
pharmaceutical industry, it does not have the temporal scope to assess the stability and 
long-term permanence of the institutionalization of integrated CSR.  As I said in my 
conclusion, although it appears that companies are all on a path toward integration, the 
presence of variables (Section 5.5, p. 291) with the potential to stabilize or destabilize, 
progress or divert institutionalization questions the strength of that assumption.  If I 
cannot confidently assume how this process is going to end, if at all, then an area of 
future research would be to turn my research into a longitudinal study by revisiting the 
respondents and their companies in 5-10 years’ time (assuming they would still be 
available and willing to participate).  It may be possible to identify what variables, if any, 
influenced the institutions and their current direction toward CSR integration.  I believe 
the methodology used in this study would be similarly effective in examining why and 
how companies within the pharmaceutical industry did or did not institutionalize CSR 
integration.   
The extensive content of interviews and, especially, websites provides 
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opportunity for further data analysis.  For instance, this thesis examined CSR at the 
company and industry level using grounded theory and institutional theory, which was 
supported by triangulation between interviews (primary data) and websites/CSR reports 
(secondary data), to determine why and how companies engage in it.  Secondary data 
could be reanalysed using discourse analysis to further analyze the construction and 
function of language in communication strategies and the probable effect it has on 
institutional change.  Furthermore, a longitudinal approach to the analysis of website 
discourse would also be effective, and could identify how discourses change over time, 
if depicted strategies and features are adopted across one or more companies, and how 
it relates to the relative stability of the institutionalization of integrated CSR.  Another 
option would be to use modified content analysis (see Suddaby & Greenwood, 2005) to 
identify and gauge the frequency of rhetorical strategies to shape the framing of CSR 
strategies at different companies.  Companies included in websites and CSR report 
analysis could be expanded for both methods of data analysis because they would not 
be tied to respondent participation and, therefore, there would not be a requirement for 
confidentiality, thereby allowing for company names, products, and examples explicitly. 
An interesting tangent of my work would be to examine CSR within other similarly 
controversial industries.  For example, banking and oil/gas are two industries that 
respondents said are also controversial and have poor reputations similar to that of 
companies in the pharmaceutical industry.  Each of these industries is noted for both 
their integral function within society and the ethical/environmental/social controversies 
that dominate their reputations.  They may lack the inherently ‘good purpose’ like 
companies involved in healthcare, but would still provide further insight into industries 
that could experience similar institutional pressures and how the actors within the social 
context are responding.  I am curious as to why and how they react to these pressures 
and what are the similarities and differences between them and the pharmaceutical 
industry’s current process of institutional change.   
Furthermore, I would like to look at companies considered CSR leaders or 
entrepreneurs who advocate, implicitly and explicitly, the business case for greater 
symbiotic sustainability.  I used the example of Interface Global in the literature review 
(p. 63) as an example of a company that used some of the opportunities created by 
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‘green technology’ to increase company profits while being environmentally sustainable.  
It would be informative to examine the contextual and institutional elements that formed, 
and were leveraged by, Interface’s leadership to construct openness to a logic that, at 
the time, could not be reinforced by empirical evidence.   
Examining the institutional entrepreneurs in other industries brings up another 
important avenue of research to pursue: who and/or what made Company C different 
from the other pharmaceutical companies, and what role did those differences play in 
transforming Company C into an industry leader and advocate for CSR integration.  
Specifically, how its historical foundations and experiences, understandings, leadership, 
workforce, and societal interactions and relationships influence its institutional 
perception of CSR and its role within the industry.  My interview with respondent 19 was 
far too brief to comprehensively examine all of these factors; especially, how they 
interacted to reach outside the traditional industry logics to capture and frame the 
potential opportunities they attribute to integrated CSR.   
I would like to interview employees from throughout the hierarchy and make 
observations of day-to-day activities as a way to immerse myself in the culture of 
Company C.  By doing so, I intend not only to have a hands-on experience, but also to 
create a basis from which to evaluate whether or not they are walking-the-talk.  
Furthermore, I would also like to examine what elements of Company C’s institution 
have been injected into the circulating concepts of CSR within the industry, potentially 
influencing the trajectory of institutionalization at other companies.   
Overall, using grounded theory and institutional theory to examine CSR within 
any industry should prove to be fruitful research; therefore, I believe there is great 
potential for expanding my research into these areas.  The areas I just discussed are 
the most notable, but I remain open to other opportunities and collaborations that might 
emerge in the future.   
 
6.2 Implications of Research 
6.2.1 Implications for the Pharmaceutical Industry  
 My research provides employees of pharmaceutical companies with an 
opportunity to voice their thoughts and enhance their understanding of CSR within the 
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context of the industry.  Specifically, the gaps identified in the literature review displayed 
a ‘battle of perceptions’ between those within and outside the industry (Section 2.3.2, p. 
79).  Instead of encouraging the arguments of either side of this battle, my research has 
clarified a number of contested areas such as the overall healthcare role of the 
pharmaceutical industry and how CSR is changing to play an evermore-important part 
of that role.   
 By using constructivist grounded theory and then institutional theory to analyze 
the previously assumed perspectives of pharmaceutical employees, I identified that 
most have an expanded conception of the industry’s role and attributed responsibilities 
that is proactive and goes beyond the passivity related to the traditional reliance on 
product creation as sufficient CSR.  The amount of employee exposure to areas of 
institutional overlap appears to be making companies more open to external 
conceptions, which is further increased by an economic justification that integrated CSR 
can lead to long-term success.    
 The specific implications my research has for the industry is that it provides an 
overview of circulating ideas of CSR that are being adopted by different companies, 
albeit identities of these companies remain confidential.  Almost as a resource for 
institutional entrepreneurs, my research shows why many actors within the institutional 
context have similar conceptions of how the integration of CSR will be sustainable.  
Therefore, by explaining how CSR is being framed and how that affects others’ 
perceptions, I may actually be furthering its circulation by compiling and communicating 
its many features and the strategies for reinforcing it.  Additionally, respondents and 
other interested industry-related actors might identify my work as providing some level 
of cross-company legitimacy for their CSR perspectives, practices, and structures.  
Notably, the critique of traditional forms of CSR may serve to delegitimize the practices 
and structures of companies engaging in primarily traditional types of CSR (e.g. basic 
philanthropy and volunteering).  
 Overall, my research is a resource for respondents and other employees to 
compare CSR at their companies to my substantive and institutional theories.  However, 
my research did not provide empirical evidence as to whether or not traditional, 
expanded, or integrated CSR has or will be successful according to the framed purpose 
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of each perspective.  
 
6.2.2 Implications for Corporate Social Responsibility Research 
My results and discussion not only depicted how institutional changes are 
altering why and how companies in one industry engage in CSR, but how concepts of 
CSR are evolving as well.  For example, my literature review explained the many 
theories communicating the potential of CSR as a transformative force in business 
(Benett et al., 2009; Googins et al., 2007)—a force that relies on and leverages its 
ability to address the symbiotic needs of both business and society.   
In the pharmaceutical industry, the progression of CSR perspectives resembles 
the historical evolution of CSR (Section 1.2, p. 19).  However, there was a delay in the 
societal circulation of evolving CSR perspectives described in the literature and when 
they took effect in the industry.  It appears external theorization that is reinforced with 
sporadic, if any, practical examples of new forms of CSR does not automatically cause 
immediate adoption by most companies.  For example, this study showed how nearly a 
perfect storm of environmental conditions and uncertainties was required to open up the 
historically stable institutions of companies to alternatives.   
 The concept of a symbiotic balance between societies and business is not new, 
with discussions of it dating back to Aristotle (Mele, 2008).  CSR is the current 
incarnation, or title, of this balance and conveys the growing ideas in the current societal 
context of how to tend to the needs of the business/society relationship.  The same was 
observed with regard to economic policies and how individual self-interest should be 
balanced with the common good (Smith, 1776).  I theorize that when greater levels of 
externalities, and therefore, inequality, coercion, and uncertainty, are created by 
businesses within a society there will be more vocalization and theorization around how 
to improve social responsibilities of companies and how it can improve the performance 
of businesses as well.   
 Overall, my examination of CSR and its socio-organic evolution within the context 
of one industry illustrated a changing global construct that is shaped by the 
transformative and relational theories expressed by individuals and groups.  The 
temporal/spatial differences feeding the growth of this construct reflects the 
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personalized and group processes of bricolage that compile and circulate new and 
recirculate translated and edited ideas; all of which continually influences the social 
constructions of expected roles and responsibilities of business and society.  I theorize 
that CSR is an aspect, albeit an important one, of a larger process of people trying to 
understand their connectedness to each other and the inherent responsibilities attached 
to these relationships.  Similar to the ‘corporate’ attachment to ‘social responsibility’, 
‘government’ can be used to create GSR because I believe the foundational argument 
of ‘SR’ is to advocate that the individuals and groups with power and control over others 
should use such positions of power in a more symbiotic way.   
Therefore, my main contribution to CSR research is that I perceive SR as 
symbiotic responsibility, and its varying formations comprise the expectations for those 
with the capabilities to influence or shape the symbiotic interdependency, to do so 
responsibly and beyond their own self-interest.  In other words, the groups 
(corporations, government, NGOs, etc.) and individuals (religious leaders, billionaires, 
etc.) with the resources and capabilities to leverage the inherent interdependency within 
societies should be responsible in how they use such power, and even further, how it 
can be used to improve the common good.  The push for integrating such 
responsibilities is about moving modern economic institutions away from conceiving 
responsibilities to the common good as satisfied simply through the operation of a 
business (shareholder perspective), to one that acknowledges a symbiotic relationship 
(stakeholder perspective) and cognitively embeds how to leverage opportunities for 
mutual benefit into the core business strategy (institutionalized logic of integrated CSR).      
  
6.2.3 Implications for Grounded Theory Research 
Grounded theory, much like institutional theory, has been pulled in many 
directions, although mostly on epistemological grounds.  Originating as more positivist 
(Glaser and Strauss, 1967), grounded theory has branched off into post-positivist 
(Strauss & Corbin, 1998) and constructivist approaches (Charmaz, 2005).  The latter I 
selected as the main foundation of my methodology, but I included aspects from other 
grounded theorists as well (Strauss & Corbin, 1998; McCann & Clark, 2003a; Suddaby, 
2006), to round out the specifics of my methods.  In doing so, I attempted to stay faithful 
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to my methodology and not try to ‘reinvent the wheel’.  Therefore, my use of grounded 
theory maintained such faithfulness until the end of my results section.    
However, in attempting to validate my theory by comparing its areas of overlap 
with other theories, I identified how it could be further modified and articulated using 
institutional theory (implications of which follow), and vice versa.  As a result, the main 
implication for grounded theory from my work was to illustrate its capabilities in 
providing creativity to enhance the clarity and scope of other theoretical frameworks 
used to explain social phenomena.   
Grounded theory as a methodology was used to construct a substantive theory, 
which in itself is informative, novel, and useful.  Nevertheless, the potential of the 
substantive theory can provide additional theoretical insight into, or verification of, 
conclusions made by other theories.  If institutional theory is comprised of an array of 
substantive theories that are pieced together by scholars to explain its foundational and 
specific elements, then grounded theory provides some of the substantive theories that 
are supported by empirical evidence to enhance the framework of such meta-theories.  
In general, this process is not perfect, obviously, and it has resulted in some 
fragmentation and divergence within institutional theory.   
 
6.2.4 Implications for Institutional Theory Research 
 As was just discussed, institutional theory provided a valuable framework to re-
analyze my substantive theory; but to do so I had to examine its theoretical 
underpinnings.  My research into its history revealed a lot of similarity to the ongoing 
theoretical struggles among grounded theorists.  For example, some research pathways 
like isomorphism became overly focused on proving a single outcome, similarity, rather 
than why differences occur (Greenwood et al., 2008).  Additionally, there have been 
many differences of opinion regarding its foundational elements; especially since the 
backgrounds of those researching in the area varied (e.g. resource dependency theory, 
organizational ecology, etc.).   
Scott (2008) attempted to group the foundational elements of institutional theory 
into three pillars: regulative, normative, and cultural-cognitive.  A stream of relation is 
observable throughout institutional research regarding these pillars.  For example, the 
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three types of legitimacy (pragmatic, moral, and cognitive) and the mechanisms of 
transmission (coercive, normative, and mimetic) each can be interpreted as relating to 
one of the pillars, respectively.  Even the definition of institutional logics (p. 241) is 
comprised of concepts from each of the three pillars.  However, since institutions are 
thought of as primarily cognitive (Suchman, 1995; Suddaby & Greenwood, 2005), then 
questions arise regarding the other two pillars: regulative and normative.   
Furthermore, theorizing about the relative weight of each pillar in building, 
maintaining, and changing institutions is a matter of great debate.  One theory is that 
when practices or structures become cognitively embedded there is virtually no 
necessity for the presence of regulatory frameworks and normative evaluations because 
there is no need for reflection when each has become taken-for-granted within a 
cognitive framework (Hirsch, 1997).  However, I must contest that I perceived some 
relation among types of legitimacy because as the framing of an innovation is 
contested, building and maintaining its pragmatic and moral legitimacy appears to be 
crucial in whether it is successful in dislodging or modifying the dominant logic.  Such 
legitimacy may prop-up an innovation, or solution, as it goes through the 
institutionalization process where cognitive legitimacy is strengthened to a point of 
taken-for-grantedness.   
 I believe that institutionalization is a continual process because of the differences 
among individuals within an organization.  The pluralistic environments within (e.g. 
diverse workforce) and external (e.g. transnational operations) to institutions make it 
nearly impossible to operate in isolation or have members universally and completely 
adhere to preferred institutional logics, which of course allows for the possibility of 
change.   
 Upon writing my discussion and conclusions, I identified the constructivist stream 
of research that has heavily contributed to the organization-based branch of institutional 
theory.  Some prominent examples include how employees relate to, and interact with, 
their social worlds; how those same relationships influence and reinforce institutional 
logics, changing or stable; how circulating ideas are translated, edited, and imitated; 
how the increasing circulation of ideas enhances their memetic features for further 
transmission; and the power of framing and types of discourse to shape and direct 
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institutional change.  Notably, Berger and Luckmann’s (1967) three phases in the 
construction of common meaning present a great foundation for how institutional 
change can occur through socialization, including, in the case of the pharmaceutical 
industry, how it can be directed toward preferred ends.  Furthermore, it sheds light on 
the power of language and discourse in building, maintaining, and discrediting 
institutions (Phillips & Malhotra, 2008; Phillips, Lawrence & Hardy, 2004; Suddaby & 
Greenwood, 2005).  Overall, I think that this area of institutional theory should receive 
greater attention in the future.   
In the end, I found that using institutional theory as a lens to interpret my 
substantive theory highlights its effectiveness as a constructivist research tool to better 
explain the micro and macro social processes and interactions constructing 
phenomena.   
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Appendix A   
 
Instrument – Interview Guide (Version 1) 
 
Initial Open-ended Questions focusing on collective practices 
 
• Briefly describe the CSR activities your company is involved in. 
o Probe: Ask influences of scope and size of CSR activities. 
 
• How does your company decide on where to focus its CSR programs? 
o Probe: Ask about their exclusion/inclusion criteria. 
 
• What outside pressures do you see as influencing your company’s decisions 
regarding CSR? 
o How do you see these pressures affecting companies in other industries? 
o Probe: Is the pharmaceutical unique in regard to these pressures? 
 
• How has the condition of the global economy affected your company’s CSR? 
o Probe: Look into links of whether financial motivations are tied into CSR 
motivations. 
 
• What are your company’s reasons for engaging in CSR? 
o Probe: Look into whether differences exist between the participant and 
there company. 
 
• Describe the results that you have attained from engaging in CSR? 
o How do these results benefit your company? 
o Probe: Ask about financial, reputational, and moral benefits. 
 
• Describe any limits placed on current or potential CSR programs? 
o Probe: Ask if lack of benefits is justifiable. 
 
• What positive change(s) to your company’s CSR have you observed? 
 
• What negative change(s) to your company’s CSR have you observed? 
o Probe: Ask for details and reasoning for answers to both questions. 
 
• What are the values of your company? 
o Probe: Look into differences between the participant and their company. 
 
• How have your company’s values changed or remained constant? 
o Probe: Ask for explicit examples, reasoning for each possible answer, and 
if CSR is a factor. 
 
• How do you see the values of your company relating to your CSR programs? 
o Probe: Is it the same relationship with all programs and policies? 
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Intermediate Questions focusing on the Individual’s participation and views 
 
• How do you define CSR? 
o Probe: Look into whether similarities or differences occur between 
participant and their company. 
 
• Thinking about a CSR program or event that you have had experience with, 
describe what your involvement was and how you felt about it. 
o Probe: Look into their motivations for involvement and what benefits they 
took away from the experience. 
 
• How does your position in the company shape the experience you have with 
CSR? 
o Probe: Look into whether similarities or differences occur between 
participant and other positions in the company. 
 
• How have your feelings about CSR changed since taking your position with the 
company? 
o Probe: Look into the specific influences for the change. 
 
• In what ways have you watched CSR evolve in its use by your company? 
o Probe: Ask if the evolution has been positive or negative. 
 
Ending Questions 
 
• Is there anything that you might not have thought about before that occurred to 
you during this interview? 
 
• Is there anything you think I should know to understand CSR and/or values at 
your company better? 
 
 
• Is there anything that you would like to ask me? 
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Instrument – Interview Guide (Version 2) 
 
Initial Open-ended Questions focusing on collective practices 
 
• How do you define CSR? 
o Probe: What actions and behaviours do you see representing CSR? 
o Probe: How does your company define CSR? 
 
• Who or even what inside your company pushes or drives CSR? 
o Probe: How do they push, drive or influence CSR? 
o Probe: What other areas do they influence? 
 
• What pressures outside of your company affect your CSR decisions? 
o Probe: How does stakeholder needs come into play? 
o Probe: Are these pressures unique to the pharmaceutical industry? Why 
or why not? 
 
• What motivates your company to engage in CSR? 
o Probe: How did these motivations develop? 
o Probe: How do or don’t you relate to these motivations? 
 
• How does your company decide on where to focus its CSR programs? 
o Probe: How did you develop your exclusion/inclusion criteria? 
 
• Describe any size or scope limits placed on current or potential CSR programs? 
o Probe: How are limits determined? 
o Probe: What is the reason for limits? Are there special circumstances? 
o Probe: How would it be justified if there were no benefits? 
 
• What have you achieved from engaging in CSR? 
o Probe: How do these results benefit your company? 
o Probe: How do you recognize results? 
o Probe: How do you measure results? 
o Probe: What role does reporting play for CSR? 
 
• If you are going to create or engage in a new CSR program or policy, what things 
need to happen or be accounted for it to be successful? 
o Probe: What factors contribute to a successful CSR venture? 
 
• What importance does authenticity of CSR have on people’s perception internally 
and externally of the company when engaging in CSR? 
o Probe: Are there methods to try to ensure authenticity? 
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o Probe: Are there any difficulties with scepticism around authenticity? 
 
• Describe how it might or might not be necessary to differentiate your CSR 
programs and policies from other companies? 
o Probe: How about from other pharmaceutical companies? 
 
• What are the values of your company? 
o Probe: How do your values line-up with your company’s? 
o Probe: Since starting with the company, how have you observed your 
company’s values changing or remaining constant? 
o Probe: Ask for explicit examples, reasoning for each possible answer, and 
if CSR is a factor. 
 
• How do you see the values of your company relating to your CSR programs? 
o Probe: Is it the same relationship with all programs and policies? 
 
• Describe how ethics may or may not interact with CSR goals, programs, policies 
etc. 
 
Intermediate Questions focusing on the Individual’s participation and views 
 
• How have you been personally been involved in a CSR program or policy? 
o Probe: What kind of experience did you take away from it? 
o Probe: What were your motivations for becoming involved? 
 
• In what ways have you watched CSR evolve in its use by your company? 
o Probe: Where do you think CSR at your company is heading? In general? 
o Probe: Do you see its evolution being tied to the industry’s desire to 
constantly innovate? 
 
Ending Questions 
 
• Is there anything that you might not have thought about before that occurred to 
you during this interview? 
 
• Is there anything you think I should know to understand CSR and/or values at 
your company better? 
 
• Is there anything that you would like to ask me? 
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Instrument – Interview Guide (Version 3) 
 
Initial Open-ended Questions focusing on collective practices 
 
• How do you define CSR? 
o Probe: Does the definition vary by region – for example – Canada and the 
US? 
 
• Internally, where does the drive for CR come from? 
o Probe: How necessary is it for regional personnel to drive it in their 
corresponding regions? 
 
• Externally, what pressures your company in regard to CR strategy development? 
o Probe: How does stakeholder needs come into play? 
o Probe: Are these pressures unique to the pharmaceutical industry? Why 
or why not? 
 
• What motivates your company to engage in CSR? 
o Probe: How did these motivations develop? 
o Probe: How do or don’t you relate to these motivations? 
 
• How is the global CR strategy customized in different regions – the US for 
example? 
o Probe: Is there a delay in the adoption and implementation of the global 
CR strategy in differing regions? 
 
• How does your company decide on where to focus its CSR programs in a region 
like the US? 
o Probe: How did you develop your exclusion/inclusion criteria? 
 
• When designing a global CR strategy, how do you prioritize what will get funded 
in a region like the US over a region like Canada?  Do the regions decide off of a 
framework? 
 
• What have you achieved from engaging in CSR globally and in a more micro 
example –the US? 
o Probe: How do these results benefit your company? 
o Probe: How do you recognize results? 
o Probe: How do you measure results? 
o Probe: What role does reporting play for CSR? 
 
• What are the required factors needed to ensure a CR strategy like yours is 
effective? 
 
• What importance does authenticity of CSR have on people’s perception internally 
and externally of the company when engaging in CSR? 
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o Probe: How do you ensure the transmission of such authenticity from the 
global to the regional level-US as an example 
o Probe: Are there any difficulties with scepticism around authenticity? 
 
• Describe how it might or might not be necessary to differentiate your CSR 
programs and policies from other companies? 
o Probe: How about from other pharmaceutical companies? 
 
• What are the values of your company?  Do they vary across regions? 
o Probe: How does your values line-up with your company’s? 
o Probe: Since starting with the company, how have you observed your 
company’s values changing or remaining constant? 
o Probe: Ask for explicit examples, reasoning for each possible answer, and 
if CSR is a factor. 
 
• How do you see the values of your company relating to your CSR programs? 
o Probe: Is it the same relationship with all programs and policies? 
 
• Describe how ethics may or may not interact with CSR goals, programs, policies 
etc. 
 
• In what ways have you watched CSR evolve in its use by your company? 
o Probe: Where do you think CSR at your company is heading? In general? 
o Probe: Do you see its evolution being tied to the industry’s desire to 
constantly innovate? 
 
Ending Questions 
 
• Is there anything that you might not have thought about before that occurred to 
you during this interview? 
 
• Is there anything you think I should know to understand CSR and/or values at 
your company better? 
 
• Is there anything that you would like to ask me? 
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Appendix B  
 
Memo #16 – Focusing/evolution of CSR 
 
The history of the focusing of CSR seems tied to its evolution in the company of the first 
interview.  The interviewee stated that the original approach to CSR was a ‘Shotgun 
Approach’ and it may have worked at first but as the company grew to a substantial 
larger size more requests for donations grew exponentially.  The company is concerned 
with their image and the owners have a desire and expectation of participatory and 
effective CSR.  The combination of the motivations and the recognition that followed 
created more groups wanting a share of their CSR efforts.  It quickly become far to time 
and money consuming to try and fulfill each request.  Additionally, the amount of 
employee requests increased with more employees and increased participation in their 
local communities.  When the overwhelming requests became too much, the shotgun 
approach was most likely to spread out causing an over-distribution of CSR that was 
more superficial because of its inability to help to a desired effect.  It consumed too 
many resources while being incapable of having the desired impact set-out by the 
owners/executives.   
 
The only way to resolve the lack of focus was to sit down and strategize the best 
framework of guidelines that would address both the needs of the company and 
designated CSR targets.  They had to go from a shotgun approach to more of a ‘rifle 
approach’ where by narrowing down the targets it will have a deeper impact.  In 
essence these guidelines lay-out the exclusion/inclusion criteria needed to focus the 
targets of CSR to maximize the effect while reducing inefficiencies.   It is clear how the 
exclusion/inclusion criteria are applied to the community perspective of CSR but it is not 
clear how it would be for business and healthcare.  Obviously they must have 
restrictions on drug access because they cannot sustain free and total access to drugs 
but it was unclear in regard to ‘mortar and brick’ work in regard to pharmacy colleges.  
(This part would need to be examined further).  And although interviewee commented 
about the integration of perceived Canadian values into their CSR, there community 
programs are only local and not national – limited to operation areas and employee 
areas of residence.   
 
It has to be questioned whether the focus of CSR can only be attributed to the 
limitations presented by overwhelming requests and increasing expectations.  Could it 
be that as the company grew and CSR become international more prominent that the 
company realized the business case for CSR required a complex strategy with certain 
guidelines in place to ensure it works as expected?  The evolution of CSR itself may 
have a role in the focusing of programs.  Identifying how other companies can use it to 
their advantage while still ensuring the fulfill obligations or responsibility to society.  
Basically, how they can satisfy the ever-changing expectations tied to a license to 
operate which is coincidently tied to image and perception as well.  The companies are 
increasingly expected to fulfill new responsibilities related to the external costs of their 
operation and not satisfying these requirements can cause backlash from both society 
and government (i.e. new regulation).  Focusing and strategizing CSR can, for example, 
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stave off or prevent the introduction of mandatory CSR regulation, which currently does 
not exist. 
 
Finally, focusing of CSR is better for perception because a ‘shotgun approach’ can be 
attributed to a lack of planning and even effort in CSR programs and policies.  A strong 
strategy gives the perception that it is being taken seriously and has become an integral 
and everyday part of business operations.   
 
 
Memo #49 – Influence of personal perception and job locations within company 
 
Similar to other interviewees (add in Val), interviewee 12 seems to have a noticeably 
different view of CSR in their respective company in comparison to those who are 
directly involved in the decision-making of CSR.  Interviewee is more on the periphery of 
the company with a regional manager position and the distance from the country 
headquarters seems to result in a couple tendencies – Avoidance of detailing 
company perception, less perception of negative features to CSR, doesn’t view 
pressures to engage in CSR, and promotes CSR as inherent to pharma.  I think 
that a distinct separation in level of communication and understanding of CSR 
according to position in the company has substantial effect on their perceptions and 
tendencies.  Field positions are, as their title states, distanced from the main operations 
of the company and I think this may have dramatic effects on their perceptions – it adds 
uncertainty as to policies and what is acceptable to say.  Their limited information about 
corporate perspectives and sometimes policies makes them err on the side of caution 
and provide more what they view as pro industry comments.  For instance interviewee 
12 talked about: Cannot perceive anything negative about CSR, does not perceive 
requests as pressures, hesitant to call CSR a requirement – natural instead, 
pharma culture inherent to give back – second nature.  It almost appears as 
answers from a communications department that are trying to positively portray CSR.  
However, it becomes clear that their perceptions vary somewhat from these comments 
because of a number of contradictions to the previous areas of discussion: 
Controversy can block some CSR, CSR has reputational benefits, Unaware of 
CSR achievements and motivations (although list a number of them), 
understands controversial nature of some philanthropy.  Additionally, interviewee 
12 stated that they don’t see pressure to engage in CSR but also states that CSR 
emerged from HIV crisis in Africa, there are far too many requests to satisfy, pharma is 
unjustly portrayed in the media and CSR doesn’t get enough credit etc.  The unfair 
portrayal or reputation of the industry came up numerous times.  It appears that 
being located inside the CSR prioritized department grants knowledge on those 
personnel and they become more candid because of their greater knowledge of CSR 
strategy at the company.  In contrast, those away from the CSR prioritized department 
that are also lower in positional rank are exposed to CSR in a less comprehensive way 
that makes them hesitant or unable to create the links between topics that CSR 
inclusive employees have.  Their perceptions alters to include hesitancy on topics as to 
create a more pharma-centric view of CSR but contradictory statements reveals the 
altered perception, whether they know it or not.   
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It is also interesting that interviewee (12), similar to others, see the field employees are 
the eyes and ears of the organization.  They appear to be one of the main vehicles of 
the company to identify the needs of stakeholders and others and then begin the 
filtering process to decide CSR engagement targets of philanthropy.  It seems their 
roles are mostly relegated to philanthropy and volunteering with higher level CSR 
strategies being designed more at the country headquarter level.  They act as 
ambassadors to help identify needs or opportunities in their respective area.  However, 
the communications of CSR strategy appear to be disconnected to these employees 
and you have to wonder if they would be more effective if they had a better 
understanding of CSR at the company; ineffective CSR strategy transmission means it 
has to be less prioritized at the company.  For example the interviewee (12) stated they 
could not comment or were unaware of multiple topics discussed.  Maybe this 
disconnect is why companies infused corporate responsibilities into their main strategy 
rather than push CSR as a separate thread of strategy – create a culture over a 
strategy.   
 
 
Memo #66 – The influence of drivers on strategy to realize the anticipated benefits 
 
The drivers of CSR represent a mix of external and internal pressures placed on the 
company that later become translated into motivations that seek some form of benefit 
from fulfilling the opportunities that drivers present, whether it be risk management, 
synergistic programs, moral obligation etc.  Interviewee brings another perspective onto 
what drivers are pushing the industry towards further CSR.  The most basic but maybe 
also most important driver is that CSR has become universally important.  Since it 
has reached this stage, it becomes an obvious priority for managers because when 
anything becomes that important there has to be a litany of opportunities and even risks 
associated with either embracing or ignoring it.  Interviewee discussed a lot about the 
association of CSR and managing risks because, at least in part, controversies 
create some of the CSR priorities as a reaction to realized risk.  Risk matrices are 
actually developed to try and map out possible risks, if they are being neutralized or 
avoided, and if any opportunities exist within the risks.  Other risks are associated or 
maybe categorized as matter of a license to operate – the company has to satisfy some 
external and internal parties expectations to be granted a intangible ‘license to operate’.  
Externally, there are numerous group and individuals within the complex social context 
(regs, stakes, social), and interviewee states a big part of license to operate on the 
micro scale is with community expectations.  If the company is going to be part of a 
community and have the ability to operate freely there then they have be compliant with 
laws, regulation and some level of the normative views of the region.  Additionally, since 
these other two parties are brought up repeatedly throughout the interviews, 
government and patients represent two other significant groups that heavily weigh on 
the license to operate of the company.  Internally, employees are seen as significant 
drivers of CSR.  The new generation of employees is more demanding of CSR type 
attributes within the company that they work for.  They desire a workplace or company 
that embraces normative concepts like work-life balance and opportunities to actively 
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engage and even help design CSR programs and policies.  Basically, they want to be 
part of a company that they can be morally proud to work for.  And this appears to 
include the top of the organization as well because the top level drives CSR and 
desire for it to become part of the company’s DNA.  Additionally, the top driving 
CSR incentives and makes employees proud, so walk the talk at the top is vital to 
CSR for employees to endorse it and for the company to embrace it.  So what happens 
is that both the top and bottom are driving CSR and they meet in the middle – 
where CSR is created.   
 
What is unknown is the old chicken and the egg idea with drivers and benefits – were 
the benefits there before the drivers or vice versa?  Or have they evolved hand in hand 
over the years; as drivers become bigger and more articulated the availability of benefits 
from the process of satisfying drivers increased and became for apparent.   
 
The in discussing the benefits of engaging in CSR with interviewees it is common that 
more generalized benefits are provided and not very specific ones – could be related to 
the difficulty to measure CSR.  None of the drivers completely state that they will benefit 
the financial performance of the company, which does reflects the literature on the 
subject.  Interviewee thinks that the best way to maximize benefits of CSR is to achieve 
CSR goals that are win-win and there are multiple TBL advantages to local 
production.  This view reflects movement towards a CSR philosophy that utilizes 
synergistic value creation.  And this entails combo CSR strategies in regions to 
boost benefits with a goal to create social-economic combo benefits.  The 
interviewee understands and wishes to use the opportunities that reside in the concept 
that there are layers of internal and external benefits that stem from CSR.  The 
layers of benefits combine or add to the use of CSR to boost the business-society 
bond, which makes sense because if the bond is strengthened between the two it can 
be assumed that whatever benefits will in turn benefit the other, and that can lead to 
exponential increase for both over time.     
 
Another substantial area that was discussed with regard to the benefits is the idea of 
risk management.  I think this really reflects the idea that CSR can create a better, 
external perspective or mindset for the company and it results in more effective 
scans and identification of both risks and opportunities.  So CSR can protect 
against problems for the company.  This can definitely be linked back into the idea of 
a guiding CSR philosophy where all employees become reinforced with proper, 
responsible actions and behaviours.  What could be better than an almost hive mindset 
that instinctively protects against problems/controversies while promoting the corporate 
responsibilities with every action and behaviour.  And interviewee 16 even states that 
they desire ambassador program to manifest through all employee actions and 
behaviours.  So the priority of the interviewee (16) is to consult with various 
departments to find best methods of CSR to create a business case.   
 
Additional benefits from engaging in CSR reflect the satisfying the new generation of 
employees and that through effective CSR the company is more competitive to recruit 
and retain employees because of the added satisfaction of working for a company that 
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has embraced a solid CSR plan.  What is unknown is if the same incentive exists for 
higher up or top level employees – do they want to work at companies where CSR is a 
priority of business strategy?   
 
One benefit that may actually be connected to the financial performance of the company 
and CSR is that CSR competition manifests itself in the DJSI.  So if the company is 
perceived to be more CSR able they may rank higher on the DJSI index which would 
attract more TBL investors.  Now the index isn’t that huge right now but if it grows it 
holds a lot of potential to raise the incentive to better engage in CSR.  The combination 
of benchmarking for the index and other indexes like ATMI maybe the financial and 
competition incentive to better promote CSR.  Since it is extremely difficult to measure 
the social effects of CSR, then maybe by linking the indexes to investing potential will 
finally link CSR to the financial performance of the company somewhat.   
 
The partnerships and relationships appear to be what benefits the most from effectively 
engaging in CSR, especially if it is better merged with the overall business strategy of 
the company.  Of course, enhancing partnerships and relationships is tied to the license 
to operate (externally and internally).  Being open and transparent is the key to a 
healthy and trusting relationship, and from this the battle of perceptions can be best 
neutralized.  Additionally, partnerships bring proximity to targets and this will 
influence the mindset of those involved.  Employees, presumably, will become more 
motivated to engage in CSR and targets perceptions of the company will be more 
positive – win-win.   
 
 
Use healthcare as bridge to benefits as motivation.  Not to say the company did not 
already has these motivations but they were enhanced or highlighted by the drivers 
(think conceptual diagram) 
 
 
Memo #69 – Some thoughts about CSR philosophy 
 
Through the development of a strategy to implement a business case application of 
CSR at any company a philosophy or perspective has to emerge to incentives the 
process.  This philosophy is not the same for each and every company nor would it be 
the same across employees and departments of an organization.  It has become clear 
the variance in perspective of CR varies greatly with proximity to the development of 
strategies.  Being exposed to the implementations does not garnering the same 
perspective as being part of the strategy development.  In this fact, is where the gap 
exists in the CSR philosophy being a mindset across the company and the cultural 
change necessary to accomplish this task.  That is why, most likely at least, that when 
CR is purposely merged with the overall business strategy it resonates more with all 
employees, unifying around a common point – the corporation’s overall business 
strategy.  Common ground for unifying their perspectives is an integral part of the 
process but the CSR philosophy is constructed from experience and proximity to CSR 
itself.  So, all employees need to be encouraged and reinforced to engage in CSR 
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activities to gain first-hand a perspective of its purpose and potential benefits.  That 
means proper allocation of resources, organization and communications are necessary 
to bring a unified perspective to thousands of employees. The true example of a unified 
CSR philosophy would be in the majority of employees becoming manifestations of the 
CR/business strategies by being authentic ambassadors of the goals and values of the 
organization in all of their actions and behaviours with those internal to the company 
and externally in society or with stakeholders etc.  If employees become such 
ambassadors it reinforces CSR throughout the organization and the business should 
naturally becomes responsible in all its actions because all employees are aware their 
normative responsibilities.   
 
 
Memo #84 -- The role of values 
 
Trying to pinpoint the exact articulation of values is difficult because all the interviewees 
that are from companies with enhanced CSR (stage 2 or 3) discuss the importance and 
link between CSR and values.  Now the values are not only there as a link to CSR but 
also as a framework to guide the decision-making of the business.  As discussed from 
interview 19, the company which has the most evolved CSR, the reinforcement and 
adoption of values is integral to the development of a value-based management system 
at the company.  As companies move towards more evolved CSR, then are they also 
moving away from a rules-based company to value-based.  The previous rules-based 
management system did not work for the pharmaceutical industry, and this can be 
observed in how their reputations have continued to drop.   
 
Value statements have been observed at every company and they all have been 
present in those companies for extended periods of time, usually since the beginning of 
the company.  But it may not have been until the values were so well manifested via 
CSR that a value-based decision-making process could be realized.  The past 
controversies show that the value statement of the organization was not well embedded 
into the mindset of all the employees.  To cope, companies created more rules, but 
rules create red tape and may not curb the behaviour (‘crime’ goes up).  The movement 
towards more CSR created a pathway to manifest the values in the company in 
initiatives.  Slowly, the values are manifested through an evolving CSR strategy.  Once 
the strategy reaches the end of stage 2 to the beginning of stage 3, it starts becoming 
more integrated into the business strategy.  Interviewee 19’s company showed this 
process well, while interviewee 20’s company is on the cusp of taking the step towards 
where company 19 currently resides.  As CSr and the overall business strategy become 
one and the same, the values are echoed and reinforced through every action and 
behaviour of the company.  Values not become succinct with the overall strategy of the 
business – for the first time ever.  So the process of moving CSR into the business 
strategy allows the company or is the necessary process for companies to become 
value-based organizations; which, notably, is also more successful for organizations.  
The size and scope of MNCs makes the value-based process incredibly complex.  CSR 
maybe the best method to inject values into the overall mindset of the organizations and 
have employees rally around their business strategy with is synonymous with their CSR 
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strategy and its manifested values.  
 
 
Memo #89 – CSR strategy, benefits/drivers, employees/values and the CIP 
process 
 
The strategy or purpose for CSR at interviewee 22’s company is similar to the ideas put 
forth from interviewee 21 – a very idealistic approach to CSR.  The moral inclination to 
use the abilities of the pharmaceutical industry is the very strategy for the 
pharmaceutical industry – the benefits and drivers are fuelled by the moral obligation to 
engage in CSR and then the strategy is based off these principles (or at least 
communicated to the employees that way).  So, we will look at the benefits and drivers, 
how they develop into the CSR strategy and how the development of the CIP occurs in 
progress. 
 
22 views CSR as a fair expectation of the public because they feel that there is a 
higher purpose attached to the healthcare industry and it has inherent 
responsibilities attached to it.  As described in earlier memos, there is thinking 
amongst pharmaceutical employees that their industry is not like other industries, that it 
is more important in the sense that it has a higher level of responsibilities because it has 
the capabilities to help so many people through their products and actions.  Because 
CSR helps people’s lives and is therefore self-fulfilling, it becomes a natural driver 
with employees who share the same values.  The interviewee explained that although 
the industry has an image problem, CSR should was not birthed from a public image 
crisis but it does have a role to play in regaining public confidence, which will 
help mitigate industry backlash.  The inherent link between the healthcare industry 
and CSR creates a motivation for public health and therefore CSR is a natural 
extension or maybe expression of this.   
 
The values of the company are expected to be manifested in the actions and 
behaviours of employees.  The values set out intangible guidelines that are suppose to 
influence the company and kind of rudder them through their operations as guide posts 
towards being a successful and sustainable organization.  IF values are not properly 
reinforced from all levels and continually updated through better articulation to reflect 
the times, then the values may just become a figure-head motto of sorts that is not 
really all that authentic.  The values associated with operating in the healthcare system 
should translate or resonate with current and recruited employees. Interviewee 22 
discusses this in depth and really paints an idealistic picture for employees - All 
employees drawn to company for mission, All levels of employees agree CSR is 
important, Employees know-resonate values, Employees beleive working for 
bigger cause - manifested CSR, and Most employees understand CSR in fabric of 
company.  The interviewee really tries to emphasize that the organization is very much 
like a family and it shares and embraces the values which originated with the founding 
of the company and its original leaders.  What employees also embrace is the concept 
that they are working for a company that is part of the healthcare industry and it has a 
more significant role to play in society – it can directly impact the health of citizens.  The 
 
 
297 
company’s assets and expertise put them in a unique position to be able to have 
substantial impact on the health of citizens in more ways than just innovating and 
providing pharmaceuticals.  As a result, the values the company was founded on are 
representative of their perceived, enhanced role in maintaining or helping the health of 
society – not only do they have a duty to innovate and produce pharmaceuticals but 
they also have to do it in a responsible way.   When it comes to recruitment, the 
company looks to hire employees to drive CSR; they want employees that already 
express the values the company holds dear.  And this falls in line with the expectations 
of the younger generation of employees - Younger gen big sense of purpose and 
Younger gen. wants legacy building.  To be able to recruit the employees with not 
only the best talent but also ones that attune to the values of the company, they need to 
engage in authentic CSR to be considered as a suitable employer.  Employees have to 
be empowered to access and participate in CSR, have some routes to partake in its 
directions, and be privy to see the outcomes that are occurring from it.  For this the 
company can be successful at their goal of hiring those with a mindset that is 
congruent with the corporate mission.  The employees’ engagement in CSR is 
evidence of them living the values of the company and is a measurable area to 
identify if employees do in fact share a similar value-infused mindset.  The values 
of the company appear to be the stitching of the company that holds all these aspects 
together, while CSR is a natural extension of the values that are based on those 
inherent to the business orientation of this industry.   
 
There are a number of benefits for the company’s in terms of employees that spawn 
from properly engaging in CSR (these benefits can vary according the perception of 
appropriate CSR by each employee).  The business case for CSR emerges in overt 
examples but also more intangible ways.  For example, while engaging in CSR in an 
emerging market the company may be able to visibly enhance the healthcare 
infrastructure of the area (which may be measurable).  On the other hand, by engaging 
in CSR the company and its employees can a better external perspective with their 
proximity to the initiatives and communications about CSR - Benefits created from 
external perspective - personal 
External perspective-consecutiveness from CSR, External proximity grants better 
understanding of customer, Job enhanced by community perspective, and Perspective 
from CSR engagement creates opportunities.  By not operating in a silo and being 
actively engaged and attune to the needs and expectations of your stakeholders a 
better perspective emerges that grants the company the ability to better understanding 
of their customers and the environment in which they operate.  The enhanced external 
perspective creates better scanning for opportunities (i.e. more opportunities for the 
company are identified that may have previously remained unseen).  Basically, CSR 
helps to develop a better mindset that is more externally oriented and entrenched in the 
environment that the company works in and affects.  Most importantly, the expansion of 
perspective identifies better opportunities but these opportunities tend to require, at 
least at the higher level of CSR programs, innovative approaches to ensure success for 
all parties involved.  By having to be innovative in approach it makes employees think 
innovatively which actually helps to enhance their skills set on top of the self-fulfilling 
nature already discussed about CSR.  As CSR is engaged in more, the leadership 
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motivation supported CSR evolution. 
 
The evolution of CSR has been witnessed within each of the interviewee’s companies.  
Of course CSR started with the industries - Healthcare link inherent responsibilities.  
CSR has been part of the fabric of the company since it began and the founder 
articulated the still used values that embraced the ideas of CSR – long history of CSR 
mindset among employees.  But CSR did not evolve for a long time.  But once it did 
start to evolve it became a natural extension of their healthcare responsibilities – or 
maybe a better and more focused extension.  Although it (22) did not evolve out of a 
public image crisis, it has evolved to be more public and has a role in regaining 
public confidence.  So, although the poor reputation of the industry did not start the 
evolution it has become a part of its fast or indirect benefit of engaging in CSR.  
Interviewee (22) touched on a previous subject that the industry may have been too 
private and as they have become more transparent and public, CSR has in turn 
increased as well - Lack of transparency has lead to regulations.  Leaders have 
endorsed this move into CSR in some companies and it appears that the greater the 
motivation to engage in CSR by leaders is in turn motivational to employees and 
the evolution of CSR.  CSR now is used on a much more global and complex level to 
address social needs at the macro-public health level.  The evolution of CSR occurs 
but there are questions about its future because the uncertainty of the industry’s 
future – patents, pipeline, healthcare costs etc. and it may not be sustainable if 
there is not a measureable ROI.  The awareness of CSR appears to be an issues 
because even though interviewee sees CSR being robust across the top pharma 
companies but he is unsure of its evolution in comparison to other industries – 
germane.   
 
As a result of the evolution of CSR new strategies have emerged to manifest the current 
and projected perspective of it.  I think one code that really shows the strategy for CSR 
is – build system for access to medicine.  In pursuit of this goal the company must be 
innovative because the traditional methods of CSR that centered on basic philanthropy 
and volunteerism.  Using both of those as a basis, they were evolved to become parts 
of complex strategies to innovatively address social needs using the assets and 
resources of the business while creating synergistic benefits.  CSR has now evolved 
into a rubric or umbrella that envelops the actions of the entire company because they 
realize that you cannot have an embedded CSR strategy and not be responsible in all 
peripheral actions and behaviours.  So in way, CSR has become the manifested guiding 
philosophy that reinforces the values that have historical presence within the company.  
CSR is a better method to create a value-based system of operations – almost like a 
positive-based hive mind.  A true company CSR mind-set has not been achieved to 
date as interpreted in the following code - Ingrain CSR mindset - will survive 
company reductions.  It is the intangible goal of CSR but there are also many tangible 
and more measurable goals for CSR, include - Improving patient outcomes SR and 
motivation, Improving patient outcomes through variety of means priority, 
Partner with government healthcare to provide better access, Partnerships to 
enhance CSR goals, Partnerships to help shape environment for better patient 
access, Social issue impact important – emerging, Use CSR to build-enhance 
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relationships within company - team building, Focus on improving peoples not 
just patients lives, Drugs part of mission to help peoples’ lives, Engage in 
partnerships at community level.  In the pursuit of better access to medicine and 
overall public health, the company will utilize their expertise in combination with others 
expertise using partnerships in attempts to innovatively address the obstacles in the 
way of better public health.  No single company can have a large impact on overall 
public health but through strategic focus they can address a few aspects in regions 
around the world that can have substantial impact for those populations.  Additionally, 
community work around operations helps to enhance the community that they exist 
within, and this reflects a micro example of symbiotic relationship between business and 
society.  The motivation of public health shows that CSR is the natural extension 
of this priority.  They can address this priority through the production of 
pharmaceutical products but their size, scope, expertise, and capabilities places 
additional responsibilities on them to embrace a larger social responsibility to ensure 
access, affordability and availability of their products.  In addition to this, the majority of 
companies now refer to themselves as healthcare companies because of their product 
line that is increasingly becoming more diversified to include things like animal health, 
medical products, and OTC medications.  As they move into this space it is likely that 
the responsibilities must move in turn.  Access to medicine responsibilities broadens 
into public health responsibilities but, however, this does not mean that funding 
increases to CSR.  They must still focus CSR to make sure it is effective and efficient, 
but it now uses a broader set of complex programs to help things like, for example, 
enhancing health infrastructure and educate to increase health knowledge.  A healthier 
population actually makes more money and this means they can afford more healthcare 
products (win-win situation?). This approach uses Scientific-system-community 
elements to target CSR in a broad fashion that can best address a few areas of public 
health.   
 
The widgets in the evolution of CSR machine is the four main areas of the CIP.  The 
continual improvement process is four interdependent areas that span across the 
organization and the changes that occur to these four areas make the necessary 
changes to achieve the evolutionary goals of CSR.   The CSR programs are the result 
of the strategic choices and focusing of CSR.  They need employees for implementation 
to occur, communications makes sure that motivations and perceptions are aligned to 
drive CSR forth, and the measuring is an integral part to providing verification of 
success to internal and external parties. 
 
For interviewee 22, their company have developed and implemented numerous 
programs that range in size and complexity.  The programs range from the local, which 
are simple and usually based on philanthropy and volunteerism, and global which are 
complex and sometimes represent the ‘flagship’ programs the company uses to best 
publicly display their commitment.  And the complex programs, which are usually are 
also global programs, are large displays of the commitment to CSR by the 
company and its leaders.  On more of the simple side, philanthropy is important and 
the majority of philanthropy resides in a foundation that is technically separate from the 
organization but really is tied to its financial health.  Employee oriented philanthropy 
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tends to be facilitated by the company in the form of deductions from their pay-cheque 
and matching programs.  Another is employee empowered philanthropy where they can 
collectively choose a charity at an affiliate and direct corporately given funds towards a 
charity of their choice.  To facilitate the success of a lot of their programs partnerships 
are made to enhance relationships and the levels of expertise – make it comprehensive.  
Although the company does have a complex range of expertise to address many 
healthcare related situations, partnerships are needed to fill in gaps, which can include 
those that are information related.  There are partnerships with community groups, 
NGOs, and governments.  Stakeholders seem to represent a lot of the partnerships 
but also mutual interest partnerships to help best address a social need – partnerships 
to enhance CSR goals and help shape better environment, for example, patient 
access.  One area that seems to be a huge focus of global CSR is complex and 
innovative approaches address social issues in emerging countries.   
 
The HR sections has been detailed in regard to employees earlier in this memo 
and the groups of employees and executives that are responsible for the 
strategizing, creation, implementation, and reporting of CSR.   
 
Communication of CSR is a priority for each company because it  integral part of 
information transfer so that perspectives can be shared and values can be reinforced for 
example – it strengthens the CSR infrastructure and gets more buy-in internally and 
externally.  Communication of CSR reinforces it; visible support to reinforce CSR; 
and outreach reflects responsibility.  Communication of successful CSR and also the 
intentions of CSR help to drive CSR implementation and development but also bring 
authenticity and/or credibility to their actions with both employees and society.  More 
discussion of communication is present within previous memos.   
 
Measurement is the key to bringing verification to the success or failure of CSR 
engagement.  Of course, it is not that black and white, but measures can help gauge the 
level of success of the intended outcomes.  These types of measures can help 
companies figure out what may need to be tweaked in a program to enhance its level of 
success.  Interviewee discussed the measurement of CSR in their interview and what 
they explained is the paradoxical problem that currently plagues more socially oriented 
CSR – how do you move past superficial measurements to actually assess direct links 
to successful outcomes by CSR interventions.  The superficial measures are generally 
simple input-output measures, and these include: Success measured at times on 
employee part. levels; measure employee engagement levels - hours etc.; and 
measure and encourage employee participation.  These type of measures are 
generally done by survey or simple numerical analysis based on budgets, participants 
etc.  The difficulty is in measuring the outcomes of the complex programs which have 
outcomes that are not easily linked to the CSR program or intervention.  The complex 
web of synergistic benefits is not easy to measure.  Since we are dealing with business, 
the ROI is one of the most important signs of business related success and can play a 
key factor in ensuring the sustainability of CSR within companies.  But tangible 
measures of CSR are very hard to measure and the ROI of CSR will be a big test 
for the future of CSR.  
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Appendix C 
 
 
 
You are invited to participate in a study entitled Corporate Social Responsibility 
within the Canadian and American Pharmaceutical Industry. Please read this form 
carefully, and feel free to ask questions you might have. 
 
Researchers  
 
Tim West, PhD (student) and Roy T Dobson, MBA, PhD 
College of Pharmacy & Nutrition, Division of Pharmacy 
University of Saskatchewan 
110 Science Place 
Saskatoon, SK S7N 5C9 
 
Phone: (306) 966.6346 
Fax: (306) 966.6377 
Email: tim.west@mail.usask.ca 
 
Purpose and Procedure 
 
The purpose of this study is to obtain information on pharmaceutical corporations' 
motivations and orientations towards engaging in corporate social responsibility (CSR).  
To accomplish this, semi-structured interviews with pharmaceutical executives are 
being conducted.  The executives will be representatives of the corporation, with 
experience in the CSR decision-making process, who can provide insight into the 
motivations for CSR and the values of their company.  
 
One respondent will be interviewed at a time, with the interviews scheduled to last less 
than one hour.  The interview will be conducted in a private room, and will be tape 
recorded and transcribed at a later date.  To ensure confidentiality, each respondent's 
name, corporation, and product orientation (brand name or generic) will be de-identified 
using letter-based identification codes.  The presentation and/or publication of results 
will use the identification codes to ensure a participants’ personal and company 
information remains confidential 
 
During the span of the interview, the interviewer (Tim West) will give a short explanation 
of the study and then begin to ask questions to the participants.  The semi-structured 
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interview format will allow the interviewer to deviate from planned questions to follow 
interesting or unexpected topics.  This study is not strictly isolated to the corporate 
viewpoints, allowing for the addition of personal opinions. 
 
Potential Risks 
 
The potential risks of this study are minimal.  Since all participants will have an 
identification code, and personal or corporate names will not be used, there is no 
chance in identifying who the participants are once the interviews have been completed.  
Only the researchers (Tim West & Roy Dobson) will have access to the consent form 
and identification codes.  After transcribing the interview tapes, each participant will 
receive a copy and have a chance to review it before the researcher proceeds to use 
the transcripts.  
 
Potential Benefits 
 
The benefits to participating corporations will be to reflect on their own approach to CSR 
and to become more informed on the current CSR environment of the pharmaceutical 
companies within Canada and the US.  
 
Storage of Data 
 
All transcripts of the interviews will be de-identified.  The linkage between the consent 
forms and data will be destroyed once participants provide final consent for the use of 
the printed transcripts.  Tape recordings, transcripts and consent forms will be stored in 
a secure, locked facility of the Research Supervisor (Dobson), at the University of 
Saskatchewan, for no less than five years.  After this time, if the tapes are deemed no 
longer needed, they will be erased; also, the transcripts and consent forms will be 
shredded if no longer required.  
 
Confidentiality 
 
As stated under the Purpose and Procedure, only the researchers will have access to 
the list identifying each participant.  For any direct quotations from a respondent when 
disseminating the results of an interview, the identifications codes will be given, with no 
connection to the respondent’s name, company or product orientation. Different 
identification codes will be created for the respondent's name, employer, and employer 
information (product names and orientation).  To ensure confidentiality, only one 
identification code at a time will be used in quotations and descriptions. This will not 
allow for linking of identification codes to occur.  
 
Right to Withdraw 
 
Your participation is voluntary, and you may withdraw from the study for any reason, at 
any time, without penalty of any sort.  You may also refuse to respond to any statement 
and/or answer any of the questions asked in the interview.  If you withdraw from the 
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study at any time, any data that you have contributed will be destroyed at your request.   
 
Questions  
 
Should you have any questions concerning the study, please feel free to ask at any 
point; you are also free to contact the researcher (Tim West) by email 
(tim.west@mail.usask.ca), facsimile (306.966.6377) or phone (306.966.6346).  This 
study has been approved on ethical grounds by the University of Saskatchewan 
Behavioural Research Ethics Board on April 3, 2009.  Should you have any questions 
regarding your rights as a participant in this study you may call the Office of Research 
Services at the University of Saskatchewan (306.966.2084).  Out of town participants 
may call collect. 
 
 
Consent to Participate 
 
I have read and understood the description provided above; I have been provided with 
an opportunity to ask questions and my questions have been answered satisfactorily.  I 
consent to participate in the study described above, understanding that I may withdraw 
this consent at any time.  A copy of this consent form has been given to me for my 
records. 
 
Name of Participant Date 
Signature of Participant Signature of Researcher 
 
 
 
 
 
 
 
 
